

(incorporated in the Cayman Islands with limited liability) (於開曼群島註冊成立之有限公司) Stock Code 股份代號: 8622



## CHARACTERISTICS OF GEM OF THE STOCK EXCHANGE OF HONG KONG LIMITED (THE "STOCK EXCHANGE") 香港聯合交易所有限公司(「聯交所」)GEM之特色

GEM has been positioned as a market designed to accommodate small and mid-sized companies to which a higher investment risk may be attached than other companies listed on the Stock Exchange. Prospective investors should be aware of the potential risks of investing in such companies and should make the decision to invest only after due and careful consideration.

Given that the companies listed on GEM are generally small and mid-sized companies, there is a risk that securities traded on GEM may be more susceptible to high market volatility than securities traded on the Main Board of the Stock Exchange and no assurance is given that there will be a liquid market in the securities traded on GEM.

Hong Kong Exchanges and Clearing Limited and the Stock Exchange take no responsibility for the contents of this report ("**Report**"), make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of the Report.

This Report, for which the directors (the "**Directors**") of Huakang Biomedical Holdings Company Limited (the "**Company**", and together with its subsidiaries, the "**Group**", "**we**" or "**our**") collectively and individually accept full responsibility, includes particulars given in compliance with the Rules Governing the Listing of Securities on GEM of the Stock Exchange (the "**GEM Listing Rules**") for the purpose of giving information with regard to the Group. The Directors, having made all reasonable enquiries, confirm that to the best of their knowledge and belief, the information contained in this Report is accurate and complete in all material respects and not misleading or deceptive, and there are no other matters the omission of which would make any statement herein or this Report misleading.

GEM乃為較其他於聯交所上市之公司帶有較高投資風險之中小型公司提供一個上市之市場。有意投資 者應了解投資於該等公司之潛在風險,並應經過審慎周詳考慮後方作出投資決定。

由於GEM上市公司通常為中小型公司,於GEM買賣之證券可能會較於聯交所主板買賣之證券承受較大 之市場波動風險,及無法保證於GEM買賣之證券會有高流通市場。

香港交易及結算所有限公司及聯交所對本報告(「**本報告**」)的內容概不負責,對其準確性或完整性亦不發 表任何聲明,並明確表示,概不對因本報告全部或任何部分內容而產生或因倚賴該等內容而引致的任何 損失承擔任何責任。

本報告乃遵照聯交所GEM證券上市規則(「GEM上市規則」)之規定而提供有關華康生物醫學控股有限公司(「本公司」,連同其附屬公司統稱「本集團」或「我們」)的資料,本公司董事(「董事」)願就本報告共同 地及個別地承擔全部責任。董事經作出一切合理查詢後確認,就彼等所深知及確信,本報告所載資料在 各重大方面均為準確及完整,且無誤導或欺詐成分及並無遺漏任何其他事項致使本報告或當中所載任何 陳述產生誤導。

## CONTENTS 目錄

Corporate Information 公司資料	3
Chairman's Statement 主席報告	5
Management Discussion and Analysis 管理層討論及分析	7
Biographies of Directors and Senior Management 董事及高級管理層之履歷	25
Corporate Governance Report 企業管治報告	34
Environmental, Social and Governance Report 環境、社會及管治報告	59
Report of the Directors 董事會報告	93
Independent Auditor's Report 獨立核數師報告	116
Consolidated Statement of Profit or Loss and Other Comprehensive Income 綜合損益及其他全面收益表	125
Consolidated Statement of Financial Position 綜合財務狀況表	126
Consolidated Statement of Changes in Equity 綜合權益變動表	128
Consolidated Statement of Cash Flows 綜合現金流量表	130
Notes to the Consolidated Financial Statements 綜合財務報表附註	132
Financial Summary 財務概要	228

# **CORPORATE INFORMATION** 公司資料

# Board of Directors 董事會

**Executive Directors 執行董事** Mr. Zhang Shuguang (*Chairman*) 張曙光先生(*主席*) Mr. Zhang Chunguang 張春光先生 Mr. Poon Lai Yin Michael 潘禮賢先生 Mr. He Jiaming 何嘉明先生

# Independent Non-executive Directors 獨立非執行董事

Dr. Chow Kwok Fai Joseph (appointed on 16 December 2020) 周國輝博士(於二零二零年 十二月十六日委任) Dr. Cheng Faat Ting Gary (appointed on 1 September 2020) 鄭發丁博士 (於二零二零年九月一日委任) Mr. Chan Kin Sang 陳健生先生 Dr. Yeung David Wai Chow (resigned on 16 December 2020) 楊煒秋醫生(於二零二零年 十二月十六日辭任) Mr. Kwok Chi Shing (resigned on 1 September 2020) 郭志成先生 (於二零二零年九月一日辭任)

#### Audit Committee 審核委員會

Dr. Cheng Faat Ting Gary (Chairman) (appointed on 1 September 2020) 鄭發丁博士(主席) (於二零二零年九月一日委任) Dr. Chow Kwok Fai Joseph (appointed on 16 December 2020) 周國輝博士(於二零二零年 十二月十六日委任) Mr. Chan Kin Sang 陳健生先生 Mr. Kwok Chi Shing (resigned on 1 September 2020) 郭志成先生 (於二零二零年九月一日辭任) Dr. Yeung David Wai Chow (resigned on 16 December 2020) 楊煒秋醫生(於二零二零年 十二月十六日辭任)

#### Remuneration Committee 薪酬委員會

Dr. Cheng Faat Ting Gary (Chairman) (appointed on 1 September 2020) 鄭發丁博士(*主席)* (於二零二零年九月一日委任) Dr. Chow Kwok Fai Joseph (appointed on 16 December 2020) 周國輝博士(於二零二零年 十二月十六日委任) Mr. Zhang Chunguang 張春光先生 Mr. Kwok Chi Shing (resigned on 1 September 2020) 郭志成先生 (於二零二零年九月一日辭任) Dr. Yeung David Wai Chow (resigned on 16 December 2020) 楊煒秋醫生(於二零二零年 十二月十六日辭任)

#### Nomination Committee 提名委員會

Mr. Zhang Shuguang (Chairman) 張曙光先生(主席) Dr. Chow Kwok Fai Joseph (appointed on 16 December 2020) 周國輝博士(於二零二零年 十二月十六日委任) Mr. Chan Kin Sang 陳健生先生 Dr. Yeung David Wai Chow (resigned on 16 December 2020) 楊煒秋醫生(於二零二零年 十二月十六日辭任)

## **Compliance Adviser**

**合規顧問** Ever-Long Securities Company Limited 長雄證券有限公司

#### Company Secretary 公司秘書

Mr. Chau Lai Ki 周麗麒先生

#### **Authorised**

#### Representatives (for the purposes of the GEM Listing Rules) 授權代表(就 GEM上市規則而言)

Mr. Zhang Shuguang 張曙光先生 Mr. Poon Lai Yin Michael 潘禮賢先生

## **Compliance Officer**

合規主任 Mr. Poon Lai Yin Michael 潘禮賢先生

#### Legal Advisers as to Hong Kong laws 有關香港法例的法律顧問

3

Tung, Ng, Tse & Lam Solicitors 董吳謝林律師事務所 CORPORATE INFORMATION

公司資料

#### Auditor 核數師

Mazars CPA Limited 中審眾環(香港)會計師事務所 有限公司

#### Registered Office 註冊辦事處

Cricket Square, Hutchins Drive, P.O. Box 2681, Grand Cayman, KY1-1111, Cayman Islands

#### Principal Place of Business in Hong Kong 香港主要營業地點

The Floor, Effectual Building, 16 Hennessy Road, Wanchai, Hong Kong 香港 灣仔 軒尼詩道16號 宜發大廈3樓

#### Principal Place of Business in the PRC 中國主要營業地點

1–3/F, Building D, Shenzhen Junxuan, No. 16 Yinkui Road, Kui Xin Community, Kui Chong Office, Dapeng New District, Shenzhen, The PRC 中國 深圳市 大鵬新區 葵新社區 銀葵路16號 深圳君軒D棟一至三層

#### Principal Share Registrar and Transfer Office in the Cayman Islands 開曼群島股份過戶登記處

Conyers Trust Company (Cayman) Limited Cricket Square, Hutchins Drive, P.O. Box 2681, Grand Cayman KY1-1111, Cayman Islands

#### Hong Kong Share Registrar and Transfer Branch Office 香港股份過戶登記分處

Tricor Investor Services Limited Level 54, Hopewell Centre, 183 Queen's Road East, Hong Kong 卓佳證券登記有限公司 香港 皇后大道東183號 合和中心54樓

#### Company's Websites 公司網址

http://www.huakangbiomedical.com

#### Stock Code

股份代號 8622

4

# CHAIRMAN'S STATEMENT 主席報告

Dear Shareholders,

It is with great pleasure that, on behalf of the board of directors (the "**Board**") of Huakang Biomedical Holdings Company Limited, I hereby present the Group's annual results for the year ended 31 December 2020 to all the shareholders.

#### **OVERVIEW**

2020 was a tough year. The outbreak of the novel coronavirus (COVID-19) epidemic (the "Epidemic") led our factory in the People's Republic of China (the "**PRC**") to halt productions and sales for more than around five weeks. The Epidemic also significantly affected the purchases from hospitals in the PRC (i.e. ultimate end customers) as they reserved more capacity and resources to handle serious patients who suffered from the Epidemic. As a result, our business was seriously affected in the first half of 2020. Following a series of management improvements and business revamp after July 2020, our revenue resumed to normal in the second half of 2020 as we recorded a revenue in the PRC of approximately Renminbi ("RMB") 14.0 million for the six months ended 31 December 2020 compared to approximately RMB13.8 million of the corresponding period of year 2019.

We also recognised the strong demand for rapid Point-Of-Care diagnostic testing ("**POCT**") under immunoassay techniques. We carried out preliminary selection and evaluation of a supporting test platform in the second half of 2020. We intended to purchase equipment for research and development of the supporting test platform in the future. 親愛的股東:

本人謹代表華康生物醫學控股有限公司董事 會(「**董事會**」),欣然向全體股東提呈本集團 截至二零二零年十二月三十一日止年度之年 度業績。

### 概覽

二零二零年為艱難的一年。新型冠狀病毒 (COVID-19)疫情(「疫情」)爆發,導致我們位 於中華人民共和國(「中國」)的工廠暫停生產 及銷售超逾大約五週。疫情亦對來自中國醫 院(即最終終端客戶)的採購產生重大影響, 因為彼等需保留較多的醫院容量及資源,以 處理該等受疫情影響的重症患者。因此,我 們的業務於二零二零上半年受到嚴重影響。 繼於二零年七月後執行一系列管理改進 措施及業務調整之後,我們的收益於二零二 零年下半年回歸正常,原因為我們於截至二 零二零年十二月三十一日止六個月在中國錄 得收益約人民幣(「人民幣」)14.0百萬元,而 二零一九年同期約為人民幣13.8百萬元。

我們亦確認對使用免疫測定技術進行快速即 時檢驗(「**即時檢驗**」)之需求強勁。我們於二 零二零年下半對支持檢測平台進行了初步甄 選及評估。我們擬採購設備,用於日後研發 支持檢測平台。



Despite the difficulties arising from the Epidemic, we commenced a new business stream in Canada and Hong Kong for the sales of vitamins and supplements under our own registered brand "Nutronic". The relevant products have been gradually launched in the market.

On 3 June 2020, it is our pleasure to establish a company, namely Smartronic Limited ("**Smartronic**"), with Smartac International Holdings Limited (stock code: 395.HK), in which we hold 49% of its equity interests, for the purposes of sales, marketing and distribution of Nutronic's supplements through crossborder e-commerce platform(s) and channels in the PRC.

#### FORWARD

Going forward, we will actively seek potential business opportunities that would facilitate the sales of the Group's products in the PRC, Hong Kong and overseas.

Lastly, on behalf of the Board, I would like to take this opportunity to express my sincere gratitude to all staff members for their dedicated contributions and unwavering commitment to deliver the best service to our customers over the years. My appreciation also goes to all shareholders, business associates, partners and valued customers for their generous support and confidence in the Company. We will continue with our endeavour to pursue growth of our business and create value for our shareholders. 儘管疫情帶來諸多困難,我們已於加拿大及 香港開展一項新的業務流,以銷售自身註冊 品牌「Nutronic」旗下的維他命及保健品。有 關產品已逐步推出市場。

於二零二零年六月三日,本集團欣然與環球 智能控股有限公司(股份代號: 395.HK)成 立一間公司,即智能創力有限公司(「智能創 力」),而本集團持有其49%之股權,以透過 中國的跨境電商平台及渠道銷售、營銷及分 銷Nutronic保健品。

#### 展望

展望未來,我們將積極物色潛在業務機會, 以推動本集團產品於中國、香港及海外地區 之銷售。

最後,本人謹代表董事會,藉此機會衷心感 謝全體員工多年來不遺餘力、堅定不移地致 力為客户提供最優質的服務。本人亦感謝所 有股東、業務夥伴、合作夥伴及重要客户對 本公司的慷慨支持和信任。我們將繼續竭力 推動業務增長,為股東創造價值。

Zhang Shuguang	張曙光
Chairman	主席
Hong Kong, 24 March 2021	香港,二零二一年三月二十四日

6

#### **BUSINESS REVIEW**

#### **Existing business**

Our Group specialises in the research and development, manufacture and sales of a wide range of in-vitro diagnostic ("**IVD**") reagents in the PRC, particularly focusing on the PRC male fertility IVD reagent market.

The Group has also diversified its business to vitamins and supplements products for the markets in the PRC, Hong Kong and overseas.

For the year ended 31 December 2020, our Group experienced a significant decrease in revenue from the sales of our male fertility IVD reagent products. Such significant decrease was mainly attributable to the Epidemic since a number of provinces and municipalities in the PRC have taken emergency public health measures and various other actions to prevent the spread of the Epidemic, including crowd-control and/or stay-home policies or orders. As a result of the Epidemic, our PRC factory halted productions and sales for more than around five weeks. Sales from our ultimate end customers (i.e. hospitals) in the PRC were significantly affected. Our Group had a significant decrease in the average sales volume of our male fertility IVD reagent products ranging from approximately 8.5% to approximately 45.1%, detection kit for immunoglobulin G (IgG) antibody to Schistosoma japonicum by approximately 42.2% and detection kit for viral capsid antigen (VCA) immunoglobulin (IgA) antibody to Epstein-Barr Virus ("EBV") by approximately 19.7%, while average selling prices for some of our products in the PRC also slightly decreased.

#### 業務回顧及前景

#### 現時業務

本集團專注於在中國研發、生產及銷售各種 體外診斷(「體外診斷」)試劑,尤其專注於中 國男性不育體外診斷試劑市場。

本集團亦將其業務多元化至銷售維生素及保 健品產品到中國、香港及海外的市場。

截至二零二零年十二月三十一日止年度,本 集團銷售男性體外診斷試劑產品的收益顯著 減少,該顯著減少乃主要由於疫情所致,因 為中國多個省市已採取緊急公共衛生措施, **並採取各種其他行動預防疫情傳播,包括採** 取人群控制及/或居家政策或命令。由於爆 發疫情,我們的中國工廠已暫停生產及銷售 超過大約五週。我們中國最終終端客戶(即 醫院)之銷售受到重大影響。本集團男性不 孕體外診斷試劑產品的平均銷量大幅減少約 8.5%至約45.1%,及日本血吸蟲免疫球蛋 白G(「IgG」)抗體檢測試劑盒及EB病毒(「EB 病毒」)病毒衣殼抗原(「VCA」)免疫球蛋白A (「IgA」)抗體檢測試劑盒的平均銷量分別減 少約42.2%及約19.7%,而部份產品於中國 的平均售價亦略有下降。

Despite the difficulties during the period of the Epidemic, the Group continued to expand its sales channel for IVD reagents and auxiliary reproductive supplies and equipment business in the PRC. The Company sold products to 22 new direct sale customers and 73 new distributors during the year ended 31 December 2020. On 23 November 2020, Shenzhen Huakang Bio-Medical Engineering Limited\* was granted with the International Organisation for Standardisation 13485 Certificate for meeting the regulatory requirements of the design, development, production and sales of IVD reagents. As such, it demonstrated that the Group's products have reached the international standard and our capacity on research and development as well as our quality management system have been continually improved.

#### **New business**

Our Group has been granted a total of 23 natural health product licences by the Natural Health Products Directorate of Health Canada for our own registered brand "Nutronic". The relevant products were distributed through Smartronic's cross-border e-commerce platform(s) and channels, such as Tmall, JD.com, Xiaohongshu and Wechat mini program.

#### FUTURE STRATEGIES AND PROSPECTS

Our Group had ten recent research projects in progress, mainly focusing on diagnostic of male and female infertility. Further, our Group will complete the PRC's medical devices registration for some of the research projects that will be launched to the market in 2021. In particular, with a satisfactory result for the production of POCT, the Group intended to further invest in the research and development of POCT, including purchasing raw materials and equipment as well as setting up a new production line for further production expansion. 儘管疫情期間困難重重,但本集團仍繼續擴 大體外檢測試劑及輔助生育用品及設備業務 於中國的銷售渠道。截至二零二零年十二月 三十一日止年度,本公司向22名新直銷客戶 及73名新分銷商銷售產品。於二零二零年 十一月二十三日,深圳華康生物醫學工程有 限公司獲授國際標準化組織13485證書,以 證明體外診斷試劑的設計、開發、生產及銷 售已符合監管要求。因此,其印證了本集團 的產品已達到國際標準化水平,及我們的研 發能力及質量管理體系已不斷提升。

#### 新業務

本集團就我們自己的註冊品牌「Nutronic」已 獲得加拿大衛生部天然健康產品管理委員會 授予合共23份天然保健產品牌照。相關產品 在智能創力的跨境電子商務平台及渠道(如 天貓、京東、小紅書及微信小程序)銷售。

#### 未來策略與前景

本集團近期有10個在研項目,主要集中於男 性及女性不孕診斷。另外,本集團將就將於 二零二一年面市的部分研究項目完成中國醫 療器械註冊。尤其是,由於即時檢驗生產取 得令人滿意的結果,本集團擬進一步投資研 發即時檢驗,包括採購原材料及設備以及設 立新生產線以進一步擴張生產。

\* The English name is for identification purpose only



## 管理層討論及分析

#### **FINANCIAL REVIEW**

#### Revenue

The Group's revenue decreased by approximately RMB3.5 million, or approximately 13.7%, from approximately RMB25.5 million for the year ended 31 December 2019 to approximately RMB22.0 million for the year ended 31 December 2020. The decrease in revenue was mainly due to a decrease in sales of biological reagents in the PRC of approximately RMB4.4 million.

Sales of biological reagents included male fertility IVD reagents, parasite antibody detection reagents and EBV antibody detection reagents. Due to the Epidemic, these sales sharply decreased to approximately RMB19.8 million for the year ended 31 December 2020 compared with approximately RMB24.2 million for the year ended 31 December 2019.

Sales of male fertility IVD reagents products remained our major product which accountined for approximately 75.3% of our total sales of biological reagents and auxiliary reproductive supplies and equipment in the PRC for the year ended 31 December 2020. Revenue from this segment for the year ended 31 December 2020 was approximately RMB16.0 million, which represented a decrease of approximately RMB3.4 million or approximately 17.5% from approximately RMB19.4 million for the year ended 31 December 2019.

#### 財務回顧

#### 收益

本集團於截至二零二零年十二月三十一日止 年度的收益由截至二零一九年十二月三十一 日止年度的約人民幣25.5百萬元減少約人民 幣3.5百萬元或約13.7%至約人民幣22.0百 萬元。收益減少乃主要由於中國的生物製劑 銷售額減少約人民幣4.4百萬元所致。

銷售生物製劑包括男性不育體外診斷試劑、 寄生蟲系列檢測試劑及EB病毒檢測試劑。由 於疫情,截至二零二零年十二月三十一日止 年度之銷售額急劇下降至約人民幣19.8百萬 元,而截至二零一九年十二月三十一日止年 度則約為人民幣24.2百萬元。

男性不育體外診斷試劑產品仍為我們的主要 產品,其於截至二零二年十二月三十一日止 年度之銷售額佔生物製劑及輔助生育用品及 設備總銷售額約75.3%。該分部於截至二零 二零年十二月三十一日止年度之收益約為人 民幣16.0百萬元,較截至二零一九年十二月 三十一日止年度的約人民幣19.4百萬元減少 約人民幣3.4百萬元或約17.5%。

The decrease in sales of parasite antibody detection reagents was approximately RMB599,000, or approximately 17.1%, from approximately RMB3.5 million for the year ended 31 December 2019 to approximately RMB2.9 million of the year ended 31 December 2020. The sales of EBV antibody detection reagents decreased approximately RMB243,000 or approximately 19.9% from approximately RMB1.2 million for the year ended 31 December 2019 to approximately RMB978,000 for the year ended 31 December 2020.

Sales of vitamins and supplements was a new business that generated approximately RMB776,000 (2019: Nil) for the year ended 31 December 2020.

#### **Gross Profit and Gross Profit Margin**

The Group recorded gross profit of approximately RMB14.7 million for the year ended 31 December 2020, which represented a decrease of approximately RMB3.2 million, or approximately 17.9%, from approximately RMB17.9 million for the year ended 31 December 2019.

The Group's gross profit margin remained relatively stable at approximately 67.0% for the year ended 31 December 2020 as compared to the gross profit margin of approximately 70.2% for the year ended 31 December 2019.

#### Other Income and Other Gains and Losses

Other income significantly increased by approximately RMB390,000 or approximately 150.0%, from approximately RMB260,000 for the year ended 31 December 2019 to approximately RMB650,000 for the year ended 31 December 2020, primarily because we received government grants in respect of COVID-19 provided by Hong Kong local government authorities.

The Group recorded other losses of approximately RMB1.1 million for the year ended 31 December 2020, but the Group also recorded other gains of approximately RMB508,000 for the year ended 31 December 2019. Such change was mainly due to fluctuations in foreign exchange rate between foreign currency and RMB, the majority of which was unrealized foreign exchange loss.

寄生蟲系列檢測試劑之銷售額由截至二零 一九年十二月三十一日止年度之約人民幣 3.5百萬元減少約人民幣599,000元或約 17.1%至截至二零二零年十二月三十一日止 年度的約人民幣2.9百萬元。EB病毒檢測試 劑之銷售額由截至二零一九年十二月三十一 日止年度的約人民幣1.2百萬元減少約人民 幣243,000元或約19.9%至截至二零二零年 十二月三十一日止年度的約人民幣978,000 元。

銷售維他命及保健品乃一項新業務,其於截 至二零二零年十二月三十一日止年度產生之 銷售額約為人民幣776,000元(二零一九年: 無)。

#### 毛利及毛利率

本集團截至二零二零年十二月三十一日止 年度錄得毛利約人民幣14.7百萬元,較截至 二零一九年十二月三十一日止年度之約人民 幣17.9百萬元減少約人民幣3.2百萬元或約 17.9%。

本集團的毛利率保持相對穩定,截至二零二 零年十二月三十一日止年度為約67.0%,而 截至二零一九年十二月三十一日止年度的毛 利率為約70.2%。

#### 其他收入及其他收益及虧損

其他收入由截至二零一九年十二月三十一日 止年度約人民幣260,000元大幅增加約人民 幣390,000元或約150.0%至截至二零二零 年十二月三十一日止年度約人民幣650,000 元,此乃主要由於我們收到香港當地政府機 構提供之有關COVID-19的政府補助。

本集團於截至二零二零年十二月三十一日止 年度錄得其他虧損約人民幣1.1百萬元,但 本集團亦於截至二零一九年十二月三十一日 止年度錄得其他收益約人民幣508,000元。 有關變動主要由於外幣與人民幣匯率的波 動,其中大部分為未變現匯兑虧損。



管理層討論及分析

#### **Impairment Losses**

The Group recorded impairment losses on trade receivables of approximately RMB787,000 for the year ended 31 December 2020, while the Group recorded reversal of impairment losses on trade receivables of approximately RMB250,000 for the year ended 31 December 2019, which was mainly attributable to the Epidemic that affected the repayabilities of the Group's debtors.

Following our evaluation and assessment on the Group's fixed assets in a prudent manner together with the adverse impact of the Epidemic on the business and operation environment in the PRC, the Group recognised an one-off non-cash provision for impairment loss on property, plant and equipment of approximately RMB2.6 million during the year ended 31 December 2020.

#### **Selling and Distribution Expenses**

Selling and distribution expenses slightly increased approximately RMB347,000 or approximately 5.1%, from approximately RMB6.8 million for the year ended 31 December 2019 to approximately RMB7.1 million for the year ended 31 December 2020. The increase was primarily attributable to additional headcounts for dealing with the sales and marketing of vitamins and supplements in Hong Kong and overseas.

#### **Administrative Expenses**

Administrative expenses increased from approximately RMB9.7 million for the year ended 31 December 2019 to approximately RMB10.2 million for the year ended 31 December 2020, which represented an increase of approximately RMB512,000 or approximately 5.3%. Such an increase was mainly attributable to purchasing epidemic prevention supplies of approximately RMB348,000 and remuneration for appointment of a medical advisor with effect from 31 January 2020 of approximately RMB458,000.

#### 減值虧損

本集團於截至二零二零年十二月三十一日 止年度錄得貿易應收款項減值虧損約人民 幣787,000元,而本集團於截至二零一九年 十二月三十一日止年度錄得貿易應收款項減 值虧損撥回約人民幣250,000元,主要乃由 於疫情影響償還本集團應收賬款的能力。

繼對本集團固定資產以及疫情對中國業務及 營運環境之不利影響進行審慎估值及評估 後,本集團於截至二零二零年十二月三十一 日止年度確認物業、廠房及設備減值虧損之 一次性非現金撥備約人民幣2.6百萬元。

#### 銷售及分銷開支

銷售及分銷開支由截至二零一九年十二月 三十一日止年度約人民幣6.8百萬元略微增 加約人民幣347,000元或約5.1%至截至二零 二零年十二月三十一日止年度約人民幣7.1 百萬元。該增長乃主要歸因於在香港及海外 地區銷售及營銷維他命及保健品的人員增 加。

#### 行政開支

行政開支由截至二零一九年十二月三十一 日止年度約人民幣9.7百萬元增加約人民 幣512,000元或約5.3%至截至二零二零年 十二月三十一日止年度約人民幣10.2百萬 元。該增加乃主要由於購買防疫物資約人 民幣348,000元及自二零二零年一月三十一 日起,委任醫療顧問之薪酬約為人民幣 458,000元。

#### **Research and Development Expenses**

Research and development expenses increased from approximately RMB1.8 million for the year ended 31 December 2019 to approximately RMB2.3 million for the year ended 31 December 2020, which represented an increase of approximately RMB491,000 or approximately 27.9%. Such an increase was mainly attributable to purchasing raw materials and equipment for research and development of chemiluminescence technology and POCT, and formulating vitamins and supplements products.

#### **Finance Costs**

During the year ended 31 December 2020, finance costs representing the interest on lease liabilities under application of Hong Kong Financial Reporting Standard ("**HKFRS**") 16 was approximately RMB74,000 as compared to approximately RMB72,000 for the year ended 31 December 2019.

#### **Results for the year**

The loss attributable to owners of the Company was approximately RMB11.6 million for the year ended 31 December 2020 as compared to approximately RMB284,000 for the year ended 31 December 2019. Excluding the above-mentioned non-recurring equitysettled share-based payment expenses and impairment loss on property, plant and equipment, the Group recorded an adjusted loss before tax of approximately RMB6.2 million for the year ended 31 December 2020, compared to approximately RMB284,000 for the year ended 31 December 2019.

Basic loss per share for the year was RMB2.91 cents, as compared to RMB0.07 cents for the year ended 31 December 2019.

#### 研發開支

研發開支由截至二零一九年十二月三十一 日止年度約為人民幣1.8百萬元增加約人民 幣491,000元或約27.9%至截至二零二零年 十二月三十一日止年度約為人民幣2.3百萬 元。該增加主要歸因於購買化學發光技術及 即時檢驗研發所需原材料及設備及制定維他 命及保健品配方。

#### 融資成本

截至二零二零年十二月三十一日止年度,融 資成本指於應用香港財務報告準則(「**香港財** 務報告準則」)第16號後租賃負債的利息約為 人民幣74,000元,而截至二零一九年十二月 三十一日止年度則約為人民幣72,000元。

#### 年內業績

截至二零二零年十二月三十一日止年度, 本公司擁有人應佔虧損為約人民幣11.6百萬 元,對比截至二零一九年十二月三十一日止 年度約人民幣284,000元。撇除上述非經常 性以股權結算之股份基礎付款開支及物業、 廠房及設備減值虧損後,本集團於截至二零 二零年十二月三十一日止年度錄得經調整 除税前虧損約人民幣6.2百萬元,而截至二 零一九年十二月三十一日止年度約為人民幣 284,000元。

本年度每股基本虧損為人民幣2.91分,對比 截至二零一九年十二月三十一日止年度每股 人民幣0.07分。



管理層討論及分析

#### Taxation

The PRC enterprise income tax rate applicable to the Group's operating subsidiary in the PRC was 15% (2019: 15%).

#### Dividend

The Board did not recommend payment of the final dividend for the year ended 31 December 2020 *(2019: Nil)*.

The declaration, payment, and amount of future dividend will be decided by the Board and will depend upon, among other things, the Group's results of operations, capital requirements, cash flows, general financial condition and such other factors as the Board may consider important.

# LIQUIDITY, FINANCIAL RESOURCES AND CAPITAL STRUCTURE

Our Group funded the liquidity and capital requirements primarily through internally generated fund from operating activities and proceeds from the listing on the GEM of the Stock Exchange (the "**Listing**").

As at 31 December 2020, our Group recorded total cash and bank balances of approximately RMB41.9 million compared to approximately RMB48.8 million as at 31 December 2019, which were placed with major banks in the PRC and Hong Kong and denominated in RMB, Hong Kong Dollars ("**HK\$**"), United States Dollars ("**US\$**") and Canadian Dollars ("**CAD\$**"). The decrease was mainly due to the payments of daily operating expenses and research and development expenses in the PRC.

As at 31 December 2020, the lease liabilities under application of HKFRS 16 was approximately RMB2.6 million (2019: approximately RMB1.6 million). The gearing ratio of our Group calculated based on the lease liabilities divided by total equity as at 31 December 2020 was approximately 4.3% (2019: approximately 2.3%).

#### 税項

本集團於中國營運的附屬公司適用之中國企業所得税率為15%(二零一九年:15%)。

#### 股息

董事會不建議派付截至二零二零年十二月 三十一日止年度之末期股息(*二零一九年: 無)*。

日後是否宣派股息,以及支付股息之方法及 金額,均由董事會決定,並將視乎(其中包 括)本集團之經營業績、資本需要、現金流 量、整體財務狀況及董事會認為重要之其他 因素而定。

#### 流動資金、財務資源及資本架構

本集團主要透過經營活動所產生的內部資金 及自聯交所GEM上市(「上市」)所得款項,為 流動資金及資本需求提供資金。

於二零二零年十二月三十一日,本集團錄 得現金及銀行結餘總額約為人民幣41.9百萬 元,而於二零一九年十二月三十一日,本集 團之現金及銀行結餘總額約為人民幣48.8百 萬元,分別存放於中國及香港主要銀行,並 分別以人民幣、港元(「**港元**」)、美元(「**美** 元」)及加拿大元(「加元」)計值。該減少乃主 要由於中國的日常營運開支和研發開支付 款。

於二零二零年十二月三十一日,應用香港財 務報告準則第16號後的租賃負債約為人民幣 2.6百萬元(二零一九年:約人民幣1.6百萬 元)。於二零二零年十二月三十一日,本集 團的資本負債比率(按租賃負債除以權益總 額計算)約為4.3%(二零一九年:約2.3%)。

There has been no change in the capital structure of the Company since the Listing. The capital structure of the Group comprised of issued share capital and reserves. The equity attributable to owners of the Company amounted to approximately RMB61.9 million as at 31 December 2020 (2019: approximately RMB70.7 million).

**EMPLOYEES AND REMUNERATION POLICIES** 

As at 31 December 2020, the Group had 80 full-time employees (2019: 73). Staff costs recognised in profit or loss amounted to approximately RMB13.7 million (2019: approximately RMB10.2 million) for the year ended 31 December 2020 (including directors and other employee salaries and retirement benefits). Remuneration policies and packages for the Group's employees were based on individual qualifications, performance, experience, and conditions prevailing in the industry. In addition, various training sessions have been offered to employees to enhance their product and market knowledge.

#### PRINCIPAL RISKS AND UNCERTAINTIES

The Group believed that there were certain risks and uncertainties involved in the operations, some of which were beyond the Group's control. A detailed discussion of the risk factors was set forth in the section headed "Risk Factors" in our prospectus dated 30 November 2018 (the "**Prospectus**"). 自上市起,本公司的資本架構並無任何變動。本集團的資本架構包括已發行股本及儲備。本公司擁有人應佔權益於二零二零年 十二月三十一日約為人民幣61.9百萬元(二 零一九年:約人民幣70.7百萬元)。

#### 僱員及薪酬政策

於二零二零年十二月三十一日,本集團擁有 80名全職僱員(二零一九年:73名)。截至 二零二零年十二月三十一日止年度,於損益 確認的員工成本為約人民幣13.7百萬元(二 零一九年:約人民幣10.2百萬元)(包括董事 及其他僱員薪金及退休福利)。本集團僱員 的薪酬政策及待遇乃按照僱員個別資歷、表 現、經驗及業界當時情況而定。此外,僱員 獲提供多項培訓以提高其產品及市場知識。

#### 主要風險及不明朗因素

本集團認為,營運涉及若干風險及不明朗因 素,其中有一部分乃本集團無法控制。有關 風險因素的詳細討論載於日期為二零一八年 十一月三十日之招股章程(「招股章程」)「風 險因素」一節。



#### FOREIGN EXCHANGE EXPOSURE

The functional currencies of our operations, assets and liabilities were mostly denominated in RMB. Therefore, we were not exposed to any significant foreign exchange risk for realised losses, except for our HK\$, US\$ and CAD\$ denominated bank balances. The Group currently did not have a foreign currency hedging policy. The Group did not engage in any derivatives agreements and did not commit to any financial instruments to hedge its foreign exchange exposure throughout the year ended 31 December 2020. The management will closely monitor foreign currency exposure and will consider hedging significant foreign currency exposure should the need arises.

#### **TREASURY POLICIES**

The Group will continue to employ a prudent treasury policies in managing the Group's cash balances and maintain a strong and healthy liquidity to ensure that the Group is well placed to take advantage of future growth opportunities.

# MATERIAL ACQUISITIONS AND DISPOSALS OF SUBSIDIARIES AND AFFILIATED COMPANIES

For the year ended 31 December 2020, save as the acquisition of 49% equity interests in Smartronic Limited in relation to the operation of the cross-border e-commerce platforms (details of which were set out in the Company's announcement dated 3 June 2020), the Group did not make any material acquisitions and disposals of subsidiaries and affiliated companies.

#### 外匯風險

我們營運、資產及負債的功能貨幣大部分以 人民幣計值。因此,除我們的港元、美元及 加元計值銀行結餘外,我們並無面臨任何變 現損失的重大外匯風險。本集團現時並無外 匯對沖政策。本集團並無參與任何衍生工具 協議,且並無承諾任何金融工具以對沖其於 截至二零二零年十二月三十一日止年度的外 匯風險。管理層將密切監控外匯風險,並將 於有需要時考慮對沖重大的外幣風險。

#### 庫務政策

本集團將繼續採用審慎的庫務政策管理本集 團的現金結餘,並維持穩健的流動資金,以 確保本集團作好準備把握日後的增長機遇。

#### 重大收購及出售附屬公司及關聯公司

截至二零二零年十二月三十一日止年度,除 就營運跨境電子商務平台收購智能創力有限 公司之49%股份權益外(詳情展示於本公司 日期為二零二零年六月三日之公告),本集 團並無作出任何重大收購及出售附屬公司及 關聯公司。

#### SIGNIFICANT INVESTMENT HELD

As at 31 December 2020, the Group did not hold any significant investment.

#### **PLEDGE OF ASSETS**

As at 31 December 2020, the Group pledged a motor vehicle for lease liabilities with aggregate net carrying amount of approximately RMB434,000 (*31 December 2019: approximately RMB542,000*).

#### **CAPITAL COMMITMENTS**

As at 31 December 2020, the Group had capital commitments of approximately RMB26,000 (*31 December 2019: approximately RMB78,000*) in respect of the acquisition of property, plant and equipment.

#### **CONTINGENT LIABILITIES**

As at 31 December 2020, the Company had no outstanding corporate guarantee (*31 December 2019: Nil*). As at 31 December 2020, the Group had no banking facilities and did not have any significant contingent liabilities (*31 December 2019: Nil*).

#### FUTURE PLANS FOR MATERIAL INVESTMENTS OR CAPITAL ASSETS

Save as disclosed in the section headed "Future Plans and Use of Proceeds" in the Prospectus, the Group does not have other plans for material investments and capital assets as at the date of this Report.

#### 所持重大投資

於二零二零年十二月三十一日,本集團並無 持有任何重大投資。

#### 資產抵押

於二零二零年十二月三十一日,本集團就租 賃負債抵押汽車,總賬面淨值約為人民幣 434,000元(二零一九年十二月三十一日:約 人民幣542,000元)。

#### 資本承擔

於二零二零年十二月三十一日,本集團就購 買物業、廠房及設備擁有資本承擔約人民幣 26,000元(二零一九年十二月三十一日:約 人民幣78,000元)。

#### 或然負債

於二零二零年十二月三十一日,本公司 概無尚未償還公司擔保(二零一九年十二 月三十一日:無)。於二零二零年十二月 三十一日,本集團概無銀行融資及並無任 何重大或然負債(二零一九年十二月三十一 日:無)。

#### 有關重大投資或資本資產的日後計劃

除招股章程「未來計劃及所得款項用途」一節 所披露者外,本集團於本報告日期並無其他 有關重大投資及資本資產的計劃。



# USE OF PROCEEDS FROM SHARE OFFER

The shares of the Company (the "**Shares**") were listed on the GEM of the Stock Exchange on the Listing Date at HK\$0.5 per Share. The net proceeds from the Share Offer (as defined in the Prospectus), after deduction of underwriting fees and commission, and other estimated expenses payable by the Company in connection with the Share Offer, amounted to approximately HK\$16.6 million out of which approximately HK\$11.9 million remained unutilised as of 1 January 2020. During the period from the Listing on 13 December 2018 (the "**Listing Date**") to 31 December 2020, the Group did not change its plans on use of proceeds as stated in the section headed "Future Plans and Use of Proceeds "in the Prospectus.

The utilisation of net proceeds from the Share Offer by the Group is set out below:

#### 股份發售所得款項用途

本公司股份(「**股份**」)於上市日期於聯交所 GEM上市,每股股份為0.5港元。股份發售 (定義見招股章程)所得款項淨額(經扣除包 銷費用及佣金以及本公司就股份發售應付的 其他估計開支)為約16.6百萬港元,其中約 11.9百萬港元於二零二零年一月一日尚未動 用。自於二零一八年十二月十三日上市(「上 市日期」)至二零二零年十二月三十一日期 間,本集團並無改變其於招股章程[未來計 劃及所得款項用途]一節所述所得款項用途 計劃。

本集團對股份發售所得款項淨額的使用情況 載列如下:

As at 31 December

	於十二月三十一日						
				<b>2019</b> 二零一九年		) <b>20</b> 二零年	
Use of Net Proceeds 所得款項淨額用途	Amount of Net allocated upor 上市時分配 所得款項況 (HK\$ million) <sup>(1)</sup> (百萬港元) <sup>(1)</sup> (ノ	n listing 配的 爭額 (RMB'000) <sup>(2</sup>		ーマ パキ Unutilised proceeds 未動用 所得款項 (RMB'000) (人民幣千元)	→ Actual use of proceeds 所得款項 實際用途 (RMB'000) (人民幣千元)	ーマー Unutilised proceeds 未動用 所得款項 (RMB'000) (人民幣千元)	Notes 附註
Developing new products, improving our existing products and carrying out international cooperation projects 開發新產品、改良我們的現有產品及開 展國際合作項目	6.9	6,087	41.5%	4,710	2,919	3,168	(3)
Expanding our sales network and enhancing our marketing activities 擴展我們的銷售網絡及加強我們的市場 推廣活動	4.5	4,011	27.3%	1,451	3,175	836	(3)
Developing auxiliary reproductive supply business 發展輔助生育用品業務	4.5	4,011	27.9%	4,100	-	4,100	(4)
Working capital 營運資金	0.6	481	3.3%	281	481		
Total 總計	16.6	14,679	100%	10,542	6,575	8,104	



Notes:

- The net proceeds from the Share Offer based on the Offer Price of HK\$0.50 per Offer Share.
- (2) Translation based on the exchange rate of RMB1.00 to HK\$1.13.
- (3) The expansion plan of developing new products, improving our existing products and expanding our sales network and enhancing our marketing activities were delayed due to the impact of the Epidemic and the difficulty to hire expected number of suitable personnel of different positions. In view of these, the relevant net proceeds which were originally expected to be utilised by 31 December 2020 is currently expected to be utilised by 31 December 2021.
- (4) The expansion plan of developing the business of the auxiliary reproductive supplies was delayed because the Company continued to analyse the market demand of the culture medium and outlook of the PRC auxiliary reproductive supply market and it is expected to take additional time to observe the potential impact of the Epidemic on auxiliary reproductive supply market. In view of this, the relevant net proceeds which were originally expected to be utilised by 31 December 2020 is currently expected to be utilised by 31 December 2021.

The business objectives, future plans and planned use of proceeds as stated in the Prospectus were based on the best estimation and assumption of future market conditions made by the Group at the time of preparing the Prospectus while the proceeds were applied based on the actual development of the Group's business and the industry.

As at 31 December 2020, all unutilised proceeds of approximately RMB8.1 million were deposited with major banks in the PRC.

附註:

- 基於每股發售股份之發售價0.50港元之股份 發售所得款項淨額。
- (2) 基於人民幣1.00元兑1.13港元之匯率換算。
- (3) 開發新產品、改良我們的現有產品及擴展我 們的銷售網絡及加強我們的市場推廣活動的 擴張計劃因疫情影響及難以聘用預期數量不 同崗位的人員而延遲,原預期二零二零年 十二月三十一日前動用的所得款項淨額現預 期於二零二一年十二月三十一日前動用。
- (4) 開展輔助生育用品業務的擴張計劃因本公司 對培養基的市場需求及中國輔助生育用品供 應市場的前景繼續進行分析,及現預期需額 外時間觀察疫情對輔助生育用品市場的潛在 影響。基於如此,原預期二零二零年十二月 三十一日前動用的所得款項現預期於二零 二一年十二月三十一日前動用。

招股章程所述的業務目標、未來計劃及所得 款項計劃用途乃基於本集團於編製招股章程 時對未來市場狀況所作的最佳估計及假設, 而所得款項則根據本集團業務及行業的實際 發展動用。

於二零二零年十二月三十一日,全部未動用 所得款項約人民幣8.1百萬元存放於中國主 要銀行。



# Comparison of Business Objectives with Actual Business Progress

The proceeds raised from the Listing are intended to be used for further strengthening our market position and expanding our market shares by pursuing our business strategies. An analysis comparing the business objectives as set out in the Prospectus with the Group's actual business progress for the period from the Listing Date up to 31 December 2020 is set out below:

#### 業務目標與實際業務進度比較

上市所得款項旨在透過按照我們的業務策略 進一步增強我們的市場地位及擴大我們的市 場份額。招股章程所載業務目標與本集團自 上市日期直至二零二零年十二月三十一日止 之實際業務進度比較分析載列如下:

Business objectives as set out in the Prospectus 招股章程所載業務目標	Actual business progress for the period from the Listing Date to 31 December 2020 自上市日期至二零二零年十二月三十一日之實際業務進度
Development of new products 開發新產品	(i) The Group has completed the clinical trials of vitro diagnostic reagents for sperm nuclear DNA integrity reagent and is proceeding with the Class II medical device registration; (ii) spermatozoa diagnostic reagent and sperm mitochondrial diagnostic reagent were in the preliminary research phase but we already completed the flow cytometry technology platform; (iii) anti-mullerian hormone with the application of chemiluminescence technology was completed with the required documentation and was undergoing the demonstration stage of the research and development program; and (iv) the Group has manufactured the semen biochemical immunoassay equipment and we are in the position to conduct sale with our improved products after the Class II medical device registration.
	(i)本集團已完成精子核DNA完整性體外診斷試劑的臨床試驗,並計劃進 行第二類醫療器械註冊;(ii)精子診斷試劑及精子線粒體診斷試劑處於初 步研究階段,然而我們已完成流式細胞術技術平台;(iii)應用化學發光 技術的抗苗勒氏管激素已完成所需的文檔工作,並正進行研究及開發計 劃示範階段;及(iv)本集團已完成生產精液生化免疫檢測設備,且準備 於第二類醫療器械註冊後銷售經我們改進的產品。
	As at 31 December 2020, the Group filled up the positions of 2 research and development personnel (1 external recruitment and 1 internal transfer), 2 technicians (both internal transfer) and 2 production workers (1 external recruitment and 1 internal transfer). The Group was unable to hire the expected number of suitable research and development personnel, technicians and production workers whose experience and qualifications meet with the requirements of relevant positions as a result of the limited supply of suitable personnel in the market.
	於二零二零年十二月三十一日,本集團已填補二名研發人員(一名外部 招聘及一名內部調任)、二名技術人員(內部調任)及二名生產人員(一名 外部招聘及一名內部調任)的職位。由於市場上適當人選供應有限,本 集團未能聘請預期數目的具備符合相關職位所要求經驗及資格的合適研 發人員、技術人員及生產人員。



Business objectives as set	Actual business progress for the period from the Listing Date to
out in the Prospectus	31 December 2020
招股章程所載業務目標	自上市日期至二零二零年十二月三十一日之實際業務進度

Improving existing products 改良我們的現有產品 (i) The Group has submitted the Class II medical device registration to Guangdong Food and Drug Administration for the improved products for "seminal plasma fructose quantitative assay kit" and "seminal plasma neutral alpha-glucosidase quantitative assay kit" and they are undergoing the approval process; (ii) Shenzhen Huakang was granted with the International Organisation for Standardisation 13485 ("**ISO 13485**") Certificate on 23 November 2020 for meeting the regulatory requirements of the design, development, production and sales of IVD reagents (Please refer to the voluntary announcement announced on 24 December 2020 for further details); and (iii) The Group has provided training to our staff to familiarise with the ISO 13485 quality management system to improve the Group's capacity on research and development.

> (i)本集團已就改良產品「精漿果糖定量檢測試劑盒」及「精漿中性 a 一葡 萄糖苷酶定量檢測試劑盒」向廣東省食品藥品監督管理局提交第二類醫 療器械註冊,他們正在進行批准程序:(ii)深圳華康於二零二零年十一月 二十三日獲授國際標準化組織13485證書(「ISO 13485」),以證明體外 診斷試劑的設計和開發以及生產和銷售已符合監管要求(請參考二零二 零年十二月二十四日的自願性公告以瞭解更多詳情);及(iii)本集團已向 我們的員工提供培訓,以便他們對ISO 13485質量管理體系更為熟習, 從以提高本集團的研發能力。

> As at 31 December 2020, the Group was unable to hire suitable research and development personnel, technicians and production workers whose experience and qualifications meet the requirements of the relevant positions as a result of the limited supply of suitable personnel in the market. Our Group's existing staff took up the work on a temporary basis.

> 於二零二零年十二月三十一日,由於市場上適當人選供應有限,本集團 未能聘請具備符合相關職位所要求經驗及資格的合適研發人員、技術人 員及生產人員。本集團現有員工可暫時負責有關工作。



Business objectives as set	Actual business progress for the period from the Listing Date to
out in the Prospectus	31 December 2020
招股章程所載業務目標	自上市日期至二零二零年十二月三十一日之實際業務進度

Expanding our sales network and enhancing our marketing activities 擴展我們的銷售網絡及 加強我們的營銷活動 Our staff (i) explored and paid visits to a number of potential and new customers located in the northern part of the PRC; (ii) participated in several annual conferences and academic conferences held throughout the PRC; (iii) recruiting a project manager to liaise with international cooperation and lead the projects.

我們的員工(i)已物色及拜訪中國北部的若干潛在客戶及新客戶;(ii)參與 於全中國各地舉行的幾次年度會議和學術會議;及(iii)招聘項目經理以 與國際合作保持聯絡並領導項目。

As at 31 December 2020, the Group had recruited four sales and marketing personnel and two technicians. The Group was unable to hire the expected number of suitable sales and marketing personnel whose experience and qualifications met the requirements of relevant positions as a result of the limited supply of suitable personnel in the market.

於二零二零年十二月三十一日,本集團已聘請四名銷售及營銷人員及二 名技術人員。由於市場上適當人選供應有限,本集團未能聘請預期數目 的具備符合相關職位所要求經驗及資格的合適銷售及營銷人員。

Developing auxiliary reproductive supply business 發展輔助生育用品業務 The Group is still analysing the market demand of targeted medium and outlook of the PRC auxiliary reproductive supply market.

本集團仍對培養基的市場需求及中國輔助生育用品供應市場的前景進行分析。

#### SHARE OPTION SCHEME

The Company has adopted the Share Option Scheme pursuant to an ordinary resolution passed by the shareholders in the extraordinary general meeting on 13 January 2020 (the "**Share Option Scheme**"). The Share Option Scheme is a long-term incentive scheme of the Company to reward its employees, Directors and other eligible participants for their contributions to the Group and to assist the Group in its recruitment and retention of high calibre employees and other eligible participants who are instrumental to the growth and development of the Group.

On 9 April 2020, the Company announced the granting of an aggregate of 26,008,000 share options, subject to the acceptance by the grantees, at an exercise price of HK\$0.125 per Share of the Company to the eligible persons under the Share Option Scheme. The market price of the Company's shares at the date of grant was HK\$0.125 per Share. All of the share options are exercisable from the date of acceptance by a grantee to 8 April 2030 (both days inclusive). Each of the grantees has paid HK\$1 to the Company on acceptance of the offer of share option. Details are set out in the Company's announcement dated 9 April 2020.

### 購股權計劃

本公司已根據股東於二零二零年一月十三日 的股東特別大會上通過的一項普通決議案採 納購股權計劃(「**購股權計劃**」)。購股權計 劃乃本公司的長期激勵計劃,旨在獎勵其僱 員、董事及其他合資格參與者對本集團作出 貢獻,同時協助本集團招聘及挽留高素質僱 員及其他對本集團成長及發展至關重要的合 資格參與者。

於二零二零年四月九日,本公司公佈根據購 股權計劃向合資格人士授出合共26,008,000 份購股權,惟受限於承受人接納,行使價為 每股本公司股份0.125港元。於授出日期, 本公司股份的市價為每股股份0.125港元。 全部購股權可由承接人接納日至二零三零年 四月八日行使(包括首尾兩日)。各承授人已 於接納購股權要約時向本公司支付1港元。 有關詳情載於本公司日期為二零二零年四月 九日的公告。



The movement during the year and the options outstanding as at 31 December 2020 were as follows:

二零二零年十二月三十一日尚未行使購股權 的年內變動情況如下:

	Number of share options 購股權數目					
			Exercised	Forfeited	At	
	At 1 January	Granted during	during	during the	31 December	
Category of grantees	2020	the year	the year	year	2020	
	於二零二零年			於年內	在二零二零年	
承受人類別	一月一日	於年內授出	於年內行使	被沒收	十二月三十一日	
Executive Directors						
執行董事						
Mr. Zhang Shuguang						
(note)						
張曙光先生 <i>(附註)</i>	-	4,000,000	-	-	4,000,000	
Mr. Zhang Chunguang						
(note)						
張春光先生 <i>(附註)</i>	-	4,000,000	_	-	4,000,000	
Mr. Poon Lai Yin Michael (note)						
潘禮賢先生 <i>(附註)</i>	-	4,000,000	_	_	4,000,000	
Mr. He Jiaming (note)						
何嘉明先生 <i>(附註)</i>	-	4,000,000	_	-	4,000,000	
Other employees (note)						
其他員工(附註)		10,008,000	_	(504,000)	9,504,000	
Total						
總計		26,008,000	-	(504,000)	25,504,000	
			<i>(</i> ())			

Note:

附註:

The closing price of the Shares immediately before the date on which the options were granted during the year ended 31 December 2020 is HK\$0.125. The exercise price is HK\$0.125. The exercise period during which the options may be exercised is the period from the date of acceptance to 8 April 2030 (both days inclusive). The date of grant was 9 April 2020. 於截至二零二零年十二月三十一日止年度內所 授出之購股權的當日前之股份收市價為0.125港 元。行使價為0.125港元。可行使購股權之行使 期由接納購股權當日至二零三零年四月八日(首 尾兩天包括在內)。授出日期為二零二零年四月 九日。

All the existing share options of the Company are vested upon granting. Forfeiture of share options are transferred from share option reserve to accumulated profits or losses within the equity of the Company.

During the year ended 31 December 2020, share options were granted on 9 April 2020. The fair value of the share options determined at the date of grant using the binomial model was approximately RMB2,660,000 and recognised in profit or loss during the year ended 31 December 2020 as equity-settled share-based payment expenses.

The following assumptions were used to calculate the fair values of share options:

Closing share price immediately	HK\$0.123
before date of grant	
Grant date share price	HK\$0.125
Exercise price	HK\$0.125
Expected life	ten years
Expected volatility	103.1%
Dividend yield	nil
Risk-free interest rate	0.778%

The binomial model has been used to estimate the fair value of the share options. The value of the share options is subject to the limitations of the binomial model and a number of assumptions which are subjective and difficult to ascertain. Changes in the subjective input assumptions could materially affect the fair value estimate.

#### SUBSEQUENT EVENTS

Save as disclosed elsewhere in the consolidated financial statements, since 31 December 2020 up to the date of this Report no significant events affecting the Company have taken place.

本公司之所有現有購股權乃於授出時歸屬。沒收 之購股權由購股權儲備轉撥至本公司權益內的累 計損益中。

截至二零二零年十二月三十一日止年度,購股權 乃於二零二零年四月九日授出。於授出日期使用 二項式模式釐定之購股權之公平值約為人民幣 2,660,000元及於截至二零二零年十二月三十一 日止年度之損益中確認為以股權結算之股份基礎 付款開支。

計算購股權之公平值時已使用以下假設:

緊接授出日期之前的收	0.123港元
市股價	
授出日期之股價	0.125港元
行使價	0.125港元
預期年期	十年
預期波幅	103.1%
股息率	無
無風險利率	0.778%

二項式模式乃用於估計購股權之公平值。購股權 之價值受限於二項式模式的限制及多項假設,相 關假設屬主觀因素且難以確定。主觀輸入值假設 如有變動會對公平值估值造成重大影響。

#### 期後事項

除綜合財務報表其他部分所披露者外,自二 零二零年十二月三十一日直至本報告日並無 發生影響本公司的重大事件。

#### **EXECUTIVE DIRECTORS**

**Mr. Zhang Shuguang**, aged 50, is our executive Director and chairman of our Board. He joined our Group in September 2003 and was appointed as our Director on 3 August 2017 and was re-designated as our Executive Director on 25 September 2017. He is mainly responsible for the management of our Board, giving strategic advice and guidance on the business and operations of our Group.

Mr. Zhang Shuguang held a bachelor's degree and master's degree in engineering from Nippon Institute of Technology, Japan and has over 15 years of experience in the IVD reagents industry in the PRC.

Mr. Zhang Shuguang is the brother of Mr. Zhang Chunguang, who is an executive Director and the chief executive officer of our Group. Mr. Zhang Shuguang is also the brother of Mr. Chang Yim Yang, who is our Controlling Shareholder (as defined in the GEM Listing Rules) ("**Controlling Shareholder**") and a member of our senior management.

**Mr. Zhang Chunguang**, aged 53, is our executive Director and chief executive officer of our Group. He joined our Group in July 2008 and was appointed as our Director on 3 August 2017 and re-designated as our executive Director on 25 September 2017. He is mainly responsible for our business operations and the day-today management of our Group.

Mr. Zhang Chunguang graduated from Hubei Institute of Economics, in the PRC, majoring in economic English and has over 10 years of experience in the IVD reagents industry in the PRC.

Mr. Zhang Chunguang is the brother of Mr. Zhang Shuguang, who is an executive Director and the chairman of our Board. Mr. Zhang Chunguang is a Controlling Shareholder and a member of our senior management, who is also the brother of Mr. Chang Yim Yang.

### 執行董事

**張曙光先生**,50歲,為我們的執行董事及董 事會主席。彼於二零零三年九月加入本集團 並於二零一七年八月三日獲委任為我們的董 事並於二零一七年九月二十五日調任為我們 的執行董事。彼主要負責管理董事會、就本 集團之業務及營運提供戰略建議及指導。

張曙光先生持有日本工業大學工程學學士學 位及碩士學位及於中國體外診斷試劑行業擁 有逾15年經驗。

張曙光先生為本集團執行董事及行政總裁張 春光先生之胞弟。張曙光先生亦為控股股東 (定義見GEM上市規則)(「控股股東」)及我們 的高級管理層成員張賢陽先生之胞弟。

**張春光先生**,53歲,為本集團的執行董事及 行政總裁。彼於二零零八年七月加入本集團 並於二零一七年八月三日獲委任為我們的董 事並於二零一七年九月二十五日獲調任為我 們的執行董事。彼主要負責本集團的業務營 運及日常管理。

張春光先生畢業於中國湖北經濟管理大學, 主修經濟英語及於中國體外診斷試劑行業擁 有逾10年經驗。

張春光先生為執行董事及董事會主席張曙光 先生之胞兄。張春光先生亦為控股股東及我 們的高級管理層成員,其亦為張賢陽先生之 胞弟。

**Mr. Poon Lai Yin Michael ("Mr. Poon")**, aged 49, is our executive Director, chief financial officer and compliance officer of our Group. Mr. Poon joined our Group as our Director on 3 August 2017. On 25 September 2017, Mr. Poon was designated as our executive Director and appointed as our compliance officer. Mr. Poon is responsible for the financial management and corporate finance of our Group.

Mr. Poon held a bachelor's degree in administrative studies from York University, Canada and master's degree in practising accounting from Monash University, Australia. Mr. Poon has been a fellow member of Hong Kong Institute of Certified Public Accountants ("**HKICPA**") since July 2009, and a member with CPA Australia since March 2000 respectively. Mr. Poon passed the qualification examination of Asset Management Association of China in 2016. Mr. Poon has over 20 years of experience in financial reporting, business advisory, auditing, taxation, accounting, merger and acquisition.

Mr. Poon is currently an independent non-executive director in a number of Hong Kong listed companies, namely China Uptown Group Company Limited (stock code: 2330.HK) since 29 November 2006, Smartac International Holdings Limited (formerly known as Smartac Group China Holdings Limited, Sino Dragon New Energy Holdings Limited, China Zirconium Limited and Asia Zirconium Limited) (stock code: 0395.HK) since 29 January 2010, Teamway International Group Holdings Limited (formerly known as Jin Bao Bao Holdings Limited) (stock code: 1239.HK) since 19 March 2019, and LFG Investment Holdings Limited (stock code: 3938.HK) since 10 September 2019, the shares of these companies are listed on the main board of the Stock Exchange, and Niche-Tech Group Limited (stock code: 8490.HK) since 28 June 2019, the shares of which are listed on GEM.

**潘禮賢先生(「潘先生」)**,49歲,為本集團的 執行董事、首席財務官兼合規主任。潘先生 於二零一七年八月三日加入本集團擔任我們 的董事。於二零一七年九月二十五日獲指派 為我們的執行董事及獲委任為我們的合規主 任。潘先生負責本集團的財務管理及企業融 資。

潘先生持有加拿大約克大學管理研究學士學 位及澳洲莫納什大學會計學基礎碩士學位。 潘先生自二零零九年七月及二零零零年三 月起分別為香港會計師公會(「**香港會計師公** 會」)資深會員及澳洲會計師公會會員。潘先 生於二零一六年通過中國證券投資基金業協 會從業資格考試。潘先生於財務申報、業務 諮詢、審計、税務、會計、併購方面擁有逾 20年經驗。

潘先生現時為若干香港上市公司之獨立非執 行董事,即自二零零六年十一月二十九日起 於中國上城集團有限公司(股份代號:2330. HK),自二零一零年一月二十九日起於環球 智能控股有限公司(前稱中國智能集團控股 有限公司、中國龍新能源控股有限公司、中 國鋯業有限公司及亞洲鋯業有限公司)(股份 代號:0395.HK),自二零一九年三月十九日 起於Teamway International Group Holdings Limited(前稱金寶寶控股有限公司)(股份代 號:1239.HK)及自二零一九年九月十日起 於LFG投資控股有限公司(股份代號: 3938. HK)任職,該等公司之股份於聯交所主板上 市,以及自二零一九年六月二十八日起於駿 碼科技集團有限公司(股份代號:8490.HK) 任職,其股份於GEM上市。



**Mr. He Jiaming ("Mr. He")**, aged 35, is our executive Director. Mr. He joined our Group as a business development director in January 2019. Mr. He is mainly responsible for evaluating and developing new products in connection with male fertility and exploring overseas business cooperation opportunities.

Mr. He graduated from University of Manchester in the United Kingdom in 2010, with a combined bachelor and master degree in chemistry and has over four years of experience in the fields of biochemistry and international trading.

#### INDEPENDENT NON-EXECUTIVE DIRECTORS

**Dr. Chow Kwok Fai Joseph ("Dr. Chow")**, aged 48, was appointed as our independent non-executive Director on 16 December 2020. Dr. Chow is responsible for supervising our Group's compliance, corporate governance matters and providing independent advice to our Group.

Dr. Chow graduated from the Monash University in October 1997 with a degree in the Bachelor of Science. He obtained a Master of Medical Sciences degree and a Doctor of Philosophy degree in November 2000 and November 2007 respectively in the University of Hong Kong.

Dr. Chow has more than 20 years of experiences in the fields of biomedical testing and molecular diagnostics technology. Since April 2018, Dr. Chow has been the chief executive officer of Zhejiang Thunderbio Innovation Limited\* (浙江達普生物科技有限公司) ("**Thunderbio**") and Dr. Chow has led his team of inventors and experts at Thunderbio in commercializing the application of molecular diagnosis and microfluidic technology, being the technology with growing applications in more efficient biomedical testing.

何嘉明先生(「何先生」),35歲,為本集團的 執行董事。何先生於二零一九年一月加入本 集團擔任業務發展董事。何先生主要負責評 估及開發與男性不育相關的新產品,以及尋 找海外業務合作機會。

何先生於二零一零年畢業於英國曼徹斯特大 學,持有化學學士及碩士學位,在生物化學 及國際貿易領域擁有逾四年的經驗。

#### 獨立非執行董事

**周國輝博士(「周博士」)**,48歲,於二零二零 年十二月十六日獲委任為我們的獨立非執行 董事。周博士負責監察本集團的合規、企業 管治事宜及向本集團提供獨立意見。

周博士於一九九七年十月畢業於莫納什大學 理學學士,並分別於二零零零年十一月及二 零零七年十一月取得香港大學的醫學碩士及 哲學博士學位。

周博士在生物醫學和分子診斷技術領域擁有 20多年的經驗。自二零一八年四月以來, 周博士一直擔任浙江達普生物科技有限公司 (「浙江達普」)首席執行官,並領導浙江達普 的發明家和專家團隊商業化分子診斷和微流 技術的應用,該技術在更有效的生物醫學檢 測中日益得到廣泛的應用。

\* The English name is for identification purpose only

**Dr. Cheng Faat Ting Gary ("Dr. Cheng")**, aged 53, was appointed as our independent non-executive Director on 1 September 2020. Dr. Cheng is responsible for supervising our Group's compliance, corporate governance matters and providing independent advice to our Group.

Dr. Cheng obtained a Bachelor's degree in Accounting (Honours) and Master's degree of Business Administration from Southern Illinois University, the United States of America ("**USA**"), in 1992 and 1994 respectively, and a Doctor of Business Administration degree from the City University of Hong Kong with research area in "Independent Non-Executive Director and Corporate Governance" in 2011. Dr. Cheng has been a certified public accountant in both Hong Kong and USA and a Certified Tax Advisor of the Taxation Institute of Hong Kong. Dr. Cheng has over 25 years of experiences in financial reporting, business advisory, auditing, accounting, tax investigation and liquidation. Dr. Cheng Limited.

Dr. Cheng currently serves as charter president and honorary advisor of the Lions Club of Huaxia Hong Kong and committee member of Social Welfare Advisory Committee of Hong Kong Special Administrative Region.

Dr. Cheng is currently an independent non-executive director in a Hong Kong listed company, namely Smartac International Holdings Limited (formerly known as Smartac Group China Holdings Limited, Sino Dragon New Energy Holdings Limited, China Zirconium Limited and Asia Zirconium Limited), a company whose shares are currently listed on the Main Board of the Stock Exchange (stock code: 395.HK) since 16 November 2001.

鄭發丁博士(「鄭博士」),53歲,於二零二 零年九月一日獲委任為我們的獨立非執行董 事。鄭博士負責監察本集團的合規、企業管 治事宜及向本集團提供獨立意見。

鄭博士分別於一九九二年及一九九四年畢業 於美利堅合眾國(「美國」)南伊利諾州大學會 計學學士(一級榮譽)及工商管理學碩士,於 二零一一年獲頒香港城市大學工商管理博士 學位,研究領域為「獨立非執行董事和企業 管治常規」。鄭博士為香港及美國的資深註 冊會計師,以及香港税務學會的註冊税務顧 問。鄭博士在財務報告、業務顧問、審計、 會計、税務調查及清盤方面擁有超過25年的 經驗。鄭博士目前為加多利會計師事務所有 限公司的董事總經理。

鄭博士現時擔任香港華夏獅子會創會會長及 榮譽顧問及香港特別行政區社會福利諮詢委 員會成員。

鄭博士自二零零一年十一月十六日起擔任 環球智能控股有限公司(前稱為中國智能集 團控股有限公司、中國龍新能源控股有限公 司、中國鋯業有限公司及亞洲鋯業有限公 司),一間於聯交所主板上市之公司(股份代 號:395.HK)之獨立非執行董事。

**Mr. Chan Kin Sang ("Mr. Chan")**, aged 69, was appointed as our independent non-executive Director on 26 November 2018. Mr. Chan is responsible for supervising our Group's compliance, corporate governance matters and providing independent advice to our Group.

Mr. Chan graduated from the University of Hong Kong with a bachelor's degree in laws in November 1979. Mr. Chan was admitted as a notary public in April 1997. Mr. Chan is currently a fellow of the Hong Kong Institute of Directors, a China-appointed attesting officer and a practising solicitor in Hong Kong. Mr. Chan has over 30 years of experience in legal practice in Hong Kong and Mr. Chan is currently the partner of the Peter K.S. Chan & Co.

Mr. Chan is currently an independent non-executive director in a number of Hong Kong listed companies, namely China Fortune Financial Group Limited (stock code: 290.HK) since 9 July 2014, and Pak Tak International Limited (stock code: 2668.HK) since 3 April 2018, the shares of them are listed on the main board of the Stock Exchange. Mr. Chan is currently also a director of Guanghe Landscape Culture Communication Co., Limited (stock code: 600234.SH) since 28 June 2016, a company listed on the Shanghai stock exchange but Mr. Chan resigned from the said post on 16 October 2020. In addition, Mr. Chan is currently also a non-executive director of Sino Harbour Holdings Group Limited (stock code: 1663.HK) since 1 April 2020, a company listed on the Main Board of the Stock Exchange.

**陳健生先生(「陳先生」)**,69歲,於二零一八 年十一月二十六日獲委任為我們的獨立非 執行董事。陳先生主要負責監管本集團之合 規、企業管治事宜及為本集團提供獨立意 見。

陳先生於一九七九年十一月畢業於香港大 學,獲得法學學士學位。陳先生於一九九七 年四月獲認可為公證人。陳先生現為香港董 事學會資深會員、中國委託公證人及香港執 業律師。陳先生於香港法律實務方面擁有逾 30年經驗及現時為陳健生律師行合夥人。

陳先生目前為數家香港上市公司之獨立 非執行董事,即自二零一四年七月九日 起於中國富強金融集團有限公司(股份 代號:290.HK)及自二零一八年四月三 日起於百德國際有限公司(股份代號: 2668.HK)任職,該等公司股份於聯交所主 板上市。陳先生目前亦為山西廣和山水文化 傳播股份有限公司(股份代號:600234.SH) 之董事,自二零一六年六月二十八日起任 職,該公司於上海證券交易所上市,但陳先 生已於二零二零年十月十六日辭任上述董事 一職。此外,陳先生目前亦為漢港控股集團 有限公司(股份代號:1663.HK)之非執行董 事,自二零二零年四月一日起任職,該公司 於聯交所主板上市。

Details of the Directors who resigned during the period from 1 January 2020 to the date of this Report are set out below:

**Dr. Yeung David Wai Chow ("Dr. Yeung")**, aged 74, was appointed as our independent non-executive Director on 26 November 2018 and resigned on 16 December 2020. Dr. Yeung was responsible for supervising our Group's compliance, corporate governance matters and providing independent advice to our Group.

Dr. Yeung obtained a bachelor's degree in medicine and surgery and master's degree in social sciences (behavioural health) from the University of Hong Kong in October 1971 and November 2010, respectively. Dr. Yeung currently holds medical practitioner licences in Hong Kong and California, the United States respectively. Dr. Yeung also obtained a certificate from the American Board of Nuclear Medicine, American Board of Pediatrics and American Board of Integrative Holistic Medicine in the United States in December 1975, September 1976 and December 2016, respectively.

Dr. Yeung has over 40 years of experience in nuclear medicine and management. Dr. Yeung had worked in several hospitals and a university with respect to nuclear medicine. He is currently the honorary professor of the department of diagnostic radiology of the University of Hong Kong.

於二零二零年一月一日至本報告日期止期間 辭任之董事詳情載於下文:

**楊煒秋醫生(「楊醫生」)**,74歲,於二零一八 年十一月二十六日獲委任為我們的獨立非 執行董事,及於二零二零年十二月十六日辭 任。楊醫生曾負責監察本集團的合規、企業 管治事宜及向本集團提供獨立意見。

楊醫生分別於一九七一年十月及二零一零年 十一月取得香港大學內外全科醫學士學位 以及社會科學(行為健康)碩士學位。楊醫 生目前分別持有香港及美國加州的醫療執 業牌照。楊醫生亦於一九七五年十二月、 一九七六年九月及二零一六年十二月於美國 分別獲取美國核醫學委員會、美國兒科委員 會及美國整合整體醫學委員會頒發的專科文 憑。

楊醫生於核醫學及管理擁有逾40年經驗。楊 醫生於數家醫院及一間大學擔任核醫學相關 職位。彼目前為香港大學放射診斷學系名譽 教授。



**Mr. Kwok Chi Shing ("Mr. Kwok")**, aged 59, was appointed as our independent non-executive Director on 26 November 2018 and resigned on 1 September 2020. He was responsible for supervising our Group's compliance, corporate governance matters and providing independent advice to our Group.

Mr. Kwok obtained master's degree in arts in economics with accountancy from The University of Aberdeen, the United Kingdom in July 1986. Mr. Kwok has been a chartered accountant in Scotland, the United Kingdom since November 1989. Mr. Kwok has been a certified public accountant, certified tax advisor and certified financial planner in Hong Kong since January 1991, June 1992 and October 2001 respectively. Mr. Kwok became a member of China Mergers & Acquisitions Association in March 2014. He has more than 20 years of experience in audit assurance, cross border taxation and project finance. He is currently the director of LKKC C.P.A. Limited.

Mr. Kwok has been a director of Pok Oi Hospital, Hong Kong since 2015 and he was appointed as the founding second vice president of the Lions Club of Hong Kong New Territories West Limited in 2015.

Mr. Kwok is currently an independent non-executive director in a number of Hong Kong listed companies, namely (i) DTXS Silk Road Investment Holdings Company Limited (stock code: 620.HK) since 29 May 2020, and Grand Ocean Advanced Resources Co. Ltd (stock code: 65.HK) (formerly known as Angel Technology Co Ltd), the shares of both are listed on the main board of the Stock Exchange; and (ii) Speed Apparel Holding Limited (stock code: 8183.HK) since 23 January 2017, Hang Chi Holdings Limited (stock code: 8405.HK) since 21 June 2017, the shares of both are listed on GEM.

**郭志成先生(「郭先生」)**,59歲,於二零一八 年十一月二十六日獲委任為我們的獨立非執 行董事,及於二零二零年九月一日辭任。彼 曾負責監察本集團的合規、企業管治事宜及 向本集團提供獨立意見。

郭先生於一九八六年七月取得英國蘇格蘭亞 巴甸大學經濟及會計學文學碩士學位。郭先 生於一九八九年十一月起為英國蘇格蘭特許 會計師公會會員。郭先生分別自一九九一年 一月、一九九二年六月及二零零一年十月起 為香港執業會計師、註冊税務顧問及認可財 務策劃師。郭先生於二零一四年三月成為中 國併購公會會員。郭先生於審計核證、跨境 税務及項目融資方面擁有逾20年的經驗。 彼現時擔任國信會計師事務所有限公司之董 事。

郭先生自二零一五年起為香港博愛醫院之董 事,並自二零一五年起獲委任為香港新界西 獅子會有限公司創會第二副會長。

郭先生目前為數家香港上市公司之獨立非執 行董事,即(i)自二零二零年五月二十九日起 於大唐西市絲路投資控股有限公司(股份代 號:620.HK)任職,及於弘海高新資源有限 公司(前稱英君技術有限公司)(股份代號: 65.HK)任職,該兩間公司股份於聯交所主 板上市;和(ii)自二零一七年一月二十三日起 於尚捷集團控股有限公司(股份代號:8183. HK)任職及自二零一七年六月二十一日起於 恒智控股有限公司(股份代號:8405.HK)任 職,該兩間公司股份於GEM上市。

For information regarding changes in composition of the Board for the period from 1 January 2020 to the date of this Report, please refer to page 37 of this Report.

#### SENIOR MANAGEMENT

**Mr. Chang Yim Yang**, aged 58, is vice chairman and a director of Shenzhen Huakang Bio-Medical Engineering Limited\* ("**Shenzhen Huakang**") and a director of King Grace Company Limited ("**King Grace**"). He joined our Group in September 2003 and has been mainly responsible for the general management and business development of Shenzhen Huakang. He has over 16 years of experience in mergers and acquisitions as well as capital market operations.

Mr. Chang Yim Yang is the brother of Mr. Zhang Shuguang, who is our Controlling Shareholder, our executive Director and chairman of our Board. Mr. Chang Yim Yang is also the brother of Mr. Zhang Chunguang, who is an executive Director and the chief executive officer of our Group.

**Mr. Chau Lai Ki**, aged 37, is the financial controller of our Group and our company secretary. He is mainly responsible for the financial management and company secretarial matters of our Group. He joined our Group and was appointed as company secretary of our Company on 25 September 2017. He was further appointed as financial controller of our Group on 7 November 2017.

Mr. Chau Lai Ki held a master's degree in professional accounting from The Hong Kong Polytechnic University. He is a practising member of the HKICPA and has over 14 years of experience in the finance and accounting industry.

有關於二零二零年一月一日至本年報日期止 期間董事會組成變動的資料,請參閱本報告 第37頁。

#### 高級管理層

張賢陽先生,58歲,為深圳華康生物醫學工 程有限公司(「深圳華康」)副主席及董事以及 King Grace Company Limited(「King Grace」) 董事。彼於二零零三年九月加入本集團及主 要負責深圳華康的整體管理及業務發展。彼 於併購及資本市場運作方面擁有逾16年經 驗。

張賢陽先生為控股股東、執行董事兼董事會 主席張曙光先生之胞兄。張賢陽先生亦為本 集團執行董事及行政總裁張春光先生之胞 兄。

周麗麒先生,37歲,為本集團財務總監及公司秘書。彼主要負責本集團的財務管理及公司秘書事宜。彼於二零一七年九月二十五日加入本集團並獲委任為本公司公司秘書。彼於二零一七年十一月七日進一步獲委任為本集團財務總監。

周麗麒先生持有香港理工大學專業會計碩士 學位。彼為香港會計師公會執業會員及於財 務及會計行業擁有逾14年經驗。



**Mr. Fu Jianhua**, aged 55, is the deputy general manager and chief technology officer of Shenzhen Huakang. He joined our Group in January 2014 and is mainly responsible for the technology research and development of our Group.

Mr. Fu Jianhua held a bachelor's degree in science from Wuhan University, the PRC and has over 18 years of experience in the medical devices and IVD reagents industry in the PRC.

#### **COMPLIANCE OFFICER**

**Mr. Poon Lai Yin Michael** was appointed as the compliance officer of our Company on 25 September 2017. For his qualifications and experience, please refer to the paragraph headed "Executive Directors" in this section.

#### **COMPANY SECRETARY**

**Mr. Chau Lai Ki** was appointed as our company secretary on 25 September 2017. He is also the financial controller of our Group. For his qualifications and experience, please refer to the paragraph headed "Senior Management" in this section. **傅劍華先生**,55歲,為深圳華康的副總經理 及首席技術官。彼於二零一四年一月加入本 集團及主要負責本集團的技術研發。

傅劍華先生持有中國武漢大學理學士學位及 於中國醫療器械及體外診斷試劑行業擁有逾 18年經驗。

#### 合規主任

潘禮賢先生於二零一七年九月二十五日獲委 任為本公司的合規主任。有關彼之資歷及經 驗,請參閱本節「執行董事」一段。

#### 公司秘書

**周麗麒先生**於二零一七年九月二十五日獲委 任為我們的公司秘書,彼亦為本集團之財務 總監。有關彼之資歷及經驗,請參閱本節 「高級管理層」一段。 **CORPORATE GOVERNANCE REPORT** 企業管治報告

Pursuant to Rule 18.44 of the GEM Listing Rules, the Board is pleased to present this corporate governance report for the year ended 31 December 2020. This Report highlights the key corporate governance practices of the Company. 根據GEM上市規則第18.44條,董事會欣然 提呈截至二零二零年十二月三十一日止年度 的企業管治報告。本報告概述本公司的主要 企業管治常規。

#### **CORPORATE GOVERNANCE PRACTICES**

The Board is committed to achieving high corporate governance standards.

The Board believes that good corporate governance standards are essential in providing a framework for the Company to safeguard the interests of shareholders, enhance corporate value, formulate its business strategies and policies, and enhance its transparency and accountability.

The Company has applied the principles and code provisions as set out in the Corporate Governance Code (the "**CG Code**") contained in Appendix 15 of the GEM Listing Rules.

The Company has adopted and complied with, where applicable, the CG Code during the year ended 31 December 2020 and up to the date of this Report (the "**Relevant Period**").

The board will continue to monitor and review the Company's corporate governance practices to ensure compliance with the CG Code.

The Board conducted reviews of the system of internal controls of the Group to ensure an effective and adequate internal control system is in place. The Board also convened meetings to discuss financial, operational and risk management control.

#### 企業管治常規

董事會致力於持守較高的企業管治標準。

董事會相信,良好的企業管治標準對為本公 司提供框架以保障股東利益、提升企業價 值、制定業務策略及政策,以及提高透明度 及問責性是必不可少的。

本公司已應用GEM上市規則附錄十五所載企 業管治守則(「**企業管治守則**」)載列的原則及 守則條文。

本公司自截至二零二零年十二月三十一日止 年度至本報告日期止期間(「**有關期間**」)已採 納及遵守(如適用)企業管治守則。

董事會將持續監察及檢討本公司的企業管治 常規,以確保遵守企業管治守則。

董事會已檢討本集團的內部監控系統,以確 保建立有效及充分的內部監控系統。董事會 亦召開會議討論財務、營運及風險管理監 控。



企業管治報告

#### MODEL CODE FOR SECURITIES TRANSACTIONS

The Company has adopted a code of conduct regarding securities transactions by the Directors on terms no less exacting than the required standard of dealings concerning securities transactions by the Directors as set out in Rules 5.48 to 5.67 of the GEM Listing Rules (the "**Model Code**") as its own code governing securities transactions of the Directors (the "**Required Standard**"). Having made specific enquiry of all the Directors, all of them confirmed that they had fully complied with the Required Standard during the Relevant Period.

Pursuant to Rule 5.66 of the Model Code, the Directors have also requested any employee of the Company or director or employee of a subsidiary of the Company (the "**relevant employees**") who, because of his office or employment in the Company or a subsidiary, is likely to possess inside information in relation to the securities of the Company, not to deal in securities of the Company when he would be prohibited from dealing by the Model Code as if he were a Director. No incident of noncompliance of the Required Standard by the relevant employees was noted by the Company.

### NON-COMPETITION UNDERTAKING

In order to maintain a clear delineation of the businesses between our Group and our Controlling Shareholders, the latter have entered into a deed of non-competition in favour of our Company (for ourselves and as trustee for each of our subsidiaries from time to time) on 27 November 2018 (the "**Deed of Non-Competition**") to the effect that each of them will not, and will procure each of their respective close associates (as defined in the GEM Listing Rules) not to, directly or indirectly participate in, or hold any right or interest, or otherwise be involved in any business which may be in competition with our businesses.

For details of the Deed of Non-Competition, please refer to the section headed "Relationship with our Controlling Shareholders – Non-competition Undertakings from Our Controlling Shareholders" in the Prospectus.

#### 進行證券交易的標準守則

本公司已採納一套有關董事進行證券交易的 操守守則作為其本身監管董事證券交易的守 則(「**必守標準**」),其條款嚴格程度並不遜於 GEM上市規則第5.48至5.67條所載有關董事 進行證券交易的必守標準(「標準守則」)。經 向全體董事作出特定查詢後,全體董事均已 確認彼等於有關期間內已遵守必守標準。

根據標準守則第5.66條,董事亦已要求本公 司的任何僱員、或本公司附屬公司的任何董 事或僱員(「有關僱員」),不利用彼等因在本 公司或附屬公司的職務或工作而可能管有與 本公司證券有關的內幕消息,在標準守則禁 止董事買賣證券之期間買賣本公司的證券。 本公司並無獲悉有關僱員違反必守標準的事 件。

#### 不競爭承諾

為保證本集團與控股股東之間的業務劃分明 確,控股股東已於二零一八年十一月二十七 日訂立以本公司(為本身及作為我們不時的 各附屬公司的受託人)為受益人的不競爭契 據(「**不競爭契據**」),據此,彼等各自將不 會並將促使彼等各自的緊密聯繫人(定義見 GEM上市規則)不會直接或間接參與任何可 能與我們的業務構成競爭的業務或於其中持 有任何權利或權益,或以其他方式從事任何 有關業務。

有關不競爭契據的詳情,請參閱招股章程 「與控股股東的關係-控股股東之不競爭承 諾」一節。

The Company has received a written confirmation from the Controlling Shareholders that they have complied with the terms of the Deed of Non-Competition in the year ended 31 December 2020. The independent nonexecutive Directors have also reviewed the status of compliance and written confirmation from the controlling shareholders, and noted that all the undertakings under the Deed of Non-Competition have been complied with by each of the Controlling Shareholders for the year ended 31 December 2020.

#### **BOARD OF DIRECTORS**

The overall management of the Group's business is vested in the Board which assumes the responsibility of leadership and control of the Group and is collectively responsible for promoting the success of the Group by directing and supervising its affairs. All Directors make decisions objectively in the interests of the Group.

The Board formulates strategies and sets directions for the Group's activities to develop its business and enhance shareholders' value. The Board also assumes the responsibilities for maintaining high standard of corporate governance, including among others, reviewing the Company's policies and practices on corporate governance, and reviewing and monitoring the Company's policies and practices in compliance with legal and regulatory requirements.

The Board has established board committees with specific written terms of reference which deal clearly with the committees' authority and duties. Details of the respective committee's terms of reference are available at the websites of the Company and the Stock Exchange.

The day-to-day management, administration and operation of the Group are delegated to the executive Directors and the senior management. The delegated functions and work tasks are periodically reviewed. Approval has to be obtained from the Board for significant transactions. 本公司已收到控股股東的書面確認,表示彼 等於截至二零二零年十二月三十一日止年度 已遵守不競爭契據的條款。獨立非執行董事 亦已檢討控股股東的遵守情況及書面確認, 並認為各控股股東於截至二零二零年十二月 三十一日止年度已遵守不競爭契據項下的所 有承諾。

#### 董事會

董事會負責本集團業務的整體管理,負有領 導及監控本集團的責任,並集體負責統管並 監督本集團事務以促使本集團成功。全體董 事應客觀地作出符合本集團利益的決策。

董事會為本集團的活動制定策略及訂立方 向,以發展本集團業務及提升股東價值。董 事會亦負有維持高標準的企業管治的責任, 包括(其中包括)審閱本公司的企業管治政策 及常規,及審閱和監管本公司於遵守法律及 監管規定方面的政策及常規。

董事會已設立董事會委員會,並訂明具體的 書面職權範圍,清楚説明委員會的職權和責 任。各委員會的職權範圍詳情可於本公司及 聯交所網站查閱。

本集團的日常管理、行政及營運工作已轉授 予執行董事及高級管理層負責。所轉授職能 及工作任務會定期進行檢討。彼等進行任何 重大交易前須獲得董事會的批准。



企業管治報告

#### **Board Composition**

During the Relevant Period, the Board comprises seven Directors of which four are executive Directors and three are independent non-executive Directors. The composition of the Board during the Relevant Period is as follows:

#### **Executive Directors**

Mr. Zhang Shuguang (Chairman)
Mr. Zhang Chunguang (Chief Executive Officer)
Mr. Poon Lai Yin Michael (Chief Financial Officer)
Mr. He Jiaming (Business Development Director) (appointed on 14 January 2020)

#### Independent Non-executive Directors

Dr. Chow Kwok Fai Joseph (appointed on 16 December 2020) Dr. Cheng Faat Ting Gary (appointed on 1 September 2020) Dr. Yeung David Wai Chow (resigned on 16 December 2020) Mr. Kwok Chi Shing (resigned on 1 September 2020) Mr. Chan Kin Sang

The biographical information of the Directors and relationships between the members of the Board are set out in the section headed "Biographies of Directors and Senior Management" on pages 25 to 33 of this Report. Mr. Zhang Shuguang, Mr. Zhang Chunguang and Mr. Chang Yim Yang (one of our senior management) are brother, and Mr. Zhang Shuguang and Mr. Chang Yim Yang are our Controlling Shareholders.

#### 董事會的組成

於有關期間,董事會由七名董事組成,其中 四名為執行董事及三名為獨立非執行董事。 於有關期間,董事會的組成如下:

#### 執行董事

張曙光先生(*主席)* 張春光先生(行政總裁) 潘禮賢先生(首席財務官) 何嘉明先生(業務發展董事) (於二零二零年一月十四日獲委任)

#### 獨立非執行董事

周國輝博士 (於二零二零年十二月十六日委任) 鄭發丁博士 (於二零二零年九月一日委任) 楊煒秋醫生 (於二零二零年十二月十六日辭任) 郭志成先生 (於二零二零年九月一日辭任) 陳健生先生

董事的履歷資料及董事會成員之間的關係載 於本報告第25至33頁「董事及高級管理層之 履歷」一節。張曙光先生、張春光先生及張 賢陽先生(高級管理層之一)為兄弟,而張曙 光先生及張賢陽先生為控股股東。

#### **BOARD AND COMMITTEE MEETINGS**

Regular Board meetings should be held at least four times a year involving active participation, either in person or through electronic means of communication, of a majority of Directors. At least 14 days' notice is given for a regular Board meeting. For all other Board meetings, notice will be given in a reasonable time in advance. The Directors are allowed to include any matter in the agenda that is required for discussion and resolution at the meeting. To enable the Directors to be properly briefed on issues arising at each of the Board meetings and to make informed decisions, an agenda and the accompanying Board papers will be sent to all Directors at least three days before the intended date of the Board meeting, or such other period as agreed. The company secretary is responsible for keeping all Board meetings' minutes. Draft and final versions of the minutes will be circulated to the Directors for comments and record respectively within a reasonable time after each meeting and the final version is open for the Directors' inspection.

#### 董事會及委員會會議

董事會定期會議應每年召開至少四次,每次 會議皆有大部分董事親身出席,或透過電子 通訊方法積極參與。定期會議通知於最少 十四天前發出。有關所有其他董事會會議, 將事先於合理時間發出通知。董事僅准將 何其他須於會上討論及議決的事宜納入議 程。為確保董事均適當知悉每次前人議 是出現的問題並做出明智的決定,將在擬召 開產會會議的日期至少三天之前(或約 開展)向所有董事發送議程和隨事會 之後的合理時間內向董事傳閱以供其發表 意見及記錄,定稿可供董事查閱。



企業管治報告

The attendance records of each Director at Board and Committee meetings, at the annual general meeting ("**AGM**") and extraordinary general meeting ("**EGM**") during the year ended 31 December 2020 are as follows: 截至二零二零年十二月三十一日止年度,各 董事在董事會及委員會會議、股東周年大會 (「**股東週年大會**」)及股東特別大會(「**股東特 別大會**」)的出席記錄如下:

		Number of meetings attended/eligible to attend 出席/可參加的會議次數					
				Remuneration	Nomination		
Name of Directors	董事姓名	Board 董事會	Committee 審核委員會	Committee 薪酬委員會	Committee 提名委員會	AGM 股東週年大會	EGM 股東特別大會
Executive Directors:	執行董事:						
Mr. Zhang Shuguang	張曙光先生	14/14	N/A	N/A	3/3	1/1	1/1
Mr. Zhang Chunguang	張春光先生	14/14	N/A	3/3	N/A	1/1	1/1
Mr. Poon Lai Yin Michael	潘禮賢先生	14/14	N/A	N/A	N/A	1/1	1/1
Mr. He Jiaming (appointed with	何嘉明先生(於二零二零年		1071				
effect from 14 January 2020)	一月十四日獲委任)	13/13	N/A	N/A	N/A	1/1	0/0
Independent non-executive Directors:	獨立非執行董事:						
Dr. Chow Kwok Fai Joseph (appointed with effect from 16	周國輝博士(於二零二零年 十二月十六日委任)						
December 2020)		0/0	1/1	0/0	0/0	0/0	0/0
Dr. Cheng Faat Ting Gary (appointed with effect from	鄭發丁博士(於二零二零年 九月一日委任)						
1 September 2020)		2/2	2/2	0/0	N/A	0/0	0/0
Dr. Yeung David Wai Chow (resigned with effect from	楊煒秋醫生(於二零二零年 十二月十六日辭任)						
16 December 2020)		14/14	6/6	3/3	3/3	1/1	1/1
Mr. Kwok Chi Shing (resigned with effect from	郭志成先生(於二零二零年 九月一日辭任)						
1 September 2020)		12/12	5/5	2/2	N/A	1/1	0/1
Mr. Chan Kin Sang	陳健生先生	14/14	7/7	N/A	3/3	1/1	1/1
Total meeting(s) held during the year ended 31 December 2020	截至二零二零年十二月三十一日 止年度內舉行的會議總數	14	7	3	3	1	1

#### CHAIRMAN AND CHIEF EXECUTIVE OFFICER

Code provision A.2.1 of the CG Code provides that the roles of chairman and chief executive officer should be separate and should not be performed by the same individual.

The positions of chairman and chief executive officer are held by Mr. Zhang Shuguang and Mr. Zhang Chunguang respectively. The roles of the chairman and the chief executive officer have been separated and assumed by different individuals to ensure a balance of power and authority so that power is not concentrated in any member of the Board. The chairman provides leadership and is responsible for the effective functioning and leadership of the Board. The chief executive officer focuses on the Company's business development and daily management and operations generally.

#### INDEPENDENT NON-EXECUTIVE DIRECTORS

During the Relevant Period, the Board at all times met the requirements of the GEM Listing Rules relating to the appointment of at least three independent non-executive directors, accounting for at least one-third of the Board, with at least one independent non-executive director possessing the appropriate professional qualifications or accounting or related financial management expertise.

Prior to their respective appointment, each of the independent non-executive Directors has submitted a written statement to the Stock Exchange confirming their independence. The Company has received from each of the independent non-executive Directors an annual confirmation of his independence pursuant to Rule 5.09 of the GEM Listing Rules and the Board considers that all the independent non-executive Directors to be independent and meet the requirements as set out in Rule 5.09 of the GEM Listing Rules. The Company considers all independent non-executive Directors are independent.

#### 主席及行政總裁

企業管治守則守則條文A.2.1條規定,主席 與行政總裁的角色應有區分,並不應由一人 同時兼任。

主席與行政總裁兩個職位分別由張曙光先生 及張春光先生擔任。主席與行政總裁的角色 已區分並由不同人士擔任,以確保權力和授 權分佈均衡,不致權力僅集中於董事會的任 何成員。主席負責領導,並負責董事會的有 效運作和領導。行政總裁主要負責本公司的 整體業務發展及日常管理和營運。

#### 獨立非執行董事

於有關期間,董事會始終符合GEM上市規則 有關委任最少三名獨立非執行董事及必須佔 董事會成員人數至少三分之一,且必須至少 有一名具備適當的專業資格,或具備適當的 會計或相關的財務管理專長的獨立非執行董 事的規定。

在獨立非執行董事各自獲委任前,彼等分別 已向聯交所呈交書面聲明確認其獨立性。本 公司已收到各獨立非執行董事根據GEM上市 規則第5.09條就其獨立性發出的年度確認, 且董事會認為所有獨立非執行董事確屬獨立 人士並符合GEM上市規則第5.09條所載規 定。本公司認為所有獨立非執行董事確屬獨 立人士。



## APPOINTMENT AND RE-ELECTION OF DIRECTORS

Each of Mr. Zhang Shuguang, Mr. Zhang Chunguang and Mr. Poon Lai Yin Michael, who were appointed on 25 September 2017, has entered into a service contract with the Company commencing from the Listing Date, which has no fixed term and can be terminated by either party giving not less than three months' notice in writing to the other party. Mr. He Jiaming, who was appointed on 14 January 2020, has entered into a service contract with the Company for an initial fixed term of three years commencing from the date of appointment and can be terminated by either party giving not less than three months' notice. Each of the independent nonexecutive Directors has entered into an appointment letter with our Company for an initial term of three years commencing from their respective appointment dates unless terminated by either party giving not less than one month's written notice to the other party. Each of the appointments is subject to termination provisions therein and provisions on retirement by rotation of Directors as set out in the Articles of Association.

Save as disclosed aforesaid, none of the Directors has entered into any service agreement or letter of appointment with the Company or any of its subsidiaries which is not determinable by the Company within one year without the payment of compensation (other than statutory compensation).

#### 董事的委任及重選

除上文所披露外,概無董事與本公司或其任 何附屬公司訂立任何服務協議或委任書,而 該服務協議或委任書是本公司不可於一年內 不支付補償而終止的(法定補償除外)。

All the Directors, including the independent nonexecutive Directors, are subject to retirement by rotation and eligible for re-election in accordance with the Articles of Association. At each AGM, one-third of the Directors for the time being, or, if their number is not a multiple of three, then the number nearest to but not less than onethird, shall retire from office by rotation, provided that every Director shall be subject to retirement by rotation at an AGM at least once every three years. A retiring Director shall be eligible for re-election and shall continue to act as a Director throughout the AGM at which he retires. The Directors to retire by rotation shall include (so far as necessary to ascertain the number of Directors to retire by rotation) any Director who wishes to retire and does not offer himself for re-election. Any further Directors so to retire shall be those of other Directors subject to retirement by rotation who have been the longest in office since their last re-election or appointment and so that as between the persons who became or were last re-elected Directors on the same day, those to retire shall (unless they otherwise agree among themselves) be determined by lot. A Director is not required to retire upon reaching any particular age.

The Company may from time to time in general meeting by ordinary resolution elect any person to be a Director either to fill a casual vacancy or as an additional Director. Any Director so appointed shall be subject to retirement by rotation.

The Board shall have the power from time to time and at any time to appoint any person as a Director either to fill a casual vacancy or as an additional Director. Any Director appointed by the Board to fill a casual vacancy shall hold office until the first general meeting of the Company after his appointment and be subject to reelection at such meeting. Any Director appointed by the Board as an addition to the existing Board shall hold office only until the next following AGM and shall then be eligible for reelection. Any such Director appointed shall not be taken into account in determining which particular Directors or the number of Directors who are to retire by rotation at an AGM. 所有董事(包括獨立非執行董事)均須根據組 織章程細則輪流退任並有資格重選連任。在 每屆股東週年大會上,當時三分之一的董事 (或倘董事人數並非三的倍數,則為最接近 但不少於三分之一的人數)應輪流退任,惟 每名董事須至少每三年在股東週年大會上退 任一次。退任董事有資格重選連任,並在其 退任的股東週年大會期間繼續擔任董事。輪 流退任的董事須包括(就有必要確定輪流退 任的董事人數而言)任何有意退任的董事及 不願重選連任的董事。任何其他須退任的董 事應為自上一次重選或獲委任以來在任時間 最長的其他須輪流退任的董事,惟倘同日有 多名董事獲委任或獲重選,則除非彼等之間 另行達成協定,否則以抽籤決定將退任董事 人選。並無規定董事屆任何特定年齡後須退 仟。

本公司可不時於股東大會上藉普通決議案選 舉任何人士為董事,以填補臨時空缺或增加 董事名額。任何如此獲委任的董事須輪流退 任。

董事會有權不時及隨時委任任何人士為董 事。以填補臨時空缺或增加董事名額。由董 事會委任以填補臨時空缺的任何董事,任職 至其獲委任後本公司的首次股東大會為止, 並可於該大會上接受重選連任。由董事會委 任以增加現有董事會名額的任何董事,只任 職至下屆股東週年大會為止,並於其時有資 格重選連任。在決定須於股東週年大會上輪 流退任的具體董事或董事人數時,任何如此 獲委任的董事不應計算在內。



**RESPONSIBILITIES OF THE DIRECTORS** 

The Board should assume responsibility for leadership and control of the Company; and is collectively responsible for directing and supervising the Company's affairs.

The Board directly, and indirectly through its committees, leads and provides direction to management by laying down strategies and overseeing their implementation, monitors the Group's operational and financial performance, and ensures that sound internal control and risk management systems are in place.

All Directors, including independent non-executive Directors, have brought a wide spectrum of valuable business experience, knowledge and professionalism to the Board for its efficient and effective functioning.

The independent non-executive Directors are responsible for ensuring a high standard of regulatory reporting of the Company and providing a balance in the Board for bringing effective independent judgement on corporate actions and operations.

All Directors have full and timely access to all the information of the Company and may, upon request, seek independent professional advice in appropriate circumstances, at the Company's expenses for discharging their duties to the Company.

The Directors shall disclose to the Company details of other offices held by them.

The Board reserves for its decision on all major matters relating to policy matters, strategies and budgets, internal control and risk management, material transactions (in particular those that may involve conflict of interests), financial information, appointment of Directors and other significant operational matters of the Company. Responsibilities relating to implementing decisions of the Board, directing and co-ordinating the daily operation and management of the Company are delegated to the management.

#### 董事會的職責

董事會負有領導及監控本公司的責任,並應 集體負責統管並監督本公司的事務。

董事會直接及透過其轄下各委員會間接領導 及指示管理層,制定策略並監督其實施、監 督本集團的營運和財務表現,並確保建立健 全的內部監控及風險管理系統。

所有董事(包括獨立非執行董事)具備廣泛而 寶貴的業務經驗、知識及專業精神,有助董 事會有效及高效地履行其職能。

獨立非執行董事負責確保本公司監管報告維 持高水平,並對董事會發揮平衡作用,在企 業行動及營運方面作出有效的獨立判斷。

全體董事均可全面並及時獲得本公司所有資料,並可應要求在適當情況下尋求獨立專業 意見以向本公司履行其職責,有關費用由本 公司承擔。

董事須向本公司披露彼等所任其他職位的詳 情。

董事會保留對所有有關本公司政策事宜、戰 略及預算、內部監控及風險管理、重大交易 (特別是可能涉及利益衝突的交易)、財務資 料、董事委任及其他重要營運事宜的重要事 項的決策權。有關執行董事會決策、指導及 協調本公司日常運作及管理的職責則轉授予 管理層。

#### **INDEMNITY OF THE DIRECTORS**

The Company has arranged appropriate insurance coverage on Directors' and officers' liabilities in respect of any legal actions taken against Directors and senior management arising out of corporate activities. The insurance coverage would be reviewed on an annual basis.

#### 董事的彌償保證

本公司已就董事及高級管理層因公司活動而 可能面臨的任何法律行動安排投購適當的董 事及高級人員責任保險。保險範圍將會每年 進行檢討。

#### CONTINUOUS PROFESSIONAL DEVELOPMENT OF DIRECTORS

Directors shall keep abreast of regulatory developments and changes in order to effectively perform their responsibilities and to ensure that their contribution to the Board remains informed and relevant.

Every newly appointed Director has received induction on the first occasion of his/her appointment to ensure appropriate understanding of the business and operations of the Company and full awareness of Director's responsibilities and obligations under the GEM Listing Rules and relevant statutory requirements.

Directors should participate in appropriate continuous professional development to develop and refresh their knowledge and skills. All Directors are encouraged to attend relevant training courses at the Company's expenses.

All the Directors were kept informed on a timely basis of major changes that may have affected the Group's business, including relevant rules and regulations. During the year, all Directors have participated in continuous professional development to develop and refresh their knowledge and skills in accordance with code provision A.6.5 contained in the CG Code.

#### 董事持續專業發展

董事應不斷了解監管發展及變動,以便有效 履行其職責,並確保對董事會作出適切貢 獻。

每名新獲委任的董事於首次獲委任時均會獲 得入職介紹,以確保其對本公司的業務及運 作有適當了解,並完全知悉其在GEM上市規 則及相關法定規定下的職責及責任。

董事應參與適當的持續專業發展,以發展及 更新彼等的知識及技能。本公司鼓勵所有董 事出席相關培訓課程,費用由本公司承擔。

所有董事均保持適時通報可能影響本集團業務的重大變化,包括相關規則及法規。年內,所有董事均已根據企業管治守則所載守則條文第A.6.5條參加持續專業發展以發展及更新其知識及技能。



The Company organised training sessions for all Directors. Such training sessions covered a wide range of relevant topics including Directors' duties and responsibilities, corporate governance and updates on GEM Listing Rules, etc. In addition, relevant reading materials including memorandum on the duties and responsibilities of the Directors have been provided to the Directors for their reference and studying.

The record of continuous professional development relating to Director's duties and regulatory and business development that have been received by the Directors for the Relevant Period are summarised as follows:

other relevant ordinances

本公司為所有董事舉辦的培訓課程。該次培 訓課程涵蓋多個相關範疇,包括董事職務和 職責、企業管治及GEM上市規則的最新資訊 等。此外,董事已獲提供相關閱讀材料,包 括董事職務及職責備忘錄,以供彼等參考及 研讀。

董事於有關期間所收到有關董事職責及監管 與業務發展的持續專業發展記錄概述如下:

		Nature of Continuous Professional Development Programmes (Notes)
Name of Directors	董事姓名	持續專業發展課程性質(附註)
Executive Directors:	執行董事:	
Mr. Zhang Shuguang	張曙光先生	A & B
Mr. Zhang Chunguang	張春光先生	A & B
Mr. Poon Lai Yin Michael	潘禮賢先生	A & B
Mr. He Jiaming	何嘉明先生	A & B
Independent non-executive Directors:	獨立非執行董事	
Dr. Chow Kwok Fai Joseph	周國輝博士	A & B
Dr. Cheng Faat Ting Gary	鄭發丁博士	A & B
Dr. Yeung David Wai Chow	楊煒秋醫生	A & B
Mr. Kwok Chi Shing	郭志成先生	A & B
Mr. Chan Kin Sang	陳健生先生	A & B
Notes:		附註:
A: Attending seminars and/or meetings ar briefings	nd/or forums and/or	A: 參加研討會及/或會議及/或論壇及/或簡 報會
B: Reading materials relevant to corpo	orate governance,	B: 閱讀與公司治理、董事職責和責任、GEM上

director's duties and responsibilities, GEM Listing Rules and 市規則及其他相關條例的有關材料

#### **BOARD COMMITTEES**

The Board has established three committees on 26 November 2018, namely, the Audit Committee, Remuneration Committee and Nomination Committee, for overseeing particular aspects of the Company's affairs. All Board committees of the Company are established with specific written terms of reference which deal clearly with their authority and duties. The terms of reference of the Audit Committee, Remuneration Committee and Nomination Committee are posted on the Company's website and the Stock Exchange's website and are available to shareholders upon request.

The list of the chairman and members of each Board committee is set out under "Corporate Information" on page 3.

#### Audit Committee

The Audit Committee consists of three independent nonexecutive Directors, namely Dr. Cheng Faat Ting Gary (Chairman), Dr. Chow Kwok Fai Joseph and Mr. Chan Kin Sang.

The terms of reference of the Audit Committee are in compliance with Rules 5.28 to 5.33 of the GEM Listing Rules and paragraph C.3 of the CG Code and Corporate Governance Report as set out in Appendix 15 to the GEM Listing Rules. The main duties of the Audit Committee are to assist the Board in reviewing the financial information and reporting process, risk management and internal control systems, effectiveness of the internal audit function, scope of audit and appointment of external auditors, and arrangements to enable employees of the Company to raise concerns about possible improprieties in financial reporting, internal control or other matters of the Company. The Audit Committee shall hold at least two meetings a year.

#### 董事委員會

董事會已於二零一八年十一月二十六日成立 三個委員會,即審核委員會、薪酬委員會及 提名委員會,以監察本公司特定方面的事 務。本公司的所有董事委員會均已制訂明確 的書面職權範圍,當中訂明其權責。審核委 員會、薪酬委員會及提名委員會的職權範圍 分別刊載於本公司網站及聯交所網站,並可 應要求向股東提供。

各董事委員會的主席及成員名單載於第3頁 「公司資料」內。

#### 審核委員會

審核委員會由三名獨立非執行董事組成,即 鄭發丁博士(主席)、周國輝博士及陳健生先 生。

審核委員會的權責範圍符合GEM上市規則 第5.28至第5.33條及GEM上市規則附錄十五 所載的企業管治守則及企業管治報告第C.3 段。審核委員會的主要職責包括協助董事會 審閲財務資料和申報程序、風險管理和內部 監控系統、內部審核職能的有效性、審核範 圍和委任外聘核數師,以及讓本公司僱員可 對有關本公司財務申報、內部監控或其他事 宜的潛在不當行為提出關注的安排。審核委 員會須每年舉行至少兩次會議。



企業管治報告

For the year ended 31 December 2020, 7 meetings have been held for the Audit Committee to review, the quarterly, interim, and annual financial results and reports and significant issues on the financial reporting, operational and compliance controls, the effectiveness of the risk management and internal control systems and continuing connected transactions.

The attendance of each member of the Audit Committee is set out in the section headed "Board and Committee Meetings" of this Report.

#### **Remuneration Committee**

The Remuneration Committee consists of three members, namely Dr. Cheng Faat Ting Gary (Chairman) and Dr. Chow Kwok Fai Joseph, both are independent nonexecutive Directors, and Mr. Zhang Chunguang, an executive Director.

The terms of reference of the Remuneration Committee are in compliance with Rules 5.34 to 5.36 of the GEM Listing Rules and paragraph B.1 of the CG Code and Corporate Governance Report as set out in Appendix 15 to the GEM Listing Rules. The primary functions of the Remuneration Committee include (i) reviewing and making recommendations on the remuneration packages of individual executive Directors and senior management, the remuneration policy and structure for all Directors and senior management; (ii) establishing formal and transparent procedures for developing such remuneration policy and structure to ensure that no Director or any of his/her associates will participate in deciding his/her own remuneration; (iii) reviewing and approving the management's remuneration proposals with reference to the Board's corporate goals and objectives; (iv) assessing performance of executive Directors; and (v) approving the terms of executive Directors' service contracts. The Remuneration Committee shall meet not less than once every year.

截至二零二零年十二月三十一日止年度,審 核委員會已召開七次會議審閱季度、中期及 年度財務業績及報告,以及有關財務報告、 營運及合規監控、風險管理及內部控制系統 以及持續關連交易有效性的重大事宜。

各審核委員會成員的出席記錄載於本報告 「董事會及委員會會議」一節。

#### 薪酬委員會

薪酬委員會包括三名成員,即兩名獨立非執 行董事鄭發丁博士(主席)及周國輝博士以及 一名執行董事張春光先生。

薪酬委員會的書面權責範圍符合GEM上市規 則第5.34至5.36條及GEM上市規則附錄十五 所載的企業管治守則及企業管治報告第B.1 段。薪酬委員會的主要職責包括(i)檢討個別 執行董事及高級管理層的薪酬待遇並提出建 議,所有董事和高級管理層的薪酬政策和結 構;(ii)建立正式和透明的程序來製定這些新 酬政策和結構,以確保概無董事或其任何聯 繫人士參與決定其本身的薪酬;(iii)因應董專 會所訂企業方針及目標而檢討及批准管理層 的薪酬建議;(iv)評估執行董事的表現;及(v) 批准執行董事服務合約任期。薪酬委員會須 每年舉行至少一次會議。

For the year ended 31 December 2020, the Remuneration Committee met 3 times to review and make recommendation to the Board on the remuneration policy and the remuneration packages of the executive Directors.

The attendance of each member of the Remuneration Committee is set out in the section headed "Board and Committee Meetings" of this Report.

Details of the remuneration of the Directors and senior management are set out in note 8 in the Notes to the consolidated financial statements for the year ended 31 December 2020.

#### **Nomination Committee**

The Nomination Committee consists of three members, namely Mr. Zhang Shuguang (Chairman), an executive Director, Dr. Chow Kwok Fai Joseph and Mr. Chan Kin Sang, both are independent non-executive Director.

The terms of reference of the Nomination Committee are in compliance with paragraph A.5 of the CG Code and Corporate Governance Report as set out in Appendix 15 to the GEM Listing Rules. The principal duties of the Nomination Committee include reviewing the Board composition, developing and formulating relevant procedures for the nomination and appointment of Directors, making recommendations to the Board on the appointment and succession planning of Directors, and assessing the independence of independent nonexecutive Directors.

For the year ended 31 December 2020, the Nomination Committee met 3 times to review among other things, the independence of the independent non-executive Directors; consider the qualifications of the retiring directors standing for election at the 2019 annual general meeting; review the structure, size and composition of the Board and review the Board diversity policy adopted by the Company. 截至二零二零年十二月三十一日止年度,薪 酬委員會已舉行三次會議,以審閲執行董事 的薪酬政策及薪酬待遇,並向董事會提出建 議。

各提名委員會成員的出席記錄載於本報告 「董事會及委員會會議」一節。

有關董事及高級管理層的薪酬詳情載於截至 二零二零年十二月三十一日止年度之綜合財 務報表附註8。

#### 提名委員會

提名委員會包括三名成員,即執行董事張曙 光先生(主席),獨立非執行董事周國輝博士 及陳健生先生。

提名委員會的權責範圍符合GEM上市規則附錄十五所載的企業管治守則及企業管治報告 第A.5段。提名委員會的主要職責包括檢討 董事會的組成、就提名及委任董事建立和制 定相關程序、就委任董事及董事繼任計劃向 董事會作出推薦建議,以及評估獨立非執行 董事的獨立性。

截至二零二零年十二月三十一日止年度,提 名委員會已舉行三次會議,以審閱(其中包 括)獨立非執行董事的獨立性;審議退任董 事於二零一九年股東週年大會的膺選資格; 審閲董事會之架構、規模及組成,以及本公 司採納的董事會多元化政策。



企業管治報告

The attendance of each member of the Nomination Committee is set out in the section headed "Board and Committee Meetings" of this Report.

In assessing the Board composition, the Nomination Committee would take into account various aspects as well as factors concerning Board diversity as set out in the Company's Board diversity policy and procedures for shareholders to propose a person for election as a Director of the Company, including but not limited to gender, age, cultural and educational background, professional qualifications, skills, knowledge and industry and regional experience etc. The Nomination Committee would discuss and agree on measurable objectives for achieving diversity on the Board, where necessary, and recommend them to the Board for adoption.

In identifying and selecting suitable candidates for directorships, the Nomination Committee would consider the candidate's character, qualifications, experience, independence and other relevant criteria necessary to complement the corporate strategy and achieve Board diversity, where appropriate, before making recommendation to the Board.

The Nomination Committee considered that an appropriate balance of diverse perspectives of the Board is maintained.

#### **CORPORATE GOVERNANCE FUNCTIONS**

The Board as a whole is responsible for performing the functions set out in the code provision D.3.1 of the CG Code.

各提名委員會成員的出席記錄載於本報告 「董事會及委員會會議」一節。

於評估董事會組成時,提名委員會將考慮本 公司董事會成員多元化政策以及股東提名人 選參選本公司董事程序所載有關董事會成員 多元化的多個方面及因素,包括但不限於性 別、年齡、文化及教育背景、專業資格、技 能、知識以及行業及地區經驗等。提名委員 會將就達致董事會成員多元化的可計量目標 進行討論並達成共識(如有必要),並就採納 該等目標向董事會作出推薦建議。

於物色及篩選合適的董事候選人時,提名委員會將在考慮候選人的特長、資格、經驗、 獨立性及對落實企業策略及達至董事會成員 多元化屬必要的其他相關準則(倘適用)後, 方向董事會作出推薦建議。

提名委員會認為董事會已維持多元化觀點的 適當平衡。

#### 企業管治職能

董事會整體負責履行企業管治守則守則條文 第D.3.1條所載的職能。

During the year, the Board had reviewed the Company's corporate governance policies and practices, training and continuous professional development of Directors and senior management, the Company's policies and practices on compliance with legal and regulatory requirements, the compliance of the Model Code and compliance manual (if any) applicable to employees and Directors, the Company's compliance with the CG Code and disclosure in this Report, and communicate with various level of staff to ascertain the implementation of policies and procedures on corporate governance.

#### **RISK MANAGEMENT AND INTERNAL CONTROLS**

The Company has in place policies and procedures in relation to risk management and internal control. The Board is primarily responsible for overseeing the risk management and internal control systems and for reviewing their effectiveness. The Company's internal control system and procedures are designed to meet its specific business needs and to minimise its risk exposure. The Company has adopted different internal guidelines, along with written policies and procedures to monitor and lessen the impact of risks which are relevant to its business and control its daily business operations. Management will identify the risks associated with the Group's day-to-day operations for review by the Board. The Board is responsible for evaluating and determining the nature and extent of the risks that the Company is willing to take in achieving the Company's strategic objectives, and ensuring that the Company establishes and maintains appropriate and effective risk management and internal control systems. The Board oversees management in the design, implementation and monitoring of the risk management and internal control systems. The Board acknowledges that such risk management and internal control systems are designed to manage rather than eliminate the risk of failure to achieve business objectives, and can only provide reasonable but not absolute assurance against material misstatement or loss.

年內,董事會已檢討本公司企業管治政策及 常規、董事及高級管理層培訓及持續專業發 展、本公司有關遵守法律及監管規定的政策 及常規、遵守標準守則及僱員及董事書面指 引(如有)的情況、本公司遵守企業管治守則 的情況以及此報告的披露,並與各級員工溝 通以確保落實企業管治政策及程序。

#### 風險管理及內部監控

本公司已制定有關風險管理及內部監控的政 策及程序。董事會主要負責監督風險管理及 内部監控系統,並檢討其成效。本公司的內 部監控系統及程序旨在滿足其具體的業務需 求,並將風險降至最低。本公司已採納不同 的內部指引,以及以書面形式訂明的政策及 程序,務求監察及減輕與其業務有關的風險 所產生的影響,並控制其日常業務營運。管 理層將識別與本集團日常營運有關的風險, 以提交董事會審查。董事會負責評估及釐定 本公司達成本公司策略目標時所願意承擔的 風險性質及程度,並確保本公司設立及維持 合適及有效的風險管理及內部監控系統。董 事會監督管理層對風險管理及內部監控系統 的設計、實施及監察。董事會知悉有關風險 管理及內部監控系統旨在管理而非消除未能 達成業務目標的風險,且僅可就防範重大失 實陳述或損失作出合理而非絕對的保證。



The Group does not have an internal audit function and is currently of the view that there is no immediate need to set up an internal audit function within the Group considering the size, nature and geography of the Group's business. The Directors are responsible for formulating and overseeing the implementation of the Group's risk management and internal control measures. The Group has engaged an external independent internal control consultant (the "IC Consultant") to conduct an internal control review on the internal control system of the Group for the year ended 31 December 2020. Such review is conducted annually. The review covers certain business cycles and procedures undertaken by the Group and make recommendations for improving and strengthening the system. The scope of the IC Consultant's review was previously determined and approved by the Board. The IC Consultant has recommended certain internal control improvement measures to the Board. The Board is of the view that no material internal control defeats have been noted. All recommendations given by the IC Consultant will be properly followed up by the Group to ensure that they are implemented within a reasonable period of time. The Directors were of the view that the risk management and internal control systems were adequate and effective to safeguard the interest of shareholders and the Group's assets.

The Board, through the Audit Committee, has conducted a review of the effectiveness of the risk management and internal control systems of the Group covering all material controls, including financial, operational and compliance controls functions. The Board considers that the Group's risk management and internal control systems are adequate and effective. The Board expects that a review of the risk management and internal control systems will be performed annually. 本集團並無內部審核功能及認為根據目前本 集團業務之規模、性質及佈局,毋須即時於 本集團內設立內部審核功能。董事負責制定 本集團的風險管理及內部監控措施及監督其 實施。本集團已委聘外部獨立內部監控顧問 (「內部監控顧問」),於截至二零二零年十二 月三十一日止年度為本集團的內部監控系 統進行內部監控檢討。此項檢討每年進行一 次。檢討涵蓋本集團實施的若干業務週期及 程序,並提出改善及加強有關系統的建議。 內部監控顧問的審查範圍先前已由董事會確 定並批准。內部監控顧問已向董事會建議了 若干內部監控改進措施。董事會認為並沒有 發現重大內部監控失誤。本集團將適當跟進 由內部監控顧問給予的所有建議,以確保該 等建議於一段合理的時間內執行。董事認 為,風險管理及內部監控系統足以有效維護 股東利益及本集團資產。

董事會透過審核委員會,就本集團的風險管 理及內部監控系統是否有效進行檢討,當中 涵蓋所有重大監控措施,包括財務、營運 及合規監控職能。董事會認為,本集團的風 險管理及內部監控系統充足及有效。董事會 預計每年對風險管理及內部監控系統進行檢 討。



#### 董事及高級管理層薪酬 **REMUNERATION OF DIRECTORS AND SENIOR** MANAGEMENT

Particulars of the Directors' remuneration for the year ended 31 December 2020 are set out in note 8 in the Notes to the consolidated financial statements.

Pursuant to code provision B.1.5 of the CG Code, the remuneration of the members of the senior management (other than the Directors) whose particulars is contained in the section headed "Biographies of the Directors and Senior Management" in this Report by band is set out below:

截至二零二零年十二月三十一日止年度的董 事薪酬詳情載於綜合財務報表附註8。

根據企業管治守則的守則條文第B.1.5條,高 級管理層成員(董事除外)(其詳情載於本報 告「董事及高級管理層履歷」一節)按範圍劃 分的薪酬如下:

		Number of individuals
Remuneration band (in HK\$)	<b>薪酬範圍</b> (港元)	人數
Nil to 1,000,000	零至1,000,000	4

#### **EXTERNAL AUDITOR AND THEIR** REMUNERATION

外聘核數師及其薪酬

Mazars CPA Limited ("Mazars") is the external auditor of the Company. The Audit Committee is responsible for making recommendation to the Board on the appointment, reappointment and removal of the external auditor, which is subject to the approval by the Board and at the general meetings of the Company by its shareholders.

During the year ended 31 December 2020, the remuneration for the audit services provided by the Company's auditor to the Group was as follows:

中審眾環(香港)會計師事務所有限公司 (「中審眾環」)為本公司外聘核數師。審核 委員會負責就外聘核數師的委任、重新委 任及罷免向董事會提出推薦建議,相關委 任、重新委任及罷免須經董事會批准及股 東於本公司股東大會上批准。

於截至二零二零年十二月三十一日止年度, 本公司核數師向本集團提供的審核服務薪酬 如下:

		HK\$	Equivalent to RMB
		港元	相當於人民幣
Annual audit service for	截至二零二零年十二月三十一日		
the year ended 31 December 2020	止年度的年度審核服務	700 000	625 000



企業管治報告

# RESPECTIVE RESPONSIBILITIES OF DIRECTORS AND AUDITOR

The Directors acknowledge their responsibilities for the preparation of accounts for the year ended 31 December 2020, which give a true and fair view of the state of affairs of the Group and of the results and cash flows for that period and comply with the requirement of the Companies Ordinance (Chapter 622 of the Laws of Hong Kong) ("Hong Kong Companies Ordinance") and the applicable disclosure provisions of the Listing Rules.

The auditor is responsible for forming an independent opinion, based on the audit, on the financial statements prepared by the Directors and reporting the opinion solely to the Company's shareholders.

The Directors are not aware of any material uncertainties relating to events or conditions that may cast significant doubt upon the Group's ability to continue as a going concern. The statement of the independent auditor of the Company about its reporting responsibilities on the financial statements is set out in the "Independent Auditor's Report" on pages 116 to 124.

### **DISCLOSURE OF INSIDE INFORMATION**

The Group acknowledges its responsibilities under the Securities and Futures Ordinance, Chapter 571 of the laws of Hong Kong and the GEM Listing Rules and the overriding principle that inside information should be announced promptly when it is the subject of a decision. The procedures and internal controls for the handling and dissemination of inside information are as follows:

 the Group conducts its affairs with close regard to the disclosure requirement under the GEM Listing Rules as well as the "Guidelines on Disclosure of Inside Information" published by the Securities and Futures Commission of Hong Kong in June 2012;

#### 董事及核數師各自的責任

董事了解其就截至二零二零年十二月三十一 日止年度編製真實公平反映本集團於相關期 間事務狀況以及業績及現金流量狀況,且符 合香港法例第622章《公司條例》(「香港公司 條例」)的規定及上市規則的適用披露規定的 賬目的責任。

核數師負責根據其審核工作就董事編製的財 務報表形成獨立意見,並僅向本公司股東報 告該意見。

董事並不知悉任何可能令本集團持續經營能 力產生重大疑問的事件或狀況的相關重大不 確定因素。本公司獨立核數師關於其就財務 報表的報告責任的聲明載於第116至124頁 的「獨立核數師報告」。

#### 內幕消息披露

本集團了解其於香港法例第571章《證券及期 貨條例》及GEM上市規則項下的責任,並知 悉首要原則是當內幕消息為決策的主題時應 立即予以公告。處理及發佈內幕消息的程序 及內部監控措施如下:

本集團在開展自身事務時,密切關注
 GEM上市規則下的披露規定以及香港
 證券及期貨事務監察委員會發佈於二零
 一二年六月的「內幕消息披露指引」;

- the Group has implemented and disclosed its policy on fair disclosure by pursuing broad, nonexclusive distribution of information to the public through channels such as financial reporting, public announcements and the Company's website;
- the Group has strictly prohibited unauthorised use of confidential or inside information; and
- the Group has established and implemented procedures for responding to external enquiries about the Group's affairs, the Board will decide, or designate appropriate persons to communicate with parties outside the Group.

#### **COMPANY SECRETARY**

Company secretary supports the Board by ensuring good information flow within the Board and that the Board policy and procedures are followed. The company secretary is responsible for advising the Board on corporate governance matters and facilitating induction and professional development of the Directors. All Directors have access to the advice and services of the company secretary to ensure that the Board procedures and all applicable laws, rules and regulations, are followed.

Mr. Chau Lai Ki was appointed as the company secretary of the Company on 25 September 2017 and has complied with all requirements relating to qualifications, experiences and training under the GEM Listing Rules. For the year ended 31 December 2020, he has undertaken not less than 15 hours of relevant professional training respectively in compliance with rule 5.15 of the GEM Listing Rules.

- 本集團已實施並公佈其公平披露政策, 尋求透過財務報告、公開公告及本公司 網站等渠道向公眾作出廣泛、非專有性 的資料發佈;
- 本集團嚴格禁止未經授權而使用保密或 內幕資料;及
- 本集團已就回應外界關於本集團事務的 查詢制定並實施相關措施,董事會將決 定或指定適當人選與本集團以外的各方 進行溝通。

#### 公司秘書

公司秘書通過確保董事會內部良好的資訊流 動以及董事會的政策及程序獲遵守而支援董 事會工作。公司秘書負責就企業管治事宜向 董事會提供意見,並負責協助董事的入職及 專業發展。所有董事均有權取得公司秘書的 意見及服務,以確保董事會程序及所有適用 法律、規則及規例獲得遵守。

周麗麒先生於二零一七年九月二十五日獲委 任為本公司的公司秘書並已遵守GEM上市規 則項下關於資格、經驗及培訓的所有規定。 截至二零二零年十二月三十一日止年度,彼 已根據GEM上市規則第5.15條接受不少於15 小時的相關專業培訓。



#### SHAREHOLDERS' RIGHTS

To safeguard shareholder interests and rights, separate resolution should be proposed for each substantially separate issue at general meetings, including the election of individual Director. All resolutions put forward at general meetings will be voted by poll pursuant to the GEM Listing Rules and poll results will be posted on the websites of the Company and of the Stock Exchange after each general meeting.

#### Convening an EGM

Pursuant to Article 58 of the Articles of Association of the Company, shareholders may convene an EGM in accordance with the "Procedures for Shareholders to convene an EGM" set out below.

#### Procedures for Shareholders to Convene an EGM

Any one or more shareholders holding at the date of deposit of the requisition not less than 10% of the paidup capital of the Company carrying the right of voting at general meetings of the Company (the "**Eligible Shareholder(s)**") shall at all times have the right, by written requisition to the Board or the company secretary for the purpose of requiring an EGM to be called by the Board for the transaction of any business specified in such requisition, including making proposals or moving a resolution at the EGM.

Eligible Shareholders who wish to convene an EGM for the purpose of making proposals or moving a resolution at the EGM must deposit a written requisition (the "**Requisition**") signed by the Eligible Shareholder(s) concerned (the "**Requisitionist(s**)") at the principal place of business of the Company in Hong Kong (presently located at 3rd Floor, Effectual Building, 16 Hennessy Road, Wanchai, Hong Kong) for the attention of the company secretary. The Requisition must state clearly the name(s) of the Requisitionist(s) concerned, his/her/their shareholdings in the Company, the reason(s) to convene an EGM and the proposed agenda.

#### 股東權利

為保障股東權益及權利,於股東大會上應就 各個別重要事項(包括各董事的選舉)提呈獨 立的決議案。於股東大會上提呈的所有決議 案將根據GEM上市規則進行投票表決,投票 結果將於相關股東大會後在本公司及聯交所 網站公佈。

#### 召開股東特別大會

根據本公司組織章程細則第58條,股東可根 據下文所載「股東召開股東特別大會的程序」 召開股東特別大會。

#### 股東召開股東特別大會的程序

任何於提交要求日期持有不少於10%附帶於 本公司股東大會上投票權利的本公司繳足股 本的一名或多名股東(「合資格股東」)隨時有 權通過向董事會或公司秘書發出書面要求, 而要求董事會召開股東特別大會,以在股東 特別大會上處理相關要求中所列明的任何事 務,包括提出建議或提呈決議案。

有意召開股東特別大會以在股東特別大會上 提出建議或提呈決議案的合資格股東(「要求 人」)須將經所涉合資格股東簽署的書面要求 (「要求」)遞交至本公司的香港主要營業地點 (當前位於香港灣仔軒尼詩道16號宜發大廈 3樓),收件人為公司秘書。要求須列明所涉 要求人的姓名/名稱、其於本公司的股權、 召開股東特別大會的理由及建議議程。

The Company will check the Requisition and the identity and shareholding of the Requisitionist(s) will be verified with the Company's branch share registrar in Hong Kong. If the Requisition is found to be proper and in order, the company secretary will ask the Board to convene an EGM and/or include the proposal(s) made or the resolution(s) proposed by the Requisitionist(s) at the EGM within two months after the deposit of the Requisition. On the contrary, if the Requisition has been verified as not in order, the Requisitionist(s) will be advised of the outcome and accordingly, the Board or the company secretary will not call for an EGM nor include the proposal(s) made or the resolution(s) proposed by the Requisitionist(s) at the EGM.

If within 21 days of the deposit of the Requisition the Board or the company secretary fails to proceed to convene such EGM, the Requisitionist(s) himself/herself/ themselves may do so in the same manner, and all reasonable expenses incurred by the Requisitionist(s) as a result of the failure of the Board or the company secretary to convene an EGM shall be reimbursed to the Requisitionist(s) by the Company.

### **Putting Forward Enquiries to the Board**

For putting forward any enquiries to the Board of the Company, shareholders may send written enquiries to the Company. The Company will not normally deal with verbal or anonymous enquiries.

#### **Contact Details**

Shareholders may send their enquiries or requests as mentioned above to the following:

Address: 3rd Floor, Effectual Building, 16 Hennessy Road, Wanchai, Hong Kong

(For the attention of the company secretary)

本公司將檢查要求人的要求及身份,並在本 公司香港股份過戶登記分處核實要求人的股 權情況。倘要求被證實為適當及有效,則 公司秘書將要求董事會在要求提交後兩個月 內召開股東特別大會及/或將要求人提出的 建議或提呈的決議案納入股東特別大會。相 反,倘要求被核實為無效,則要求人將被告 知相關結果,而董事會或公司秘書將不會召 開股東特別大會,亦不會將要求人提出的建 議或提呈的決議案納入股東特別大會。

倘在要求提交後21日內,董事會或公司秘書 未能著手召開相關股東特別大會,則要求人 可自行按相同方式召開股東特別大會,而要 求人因董事會或公司秘書未召開股東特別大 會而產生的所有合理開支由本公司向要求人 作出補償。

#### 向董事會提交查詢

對於向本公司董事會提交任何查詢,股東可 向本公司發出書面查詢。本公司通常不會處 理口頭或匿名查詢。

#### 聯繫方式

股東可將其上述查詢或要求發送至以下地 址:

香港灣仔軒尼詩道16號宜發大廈3樓

(收件人為公司秘書)



企業管治報告

#### **Right to Put Forward Proposals at General Meetings**

There are no provisions allowing shareholders to propose new resolutions at the general meetings under the Companies Law (as revised) of the Cayman Islands. Subject to provisions of the Articles, Eligible Shareholders who wish to move a resolution may by means of requisition convene an EGM following the procedures set out above.

For the avoidance of doubt, shareholder(s) must deposit and send the original duly signed written requisition, notice or statement, or enquiry (as the case may be) to the above address and provide their full name, contact details and identification in order to give effect thereto. shareholders' information may be disclosed as required by law.

#### COMMUNICATIONS WITH SHAREHOLDERS AND **INVESTORS**

The Company considers that effective communication with shareholders is essential for enhancing investor relations and investor understanding of the Group's business performance and strategies. The Company also recognises the importance of transparency and timely disclosure of corporate information, which will enable shareholders and investors to exercise their rights in an informed manner and allow them to engage actively with the Company.

Information will be communicated to the shareholders through the Company's quarterly, interim and annual financial reports, the publish and posting of notices, announcements, circulars, AGMs and other EGMs that may be convened as well as all the published disclosures submitted to the Stock Exchange.

#### 於股東大會上提出建議的權利

開曼群島公司法(經修訂)並無條文批准股東 於股東大會上提呈新決議案。在細則條文的 規限下,有意提出決議案的合資格股東可透 過上述程序提出召開股東特別大會。

為免生疑問,股東須將正式簽署的書面要 求、通知或聲明、查詢(視情況而定)的正本 提交並發送至上述地址,並提供其全名、聯 繫方式及身份證明,以使相關書面要求、通 知或聲明、查詢生效。股東的資料可能會按 法律規定予以披露。

#### 與股東及投資者的溝通

本公司認為與股東間的有效溝通對於加強投 資者關係及提升投資者對於本集團業務表現 及策略的了解至關重要。本公司亦深知保證 公司消息透明度與及時披露的重要性,以便 令股東及投資者能夠在知情的情況下行使其 權利並與本公司保持積極溝通。

本公司通過季度、中期及年度財務報告、公 佈及刊發通告、公告及通函、股東週年大會 及可能召開的其他股東特別大會以及向聯交 所提交的所有公開披露向股東傳達資料。

Shareholders should direct their questions about their shareholdings to the Company's share registrar. Shareholders and the investment community may at any time make a request for the Company's information to the extent such information is publicly available. Any such questions, requests, comments and suggestions can be addressed to the Company by post to its head office and principal place of business in Hong Kong. 股東關於其股權的問題應向本公司股份過戶 登記處提出。股東及廣大投資者可隨時索取 本公司的公開資料。如有任何問題、請求、 意見及建議均可通過郵寄至本公司香港總部 及主要營業地點的方式向本公司提出。

#### **CONSTITUTIONAL DOCUMENTS**

Except for the conditional adoption of the amended and restated memorandum of association and Articles of Association (the "**M&A**") adopted by the Company on 26 November 2018 to comply with the applicable legal and regulatory requirements (including the GEM Listing Rules), which took effect from the Listing Date, there was no significant change in the constitutional documents of the Company during the Relevant Period.

The amended and restated M&A is available on the respective websites of Company and the Stock Exchange.

#### 章程文件

除本公司於二零一八年十一月二十六日遵照 適用法律及監管規定(包括GEM上市規則)有 條件採納經修訂及重述的組織章程大綱及細 則(「**大綱及細則**」)(自上市日期起生效)外, 於有關期間,本公司的章程文件無重大變 動。

經修訂及重述的大綱及細則可於本公司及聯 交所網站查閱。

### ENVIRONMENTAL, SOCIAL AND GOVERNANCE REPORT 環境、社會及管治報告

#### **INTRODUCTION**

This is the third Environmental, Social and Governance (the "ESG") Report of Huakang Biomedical Holdings Company Limited (the "**Group**") to highlight its approaches and strategies in pursuit of sustainable development during the reporting period from 1 January 2020 to 31 December 2020 (the "Reporting Period"). This ESG report covers the environmental and social performance of the Group's business operation of its manufacturing operation in Shenzhen, the PRC, namely Shenzhen Huakang, during the Reporting Period, unless otherwise stated. The Group primarily adopts the principles and basis of Environmental, Social and Governance Reporting Guide (the "ESG Reporting Guide") as set out in Appendix 20 of the GEM Listing Rules. The Group complied with all the "comply or explain" provisions set out in the ESG Reporting Guide during the Reporting Period.

The Group is a medical device supplier principally specialized in the research and development (the "**R&D**"), manufacturing and sale of wide range of biological reagents, auxiliary reproductive supplies and equipment in the PRC, which collectively accounted for 96% of the Group's total revenue during the Reporting Period. The Group's product portfolio offers 23 biological reagents, including 20 male fertility in-vitro diagnostics (the "**IVD**") reagents, 2 parasite antibody detection reagents and 1 Epstein-Barr virus (the "**EBV**") antibody detection reagent.

During the Reporting Period, the Group set up a company for the purposes of sales, marketing and distribution of self-developed healthcare supplements under the Group's registered brand "Nutronic". However, the healthcare product business is excluded from the scope since it had no significant environmental and social impacts generated, and made up less than 4% of the total revenue during the Reporting Period. There were no other major operational changes in the scope compared with the period from 1 January 2019 to 31 December 2019 (the "**Last Reporting Period**").

#### 緒言

這是華康生物醫學控股有限公司(「本集團」) 的第三份環境、社會及管治(「環境、社會及 管治」)報告,重點介紹了其於二零二零年一 月一日至二零二零年十二月三十一日的報告 期(「報告期」)內達致可持續發展的方法和戰 略。除非另有説明,本環境、社會及管治報 告涵蓋了於報告期內本集團在中國深圳生產 績效。本集團主要採納GEM上市規則附錄 二十所載之環境、社會及管治報告指引(「環 、社會及管治報告指引」)的原則及基礎。 報告期內,本集團一直遵守所有環境、社會 及管治報告指引所載的「不遵守就解釋」條文 規定。

本集團為一家醫療器械供應商,主要於中國 從事研發(「研發」)、生產及銷售生物試劑、 輔助生育用品和設備,其合共佔本集團於報 告期總收益的96%。本集團產品組合有23種 生物試劑,包括20種男性不育體外診斷(「體 外診斷」)試劑,2種寄生蟲系列檢測試劑和1 種EB病毒(「EB病毒」)檢測試劑。

於報告期內,本集團設立一家公司,以供銷 售、營銷及經銷本集團註冊品牌「Nutronic」 下自主研發的健康保健品。然而,健康產 品業務不在此範圍內,原因為其並無產生重 大的環境及社會影響,且佔報告期總收益的 百分比低於4%。跟二零一九年一月一日至 二零一九年十二月三十一日期間(「上個報告 期」)相比,該範圍沒有其他重大運營變化。 ENVIRONMENTAL, SOCIAL AND GOVERNANCE REPORT 環境、社會及管治報告

#### THE BOARD'S ESG COMMITMENT

The Board has overall responsibility for the Group's ESG strategy and reporting. Specifically, the Board is held accountable for the Group's long-term resilience with respect to potential shifts in the business landscape that may result from climate change. As the stewards for long-term performance and resilience, the Board is committed to determining the most effective way to integrate ESG considerations into its structure and committees. The Group also evaluates and monitors ESG-related risks and ensures these risks are thoroughly considered in the process of decision making and embedded into the management of risk and opportunities across the Group.

The Group strives to achieve a high level of public transparency by regularly engaging stakeholders and disclosing information in a timely and accurate manner. Accordingly, the Group maintains regular exchanges and dialogues with peers, investors and other stakeholders to encourage the sharing of methodologies and to stay informed about the latest ESG-related risks, regulatory requirements etc. The Group also tracks existing regulation and emerging regulation to ensure its ESG policies, processes and disclosures meet expectations.

Legal compliance is an essential pillar for sound corporate governance and underpins sustainable operations. The Group confirmed that it has established appropriate and effective management policies and internal control systems for ESG issues during the Reporting Period, and confirmed that the disclosed contents are in compliance with the requirements of the ESG Reporting Guide.

#### 本集團在環境、社會及管治上的承諾

董事會對本集團的環境、社會及管治策略及 匯報承擔全部責任。尤其是,董事會須就因 氣候變化可能導致的業務格局的可能轉變對 本集團的長期韌性承擔責任。作為負責長期 表現及韌性的管理者,董事會致力於確定最 有效的方式,以將環境、社會及管治考慮因 素糅合在其結構及承諾中。本集團亦評估及 監控環境、社會及管治相關風險及確認於作 出決策時充分考慮該等風險,並將該等風險 納入本集團的風險及機會管理之中。

本集團致力於透過讓持份者定期參與並及時 準確地披露信息,從而達致高水準的公開透 明度。因此,本集團與同行、投資者及其他 持份者定期保持交流及對話,以鼓勵方法共 享及知悉最新的環境、社會及管治相關風險 及監管要求等。本集團亦留意現有法規及新 興法規,以確保其環境、社會及管治政策、 流程及披露符合預期。

遵守法律及法規是健全公司治理的重要支 柱,也是可持續營運的基礎。本集團確認於 報告期內已就環境、社會及管治事宜設立合 適及有效的管理政策及內部監控系統,並確 認所披露內容符合環境、社會及管治報告指 引的要求。



#### THE GROUP'S ESG APPROACH

The Board and senior management are involved in the materiality assessment in identifying material ESG issues that impact the Group's business operation. The Group holds periodic meetings to discuss significant matters related to the operations and review management approaches of a suite of ESG issues. The Group continuously monitors ESG-related risks through implementation of appropriate systems and processes.

To echo with international concerns on climate change, the Group will begin assessing the short-, mediumand long-term materiality of climate-related risks and opportunities for the Group. The Group ensures that all its actions and responses to climate are proportionate to the materiality of climate to the Group. The Group will consider including climate-related targets and indicators in its executive incentive schemes, where appropriate.

The favorable policies and systems in the PRC enable the Group to seize new business opportunities in the emerging IVD market, and ride on the development of the biomedical industry to tackle future health challenges. To meet the increasingly sophisticated demands of customers, the Group seeks to enhance the existing products and develop new products leveraging on its vast experience and advanced technologies, and, in turn, benefits the society.

#### 本集團的環境、社會及管治方法

董事會及高級管理層均參與重要性評估,以 判定影響本集團業務營運的環境、社會及管 治的重大問題。本集團定期舉行會議,探 討業務相關的重大事項,並檢討管理層針對 一系列環境、社會及管治問題的方法。本集 團通過實施適當的系統和流程來持續監控環 境、社會及管治的相關風險。

為呼應國際上對氣候變化的關注,本集團將 開始評估其氣候相關風險及機會的短期、中 期及長期重要性。本集團確保其針對氣候的 所有行動及應對措施對於本集團的氣候重要 性而言屬適當。在適當情況下,董事會可能 會考慮將與氣候相關的目標和指標納入高管 激勵計劃。

中國的優惠政策和制度,可令本集團抓緊新 興的體外診斷試劑市場之新商機及把握生物 醫學行業的發展,以應對未來的健康挑戰。 為了滿足客戶日益增加的複雜需求,本集團 力求利用其豐富的經驗和先進的技術來增強 現有產品並開發新產品,從而造福於社會。 ENVIRONMENTAL, SOCIAL AND GOVERNANCE REPORT 環境、社會及管治報告

#### THE GROUP'S MISSION AND VISION

Enhance people's health Meet customers' needs

The Group embraces the vision in its operation practices and in provision of quality products and excellent services. Not only does the Group adheres to stringent standards and requirements to ensure that its products are up to the highest quality, it also persists in developing innovative products for worldwide healthcare needs and a better quality of life.

The Group strives to:

- be a pioneer in its core technologies;
- boost investment in R&D;
- recruit high-caliber personnel from all parts of the world;
- establish and implement quality management system effectively;
- stay innovative in various business areas;
- enhance the physical well-being of the general public;
- adhere to the customer-centric principle in business practice and take full responsibility in service delivery to customers' satisfaction;
- comply with relevant rules and regulations; and
- improve quality management system consistently for a stable product quality that meets customers' requirements.

本集團願景

#### *提高民生健康 滿足客戶需求*

本集團在其營運常規及提供優質產品和卓越 服務方面抱有願景。本集團不僅遵循嚴格的 標準和要求,以確保其產品達到最高質量, 而且還堅持開發創新產品以滿足全球醫療保 健需求和改善生活質量。

本集團致力:

- 成為核心技術的先驅;
- 增加研發的投資;
- 在世界各地招聘人才;
- 建立及實施有效的質量管理制度;
- 在各種業務領域保持創新;
- 提高大眾的身心健康;
  - 在實踐業務時堅持以客戶為中心的原則,對提供的服務承擔全部責任,以使 客戶滿意;
  - 遵守相關規則和法規;及
- 持續改善質量管理制度,以達到滿足客
   戶要求的穩定產品質量。



## STAKEHOLDER ENGAGEMENT AND MATERIALITY

The Group recognizes the importance of building positive relationships with its stakeholders. The Group maintains ongoing dialogues with key stakeholders via various communication channels including meetings, performance reviews, customer satisfaction surveys and interview sessions. Feedback obtained through regular engagement is essential in the decision-making process of the Group's operation, from improving its business performance to bringing insights for future development.

To identify material ESG issues, the Group specifically engaged both internal and external stakeholders to gain insights into ESG material topics and challenges of the Group's operation. In the materiality assessment, stakeholders were asked to rate a list of 18 topics in terms of their relevance and importance to the Group's business development and sustainability, as well as to the wider community.

Results of the materiality assessment and the consolidated list of material aspects are presented in the following matrix and table respectively.

#### 持份者參與及重要性

本集團明白與持份者建立良好關係的重要 性。本集團通過各種通訊渠道(包括會議、 績效評估、客戶滿意度調查和訪談會議)來 保持與主要持份者進行交流。透過定期參與 獲得的反饋對於對於本集團營運的決策過程 至關重要,由改進業務績效到為未來發展提 供見解。

為判定重大環境、社會及管治問題,本集團 特意委聘內部及外部持份者,以獲取本集團 業務上有關環境、社會及管治之重要議題及 挑戰的見解。進行重要性評估時,持份者須 對18項議題各自對本集團業務持續發展而言 以及對範圍更大社區的相關性及重要性,對 有關議題進行排序。

重要性評估結果和主要範疇的合併列表分別 顯示在以下矩陣及表內。





Among the environmental and social aspects, the following ESG topics were deemed as the most important by the stakeholders:

- Product and service quality
- Anti-corruption
- Labor standards
- Employment
- Occupational health and safety

在環境和社會方面,以下環境、社會及管治 主題被確定為對持份者最重要的問題:

- 產品及服務質素
- 反貪污
- ▶ 勞工準則
- 僱傭
- 職業健康與安全



#### **STAKEHOLDERS' FEEDBACK**

The Group welcomes stakeholders' feedback on its ESG approach and sustainability performance. Stakeholders may share with the Group any suggestion and view via email to: hk@szhuakang.com.

#### AWARDS, RECOGNITIONS AND MEMBERSHIPS

Since its establishment, the Group has received awards and recognitions from the governmental and international authorities acknowledging its achievements in product R&D and occupational safety and health. The Group has obtained the following awards or certifications:

#### 持份者的反饋

本集團歡迎持份者對其環境、社會及管治方 法和可持續性績效作出反饋。持份者可通過 發送電子郵件至hk@szhuakang.com與本集 團分享任何建議和見解。

#### 獎項、認可及會籍

自成立以來,本集團曾獲政府和國際權威機 構的獎項和認可,以表彰其在產品研發和職 業安全及健康方面所取得的成就。本集團已 獲得以下獎項或證書:

Awards/Recognitions 獎項/認可	Awarding authority 頒發機構
Shenzhen High and New Technology Enterprise 深圳市科技創新企業	Innovation Committee of Shenzhen Municipal Finance Committee of Shenzhen Shenzhen State Taxation Bureau Shenzhen Local Taxation Bureau 深圳市創新委員會 深圳市財政委員會 深圳市國家税務局 深圳市地方税務局
High and New Technology Enterprise 高新技術企業	Innovation Committee of Shenzhen Municipal Finance Committee of Shenzhen 深圳市創新委員會 深圳市財政委員會
Certificate of Good Manufacturing Practice Rules for Medical Devices 醫療器械生產質量管理規範證書	China Food and Drug Administration 國家食品藥品監督管理局
Work Safety Standardization 生產安全標準化	State Administration of Work Safety 國家安全生產監督管理局
ISO13485 Medical Devices - Quality Management System ISO13485 醫療器械行業質量管理體系認證	International Organization for Standardization 國際標準化組織

ENVIRONMENTAL, SOCIAL AND GOVERNANCE REPORT 環境、社會及管治報告

Moreover, the Group actively forges close ties with the industry bodies and takes part in professional associations in the biomedical community. The Group is currently the member of the following associations:

• Shenzhen Association of Medical Devices,

• Shenzhen Hi-tech Industry Association,

• Guangdong Medical Device Management Academy,

• Guangdong Food and Drug Technology Association for Evaluation and Certification,

• Shenzhen Life Science and Biotechnology Association, and

• Shenzhen Medical Device Quality Promotion Association.

These associations provide excellent platforms for expertise exchange, networking, market insights sharing and business development. 此外,本集團積極與業內機構建立緊密聯 繫,並參與生物醫學界的專業協會。本集團 目前為以下協會成員:

深圳市醫療器械行業協會,

深圳市高新技術產業協會,

廣東省醫療器械管理學會,

廣東省食品藥品審評認證技術協會,

深圳市生命科學與生物技術協會,及

• 深圳市醫療器械質量管理促進會。

該等協會為專業知識交流、網絡、市場見解 分享及業務發展提供了良好的平台。



#### A. ENVIRONMENTAL

The Group is committed to protecting the environment and remains vigilant against greenhouse gas (the "**GHG**") emissions in all its business activities. The Group's Environmental Management Policy outlines the key objectives and principles of the Group related to managing the environmental influences of its operations.

The Group mainly consumed electricity, petrol and water, and generated wastewater, and paper waste during the Reporting Period. The Group strictly abides by the laws, rules and regulations enforced by the PRC in relation to environmental protection and pollution control, including but not limited to:

- Environmental Protection Law of the PRC,
- Water Pollution Prevention and Control Law of the PRC,
- Law of the PRC on the Prevention and Control of Atmospheric Pollution; and
- Law of the PRC on the Prevention and Control of Environmental Pollution by Solid Waste.

During the Reporting Period, no material noncompliance with laws and regulations relating to air and GHG emissions, discharge into water and land, or the generation of hazardous and non-hazardous waste was recorded.

#### A. 環境

本集團致力於保護環境,並在所有活動 中就溫室氣體(「**溫室氣體**」)排放保持警 惕。本集團的環境管理政策概述有關本 集團管理其運營所產生的環境影響的主 要目標及原則。

報告期內,本集團主要消耗電力、汽油 及用水,並產生廢水及廢紙。本集團嚴 格遵守中國在環保及污染控制方面執行 的法律、規則及法規,包括但不限於:

- 中華人民共和國環境保護法,
- 中華人民共和國水污染防治法,
- 中華人民共和國大氣污染防治法,
   及
- 中華人民共和國固體廢物污染環境 防治法。

報告期內,並無重大違反有關廢氣及溫 室氣體排放、向水及土地排放或產生有 害及無害廢物的法律及法規。 ENVIRONMENTAL, SOCIAL AND GOVERNANCE REPORT 環境、社會及管治報告

#### A1. Emissions

#### A1.1 Air Emissions

The Group-owned vehicles operated on petrol were used for daily business operations during the Reporting Period, which contributed to the emission of nitrogen oxides (" $NO_x$ "), sulfur oxides (" $SO_x$ ") and respiratory suspended particles ("RSP"). Due to declining demand for business trips in times of the Epidemic, the Group consumed 42% less petrol compared with the Last Reporting Period, resulting in substantially reductions in resepctive air emissions.

#### A1. 排放物

#### A1.1 廢氣排放

報告期內,本集團以汽油推動的自持車輛用於日常業務,導致排放氮氧化物 (「NO<sub>x</sub>」)、硫氧化物(「SO<sub>x</sub>」)及可吸入 懸浮粒子(「RSP」)。由於疫情期間,商 務旅行的需求下降,本集團所消耗的汽 油較之上個報告期減少42%,導致廢氣 排放量明顯減少。

#### Air emissions (non-GHG) from mobile combustion 移動燃燒產生的廢氣排放(非溫室氣體)

				NO <sub>x</sub> (kg) 氮氧化物	RSP (kg) 可吸入懸浮粒子	SO <sub>x</sub> (kg) 硫氧化物
Fuel Sourc	e 燃料源	Usage	燃料使用	(公斤)	(公斤)	(公斤)
Petrol	汽油	For vehicles	車輛用	0.58	0.07	0.02

Note:

Emission factors for calculations on environmental parameters throughout the report were made reference to Appendix 27 of the Main Board Listing Rules and their referred documentation as set out by Hong Kong Exchanges and Clearing Limited, unless stated otherwise. 附註:

除另有説明外,整份報告中計算環境指數的 排放系數乃參照主板上市規則附錄27及香港 交易及結算所有限公司所訂其參考文件而作 出。



#### A1.2 Greenhouse Gas Emissions

During the Reporting Period, the Group's business activities contributed to the GHG emission of 145.05 tonnes of carbon dioxide equivalent ("**tCO<sub>2</sub>eq.**"), mainly carbon dioxide, methane and nitrous oxide. The overall GHG intensity for the Group was 2.04 tCO<sub>2</sub>eq. with reference to the number of full-time employees ("**FTE**"), or 0.0035 tCO<sub>2</sub>eq. per unit of product sold, representing a 25% and 51% rise respectively compared with the Last Reporting Period.

#### A1.2 溫室氣體排放

整個報告期內,本集團的經營活動產生 了145.05噸二氧化碳當量(「**噸二氧化碳** 當量」,主要為二氧化碳、甲烷及氮氧 化物)的溫室氣體排放。本集團整體的 溫室氣體排放密度為每名全職僱員(「**全** 職僱員」)2.04噸二氧化碳當量或每件售 出產品0.0035噸二氧化碳當量,較上個 報告期分別增加25%或51%。

\_ . .

			Total
	Emission	GHG Emission	GHG Emission
Scope of GHG Emissions	Sources	(tCO2eq.)	(%)
		温室氣體排放	
温室氣體排放的範圍	排放源	(噸二氧化碳當量)	(%)
Scope 1 Direct GHG Emission			
範疇1 直接溫室氣體排放			
Combustion of fuel for mobile sources	Petrol	3.95	3%
燃料燃燒(移動源)	汽油		
Scope 2 Energy Indirect GHG Emission			
範疇 <b>2</b> 能源間接溫室氣體排放			
Purchased electricity		134.95	93%
所購電力			
Scope 3 Other Indirect GHG Emission			
範疇 <b>3</b> 其他間接溫室氣體排放			
Paper waste disposal		1.02	
堆填區棄置的廢紙			
Electricity used for freshwater processing		0.97	
淡水處理所耗電力			4%
Electricity used for sewage processing		0.46	
污水處理所耗電力			
Business air travel by employees		3.70	
僱員商務差旅			
Total		145.05	100%
總計			
Note 1: Emission factors were made by re-	ference to	<i>附註1:</i> 除另有説明	外,排放系數乃參照上

Appendix 20 to the Listing Rules and their referred documentation as set out by the Stock Exchange, unless stated otherwise.

- 附註1:除另有説明外,排放系數乃參照上 市規則附錄20及聯交所所訂其參考 文件而作出。
- *Note 2:* Emission factor of 0.80 tCO<sub>2</sub>/MWh was used for purchased electricity in Guangdong Province of the PRC.
- 附註2:在中國廣東省購買電力乃採用排放 系數0.80噸二氧化碳當量噸/兆瓦 時計算。

ENVIRONMENTAL, SOCIAL AND GOVERNANCE REPORT 環境、社會及管治報告

#### A1.3 Hazardous Waste

During the Reporting Period, the Group generated a total of 3.9 tonnes of hazardous waste, mainly comprised of hazardous solids and liquids. The intensity was 0.09 kg/unit of product sold, representing a slight increase of 3% compared with the Last Reporting Period.

#### A1.4 Non-hazardous Waste

Non-hazardous waste from the Group's operations consists mainly of paper waste and domestic waste. During the Reporting Period, the Group generated a total of 1.2 tonnes of non-hazardous waste, 18% of which was paper waste derived from the Group's office operation. The overall intensity was 16.48 kg/FTE, representing a 7% drop compared with the Last Reporting Period.

#### A1.5 Measures to Mitigate Emissions

The Group continues its dedication to curbing air pollution and GHG emissions from its operations. To reduce emissions produced though its products, the Group estimates the production needs and determines the optimal production quantity in oneoff production.

The Group highly encourages employees to use public transport whenever possible. The Group has adopted the use of online conferencing tools to reduce air travels. As a result of the Group's continuous efforts, both fuel consumption and vehicle exhaust emissions reduced significantly compared to the Last Reporting Period. In the long run, the Group has established a 10-year Group-wise emission reduction target to reduce emissions by 10% by the fiscal year of 2030.

#### A1.3 有害廢棄物

於報告期間,本集團總共3.9噸有害廢 棄物,主要包括有害固體及液體。密度 為每件售出產品每單位0.09公斤,較上 個報告期略增加3%。

#### A1.4 無害廢棄物

本集團經營活動產生的無害廢棄物主要 包括廢紙及和生活垃圾。於報告期間, 本集團共產生無害廢棄物1.2噸,其中 18%為本集團辦公經營產生的廢紙。整 體密度為16.48公斤/每名全職僱員, 較上個報告期下跌7%。

#### A1.5 減排措施

本集團繼續致力於抑制其業務活動產生 的空氣污染及溫室氣體排放。為減少其 產品產生的排放,本集團估算生產需 求,並確定一次性生產的最佳產量。

本集團極力推崇僱員盡可能使用公共交 通工具。本集團已採用線上視頻會議以 減少飛機差旅。由於本集團不懈努力, 耗油量及汽車尾氣排放均較上個報告期 明顯減少。長遠而言,本集團已設立10 年集團減排目標,以期於二零三零年財 政年度前減排10%。



#### A1.6 Waste Handling and Reduction Initiatives

The Group strictly observes national laws in handling both hazardous and non-hazardous waste. Wastes are reduced and prevented at source wherever possible. Wastewater, as a kind of hazardous waste, is temporarily stored in containers, and collected by designated licensed handler for further treatment prior to disposal.

Paper waste is collected and disposed of in landfills. The Group continues to implement papersaving measures to reduce paper waste at source. For instance, the Group encourages doublesided printing, promotes the use of electronic documentations, and keeps track of paper consumption in promoting a paperless office. The paper consumption pattern was similar to the Last Reporting Period. In the long run, the Group has established a 10-year Group-wise waste reduction target to reduce waste generation by 20% by the fiscal year of 2030.

#### A2. Use of Resources

Although the Group has not established formal policies on improving resource utilization efficiency, the Group adheres to the principle of full utilization of resources and encourages employees to observe relevant practices to achieve resource conservation.

#### A1.6 廢棄物處理及減廢措施

本集團嚴格遵守處理有害廢棄物及無害 廢棄物的法律。盡可能從源頭減廢,作 出預防措施。廢水乃其中一種有害廢棄 物,其臨時存置於安全的容器中,並由 指定具牌照的工程公司負責收集,以便 於處置前作進一步處理。

收集廢紙並於堆填區棄置。本集團繼續 採取節省用紙措施,從源頭減少廢紙, 例如本集團鼓勵雙面打印、採用電子文 件及記錄用紙量,以推廣無紙化辦公。 紙張消耗模式與上個報告期相若。長遠 而言,本集團已設立10年集團減廢目 標,以期於二零三零年財政年度前減廢 20%。

#### A2. 資源使用

儘管本集團並無制定正式政策提高資源 使用效率,但本集團一直堅持充分利用 資源的原則,並鼓勵僱員遵守自然資源 保護的慣例。

# A2.1 Energy Consumption

# A2.1 能源消耗

The total energy consumption by the Group was 180,964 Kilowatt-hour ("**kWh**"), with an overall energy intensity of 2,548 kWh/FTE, and 4.39 kWh per unit of product sold during the Reporting Period.

於報告期間,本集團的總能源消耗量 180,964千瓦時(「**千瓦時**」),總能源密 度為2,548千瓦時/每名全職僱員及每 件售出產品4.39千瓦時。

Direct/indirect Energy Sources 直接/間接能源	Consumption 消耗量 (unit) (單位)	Consumption 消耗量 (kWh) (千瓦時)	E	nergy Intensity 能源密度
Petrol 汽油	1,486 L 1,486升	13,168	185 kWh/FTE 185千瓦時/	0.32 kWh/unit of product sold 0.32千瓦時/每件售出產品
	.,,		每名全職僱員	
Purchased electricity	167,796 kWh	167,796	2,363 kWh/FTE	4.07 kWh/unit of product sold
所購電力	167,796千瓦時		2,363千瓦時/ 每名全職僱員	4.07千瓦時/每件售出產品
Group total 集團總計		180,964	2,548 kWh/FTE 2,548千瓦時/ 每名全職僱員	4.39 kWh/unit of product sold 4.39千瓦時/每件售出產品
Note:			附註:	

Conversion factors were made reference to IEA Energy Statistics Manual and 2006 IPCC Guidelines for National Greenhouse Gas Inventories. 轉換系數乃參考國際能源署能源統計數據手 冊及二零零六年IPCC國家溫室氣體排放清單 指南作出。



#### A2.2 Water Consumption

Freshwater consumed for daily business operations is supplied by municipal freshwater supplier. Water is mainly used for domestic use and in the production of reagents. During the Reporting Period, the water consumption for the Group was 2,294 m<sup>3</sup>, contributing to a water intensity of 32.31 m<sup>3</sup>/FTE or 0.06 m<sup>3</sup> per unit of product sold.

# A2.3 Energy Use Efficiency Initiatives

The Group's major energy consumption is petrol consumption by vehicles and electricity consumption. The Group regularly monitors the usage of energy to achieve consumption efficiency. The Group has formulated a series of measures to achieve electricity conservation and energy efficiency. Energy conservation initiatives adopted by the Group include:

- maintaining default temperature setting of air conditioner at 25.5°C,
- choosing low-carbon and energy-efficient products and appliances,
- setting computers to energy-saving modes when idle, and
- switching off office equipment and electronic devices after office hours.

With the Group's continuous efforts, the energy intensity associated with vehicle fuel consumption was reduced from 311 kWh/FTE to 185 kWh/FTE, significantly dropped by 40% compared to the Last Reporting Period. In the long run, the Group has established a 10-year Group-wise energy reduction target to reduce electricity use by 20% by fiscal year 2030.

#### A2.2 水消耗

日常業務營運消耗的淡水乃由市政淡水 供應商供應。水主要用作生活用水及用 於生產試劑。於報告期間,本集團消耗 的淡水為2,294立方米,水密度為32.31 立方米/每名全職僱員及每件售出產品 0.06立方米。

#### A2.3 能源使用效率舉措

本集團的主要能源消耗為汽車的石油消 耗及電耗。本集團定期監控能源的使 用,以實現消耗效率。本集團已制定一 系列措施以實現節約用電及能源效率。 本集團採取的節能舉措包括:

- 維持空調的預設温度於25.5℃,
- 選擇低碳節能的產品及電器,
- 於閒置時將電腦設為節能模式,及
- 於辦公時間後關上辦公設備及電子 設備。

通過本集團堅持不懈的努力,與上個 報告期比較,車輛油耗能源密度由311 千瓦時/每名全職僱員減少至185千瓦 時/每名全職僱員,顯著降低40%。長 遠而言,本集團已設立10年集團節能目 標,以期於二零三零年財政年度前節電 20%。

#### A2.4 Water Use Efficiency Initiatives

No issue in sourcing water that is fit for purpose had been identified during the Reporting Period. To sustain water resources, the Group encourages water conservation and reminds staff members to reduce water wastage whenever possible. Compared to the Last Reporting Period, the water intensity declined by 32% measured by number of FTE. In the long run, the Group has set a 10-year Group-wise water reduction target to reduce water use by 20% by the fiscal year of 2030.

Water conservation initiatives adopted by the Group include:

- reminding employees to turn off water taps after use;
- putting up posters related to water resource conservation at prominent locations;
- monitoring the water usage patterns, and
- enforcing inspections and maintenance to prevent wastage of water resources.

#### A2.5 Packaging Materials

Paper cartons and plastics were widely used as packaging materials for different presentations of products. During the Reporting Period, a total of 3.25 tonnes packaging materials were consumed, including carton boxes, polyethylene and polypropylene, contributing to an intensity of 0.08 kg per unit of product sold, which remained unchanged as compared to the Last Reporting Period. All packaging materials have undergone rigorous quality control tests before use.

#### A2.4 水使用效率舉措

於報告期間,並無識別與採購適合用途 的水相關的問題。為使水資源得以永 續,本集團鼓勵節約用水,並提醒員工 儘可能減少浪費水源。按全職僱員數目 計算的水密度較上個報告期減少32%。 長遠而言,本集團已設立10年集團減少 用水目標,以期於二零三零年財政年度 前減少用水20%。

本集團採取的節約用水舉措包括:

- 提醒僱員使用水龍頭後將水龍頭關上;
- 於顯眼位置張貼與水資源節約有關 的海報;
- 監察用水模式;及
- 加強檢查及維護,防止浪費水資源。

#### A2.5 包裝材料

紙箱及塑料獲廣泛用於不同產品展示的 包裝材料。於報告期間,共消耗3.25噸 包裝材料,包括紙箱、聚乙烯和聚丙 烯,密度為每件售出產品0.08公斤,其 與上個報告期持平。所有包裝組件於使 用前均已進行質量控制測試。



#### A3. The Environment and Natural Resources

# A3.1 Significant Impacts of Activities on the Environment

The Group's business activities do not pose significant adverse impacts on the environment, except for minor impacts arisen from consumption of energy resources and fuels. The Group's Environmental Management Policy aims to facilitate rational and efficient use of resources such as energy, water and other raw materials. The Group also carries out various measures for reducing GHG emissions and advocating resource conversation through the 3R (namely reducing waste, reusing and recycling resources) principle. During the Reporting Period, any waste, wastewater, or emissions that posed adverse impacts to human or environment was appropriately managed, controlled, and treated prior to release into the environment.

Electricity use was the largest constituent which made up about 93% of the Group's energy use. To reduce electricity use, the Group has specifically adopted various management measures. For instances, the Group has provided education to employees to raise their awareness of energy conservation and given preference to low-carbon and energy-saving appliances.

Looking forward, the Group will persist in operating business in an environmentally responsible manner that drives continual improvement in its business processes, products, and services with little impact on the environment.

# A3. 環境及天然資源

# A3.1活動對環境的重大影響

本集團的業務活動對環境並不會造成重 大不利影響,惟能源資源及燃料消耗所 產生的細微影響除外。本集團的環境管 理政策旨在促進資源(如能源、水及其 他原材料)的合理有效使用。本集團亦 採取各項措施以減少溫室氣體排放及透 過3R(即是減少廢物、重用和回收資源) 原則倡導保護資源。於報告期間,對人 類或環境造成不利影響的任何廢物、廢 水或排放於排放至環境前均得到適當的 管理、控制及處理。

用電為最大能耗組成部分,約佔本集團 能耗的93%。為減少耗電,本集團專門 採納多項管理措施。例如,本集團教育 僱員提升節能意識,優先選擇低碳節能 設備。

展望未來,本集團將堅持以對環境負責 的方式經營業務,推動其業務流程、產 品及服務持續改進,同時不會對環境產 生太大影響。

# **B. SOCIAL**

- 1. Employment and Labor Practices
- **B1.** Employment

The Group strictly abides by all applicable laws and regulations in relation to employment in the PRC during the Reporting Period, including but not limited to:

- Labor Law of the PRC;
- Labor Contract Law of the PRC;
- The Social Insurance Law of the PRC;
- Special Rules on the Labor Protection of Female Employees;
- Social Insurance Law of the PRC;
- Regulation on Paid Annual Leave for Employees; and
- Provisions on the Prohibition of Using Child Labor.

During the Reporting Period, there was no material non-compliance with relevant laws and regulations relating to compensation and dismissal, recruitment and promotion, working hours, rest periods, and other benefits and welfare of the Group.

# B. 社會

- 1. 僱傭及勞工常規
- B1. 僱傭

於報告期間,本集團嚴格遵守與中國僱 傭有關的所有適用法律及規例,包括但 不限於:

- 《中華人民共和國勞動法》;
- 《中華人民共和國勞動合同法》;
- 《中華人民共和國社會保險法》;
- 《女職工勞動保護特別規定》;
- 《中華人民共和國社會保險法》;
- 《職工帶薪年休假條例》;及
- 《禁止使用童工規定》。


於報告期間,本集團並無有關補償及解 僱、招聘及晉升、工作時數、假期及其 他待遇及福利的重大違反法律及規例的 情況。



As of 31 December 2020, the Group had a total number of 80 employees. All of them were full-time employees. The employee structure sorted by gender, age group, function and geographical regions are shown below.

於二零二零年十二月三十一日,本集團 共有80名僱員。彼等均為全職僱員。按 性别、年齡組別、職能及地域分佈的僱 員架構載列如下。

**Distribution of Employees by Age Group** 



Distribution of Employees by Gender 僱員性別分佈

The Employee Manual outlines detailed policies regarding recruitment and dismissal, remuneration and compensation, appraisal and promotion, attendance, compensation leaves, etc. Employees are required to act in accordance with the code of conduct and ethics, which sets forth the Group's ethical standards and expectation of employees.

#### Competitive Compensation and Benefits

The Group offers equitable and competitive remuneration package to attract and retain talents. In addition to basic wages, the Group offers overtime pays, attendance bonus, seniority bonus, housing allowance, and discretionary performance bonus. The Group also safeguards the legitimate interests of its employees, respects the rights of employees to rest and leave, and regulates their working hours and their rights for various types of rest times and holidays. Apart from medical coverage and statutory holidays, employees are entitled to a range of leaves including marriage leave, maternity leave, paternity leave, sick leave and bereavement leave.

#### Performance Review and Promotion

The Group provides development opportunities to its employees through regular performance-based appraisal, so that they can understand their job performance in a clear way by receiving feedback from their supervisors, and evolve in ways that are good for their personal growth and ongoing career development. According to the promotion policy, employees are eligible for career advancement within the Group based on their competencies and suitability for higher-ranking positions. 員工手冊列明有關招聘及解僱、薪酬及 補償、考核及晉升、考勤、離職補償等 詳細政策。僱員須按操守及道德守則行 事,該守則載列本集團指導員工的道德 準則及期望。

#### 具競爭力的薪酬及福利

本集團提供公平及具競爭力的薪酬待 遇,以吸引及挽留人才。除基本工資 外,本集團亦提供考加班費、考勤獎 金、工齡獎金、住房津貼以及酌情績效 獎金。本集團亦保障其員工的法律權 利,尊重員工的休息及休假權利,規管 其工作時數、各類休息及休假的權利。 除醫療保險及法定假期外,員工有權享 有各類假期,例如婚假、產假及侍產 假、病假及喪假。

#### 績效審核及晉升

本集團通過定期績效考核為僱員提供發展機會,使他們可通過收到主管的反 饋,更清楚地了解其工作表現,並以有 利於個人成長及持續職業發展的方式發展。根據晉升政策,員工按其能力及是 否符合更高級別的職位獲得本集團內部 晉升。



# Equal Opportunity

The Group respects the differences in employees. Fairness in labor is practiced within the Group with a view to eliminating discrimination. Employees are provided with equal opportunities in respect of recruitment, employment, training and development, promotion, compensation and benefits, whether on the basis of race, religion, nationality, ethnicity, age, gender or disability. There was no non-compliance relating to equal opportunity, diversity and antidiscrimination during the Reporting Period.

#### Employee Relations

The Group strives to foster a strong sense of belonging of its employees and ensure that every voice is heard through transparent communication channels. Regular meetings are held to collect employee opinions, suggestions, and complaints which are handled promptly.

#### 平等機會

本集團尊重各僱員各有不同。為消除歧 視,本集團實行公平勞工。僱員於招 聘、僱傭、培訓及發展、晉升、補償及 福利方面,不論基於種族、宗教、國 籍、族裔、年齡、性別還是殘疾,均享 有平等機會。於報告期間,並無有關平 等機會、多元化及反歧視的不合規情 況。

#### 僱員關係


本集團致力培養員工的強烈歸屬感,確 保透過透明的溝通渠道聆聽到每名員工 的意見,並定期舉行會議收集員工意 見、建議,並及時處理有關投訴。

# Turnover

The Group considers offering a more attractive remuneration package and benefits to retain talents based on the Group's business situation. A total of 12 full-time employees have left the Group during the Reporting Period, representing an annual turnover rate<sup>1</sup> of 15%. The employee turnover rate<sup>2</sup> by gender, age group and geographical locations are as follows:

#### 僱員流失

本集團考慮根據本集團的業務情況提供 更具吸引力的薪酬待遇及福利挽留人 才。於報告期內,合共12名全職僱員離 開本集團,年度流失率1為15%。按性 別、年齡組別、職能及地域分佈劃分的 僱員流失率2如下:



**TURNOVER RATE** 

80 Annual Report 2020 年報

- <sup>1</sup> The annual turnover rate is calculated by total number of employees who left the Group in the reporting period/ number of employees as at the end of the reporting period\*100%. Employees who leave the Group within probationary period are not counted.
- <sup>2</sup> Turnover rate refers to total number of employee turnover in the specific group throughout the reporting period/total number of employees of the corresponding group as at the end of the reporting period\*100%.
- 年度流失率乃按報告期內從本集團離職僱員 總數/報告期末僱員數目\*100%計算。於 試用期內從本集團離職的僱員不計算在內。
- 流失率乃指於整個報告期內特定群體的僱 員流失總數/報告期末相應群體僱員總數 \*100%。



#### B2. Employee Health and Safety

The Group is dedicated to creating an accidentand injury-free working environment for its employees. During the Reporting Period, the Group strictly complied with all national laws, regulations and standards in safeguarding workplace health and safety, including the Law of the PRC on the Prevention and Treatment of Occupational Diseases, Production Safety Law of the PRC and Regulation on Work-Related Injury Insurance. The Group has obtained the Work Safety Standardization certification for its manufacturing operation in Shenzhen since 2016.

The Group has in place various safety rules and guidelines to address various types of situations and issues. All frontline workers are required to strictly follow the code of safe working practice. To further enforce workplace safety, the Group conducts regular health and safety audits to identify safety risks and carries out investigations for the hidden hazards.

Apart from providing personal protective equipment for employees engaging in activities that occupational hazards can potentially arise, annual health check-up is offered to ensure timely treatment can be given. Safety education and training programs are also provided for the employees to increase their awareness and improve their skills on work safety.

#### B2. 僱員健康和安全

本集團致力為每位僱員創造一個零事故、零受傷的工作環境。於報告期間, 本集團嚴格遵守所有與勞工健康及安全 有關的國家法律、法規及標準,包括 《中華人民共和國職業病防治法》、《中 華人民共和國安全生產法》及《工傷保險 條例》。本集團自二零一六年已為深圳 生產工廠取得安全生產標準化證書。

本集團已設有各項安全規則及指引以處 理各類情形及問題。所有前線員工須嚴 格遵守安全工作常規守則。為進一步加 強工作場所安全,本集團定期進行健康 及安全審核,以識別安全風險並就隱患 開展調查。

除為從事可能引起職業危害活動之僱員 提供個人防護設備之外,本集團每年提 供健康檢查以確保僱員及時獲得治療。 本集團亦為僱員提供安全教育及培訓課 程,以提升他們有關工作安全之意識及 提升他們之技能。

The Group has developed contingency plans and emergency procedures for foreseeable workplace emergencies. Emergency evacuation plans are displayed at conspicuous locations. The Group organizes fire drills every year to ensure that all employees are familiar with the evacuation routes in emergency situations.

In the past 3 years, no fatalities of the Group's employees have been recorded. No work injury case or material non-compliance with relevant laws and regulations in relation to occupational health and safety of the Group was recorded during the Reporting Period. 本集團已就可預見之工作場所緊急事件 制定應急計劃及緊急程序。緊急疏散計 劃張貼於顯眼位置。本集團每年均會組 織消防演習以確保全體僱員均熟悉於緊 急情況下之疏散路線。

在過去的三個年度,本集團僱員並無錄 得任何死亡事故。於報告期內,本集團 並無有關職業健康及安全的工傷事故或 重大違反職業健康及安全相關法律及規 例的情況。

Occupational Health and Safety Statistics in FY2020	二零二零年財政年度職業健康與 安全統計	
Work related fatality	殉職事故	0
Work injury cases >3 days	工傷事故 > 三天	0
Work injury cases ≤3 days	工傷事故 ≤ 三天	0
Lost days due to work injury	因工傷損失工作日	0 day
		0天

#### Responses to the Epidemic

In view of the Epidemic, the Group has set up an emergency response team that swiftly responded to the prevention and control of the virus. A series of anti-epidemic measures have been put in place to contain the spread of the virus in the community and protect the wellbeing of staff. In addition to stepping up the sanitation of the facilities, the Group has also enforced social distancing measures in the workplace, conducted temperature checks for employees, and provided disinfection supplies such as face masks and hand sanitizers.

Moreover, the Group has introduced isolation arrangements for employees with COVID-19 symptoms. In the event of a suspected case of COVID-19, the Group will arrange enhanced cleaning and disinfection measures at the relevant area, and report the suspected case to hospital in accordance with the reporting criteria and guidelines issued by the local government.

#### **B3.** Development and Training

Employee development is vital to the sustainable growth of the Group. The administration department is responsible for developing annual training plan pertaining to the various training needs of employees. Where appropriate, employees are assessed upon recruitment and reviewed periodically thereafter for their proficiency in vocational skills through examinations. Through providing comprehensive training programs, the Group ensures that all employees including R&D personnel, technicians or production workers whose experience and qualifications meet the requirements of relevant positions.

#### 應對疫情

鑒於疫情,本集團成立應急小組,迅速 防控病毒。本集團已推出一系列抗擊疫 情的措施,防止病毒在社區內蔓延及保 護員工的健康。除加強清潔設施外,本 集團亦於工作場所強制實行社交距離措 施,對員工測量體溫,並提供口罩及酒 精搓手液等消毒用品。

此外,本集團對出現 COVID-19症 狀的僱員進行隔離安排。倘有疑似 COVID-19病例,本集團將加強相關區 域的清潔及消毒措施,並根據當地政府 頒佈的報告標準及指引向醫院報告疑似 病例。

### B3. 發展及培訓

員工發展對本集團的可持續發展至關重 要。行政部負責制定滿足僱員各種培訓 需求的年度培訓計劃。於適當情況下, 僱員會於招聘時被評估,其後透過考核 定期審查彼等之職業技能水平。本集團 透過提供全面的培訓計劃,確保研發人 員、技術人員或生產工人等全體員工具 備滿足相關崗位要求的經驗及資質。 During the Reporting Period, the Group organized training sessions covering a broad range of topics for employees from different departments. Some of the Group's internal training programs are as follows:

.. 於報告期內,本集團為不同部門的員工組織涵蓋不同主題的培訓課程。本集團部分內部培訓計劃如下

						Participants 參與者	ants 皆				
Period 時間	Training topics 培训主題	Manager 經理	Production 生產	Quality 質量	Warehouse 倉庫	R&D Team Procurement Engineering 研發團隊 探購 工程	ocurement 效購	Engineering 工程	Admin 行政	Sales 銷售	Sales Technicians 銷售   技術員
May 2020 二零二零年五月	Workplace safety training 工作編始安全培訓		`	`	`	`	`	`	`	>	
July 2020 二零二零年七月	Departmental training on specialized knowledge 部門的專業知識培訓		`	`	`	>		`			
August 2020 二零二零年八月	Compliance and regulatory training 合規及監管培訓	`	`	`	`	`	>	>	`	>	
September 2020 二零二零年九月	Training on contamination control and clean room management 右國沃진선회비장·불ዎ토問答며 상산회		`	`	`	`	`	`	>	`	
October 2020 二零二零年十月	1997 - メンニロシントロネッショム ローエーシュール Product knowledge training 産品知識活動		`	`		`	`				>
November 2020 二零二零年十一月	Quality management system training 質量管理制度培訓		`	`	`	>	>	>	`		
December 2020 二零二零年十二月	Internal audit training on quality management system 質量管理制度內部審計培訓	`	`	`	`	`	`	`	`	`	`

During the Reporting Period, 96% of the Group's employees received trainings; the total training hours and the average training hours per employee were 371 hours and 4.63 hours per employee respectively. 於報告期內,本集團96%的僱員接受培訓,總培訓時數及每名僱員平均培訓時數分別為每名僱員371小時及4.63小時

# **ENVIRONMENTAL, SOCIAL AND GOVERNANCE REPORT** · 環境、社會及管治報告

84



環境、社會及管治報告

# Training and Development Statistics in FY2020

二零二零年財政年度培訓及發展統計

		Percentage of employees trained	Average training hours per employee 每名僱員
		受訓僱員	平均
Gender	性別	百分比	受訓時數
Male	男性	96%	5.31
Female	女性	97%	3.67

		Percentage of employees trained 受訓僱員	Average training hours per employee 每名僱員 平均
Employment category	僱傭類型	交訓僱員 百分比	平均 受訓時數
			~~~~~
Frontline employees	前線員工	97%	3.66
Middle management	中級管理層	89%	7.44
Senior management	高級管理層	100%	8.05

## B4. Labor Standards

The Group pledges to create a society free of child labor and forced labor. There was no child labor nor forced labor employed in the Group; no cases of non-compliance of relevant laws and regulations in relation to labor standards were recorded during the Reporting Period.

The Group complies with the Labor Law of the PRC, Provisions on the Prohibition of Using Child Labor and internal recruitment guidelines which prohibits the employment of workers under the age of 16 in its operation. The human resources department verifies candidates' valid identity documentation, age, and working permit to prevent child labor, forced labor and other forms of unlawful labor. As such, employees hired by the Group are deemed to meet the relevant legal requirements. Consequences of breaching the conditions include termination of contract.

#### B4. 勞工準則

本集團承諾建立一個沒有童工和強制勞 工的社會。本集團並無僱用童工或強制 勞工;於報告期間,並無發現違反勞工 準則相關法律及規例的情況。

本集團遵守《中華人民共和國勞動法》、 《禁止使用童工規定》及內部招聘指引, 禁止在其營運中僱用未滿十六歲的工 人。人力資源部會核實求職者的有效身 份證明文件、年齡及工作許可證,以防 止童工、強制勞工及其他形式的非法勞 工。因此,本集團聘用的僱員被視為符 合相關法律規定。違反條件的後果包括 終止合約。

The Group ensures reasonable working hours and paid holidays in accordance with the national employment laws and requirements. The working hours of the employees are enforced in accordance with the requirements of relevant local laws and regulations; thus, no forced labor is allowed. The Group encourages the employees to complete the daily work within the specific working hours. When overtime work during special arrangement is unavoidable, employees are eligible for overtime pays based on the agreed hourly wage.

#### 2. Operating Practices

#### **B5.** Supply Chain Management

The Group had engaged 42 suppliers during the Reporting Period. All of them were in the PRC primarily providing raw and auxiliary materials for the manufacturing of IVD reagents. The Group adopts an integrated approach in screening and evaluation of potential and existing suppliers respectively. In selecting suppliers, the Group assesses suppliers against the criteria including production capability, product efficacy and quality management system. Performances of all qualified suppliers are regularly monitored through their submissions of testing reports and documents to demonstrate their consistent compliance with the applicable statutory and regulatory requirements.

On-site assessments, when needed, are conducted to ensure that the facility, systems, and products provided by the suppliers are compliant with the requirements on quality, workplace safety and hygiene. If a significant non-conformance is proved, the Group may consider disqualifying or terminating the partnership with the concerned supplier. 本集團根據國家僱傭法律及規定確保合 理工作時長及帶薪假期。僱員的工作時 數按照當地相關法律及規例的規定執 行;因此,絕不容許強制勞工。本集團 鼓勵僱員於特定工作時間內完成日常工 作。在特殊安排而無法避免加班的情況 下,僱員可按協定的時薪領取加班費。

#### 2. 經營常規

#### B5. 供應鏈管理

本集團於報告期間已委聘42家供應商。 該等供應商均於中國主要提供用以生產 體外診斷試劑的原材料及輔助材料。本 集團採用綜合方法分別篩選及評估潛在 及現有供應商。在挑選供應商方面,本 集團按標準評估供應商,包括對其生產 能力、產品效能及質量管理體系進行評 估。所有合資格供應商的表現會透過其 提交檢測報告及文件作定期監察,以證 明其一直遵守適用的法定及監管要求。

現場評估將會在有需要時進行,以確保 供應商提供的設施、系統及產品符合質 量、工作場所安全及衛生的要求。如證 實有重大違規事項,本集團可能考慮取 消或終止與有關供應商的合作關係。



#### B6. Product and Service Responsibility

#### Quality Assurance

The Group is committed to delivering safe, effective, and reliable IVD reagent products that have attained the highest quality standards. Aligning with the Group's corporate quality values, Shenzhen Huakang has obtained the ISO 13485 for medical device manufacturing and implemented a quality management system according to the current good manufacturing practices (the "**cGMP**"). During the Reporting Period, the Group strictly complied with relevant laws and standards established by the China Food and Drug Administration (the "**CFDA**") in the manufacturing of IVD reagents and kits, which included:

- YY/T 0287-2017 standard (i.e., Medical Devices

   Quality Management Systems Requirements for Regulatory Purposes);
- Good Manufacturing Practice for Medical Devices – Appendix on In-Vitro Diagnostic Reagents;
- Good Manufacturing Practice for Medical Devices – Guidelines for Onsite Inspection of In-Vitro Diagnostic Reagents;
- Regulations on Supervision and Administration of Medical Devices;
- Contract Law of the PRC; and
- Product Quality Law of the PRC.

# B6. 產品及服務責任

# 質量保證

本集團致力提供安全、有效及可靠的體 外診斷試劑產品,該等產品均達到最高 質量標準。秉承本集團的企業質量價值 觀,深圳華康就醫療設備製造取得ISO 13485認證,並根據現行優良生產質 量管理規範(「cGMP」)執行質量管理制 度。於報告期內,本集團嚴格遵守國家 食品藥品監督管理總局(「國家食藥監總 局」)就生產體外診斷試劑及試劑盒制定 的相關法律及標準,包括:

- YY/T 0287-2017標準(即《醫療器 械一質量管理制度一用於法規的要 求》);
- 《醫療器械生產質量管理規範附錄 體外診斷試劑》;
- 《醫療器械生產質量管理規範體外 診斷試劑現場檢查指導原則》;
- 《醫療器械監督管理條例》;
- 《中華人民共和國合同法》;及
- 《中華人民共和國產品質量法》。

The Group's quality manual outlines the organizational roles, authorities, as well as responsibilities for the accountable quality management across the Group. Specific production activities are required to be performed in the designated Class 10,000 and 100,000 cleanrooms in compliance with the ISO 14644-1 Cleanroom standard. Moreover, air-sensitive reagent products are stored under controlled conditions, i.e., at a consistent temperature within the range of  $2^{\circ}C-8^{\circ}C$ .

#### Customer Services and Product Recall

The Group values the importance of customer loyalty and is committed to maintaining a stable and longterm relationship with its customers. The Group cares about the customer satisfaction throughout the entire business process from product sales to aftersales services. Customer satisfaction surveys help the Group gain valuable insight into its performance and identify improvements, thereby continuously improving the Group's product and service quality as well as enhancing customer experience. Apart from conducting customer reviews, the Group also constantly explores ways to improve its products through research and development. 本集團的質量手冊概述本集團內負責質 量管理的組織角色、權限及責任。特定 生產活動必須於指定的10,000級無塵 室及100,000級無塵室進行,以符合ISO 14644-1無塵室標準。此外,空氣敏感 試劑產品於受控條件下(即在攝氏2-8度 範圍內的穩定溫度下)儲存。

#### 客戶服務及產品召回

本集團重視客戶忠誠度的重要性,故致 力與其客戶維持穩定及長期的關係。本 集團關注從產品銷售到售後服務的整個 業務流程中的客戶滿意度。客戶滿意度 調查有助本集團收集到有關其表現的意 貴意見,認識到其改善空間,從而持續 提升本集團的產品及服務質素以及改善 客戶體驗。除進行客戶訪問外,本集團 亦持續尋求各種方式,透過研發改善其 產品。



The Group has developed effective mechanisms and handling procedures for dealing with customer complaints and product recalls. Any complaints received will be formally investigated and any necessary follow-up actions are taken in timely manner. The Group carries out investigation and identifies corrective and preventive actions for each complaint case to prevent recurrence. During the Reporting Period, the Group received no complaints related to products and services provided, and all the enquiries had been resolved to the customers' satisfaction. No material non-compliance with relevant laws and regulations in relation to customer services of the Group was identified during the Reporting Period.

The Group's product recall procedure is formulated in accordance with the Administrative Measures for Medical Device Recalls established by CFDA. The quality control department undertakes quality inspections at different stages of the production process. In the event of detecting defective products, the Group will suspend the sale of the concerned products and notify related customers immediately for product recall and replacement. There was no product recalled due to safety and health reasons and no material non-compliance with laws and regulations that have a significant impact on the Group in relation to product health and safety recorded during the Reporting Period. 本集團已開發出有效機制及處理程序, 處理客戶投訴及產品召回。凡收到的投 訴均將得到正式調查,並及時採取任何 必要跟進行動。本集團會對各投訴案任 進行調查,並確認糾正及預防措施,防 止投訴案件再次發生。於報告期內,本 集團並無收到有關產品及所提供服務之 投訴,且所有查詢均已解決,並令客戶 滿意。於報告期內,未發現本集團有關 客戶服務的重大違反法律及規例的情 況。

本集團根據國家食藥監總局頒佈的《醫 療器械召回管理辦法》制定產品召回程 序。質量控制部門於不同生產階段進行 品質檢測。倘發現缺陷產品,本集團將 停止銷售相關產品,並及時通知相關客 戶召回及替換相關產品。於報告期內, 概無因安全及健康理由而被召回的產 品,亦無錄得任何對本集團產品健康及 安全有重大影響的重大違反法律及規例 的情況。

#### Data Protection and Privacy

The Group pays special attention to confidentiality and privacy issue of the Group and third parties. The confidentiality policy stipulates that employees are prohibited to disclose confidential information (e.g., trade secrets, proprietary information, customers data, etc.) to anyone outside of the Group to others and use them for personal benefit or profit. In addition, the Group restricts access to confidential information and trade secrets, except to authorized persons permitted by the Group. No major incidents that impacted the Group's operations or infringed upon client privacy occurred during the Reporting Period.

#### Intellectual Property

The Group understands the importance of originality and appreciates the hard work of the R&D team. The Group's Intellectual Property (the "**IP**") Rights Policy aims to protect IP owned by the Group and third parties in pursuant to the Trademark Law of the PRC and Patent Law of the PRC.

Furthermore, financial incentives are offered to motivate the Group's employees for invention of new products as well as innovative patent projects. The Group also closely monitors the infringement actions in the market and combat any infringement behavior. Any unauthorized use of IP rights may give rise to legal liability. No major incidents relating to infringement of IP rights occurred during the Reporting Period.

Having the IP management system in place, the Group has accelerated the applications and maintenance of patents for its own production design and technology, ensuring the value of intellectual property are well respected and recognized within the Group. As of 31 December 2020, the Group had obtained a total of 19 issued patents for its inventions.

# 數據保護及私隱

本集團特別留意本集團及第三方的保密 及私隱事宜。保密政策規定員工禁止向 本集團任何外部人士披露機密資料(如 商業秘密、專利資料、客戶資料等), 且不得將該等資料用於個人利益或牟 利。此外,本集團禁止查閱機密資料及 商業秘密,惟本集團准許的授權人士除 外。於報告期間,概無發生任何影響本 集團營運或侵犯客戶隱私的重大事件。

#### 知識產權

本集團瞭解原創的重要性,並重視研究 團隊的努力。本集團的知識產權(「知識 產權」)政策旨在根據《中華人民共和國 商標法》及《中華人民共和國專利法》保 障本集團及第三方擁有的知識產權。

此外,本集團提供財務獎勵以激勵本集 團員工發明新產品及創新專利項目。本 集團亦密切監控市場上的侵權行為及打 擊任何侵權行為。非法使用知識產權可 能引發法律責任。於報告期間,概無發 生任何有關知識產權侵權的重大事件。

本集團設有知識產權管理系統,加快為 其自有產品設計及科技申請及維護專 利,確保知識產權的價值在本集團得到 尊重及認同。截至二零二零年十二月 三十一日,本集團已就其發明合共獲得 19項已頒發的專利。



#### **B7.** Anti-corruption

The Group has zero tolerance for bribery and corruption. The Group's ethical standards are clearly set out in the code of conduct and ethics and Employee Manual, which requires all business activities to be operated with high level of integrity. The Anti-corruption Policy strictly prohibits any corrupt acts, practices, and activities with the Group. The Group strictly controls gifts, meals, and entertainment that are recognized as the mere appearance of impropriety. Employees should report any instance or suspected instance of bribery or corruption related to the Group directly to the Group.

During the Reporting Period, the Group was in full compliance with relevant laws and regulations, including the Criminal Law of the PRC, Anti-unfair Competition Law of the PRC, Anti-money Laundering Law of the PRC and Interim Provisions on Banning Commercial Bribery. There was no concluded legal case regarding corrupt practices brought against the Group or its employees during the Reporting Period.

#### Whistle-blowing Policy

A whistle-blowing system is established for employees and other relevant parties to report any suspected misconducts, malpractices, and unlawful or unethical behaviors within the workplace. Whistle-blowers can make confidential reports to the management of the Group, and are reassured of protecting against unfair dismissal, victimization, and unwarranted disciplinary action. Every reported case will be followed through in accordance with the Whistleblowing Policy and related procedures.

# B7. 反貪污

本集團絕不容忍賄賂及貪污。本集團的 道德原則清晰列明於操守及道德守則及 僱員手冊,其中要求所有商業活動必須 在高度誠信下進行。反貪污政策嚴格禁 止與本集團的任何貪污行為、行動及活 動。本集團嚴格控制貌似不正當行為的 禮品、膳食及招待。員工應直接向本集 團舉報任何有關本集團的賄賂或貪污案 件或涉嫌賄賂或貪污案件。

於報告期間,本集團全面遵守《中華人 民共和國刑法》、《中華人民共和國反不 正當競爭法》、《中華人民共和國反洗錢 法》及《關於禁止商業賄賂行為的暫行規 定》等相關法律及規例。於報告期間, 本集團或其僱員並無涉及已審結的貪污 訴訟案件。

#### 舉報政策

本集團已為僱員及其他相關方建立舉報 機制,以舉報工作場所的可疑不當行 為、舞弊行為、及非法或不道德行為。 舉報人可向本集團管理層作出機密舉 報,並保證可免受不公平解僱、受害及 不必要的紀律處分。每宗舉報案件將按 舉報政策及相關程序跟進。

#### **B8.** Community Investment

The Group is committed to supporting the public by means of social participation and contribution as part of its strategic development. To nurture corporate culture and strengthen practices of corporate citizenship, the Group embraces human capital into the social management strategies so as to sustain its corporate social responsibility and support the Group's strategic development. The Group maintains communications with stakeholders from time to time to understand the needs of the communities where the Group operates in and to ensure the communities' interests are taken into consideration. The Group also encourages its employees to take part in various community events in hopes of strengthening team spirit while caring for the vulnerable populations. In the future, the Group will continue to discharge its corporate social responsibility to care for the community and build a harmonious society.

# B8. 社區投資

作為其戰略發展的一部分,本集團致力 參與社會活動及貢獻社會,支援公眾。 為培育企業文化及加強企業公民實踐, 本集團於社會管理策略中投入人力資本 集團於社會管理策略中投入人力資本 集團於社會責任,並支持本集團 發展。本集團不時與持份者保持罵 戰。本集團營運所在地的社區 要,並確保考慮到社區參與活動,以期 提升團隊精神,關愛弱勢群體。未來本 集團將繼續履行其企業社會責任,關愛 社區,共建和諧社會。

# REPORT OF THE DIRECTORS 董事會報告

The Directors are pleased to present their annual report together with the audited consolidated financial statements of the Group for the year ended 31 December 2020.

# **PRINCIPAL ACTIVITIES**

The Company was incorporated in the Cayman Islands under the Companies Law, Cap 22 (Law 3 of 1961, as consolidated and revised), of the Cayman Islands as an exempted company with limited liability on 3 August 2017.

The principal activity of the Company is an investment holding company. Details of the principal activities and other particulars of the principal subsidiaries of the Company are set out in note 32 in the Notes to the consolidated financial statements.

The Group is principally engaged in research and development, manufacture, marketing and sales of IVD reagents and auxiliary reproductive supplies and equipment in the PRC. There were no significant changes to the Group's principal activities during the current year.

# **BUSINESS REVIEW AND FUTURE PROSPECTS**

A discussion and analysis of the activities of the Company as required by Schedule 5 to the Hong Kong Companies Ordinance, including an analysis of the Group's financial performance, an indication of likely future developments in the Group's business and Group's key relationship with its stakeholders who have a significant impact on the Group and on which the Group's success depends, is set out in the sections headed "Chairman's Statement" on pages 5 to 6 and "Management Discussion and Analysis" on pages 7 to 24 of this Report. The above form part of this directors' report. 董事欣然呈列其年度報告連同本集團截至二 零二零年十二月三十一日止年度之經審核綜 合財務報表。

# 主要業務活動

本公司於二零一七年八月三日根據開曼群島 法律第22章公司法(一九六一年第3號法,經 綜合及修訂)在開曼群島註冊成立為豁免有 限公司。

本公司主要業務活動為投資控股。有關主要 活動及本公司主要附屬公司其他資料之詳情 載於綜合財務報表附註32。

本集團主要從事於中國研發、生產、營銷及 銷售體外診斷試劑及輔助生育用品和設備。 本年度,本集團主要業務活動概無發生重大 變動。

#### 業務回顧及未來展望

香港公司條例附表5要求對本公司業務活動 進行討論及分析,當中包括本集團財務表現 分析、本集團業務的未來可能發展態勢的跡 象及本集團與其持份者(對本集團具有重大 影響並為本集團成功加以依賴者)的主要關 係,載於本報告第5至6頁「主席報告」及第7 至24頁「管理層討論及分析」各節。上述構成 本董事會報告之一部分。



# PRINCIPAL RISK AND UNCERTAINTIES

Details of the principal risks and uncertainties of the Group are set out in notes 2 and 29 in the Notes to the consolidated financial statements and in the section headed "Management Discussion and Analysis" of this Report on page 7 to 24.

Investors are advised to make their own judgement or consult their own investment advisors before making any investment in the Shares.

# USE OF PROCEEDS FROM THE SHARE OFFER

Details of the intended uses and utilised amount are set out on page 17 of this Report.

# ENVIRONMENTAL POLICIES AND PERFORMANCE

Details of the Environmental, Social and Governance Report for the year ended 31 December 2020 are set out on page 59 to 92 of this Report.

# COMPLIANCE WITH LAWS AND REGULATIONS

The Group has adopted risk management and internal control policies to monitor the on-going compliance with the relevant laws and regulations. To the best of the Directors' knowledge, information and belief, having made all reasonable enquiries, our Group has complied in material respects with the relevant laws and regulations that have a significant impact on the business and operation of our Group during the year ended 31 December 2020.

# 主要風險及不明朗因素

本集團主要風險及不明朗因素詳情載於綜合 財務報表附註2及29以及本報告第7至24頁 「管理層討論及分析」一節內。

投資者於投資股份之前務請自行判斷或諮詢 其投資顧問。

# 股份發售所得款項用途

擬定用途及已使用金額詳情載於本報告第17 頁。

# 環境政策及表現

截至二零二零年十二月三十一日止年度的環 境、社會及管治報告的詳情載於本報告第59 至92頁。

# 遵守法律法規

本集團已採用風險管理及內部監控政策監察 持續遵守有關法律法規的情況。董事作出一 切合理查詢後,就其所深知、全悉及確信, 本集團於截至二零二零年十二月三十一日止 年度已於重大方面遵守對本集團業務及營運 有重大影響的相關法律及法規。



董事會報告

#### **FINANCIAL RESULTS**

The results of the Group for the year ended 31 December 2020 are set out in the consolidated statement of profit or loss and other comprehensive income on page 125 of this Report.

## **FINAL DIVIDEND**

The Directors does not recommend the payment of any final dividend for the year ended 31 December 2020 *(2019: Nil)*.

There is no arrangement that a shareholder of the Company has waived or agreed to waive any dividends.

# **CHARITABLE DONATIONS**

There were no charitable donations made by the Group during the year ended 31 December 2020 (2019: Nil).

#### **PROPERTY, PLANT AND EQUIPMENT**

Details of movements in property, plant and equipment during the year are set out in note 12 in the Notes to the consolidated financial statements.

# **SHARE CAPITAL**

Details of the movement in share capital of the Company are set out in note 26 in the Notes to the consolidated financial statements.

# RESERVES

Details of movement in the reserves of the Group and of the Company during the year ended 31 December 2020 are set out in the consolidated statement of changes in equity on page 128 and note 34(b) in the Notes to the consolidated financial statements respectively.

# 財務業績

本集團截至二零二零年十二月三十一日止年 度業績載於本報告第125頁綜合損益及其他 全面收益表。

# 末期股息

董事不建議派付截至二零二零年十二月 三十一日止年度的任何末期股息(二零一九 年:無)。

概無本公司股東已放棄或同意放棄任何股息 的安排。

# 慈善捐獻

截至二零二零年十二月三十一日止年度,本 集團並無作出慈善損獻(*二零一九年:無)*。

# 物業、廠房及設備

年內物業、廠房及設備變動詳情載於綜合財務報表附註12。

# 股本

本公司股本變動詳情載於綜合財務報表附註 26。

# 儲備

於截至二零二零年十二月三十一日止年度, 本集團及本公司之儲備之變動詳情分別載於 第128頁綜合權益變動表及綜合財務報表附 註34(b)。 **REPORT OF THE DIRECTORS** 董事會報告

## **DISTRIBUTABLE RESERVES**

Under the Companies Law of the Cayman Islands, the Company may pay dividends out of the profit or the share premium account in accordance with the provisions of Articles of Association, provided that immediately following the date on which the dividend is proposed to be distributed, the Company remains able to pay the debts as and when they fall due in the ordinary course of business. As at 31 December 2020, the Company's reserves available for distribution to shareholders comprising share premium and accumulated profits of the Group, amounted to approximately RMB51.4 million.

# FIVE-YEAR FINANCIAL SUMMARY

A summary of the results and assets and liabilities of the Group for the most recent four years is set out in the section headed "Financial Summary" on page 228 of this Report.

# DIRECTORS

The Directors during the year ended 31 December 2020 and up to the date of this Report were as follows:

#### **Executive Directors**

Mr. Zhang Shuguang (Chairman)
Mr. Zhang Chunguang (Chief Executive Officer)
Mr. Poon Lai Yin Michael (Chief Financial Officer)
Mr. He Jiaming (Business Development Director) (appointed on 14 January 2020)

#### Independent Non-executive Directors

Dr. Chow Kwok Fai Joseph (appointed on 16 December 2020) Dr. Cheng Faat Ting Gary (appointed on 1 September 2020) Dr. Yeung David Wai Chow (resigned on 16 December 2020) Mr. Kwok Chi Shing (resigned on 1 September 2020) Mr. Chan Kin Sang

# 可供分派儲備

根據開曼群島公司法,本公司可根據組織章 程細則條文以溢利或股份溢價賬支付股息, 惟於緊隨建議分派股息當日後,本公司於日 常業務過程中仍可支付到期債務。於二零二 零年十二月三十一日,本公司可供分派予股 東的儲備包括本集團股份溢價及累計溢利, 金額約為人民幣51.4百萬元。

#### 五年財務概要

本集團最近四年之業績及資產及負債概要載 於本報告第228頁「財務概要」一節。

## 董事

截至二零二零年十二月三十一日止年度及直 至本報告日期止,董事如下:

#### 執行董事

張曙光先生(*主席)* 張春光先生(行政總裁) 潘禮賢先生(首席財務官) 何嘉明先生(業務發展董事) (於二零二零年一月十四日獲委任)

#### 獨立非執行董事

周國輝博士 (於二零二零年十二月十六日委任) 鄭發丁博士 (於二零二零年九月一日委任) 楊煒秋醫生 (於二零二零年十二月十六日辭任) 郭志成先生 (於二零二零年九月一日辭任) 陳健生先生



董事會報告

Pursuant to the Articles of Association, at each general meeting, one-third of the Directors for the time being shall retire from office by rotation provided that every Director shall be subject to retirement at an annual general meeting at least once every three years. Such retiring Directors may, being eligible, offer themselves for re-election at the annual general meeting. All Directors appointed by the Board to fill a casual vacancy shall hold office until the first general meeting of shareholders after their appointment and be subject to re-election at such meeting and all Directors appointed by the Board shall hold office only until the next following annual general meeting and shall then be eligible for re-election.

Accordingly, all the current Directors will retire at the forthcoming AGM where they will offer themselves for re-election.

# **CONFIRMATION OF INDEPENDENCE**

The Company has received from each of the independent non-executive Directors an annual confirmation of independence pursuant to Rule 5.09 of the GEM Listing Rules and considers all the independent non-executive Directors to be independent.

# BIOGRAPHIES OF DIRECTORS AND SENIOR MANAGEMENT

The biographical details of the Directors and senior management are disclosed in the section headed "Biographies of Directors and Senior Management" on pages 25 to 33 of this Report.

# MANAGEMENT CONTRACTS

No contract, other than the service contracts, concerning management and administration of the whole or any substantial part of the Group's businesses was entered into or existed during the year ended 31 December 2020. 根據組織章程細則,於每屆股東大會上,當 時在任的三分之一董事須輪值退任,惟各董 事須至少每三年於股東週年大會上輪值退 任一次。有關退任董事或合資格並願意於股 東週年大會上膺選連任。董事會就填補空缺 職位委任之全部董事應任職至彼等獲委任後 召開的首次股東大會及須於有關大會上獲重 選,而獲董事會委任以加入現有董事會之全 部董事僅可任職至下屆股東週年大會及屆時 合資格膺選連任。

因此,全體現任董事將於應屆股東週年大會 上退任並願意膺選連任。

#### 確認獨立性

本公司已收到各獨立非執行董事根據GEM上 市規則第5.09條就其獨立性發出之年度確認 書,認為全體獨立非執行董事具有獨立性。

# 董事及高級管理層之履歷

董事及高級管理層履歷詳情於本報告第25至 33頁「董事及高級管理層履歷詳情」一節披 露。

# 管理合約

於截至二零二零年十二月三十一日止年度, 概無訂立或存在任何與本集團業務中全部或 任何重大部分有關之管理及行政合約(服務 合約除外)。 **REPORT OF THE DIRECTORS** 董事會報告

# **DIRECTORS' SERVICE CONTRACTS**

Each of Mr. Zhang Shuguang, Mr. Zhang Chunguang and Mr. Poon Lai Yin Michael, who were appointed on 25 September 2017, has entered into a service contract with the Company commencing from the Listing Date, which has no fixed term and can be terminated by either party giving not less than three months' notice in writing to the other party. Mr. He Jiaming, who was appointed on 14 January 2020, has entered into a service contract with the Company for an initial fixed term of three years commencing from the date of appointment and can be terminated by either party giving not less than three months' notice. Each of the independent nonexecutive Directors has entered into an appointment letter with our Company for an initial term of three years commencing from their respective appointment dates unless terminated by either party giving not less than one month's written notice to the other party.

As at 31 December 2020, no Director proposed for re-election at the forthcoming AGM has entered into a service contract with the Company, which is not determinable by the Company within one year without payment of compensation, other than statutory compensation.

# DIRECTORS' AND CONTROLLING SHAREHOLDERS' INTEREST IN CONTRACTS

Save as disclosed in note 31 in the Notes to the consolidated financial statements, no contract of significance for the provision of services to the Company or any of its subsidiaries by controling shareholders of the Company or any of its subsidiaries, no transactions, arrangements and contracts of significance in relation to the Group's business to which the Company, or any of its holding companies or subsidiaries was a party and in which a Director, Controlling Shareholders of the Company and their respective connected parties had a material interest, whether directly or indirectly, subsisted at any time during the year ended 31 December 2020.

# 董事服務合約

張曙光先生、張春光先生及潘禮賢先生(均 於二零一七年九月二十五日獲委任)各自已 與本公司訂立服務合約,自上市日期起開 始,並無固定期限,並可由任何一方向另一 方發出不少於三個月的書面通知終止。何嘉 明先生(於二零二零年一月十四日獲委任)已 與本公司訂立服務合約,自委任日期起開 始,初步固定任期為三年,並可由任何一方 發出不少於三個月的通知終止。各獨立非執 行董事已與本公司訂立委任書,自他們各 自的委任日期起初步為期三年,除非任何一 方向另一方發出不少於一個月的書面通知終 止。

於二零二零年十二月三十一日,於應屆股東 週年大會上建議重選的董事並無與本公司訂 立本公司不可於一年內在不予賠償(法定賠 償除外)之情況下終止之服務合約。

# 董事及控股股東於合約的權益

除綜合財務報表附註之附註31所披露者外, 於截至二零二零年十二月三十一日止年度內 任何時間,本公司或其任何控股公司或附屬 公司概無參與訂立本公司控股股東或其任何 附屬公司向本公司或其任何附屬公司提供服 務的重大合約或與本集團業務有關,而本公 司董事、控股股東及彼等各自關連人士於當 中直接或間接擁有重大權益的重大交易、安 排及合約。



董事會報告

# DIRECTORS' AND CHIEF EXECUTIVE'S INTERESTS AND SHORT POSITIONS IN SHARES, UNDERLYING SHARES AND DEBENTURES OF THE COMPANY OR ANY ASSOCIATED CORPORATION

As at 31 December 2020, the interests and short positions of the Directors and chief executive of the Company in the Shares, underlying Shares and debentures of the Company or any of the associated corporations (within the meaning of Part XV of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong) (the "SFO")) which, once the Shares are listed on GEM of the Stock Exchange, will have to be notified to the Company and the Stock Exchange pursuant to Divisions 7 and 8 of Part XV of the SFO (including any interest or short positions which they are taken or deemed to have under such provision of the SFO) or will be required, pursuant to section 352 of the SFO, to be entered in the register referred to therein, or will be required, pursuant to the Rules 5.46 to 5.67 of the GEM Listing Rules relating to securities transactions by the Directors, to be notified to the Company and the Stock Exchange pursuant to the Model Code for Securities Transactions by directors of listed issuers, will be as follows:

# Long Positions in the Shares

# 董事及最高行政人員於本公司及其相關 法團之股份、相關股份及債權證的權益 及淡倉

於二零二零年十二月三十一日,董事及本公 司最高行政人員於本公司或其任何相聯法團 (定義見香港法例第571章證券及期貨條例 (「證券及期貨條例」)第XV部)的股份、相關 股份及債權證中,擁有(一旦股份於聯交所 GEM上市後)須根據證券及期貨條例第XV部 第7及8分部知會本公司及聯交所的權益及淡 倉(包括根據證券及期貨條例有關條文彼等 被當作或被視為擁有的任何權益或淡倉), 或根據證券及期貨條例第352條須登記於該 條所指的登記冊內的權益及淡倉,或根據有 關董事進行證券交易的GEM上市規則第5.46 至5.67條上市發行人董事進行證券交易之標 準守則須知會本公司及聯交所的權益及淡倉 如下:

# 於股份之好倉

Ordinary shares of HK\$0.01 each of the Company

本公司每股面值0.01港元之普通股

Name of Directors/ Chief Executive	Capacity/ Nature of Interest	Number of ordinary shares held <sup>(1)</sup> 所持	Number of share options held <sup>(4)</sup> 所持	Total interest	Percentage of shareholding <sup>⑵</sup> 股權
董事/最高行政人員姓名	身份/權益性質	<b>普通股數目</b> <sup>⑴</sup>	購股權數目	權益總計	百分比(2)
Mr. Zhang Shuguang 張曙光先生	Interests of controlled corporation and concert party <sup>(3)</sup> 受控法團權益及一致行動人士 <sup>(3)</sup>	240,000,000	4,000,000	244,000,000	61.0%
Mr. Zhang Chunguang 張春光先生	Beneficial Owner 實益擁有人	-	4,000,000	4,000,000	1.0%
Mr. Poon Lai Yin Michael 潘禮賢先生	Beneficial Owner 實益擁有人	-	4,000,000	4,000,000	1.0%
Mr. He Jiaming 何嘉明先生	Beneficial Owner 實益擁有人	-	4,000,000	4,000,000	1.0%

REPORT OF THE DIRECTORS 董事會報告

Notes:

- (1) All interest stated are long positions.
- (2) The calculation is based on the total number of 400,000,000 Shares in issue as at 31 December 2020.
- (3) On 16 November 2017, Mr. Zhang Shuguang and Mr. Chang Yim Yang entered into the Acting-in-concert Confirmation ("Confirmation") to acknowledge and confirm, among other things, that they have been and will be actively cooperating, communicating, and acting in concert with each other with respect to their interest in or the business of the relevant members of our Group since they became shareholders of the Company and will continue to act in concert after the signing of the Confirmation. For further details, please refer to the section headed "History and Reorganisation" in the Prospectus. The aggregate of 240,000,000 Shares and 4,000,000 share options are deemed to be interested by them in aggregate under the SFO, consist of (i) 144,576,000 Shares held by Crystal Grant Limited ("Crystal Grant"), a company wholly owned by Mr. Zhang Shuguang, in which Mr. Zhang Shuguang is deemed to be interested under the SFO; and (ii) 95,424,000 Shares held by Ever Charming Inc. ("Ever Charming"), a company wholly owned by Mr. Chang Yim Yang, in which Mr. Zhang Shuguang is deemed to be interested as a result of being a party acting in concert with Mr. Chang Yim Yang; and (iii) 4,000,000 share options granted to Mr. Zhang Shuguang on 9 April 2020.
- (4) Details of the underlying Shares of the Company held by the Director/chief executives are set out in the section headed "Share Option Scheme".

附註:

- (1) 所有所列權益均為好倉。
- (2) 此乃基於二零二零年十二月三十一日的已發 行股份總數400,000,000股計算。
- (3) 於二零一七年十一月十六日,張曙光先生及 張賢陽先生訂立一項一致行動確認書(「確認 書」),以承認並確認(其中包括)彼等於成 為本公司股東後一直並將就彼等於本集團 有關成員公司之權益或相關業務積極合作 溝通並彼此保持一致行動,且將於簽署確 認書後繼續保持一致行動。有關進一步詳 情,請參閱招股章程「歷史及重組」一節。 根據證券及期貨條例,彼等合計被視為於 合共240,000,000股股份和4,000,000份購 股權中擁有權益,其中包括(i) Crystal Grant Limited(「Crystal Grant」,由張曙光先生 全資擁有之公司)持有之144,576,000股股 份,根據證券及期貨條例張曙光先生被視為 於其中擁有權益;及(ii) Ever Charming Inc. (「Ever Charming」,由張賢陽先生全資擁 有之公司)持有之95,424,000股股份,由於 張曙光先生為與張賢陽先生一致行動之人 士,故其被視為於該等股份中擁有權益;及 (iii)在二零二零年四月九日授於張曙光先生 4,000,000份購股權。
- (4) 董事/最高行政人員持有之本公司相關股份 的詳情載於「購股權計劃」一節。



# Long Position in the Ordinary Shares of Associated 於相聯法團普通股之好倉 Corporations

Name of Directors/ Chief Executive 董事/最高行政人員姓名	Name of Associated Corporation 相聯法團名稱	Capacity/ Nature of Interest 身份/權益性質	Number of ordinary shares held <sup>(Note)</sup> 所持普通股數目 <sup>(附註)</sup>	Percentage of shareholding 股權百分比
Mr. Zhang Shuguang	Crystal Grant	Beneficial owner	100 shares of US\$1.00 each	100%
張曙光先生	Crystal Grant	實益擁有人	100股每股1.00美元之 股份	100%

Note:

附註:

All interest stated are long positions.

所有所列權益均為好倉。

Save as disclosed above, as at 31 December 2020, none of the Directors and the chief executive of the Company had any interests or short positions in the Shares, underlying Shares or debentures of the Company or any of its associated corporations (within the meaning of Part XV of the SFO) which would have to be notified to the Company and the Stock Exchange under Divisions 7 and 8 of Part XV of the SFO (including interests or short positions which he is taken or deemed to have under such provision of the SFO) or which would be required, pursuant to Section 352 of the SFO, to be entered in the register referred to therein, or which would be required pursuant to Part XV of the SFO or Rules 5.46 to 5.67 of the GEM Listing Rules to be notified to the Company and the Stock Exchange. 除上文所披露者外,於二零二零年十二月 三十一日,概無董事及本公司最高行政人員 於本公司或其任何相聯法團(定義見證券及 期貨條例第XV部)的股份、相關股份或債權 證中擁有根據證券及期貨條例第XV部第7及 第8分部須知會本公司及聯交所的任何權益 或淡倉(包括根據證券及期貨條例有關條文 彼被當作或視為擁有之權益或淡倉),或根 據證券及期貨條例第352條須登記於該條所 述登記冊的任何權益或淡倉,或根據證券及 期貨條例第XV部或GEM上市規則第5.46條至 第5.67條須知會本公司及聯交所的任何權益 或淡倉。



# Substantial Shareholders' and Others Persons' Interests and Short Positions in Shares and Underlying Shares

As at 31 December 2020, so far as is known to the Directors, the following persons (not being a Director or chief executive of the Company) had interest or short position in the Shares or underlying Shares which fell to be disclosed to the Company and the Stock Exchange under Divisions 2 and 3 of Part XV of the SFO or as recorded in the register required to be kept by the Company pursuant to Section 336 of the SFO:

# 主要股東及其他人士於股份及相關股份之權 益及淡倉

於二零二零年十二月三十一日,據董事所 知,以下人士(既非董事亦非本公司最高行 政人員)於股份或相關股份中擁有根據證券 及期貨條例第XV部第2及第3分部須向本公 司及聯交所披露,或記錄於本公司根據證券 及期貨條例第336條須存置之登記冊內的權 益或淡倉:

	Constitut	Number of	Number of	Tatal	Deveenters of
	Capacity/	ordinary	share options	Total	5
Name of Shareholders	Nature of Interest	shares held <sup>⑶</sup> 所持	held <sup>⑷</sup> 所持	interest	shareholding 股權
股東姓名/名稱	身份/權益性質	<b>普通股數目</b> ®	購股權數目	權益總計	百分比
Crystal Grant	Beneficial owner and concert party <sup>(1)</sup>	240,000,000	4,000,000	244,000,000	61.0%
Crystal Grant	實益擁有人及一致行動人士 <sup>(1)</sup>				
Ever Charming	Beneficial owner and concert party <sup>(1)</sup>	240,000,000	4,000,000	244,000,000	61.0%
Ever Charming	實益擁有人及一致行動人士(1)				
Mr. Chang Yim Yang 張賢陽先生	Interests of controlled corporation <sup>(1)</sup> 受控法團權益 <sup>(1)</sup>	240,000,000	4,000,000	244,000,000	61.0%
Gallizul Global Investments Incorporated (" <b>Gallizul</b> ")	Beneficial owner	30,000,000	-	30,000,000	7.5%
Gallizul Global Investments Incorporated([ <b>Gallizul</b> ])	實益擁有人				
Huang Yan 黃豔	Interests of controlled corporation <sup>(2)</sup> 受控法團權益 <sup>(2)</sup>	30,000,000	-	30,000,000	7.5%



董事會報告

Notes:

- (1) On 16 November 2017, Mr. Zhang Shuguang and Mr. Chang Yim Yang entered into the Confirmation to acknowledge and confirm, among other things, that they have been and will be actively cooperating, communicating, and acting in concert with each other with respect to their interest in or the business of the relevant members of our Group since they became shareholders of the Company and will continue to act in concert after the signing of the Confirmation. For further details, please refer to the section headed "History and Reorganisation" in the Prospectus. The aggregate of 240,000,000 Shares and 4,000,000 share options are deemed to be interested by them in aggregate under the SFO, consist of (i) 144,576,000 Shares held by Crystal Grant, a company wholly owned by Mr. Zhang Shuguang, in which Mr. Zhang Shuguang is deemed to be interested under the SFO; (ii) 95,424,000 Shares held by Ever Charming, a company wholly owned by Mr. Chang Yim Yang, in which Mr. Zhang Shuguang is deemed to be interested as a result of being a party acting in concert with Mr. Chang Yim Yang; and (iii) 4,000,000 share options granted to Mr. Zhang Shuguang on 9 April 2020.
- (2) As Gallizul is owned as to 60% by Ms. Huang Yan, she is deemed to be interested in all the shares held by Gallizul
- (3) All interests stated are long positions.
- (4) Details of the underlying shares of the Company held by the substantial shareholder are set out in the section headed "Share Option Scheme".

#### 附註:

- (1) 於二零一七年十一月十六日,張曙光先生 及張賢陽先生訂立確認書,以承認並確認 (其中包括)彼等於成為本公司股東後一直並 將就彼等於本集團有關成員公司之權益或 相關業務積極合作溝通並彼此保持一致行 動,且將於簽署確認書後繼續保持一致行 動。有關進一步詳情,請參閱招股章程 歷 史及重組」一節。根據證券及期貨條例,彼 等合計被視為於合共240,000,000股股份和 4,000,000份購股權中擁有權益,其中包括 (i)Crystal Grant(由張曙光先生全資擁有之公 司) 持有之144,576,000 股股份, 根據證券 及期貨條例張曙光先生被視為於其中擁有權 益; (ii) Ever Charming (由張賢陽先生全資 擁有之公司)持有之95,424,000股股份,由 於張曙光先生為與張賢陽先生一致行動之人 士,故其被視為於該等股份中擁有權益;及 (iii)在二零二零年四月九日授於張曙光先生 4.000.000份購股權。
- (2) 由於Gallizul由黃豔女士擁有60% ,故彼被 視為於Gallizul持有的所有股份中擁有權益。
- (3) 所有所列權益均為好倉。
- (4) 主要股東持有之本公司相關股份的詳情載於 「購股權計劃」一節。



# DIRECTORS' RIGHTS TO ACQUIRE SHARES OR DEBENTURES

Save as otherwise disclosed in this Report, at no time during the year ended 31 December 2020 and up to the date of this Report, have the Directors and the chief executive of the Company and their respective close associates (as defined in the GEM listing rules) had any interests in, or had been granted, or exercised any rights to acquire benefits by means of the acquisition of shares in, or debentures of, the Company and/or its associated corporations (within the meaning of SFO).

# PERMITTED INDEMNITY PROVISION

The Articles of Association provide that Directors shall be entitled to be indemnified out of the assets of the Company against all losses or liabilities incurred or sustained in defending any proceedings, whether civil or criminal, in which judgement is given in his favour, or in which he is acquitted. The Company has maintained liability insurance to provide appropriate cover for the Directors during the year ended 31 December 2020.

# **COMPETING INTEREST**

The Directors confirm that none of the controlling shareholders or the Directors and their respective close associates (as defined in the GEM Listing Rules) is interested in any business apart from the business operated by our Group which competes or is like to compete, directly or indirectly, with our Group's business during the year ended 31 December 2020 and up to the date of this Report.

#### 董事收購股份或債權證的權利

除本報告另有披露者外,於截至二零二零年 十二月三十一日止年度任何時間直至本報告 日期,董事及本公司最高行政人員及彼等各 自之緊密聯繫人(定義見GEM上市規則)概 無於本公司及/或其相聯法團(定義見證券 及期貨條例)之股份或債權證中擁有任何權 益或獲授予或行使可藉收購本公司及/或其 相聯法團股份或債權證而獲取利益之任何權 利。

# 獲准彌償條文

組織章程細則規定,董事有權就其在獲判勝 訴或獲判無罪的任何法律訴訟(不論民事或 刑事)中進行抗辯而招致或蒙受的一切損失 或責任從本公司資產中獲得彌償。截至二零 二零年十二月三十一日止年度,本公司已續 購責任保險,為董事提供適當保障。

# 競爭權益

董事確認,於截至二零二零年十二月三十一 日止年度直至本報告日期,概無控股股東或 董事或彼等各自之緊密聯繫人(定義見GEM 上市規則)於本集團經營業務以外且直接或 間接與本集團業務構成競爭或可能構成競爭 的任何業務中擁有權益。



#### **DEED OF NON-COMPETITION**

On 27 November 2018, the Company entered into the Deed of Non-competition with each of the Controlling Shareholders of the Company. Pursuant to the Deed of Non-competition, each of the Controlling Shareholders have undertaken, jointly and severally, to the Company that they would not, and would procure their respective close associates (as defined in the GEM Listing Rules) and/ or companies controlled by the respective Controlling Shareholders not to, directly or indirectly, either on their own account or in conjunction with or on behalf of any person, firm or company, among other things, carry on, participate or be interested or engaged in or acquire or hold (in each case whether as a shareholder, partner, agent or otherwise) any business or activity which is or may be in competition with the business of the Group. Details of the Deed of Non-competition are disclosed in the section headed "Relationship with our Controlling Shareholders" of the Prospectus. The Company has received an annual declaration in writing from each of the Controlling Shareholders confirming that he/it had complied with the non-competition undertakings provided to the Company under the Deed of Noncompetition. The independent non-executive Directors have reviewed the status of compliance and enforcement of the Deed of Non-competition and confirmed that all the undertakings thereunder have been complied with since the date of the execution of the same and up to 31 December 2020.

# 不競爭契據

於二零一八年十一月二十七日,本公司與本 公司各控股股東訂立不競爭契據。根據不競 爭契據,各控股股東已共同及個別向本公司 承諾,彼等將不會並將促致彼等之各自緊密 聯繫人(定義見GEM上市規則)及/或有關 控股股東控制之公司不會自行或聯同或代表 任何人士、商號或公司直接或間接(其中包 括)進行、參與或於當中擁有權益或從事或 收購或持有(在各情況下,不論以股東、合 夥人、代理人或其他身份)與本集團業務構 成或可能構成競爭的任何業務或活動。有關 不競爭契據的詳情載於招股章程「與控股股 東的關係」一節。本公司已收到來自各控股 股東的書面年度聲明,確認彼已遵守不競爭 契據項下提供予本公司的不競爭承諾。獨立 非執行董事已檢討不競爭契據的遵守及執行 情況,並確認不競爭契據項下的所有承諾自 不競爭契據簽署日期直至二零二零年十二月 三十一日已獲遵守。

**REPORT OF THE DIRECTORS** 董事會報告

#### **RELATED PARTY TRANSACTIONS**

Details of the related party transactions of the Group for the year ended 31 December 2020 are set out in note 31 in the Notes to the consolidated financial statements. Save as mentioned in the section "Connected Transactions" below, other related party transactions did not constitute connected transactions and continuing connected transactions under Chapter 20 of the GEM Listing Rules. The Company has complied with the disclosure requirements in accordance with Chapter 20 of the GEM Listing Rules.

#### **CONNECTED TRANSACTIONS**

On 14 September 2020, a renewal tenancy agreement was entered into between Shenzhen Huakang (as tenant) and Shenzhen Junxuan Biological Technology Co., Ltd.\* ("**Shenzhen Junxuan**") (as landlord), pursuant to which Shenzhen Junxuan agrees to rent out Junxuan Property (as defined in the Prospectus) to Shenzhen Huakang for a term of three years commencing on 14 September 2020 and ending on 13 September 2023 (the "**Tenancy Agreement**").

Pursuant to HKFRS 16 "Leases", the Company shall recognise the premises leased under Tenancy Agreement as a right-of-use asset in the consolidated financial statements of the Group for the year ended 31 December 2020. The entering into of the Tenancy Agreement is regarded as an acquisition of asset under the definition of transaction as set out in Rule 19.04(1)(a) of the GEM Listing Rules. The value of the right-of-use asset initially recognized under the Tenancy Agreement for the year ended 31 December 2020 was approximately RMB1,612,000.

# 關連方交易

本集團截至二零二零年十二月三十一日止年 度的關連方交易詳情載於綜合財務報表附註 的附註31。除下文「關連交易」一節所述者 外,其他關聯方交易並不構成GEM上市規則 第20章項下之關連交易及持續關連交易。 本公司已根據GEM上市規則第20章遵守披露 規定。

# 關連交易

於二零二零年九月十四日,深圳華康(作為 承租人)與深圳市君軒生物技術有限公司 (「**深圳君軒**」)(作為業主)訂立續期租賃協 議,據此,深圳君軒同意將君軒物業(定義 見招股章程)出租予深圳華康,自二零二零 年九月十四日起至二零二三年九月十三日止 為期三年(「**租賃協議**」)。

根據香港財務報告準則第16號「租賃」,本公司須於本集團截至二零二零年十二月三十一日止年度的綜合財務報表將租賃協議項下承租的物業確認為使用權資產。按GEM上市規則第19.04(1)(a)條所載之交易的定義,訂 立租賃協議被視為收購資產。租賃協議項下 確認為使用權資產截至二零二零年十二月 三十一日止年度的金額初始確認約為人民幣 1,612,000元。



董事會報告

Pursuant to Chapter 20 of the GEM Listing Rules, a transaction was entered into by the Group with the connected person (as defined in Chapter 20 of the GEM Listing Rules) which constituted a connected transaction during the year ended 31 December 2020. The relevant applicable ratios (other than the profit ratios) under Chapter 20 of the GEM Listing Rules were less than 5.0% and the total consideration was less than HK\$3.0 million, and therefore pursuant to Rule 20.74 of the GEM Listing Rules, the connected transaction contemplated herein was fully exempt from the reporting, announcement, annual review and independent shareholders' approval requirements under Chapter 20 of the GEM Listing Rules. Details of the aforesaid transaction are as follows:

根據GEM上市規則第20章,於截至二零二零 年十二月三十一日止年度,本集團與關連人 士(定義見GEM上市規則第20章)訂立之交 易構成一項關連交易。由於GEM上市規則第 20章下的相關適用比率(溢利比率除外)低於 5.0%且總代價少於3.0百萬港元,因此根據 GEM上市規則第20.74條,其項下擬進行的 關連交易全部獲豁免遵守GEM上市規則第20 章項下之申報、公告、年度審閱及獨立股東 批准規定。上述交易的詳情如下:

Connected transaction	Connected Person	Initial recongnised amount for the year ended 31 December 2020 截至二零二零年 十二月三十一日 止年度的	
關連交易	關連人士	初始確認金額	
PRC factory rental expenses 中國廠房租賃開支	Shenzhen Junxuan 深圳君軒	RMB1,612,000 人民幣1,612,000元	Note 附註

Note:

Mr. Zhang Shuguang, our Controlling Shareholder, executive Director and chairman of our Board, holds the entire equity interest in Shenzhen Junxuan. Therefore, Shenzhen Junxuan is an associate of Mr. Zhang Shuguang pursuant to Rule 20.10(1) (c) of the GEM Listing Rules, and thus it is a connected person of our Company under the GEM Listing Rules. The transaction under the Tenancy Agreement (as defined above) constitutes a connected transaction of our Company under the GEM Listing Rules.

#### 附註:

我們的控股股東、執行董事及董事會主席張曙光 先生持有深圳君軒全部股權。因此,根據GEM上 市規則第20.10(1)(c)條,深圳君軒為張曙光先生 的聯繫人,故為GEM上市規則項下本公司之關連 人士。根據GEM上市規則,租賃協議(定義見上 文)項下之交易構成本公司之關連交易。



# KEY RELATIONSHIPS WITH EMPLOYEES, CUSTOMERS AND SUPPLIERS

The Group maintains a good relationship with its employees, and certain policies have been implemented to ensure that its employees are provided with competitive remuneration, good welfare benefits and continuous professional training. The Group also maintains good relationships with its customers and suppliers, without whom success in the Group's production and operation would be at risk.

### SHARE OPTION SCHEME

The Company has adopted the Share Option Scheme pursuant to an ordinary resolution passed by the shareholders in the extraordinary general meeting on 13 January 2020. The Share Option Scheme is a longterm incentive scheme of the Company to reward it's employees, Directors and other eligible participants for their contributions to the Group and to assist the Group in its recruitment and retention of high calibre employees and other eligible participants who are instrumental to the growth and development of the Group.

Eligible participants of the Share Option Scheme include: (a) any employee or proposed employee (whether fulltime or part-time and including any executive Director), consultants or advisers of or to the Company, any of its subsidiaries or any entity in which the Group an equity interest ("Invested Entity"); (b) any non-executive Directors (including independent non-executive Directors) of the Company, any of its subsidiaries or any Invested Entity; (c) any supplier of goods or services to any member of the Group or any Invested Entity; (d) any customer of the Group or any Invested Entity; (e) any person or entity that provides research, development or other technological support to the Group or any Invested Entity; and (f) any shareholder of any member of the Group or any Invested Entity or any holder of any securities issued by any member of the Group or any Invested Entity, and any company wholly owned by one or more persons belonging to any of the above classes.

### 與僱員、客戶及供應商的關鍵關係

本集團與僱員維持良好關係並已實施若干政 策確保為僱員提供具競爭力的薪酬、良好的 福利及持續專業培訓。本集團亦與其客戶及 供應商維持良好關係,彼等對本集團生產及 營運的成功具關鍵作用。

### 購股權計劃

本公司已根據股東於二零二零年一月十三日 的股東特別大會上通過的一項普通決議案採 納購股權計劃。購股權計劃乃本公司的長期 激勵計劃,旨在獎勵其僱員、董事及其他合 資格參與者對本集團作出貢獻,同時協助本 集團招聘及挽留高素質僱員及其他對本集團 成長及發展至關重要的合資格參與者。

購股權計劃的合資格參與者包括:(a)本公 司、其任何附屬公司或本集團持有股權之任 何實體(「投資實體」)之任何僱員或擬聘用僱 員(不論全職或兼職及包括任何執行董事)、 諮詢顧問或顧問;(b)本公司、其任何附屬公 司或任何投資實體之任何非執行董事(包括 獨立非執行董事);(c)向本集團任何成員公 司或任何投資實體提供貨品或服務的任何供 應商;(d)本集團或任何投資實體的任何客 戶;(e)向本集團或任何投資實體提供研究、 **開發或其他技術支持之任何人士或實體;及** (f)本集團任何成員公司的任何股東或任何投 資實體或本集團任何成員公司或任何投資實 體所發行的任何證券的任何持有人,以及屬 於上述任何類別的一名或多名人士所全資擁 有的任何公司。



董事會報告

Subject to the earlier termination of the Share Option Scheme in accordance with the rules thereof, the Share Option Scheme shall remain in force for a period of ten years commencing from the date of adoption.

The maximum number of shares issuable upon the exercise of options granted under the Share Option Scheme and any other share option scheme adopted by the Group (including both exercised or outstanding options) to each grantee within any 12-month period, is limited to 1% of the shares of the Company in issue at any time.

Share options granted to a Director, chief executive or substantial shareholder of the Company, or to any of their associates, are subject to approval in advance by the independent non-executive Directors of the Company. In addition, any share options granted to a substantial shareholder or an independent non-executive Director of the Company, or to any of their associates, in excess of 0.1% of the shares of the Company in issue at any time and with an aggregate value (based on the closing price of the Company's shares at the date of the grant) in excess of HK\$5 million, within any 12-month period, are subject to shareholders' approval in advance in a general meeting.

The total number of shares which may be issued upon the exercise of all options (excluding for this purpose options which have lapsed) which have been or may be granted under the Share Option Scheme and any share option scheme of the Group must not in aggregate exceed 40,000,000 shares, representing 10% of the shares of the Company in issue as at the date of approval of the Share Option Scheme and as at the end of Reporting Period and the date of approval of this Report. The maximum number of shares to be issued upon the exercise of all outstanding options granted and yet to be exercised under the Share Option Scheme and any other share option scheme of the Group must not in aggregate exceed 30% of the shares of the Company in issue from time to time. 根據購股權計劃的規則,除購股權計劃提前 終止外,購股權計劃將自採納之日起計的十 年期間有效。

於任何十二個月期間內根據購股權計劃及本 集團採納之任何其他購股權計劃(包括已行 使及未行使購股權)項下授予各承授人的購 股權獲行使時可予發行股份數目之上限,以 本公司任何時間之已發行股份之1%為限。

授予本公司董事、主要行政人員或主要股東 或彼等任何聯繫人之購股權,須先經本公司 獨立非執行董事批准。此外,於任何十二個 月期間,倘授予本公司主要股東或獨立非執 行董事或彼等任何聯繫人之任何購股權超逾 本公司任何時候之已發行股份0.1%及總值 (以本公司股份於授出日期之收市價計算)超 過5百萬港元,則須經股東於股東大會上事 先批准。

因行使根據購股權計劃及本集團任何購股 權計劃已授出或可能授出的所有購股權(就 此而言,不包括已失效的購股權)而可予發 行的股份總數,合共不得超過40,000,000 股,佔於購股權計劃批准之日以及於報告期 末及本報告批准之日的本公司已發行股份的 10%。因行使根據購股權計劃及本集團任 何其他購股權計劃獲授出但有待行使之所 有尚未行使購股權而可予發行之股份最高數 目,合共不得超過本公司不時已發行股份的 30%。 REPORT OF THE DIRECTORS 董事會報告

The offer of a grant of share options may be accepted within 30 days from the date of offer, upon payment of a nominal consideration of HK\$1 in total by the grantee. The exercise period of the share options granted is determinable by the Directors, which period may commence from the date of the offer of the share options, and ends on a date which is not later than ten years from the date of grant of the share options subject to the provisions for early termination thereof.

The exercise price of the share options is determinable by the Directors, but shall not be less than the highest of (i) the closing price of the Company's shares as quoted on the Stock Exchange's daily quotations sheet on the date of the offer; (ii) the average closing price of the Company's shares as quoted on the Stock Exchange's daily quotations sheet for the five business days immediately preceding the date of offer; and (iii) the nominal value of a share.

As at 31 December 2020, the Company had granted 25,504,000 share options under the Share Option Scheme. Please refer to paragraph headed "Share Option Scheme" in the section "Management Discussion and Analysis" (for further details).

# EMOLUMENTS OF THE DIRECTORS AND THE FIVE HIGHEST PAID INDIVIDUALS

Detail of the emoluments of the Directors and the five highest paid individuals of our Group are set out in note 8 in the Notes to the consolidated financial statements in this Report.

There was no arrangement under which a Director has waived or agreed to waive any emoluments for the year ended 31 December 2020.

Save for Directors' fees, none of the independent nonexecutive Directors is expected to receive any other remuneration for holding their office as an independent non-executive Director. 授出購股權之要約可於要約日期起計三十日 內由承授人支付名義代價合共1港元予以接納。所授出購股權的行使期由董事釐定,行 使期可由購股權的要約日期開始,並於不遲 於授出購股權日期起計十年當日結束,惟須 遵守提前終止的規定。

購股權行使價將由董事釐定,惟不可低於以 下各項之最高者:(i)於要約日期本公司股份 在聯交所每日報價表所列之收市價:(ii)本公 司股份於緊接要約日期前五個交易日在聯交 所每日報價表所列之平均收市價:及(iii)股份 之面值。

於二零二零年十二月三十一日,本公司已根 據購股權計劃授出25,504,000份購股權。有 關更多詳情,請參閱「管理層討論及分析」一 節「購股權計劃」一段。

### 董事及五名最高薪人士的薪酬

本集團董事及五名最高薪人士的薪酬詳情載 於本報告綜合財務報表附註8。

截至二零二零年十二月三十一日止年度,概 無董事根據任何安排放棄或同意放棄任何酬 金。

除董事袍金外,概無獨立非執行董事預期會 就彼等擔任獨立非執行董事收取任何其他酬 金。



### **EMOLUMENT POLICY**

The emolument policy for the employee of the Group is set up by the management on the basis of their merit, qualifications and competence. Under the emolument policy, the basis of determining the emolument payable to Directors is subject to the decision of the Remuneration Committee of the Company. As at 31 December 2020, the Group has 80 full-time employees (2019: 73) located in Hong Kong and the PRC for operation. Detail of the staff costs, including Directors' remuneration, incurred by the Group are set out in note 7 in the Notes to the consolidated financial statements in this Report.

The Remuneration Committee will review and determine the remuneration and compensation packages of the Directors' regarding their responsibilities, workload, time devoted to our Group and the performance of our Group.

### **MAJOR CUSTOMERS AND SUPPLIERS**

The Group's largest customer contributed approximately 11.2% (2019: approximately 12.2%) of the total revenue for the year while the Group's five largest customers accounted for approximately 26.3% (2019: approximately 28.5%) of the total revenue for the year. The Group's largest supplier contributed approximately 16.7% (2019: approximately 21.4%) of the total purchase for the year while the Group's five largest suppliers accounted for approximately 62.2% (2019: approximately 73.0%) of the total purchase for the year.

At no time during the year ended 31 December 2020 have the Directors, any of their associates or any Shareholder (which to the knowledge of the Directors owns more than 5% of the number of issued Shares) had any beneficial interest in any of the above major customers and suppliers during the year ended 31 December 2020.

### 薪酬政策

本集團僱員的薪酬政策乃管理層根據彼等之 特長、資格及能力設立。根據薪酬政策,應 付董事之酬金須由本公司薪酬委員會釐定。 於二零二零年十二月三十一日,本集團於香 港及中國擁有80名全職僱員(二零一九年: 73名)開展業務。有關本集團所產生員工成 本(包括董事酬金)之詳情,載於本報告綜合 財務報表附註之附註7。

薪酬委員會將根據董事各自的職責、工作 量、為本集團貢獻的時間及本集團的業績表 現檢討及釐定董事之薪酬及報酬包。

### 主要客戶及供應商

本集團最大客戶之貢獻佔年內總收益約 11.2%(*二零一九年:約12.2%)*,而本集 團五大客戶之貢獻佔年內總收益約26.3% (*二零一九年:約28.5%*)。本集團最大供 應商貢獻年內總採購之約16.7%(*二零一九年:約21.4%*),而本集團五大供應商貢獻 年內總採購之約62.2%(*二零一九年:約* 73.0%)。

於截至二零二零年十二月三十一日止年度之 任何時間,概無董事、任何彼等聯繫人或任 何股東(據董事所知擁有已發行股份數目5% 以上)於截至二零二零年十二月三十一日止 年度於任何上述主要客戶及供應商中擁有任 何實益權益。 **REPORT OF THE DIRECTORS** 董事會報告

### **INTEREST OF COMPLIANCE ADVISER**

In accordance with Rule 6A.19 of the GEM Listing Rules, the Company had appointed Ever-Long Securities Company Limited ("**Compliance Adviser**") as its compliance adviser.

As at 31 December 2020, as notified by the Compliance Adviser, save for (i) the compliance adviser agreement dated 31 May 2019 entered into between the Company and the Compliance Adviser regarding the receipt of fees for acting as the Compliance Adviser, and (ii) the participation as one of the joint bookrunners in relation to the Listing as disclosed in the Prospectus, neither the Compliance Adviser nor its directors or employees or close associates (as defined under the GEM Listing Rules) had or may have had any interest in the securities of the Company or any member of the Group (including options or rights to subscribe for such securities which require notification to the Group pursuant to Rule 6A.32 of the GEM Listing Rules as at 31 December 2020.

### **EQUITY-LINKED AGREEMENTS**

No equity-linked agreements that will or may result in the Company issuing Shares or that require the Company to enter into any agreements that will or may result in the Company issuing Shares were entered into by the Company, or subsisting during the year ended 31 December 2020.

# PURCHASE, SALES OR REDEMPTION OF LISTED SECURITIES

There were no purchases, sales or redemptions of the Company's listed securities by the Company or any of its subsidiaries during the year 31 December 2020.

### 合規顧問的權益

根據GEM上市規則第6A.19條,本公司委任 長雄證券有限公司(「**合規顧問**」)為其合規顧 問。

於二零二零年十二月三十一日,誠如合規顧問告知,除(i)本公司和合規顧問於二零一九年五月三十一日訂立有關收取擔任合規顧問的費用的合規顧問協議,以及(ii)披露於招股章程內有關作為參與上市的聯席賬簿管理人之一外,合規顧問或其董事、員工或緊密聯繫人(定義見GEM上市規則)於二零二零年十二月三十一日於本公司或本集團旗下任何其他公司的證券中概無擁有須根據GEM上市規則第6A.32條知會本集團的任何權益(包括可認購該等證券的購股權或權利)。

### 股權掛鈎協議

於截至二零二零年十二月三十一日止年度, 本公司概無訂立任何將會或可能會使本公司 發行股份或要求本公司訂立任何將會或可能 會導致本公司發行股份之協議之股權掛鈎協 議。

### 購買、出售或贖回上市證券

於截至二零二零年十二月三十一日止年度, 本公司或其任何附屬公司概無購買、出售或 贖回本公司任何上市證券。



**PRE-EMPTIVE RIGHTS** 

There are no provision for pre-emptive rights under the Company's Articles of Association or the laws of Cayman Islands which would oblige the Company to offer new shares on a pro rata basis to existing shareholders.

### SUFFICIENCY OF PUBLIC FLOAT

Based on the information that is publicly available to the Company and to the best knowledge of the Directors, the Directors confirm that the Company complies with the minimum of public float of 25% under the GEM Listing Rules since the Listing Date and up to the latest practicable date prior to the issue of this Report.

### **CORPORATE GOVERNANCE PRACTICES**

The Company is firmly committed to maintaining and ensuring a high level of corporate governance standards and will review and improve the corporate governance practices and standards constantly. Details of the principal corporate governance practices adopted by the Company are set out in the section headed "Corporate Governance Report" on pages 34 to 58 of this Report.

### **TAX RELIEF**

The Company is not aware of any relief on taxation available to the shareholders by reason of their holdings of the Shares. If the shareholders are unsure about the taxation implications of purchasing, holding, disposing of, dealing in or exercising of any rights in relation to the Shares, they are advised to consult their professional advisers.

### **MATERIAL LEGAL PROCEEDINGS**

As at 31 December 2020, the Company was not involved in any material litigation or arbitration and no material litigation or arbitration were pending or threatened or made against the Company so far as the Company is aware.

### 優先購買權

本公司組織章程細則或開曼群島法律並無有 關優先購股權之條文,要求本公司按比例提 呈新股份予現有股東。

### 充足公眾持股量

根據本公司可獲得的公開資料及就董事所深 知,董事確認,本公司自上市日期直至刊發 本報告前的最後實際可行日期已遵守GEM上 市規則下的25%最低公眾持股量規定。

### 企業管治常規

本公司堅定致力維持及確保高水平的企業管 治標準,並會不斷檢討及改善企業管治常規 及標準。本公司所採納主要企業管治常規之 詳情載於本報告第34至58頁「企業管治報告」 一節。

### 税務減免

本公司並不知悉股東因持有股份而可獲得的 任何税務減免。倘股東不確定購買、持有、 出售、買賣股份或行使與股份有關的任何權 利所涉及的税務影響,務請諮詢專業顧問的 意見。

### 重大法律訴訟

於二零二零年十二月三十一日,就本公司所 知,本公司未涉入任何重大法律訴訟或仲裁 或針對本公司之重大待決或具威脅性之訴訟 或仲裁。



### **EVENTS AFTER THE REPORTING PERIOD**

Save as disclosed in elsewhere, the Board is not aware of any material event requiring disclosure, that has taken place subsequent to 31 December 2020 and up to the date of this Report.

### **ANNUAL GENERAL MEETING**

The notice of the forthcoming annual general meeting of the Company will be published and dispatched to shareholders in the manner specified in the GEM Listing Rules in due course.

### **REVIEW BY AUDIT COMMITTEE**

The Board has established the Audit Committee with its terms of reference in compliance with Rules 5.28 to 5.33 of the GEM Listing Rules and code provisions C.3.3 and C.3.7 of the CG Code. The Audit Committee consists of three independent non-executive Directors, namely Dr. Cheng Faat Ting Gary (Chairman), Dr. Chow Kwok Fai Joseph and Mr. Chan Kin Sang.

The main duties of the Audit Committee are to assist the Board in reviewing the financial information and reporting process, risk management and internal control systems, effectiveness of the internal audit function, scope of audit and appointment of external auditors, and arrangements to enable employees of the Company to raise concerns about possible improprieties in financial reporting, internal control or other matters of the Company.

The Audit Committee has reviewed the audited consolidated financial statements and is of the opinion that the preparation of such statements complied with the applicable accounting standards, the requirements under the GEM Listing Rules and other applicable legal requirements, and that adequate disclosures have been made.

### 報告期後事項

除其他地方披露者外,董事會並不知悉任何 於二零二零年十二月三十一日後及直至本報 告日期已發生之須予披露重大事項。

### 股東週年大會

本公司應屆股東週年大會通告將適時按GEM 上市規則指定之方式刊發及寄發予股東。

### 由審核委員會審閲

董事會已成立審核委員會,並遵照GEM上市 規則第5.28至第5.33條及企業管治守則條文 第C.3.3及C.3.7條訂明其職權範圍。審核委 員會由三名獨立非執行董事組成,即鄭發丁 博士(主席)、周國輝博士及陳健生先生。

審核委員會的主要職責包括協助董事會審閲 財務資料和申報程序、風險管理和內部監控 系統、內部審核職能的有效性、審核範圍和 委任外聘核數師,以及讓本公司僱員可對有 關本公司財務申報、內部監控或其他事宜的 潛在不當行為提出關注的安排。

審核委員會已審閱經審核綜合財務報表,並 認為該等報表乃根據適用會計準則、GEM上 市規則要求及其他適用法律規定編製,並已 作出充足披露。



**INDEPENDENT AUDITOR** 

There was no change in auditor since the Listing Date except that with effect from 19 December 2019, Deloitte Touche Tohmatsu ("**Deloitte**") has resigned as the auditor of the Company and Mazars has been appointed as the new auditor on the same day to fill the casual vacancy following the resignation of Deloitte and to hold office until the conclusion of the next AGM.

The Group's consolidated financial statements for the year ended 31 December 2020 have been audited by Mazars, which would retire at the forthcoming AGM and being eligible, offers itself for re-appointment. A resolution to re-appoint Mazars as the independent auditor and to authorise the Directors to fix its remuneration will be proposed to the shareholders for approval at the forthcoming AGM.

### FORWARD LOOKING STATEMENTS

This Report contains forward looking statements with respect to the financial conditions, results of operations and business of the Group. These forward looking statements represent the Company's expectations or beliefs concerning future events and involve known and unknown risks and uncertainty that could cause actual results, performance or events to differ materially from those expressed or implied in such statements.

On behalf of the Board

**Zhang Shuguang** *Chairman and Executive Director* 

Chaiman and Executive Directo

Hong Kong, 24 March 2021

### 獨立核數師

自上市日期起,核數師並無變動,惟自二零 一九年十二月十九日起,德勤●關黃陳方會 計師行(「**德勤**」)已辭任本公司核數師,並於 同日委任中審眾環為新核數師,以填補德勤 辭任後的臨時空缺,任期直至下屆股東週年 大會結束為止。

本集團截至二零二零年十二月三十一日止年 度之綜合財務報表已由中審眾環審核,中審 眾環將於應屆股東週年大會退任,惟符合資 格及願意獲續聘。續聘中審眾環為獨立核數 師及授權董事釐定其酬金之決議案將於應屆 股東週年大會是提呈,以供股東批准。

### 前瞻性陳述

本報告載有關於本集團財務狀況、營運業績 及業務之前瞻性陳述。該等前瞻性陳述為本 公司對未來事件之預期或信念,並涉及已知 及未知之風險及不明朗因素,該等風險及不 明朗因素可能導致實際業績、表現或事件與 於該等陳述內明示或默示者顯著不同。

代表董事會

**張曙光** *主席兼執行董事* 

香港,二零二一年三月二十四日

### **INDEPENDENT AUDITOR'S REPORT** 獨立核數師報告



To the members of Huakang Biomedical Holdings Company Limited (incorporated in the Cayman Islands with limited liability)

### **OPINION**

We have audited the consolidated financial statements of Huakang Biomedical Holdings Company Limited (the "**Company**") and its subsidiaries (collectively referred to as the "**Group**") set out on pages 125 to 227, which comprise the consolidated statement of financial position as at 31 December 2020, and the consolidated statement of profit or loss and other comprehensive income, the consolidated statement of changes in equity and the consolidated statement of cash flows for the year then ended, and notes to the consolidated financial statements, including a summary of significant accounting policies.

In our opinion, the consolidated financial statements give a true and fair view of the financial position of the Group as at 31 December 2020, and of its financial performance and cash flows for the year then ended in accordance with Hong Kong Financial Reporting Standards ("**HKFRSs**") issued by the Hong Kong Institute of Certified Public Accountants (the "**HKICPA**") and have been properly prepared in compliance with disclosure requirements of the Hong Kong Companies Ordinance. MAZARS CPA LIMITED

**中審眾環(香港)會計師事務所有限公司** 42nd Floor, Central Plaza 18 Harbour Road, Wanchai, Hong Kong 香港灣仔港灣道18號中環廣場42樓

#### 致華康生物醫學控股有限公司股東

(於開曼群島註冊成立之有限公司)

### 意見

吾等已審核列載於第125至227頁華康生物 醫學控股有限公司(「貴公司」)及其附屬公司 (以下統稱「貴集團」)的綜合財務報表,該綜 合財務報表包括於二零二零年十二月三十一 日的綜合財務狀況表與截至該日止年度的綜 合損益及其他全面收益表、綜合權益變動表 及綜合現金流量表,以及綜合財務報表附 註,包括主要會計政策概要。

吾等認為,綜合財務報表已根據香港會計師 公會(「**香港會計師公會**」)所頒佈的香港財務 報告準則(「**香港財務報告準則**」)真實而公平 地反映 貴集團於二零二零年十二月三十一 日的財務狀況,以及 貴集團截至該日止年 度的財務表現及現金流量,並已按照香港公 司條例的披露規定妥為編製。



### **BASIS FOR OPINION**

We conducted our audit in accordance with Hong Kong Standards on Auditing ("**HKSAs**") issued by the HKICPA. Our responsibilities under those standards are further described in the "Auditor's Responsibilities for the Audit of the Consolidated Financial Statements" section of our report. We are independent of the Group in accordance with the HKICPA's Code of Ethics for Professional Accountants (the "**Code**"), and we have fulfilled our other ethical responsibilities in accordance with the Code. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.

### **KEY AUDIT MATTERS**

Key audit matters are those matters that, in our professional judgement, were of most significance in our audit of the consolidated financial statements for the current period. These matters were addressed in the context of our audit of the consolidated financial statements as a whole, and in forming our opinion thereon, and we do not provide a separate opinion on these matters.

### 意見的基礎

吾等已根據香港會計師公會頒佈的香港審計 準則(「**香港審計準則**」)進行審計。吾等在該 等準則下承擔的責任已在本報告/核數師就 審計綜合財務報表承擔的責任」部分中作進 一步闡述。根據香港會計師公會的專業會計 師道德守則(「**守則**」),吾等為獨立於 貴集 團,並已按照守則履行其他道德責任。吾等 相信所獲得的審計憑證能充足及適當地為我 們的意見提供基礎。

### 關鍵審計事項

關鍵審計事項是吾等的專業判斷,認為對吾 等審計本期間綜合財務報表最為重要的事 項。該等事項已於吾等審計整份綜合財務報 表及就其出具意見時處理,而吾等不會就該 等事項單獨提供意見。



### **KEY AUDIT MATTERS** (Continued)

#### Key audit matter

How our audit addressed the key audit matter

### Impairment assessment of trade receivables

As at 31 December 2020, the Group's net trade receivables amounted to approximately RMB9,503,000 and out of these trade receivables of approximately RMB7,829,000 were past due. The Group recorded net impairment losses on trade receivables of approximately RMB787,000 debited to profit or loss for the year ended 31 December 2020 and the Group's lifetime expected credit losses ("**ECL**") on trade receivables as at 31 December 2020 amounted to approximately RMB3,361,000.

The management of the Group estimates the amount of lifetime ECL of trade receivables based on provision matrix through grouping of various debtors that have similar loss patterns, after considering internal credit assessment of trade debtors and past due status of respective trade receivables. Estimated loss rates are based on historical observed default rates over the expected life of the debtors and are adjusted for forward-looking information.

In addition, trade receivables that are creditimpaired are assessed for ECL individually. The loss allowance amount of the credit impaired trade receivables is measured as the difference between the asset's carrying amount and the present value of estimated future cash flows with the consideration of expected future losses.

We identified impairment assessment of trade receivables as a key audit matter due to the significance of trade receivables to the Group's consolidated financial position and the involvement of subjective judgement and management estimates in evaluating the ECL of the Group's trade receivables at the end of the reporting period.

Related disclosures are included in Notes 2, 17 and 29 to the consolidated financial statements.

Our procedures, among others, included:

- a) Understanding key controls on how the management estimates the credit loss allowance for trade receivables;
- b) Testing the integrity of information used by management to develop the provision matrix including testing individual customers' credit assessment, on a sample basis, through analysing their nature, size and past due status with the underlying supporting documents and comparing the internal credit assessment made by management on these customers;
- c) Evaluating management's basis and judgement in determining credit loss allowance on trade receivables, including their identification of credit impaired trade receivables, the reasonableness of management's grouping of the remaining trade debtors into different categories in the provision matrix, and the basis of estimated credit loss rates applied in each category in the provision matrix (with reference to historical default rates and forward-looking information); and
- d) Evaluating the disclosures regarding the impairment assessment of trade receivables.



獨立核數師報告

### 關鍵審計事項(續)

#### 關鍵審計事項

### 吾等在審計中對關鍵審計事項的處理方式

### 貿易應收款項減值評估

於二零二零年十二月三十一日, 貴集團之貿易 應收款項淨額約為人民幣9,503,000元, 該等貿 易貿易款項中約人民幣7,829,000元已逾期。截 至二零二零年十二月三十一止年度, 貴集團錄 得貿易應收款項減值虧損淨額約人民幣787,000 元已計入損益, 而 貴集團於二零二零年十二 月三十一的貿易應收款項全期預期信貸虧損 (「預期信貸虧損」)約為人民幣3,361,000元。

貴集團管理層經考慮貿易債務人之內部信貸評 估及各貿易應收款項之逾期狀況,透過對具有 類似虧損型態的不同債務人分組根據撥備矩陣 估計貿易應收款項的全期預期信貸虧損。估計 虧損率乃基於應收賬款預期年期內的過往可觀 察違約率並就前瞻性資料作出調整計算。

此外,發生信貸減值之貿易應收款項單獨評估 預期信貸虧損。信貸減值貿易應收款項之虧損 撥備計量為資產賬面值與估計未來現金流量(經 考慮預期未來虧損)現值之差額。

吾等識別貿易應收款項的減值評估為關鍵審計 事項,乃由於貿易應收款項於 貴集團綜合財 務狀況之重要性及於報告期末評估 貴集團貿 易應收款項之預期信貸虧損時涉及主觀判斷及 管理層估計。

有關披露載於綜合財務報表附註2、17及29。

吾等之程序包括(其中包括):

- a) 了解管理層估計貿易應收款項信貸虧損撥備的關 鍵控制:
- b) 抽樣檢測管理層制定撥備矩陣所使用資料的完整 度(包括檢測單個客戶的信貸評估),檢測方式為 透過相關證明文件分析其性質、規模及逾期狀況 並比較管理層對該等客戶作出之內部信貸評估;
- c) 對管理層釐定貿易應收款項信貸虧損撥備之基礎 及判斷進行評估,當中包括彼等識別信貸減值貿 易應收款項、管理層於撥備矩陣中將餘下應收賬 款分為不同類別之合理性,以及撥備矩陣中各類 別所採用估計信貸虧損率的基準(經參考過往違 約率及前瞻性資料);及
- d) 評估對貿易應收款項減值評估之披露。

**INDEPENDENT AUDITOR'S REPORT** 獨立核數師報告

### **OTHER INFORMATION**

The directors of the Company are responsible for the other information. The other information comprises the information included in the 2020 annual report of the Company but does not include the consolidated financial statements and our auditor's report thereon.

Our opinion on the consolidated financial statements does not cover the other information and we do not express any form of assurance conclusion thereon.

In connection with our audit of the consolidated financial statements, our responsibility is to read the other information and, in doing so, consider whether the other information is materially inconsistent with the consolidated financial statements or our knowledge obtained in the audit or otherwise appears to be materially misstated. If, based on the work we have performed, we conclude that there is a material misstatement of this other information, we are required to report that fact. We have nothing to report in this regard.

### RESPONSIBILITIES OF DIRECTORS AND THOSE CHARGED WITH GOVERNANCE FOR THE CONSOLIDATED FINANCIAL STATEMENTS

The directors of the Company are responsible for the preparation of the consolidated financial statements that give a true and fair view in accordance with HKFRSs issued by the HKICPA and the disclosure requirements of the Hong Kong Companies Ordinance, and for such internal control as the directors determine is necessary to enable the preparation of consolidated financial statements that are free from material misstatement, whether due to fraud or error.

### 其他資料

貴公司董事須對其他資料負責。其他資料包括 貴公司二零二零年年報內的資料,但不 包括綜合財務報表及吾等就其發出的核數師 報告。

吾等對綜合財務報表發出的意見並不涵蓋其 他資料,吾等亦不對該等其他資料發表任何 形式的鑒證結論。

就吾等對綜合財務報表的審計而言,吾等的 責任是細閱其他資料,並在過程中考慮其他 資料與綜合財務報表或吾等於審計過程中 所了解的情況是否有重大抵觸,或似乎存在 重大失實陳述的情況。基於吾等已執行的工 作,倘吾等認為其他資料存在重大失實陳 述,吾等需要報告有關事實。就此而言,吾 等並無任何需要報告的事項。

### 董事及管治層就綜合財務報表承擔的責 任

貴公司董事須負責根據香港會計師公會頒佈 的香港財務報告準則及香港公司條例的披露 規定編製真實而公平的綜合財務報表,以及 落實其認為屬必要的內部監控,以使所編製 的綜合財務報表不存在由於欺詐或錯誤而導 致的重大失實陳述。



獨立核數師報告

### RESPONSIBILITIES OF DIRECTORS AND THOSE CHARGED WITH GOVERNANCE FOR THE CONSOLIDATED FINANCIAL STATEMENTS (Continued)

In preparing the consolidated financial statements, the directors of the Company are responsible for assessing the Group's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the directors either intend to liquidate the Group or to cease operations, or have no realistic alternative but to do so.

Those charged with governance are responsible for overseeing the Group's financial reporting process.

### AUDITOR'S RESPONSIBILITIES FOR THE AUDIT OF THE CONSOLIDATED FINANCIAL STATEMENTS

Our objectives are to obtain reasonable assurance about whether the consolidated financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. This report is made solely to you, as a body, and for no other purpose. We do not assume responsibility towards or accept liability to any other person for the contents of this report.

Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with HKSAs will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these consolidated financial statements.

### 董事及管治層就綜合財務報表承擔的責 任(續)

於編製綜合財務報表時, 貴公司董事負責 評估 貴集團持續經營的能力,並在適用情 況下披露與持續經營有關的事項,以及使用 持續經營的會計基礎,惟董事有意將 貴集 團清盤或停止經營,或除此以外別無其他實 際的替代方案則除外。

管治層須負責監督 貴集團的財務報告過 程。

### 核數師就審計綜合財務報表承擔的責任

吾等的目標為對綜合財務報表整體是否不存 在由於欺詐或錯誤而導致的重大失實陳述取 得合理保證,並出具包含我們意見的核數師 報告。本報告僅向 閣下報告,除此之外本 報告別無其他用途。吾等不會就本報告的內 容向任何其他人士負上或承擔任何責任。

合理保證是一種高水平的保證,但不能保證 按照香港審計準則進行的審計總能發現已存 在的重大失實陳述。失實陳述可以由欺詐或 錯誤引起,如果合理預期有關錯誤陳述單獨 或彙總起來會影響使用者根據綜合財務報表 所作出的經濟決定,則有關失實陳述被視為 重大失實陳述。 **INDEPENDENT AUDITOR'S REPORT** 獨立核數師報告

### AUDITOR'S RESPONSIBILITIES FOR THE AUDIT OF THE CONSOLIDATED FINANCIAL STATEMENTS (Continued)

As part of an audit in accordance with HKSAs, we exercise professional judgement and maintain professional skepticism throughout the audit. We also:

- Identify and assess the risks of material misstatement of the consolidated financial statements, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.
- Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the Group's internal control.
- Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by the directors.

### **核數師就審計綜合財務報表承擔的責任** (續)

在根據香港審計準則進行審計的過程中,吾 等作出了專業判斷,並保持專業懷疑態度。 吾等亦:

- 識別和評估由於欺詐或錯誤而導致綜合 財務報表存在重大失實陳述的風險,設 計及執行審計程序以應對該等風險,以 及獲取充足和適當的審計憑證,作為我 們意見的基礎。由於欺詐可能涉及串 謀、偽造、故意遺漏、失實陳述,或凌 駕內部監控,因此,與未能發現因錯誤 而導致的重大失實陳述相比,未能發現 因欺詐而導致的重大失實陳述的風險較 高。
- 了解與審計有關的內部監控,以設計適用於有關情況的審計程序,但並非旨在對 貴集團內部監控的成效發表意見。
- 評估董事所採用會計政策是否恰當,以 及董事所作出的會計估計及相關披露是 否合理。



獨立核數師報告

### AUDITOR'S RESPONSIBILITIES FOR THE AUDIT OF THE CONSOLIDATED FINANCIAL STATEMENTS (Continued)

- Conclude on the appropriateness of the directors' use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the Group's ability to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the consolidated financial statements or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Group to cease to continue as a going concern.
- Evaluate the overall presentation, structure and content of the consolidated financial statements, including the disclosures, and whether the consolidated financial statements represent the underlying transactions and events in a manner that achieves fair presentation.
- Obtain sufficient appropriate audit evidence regarding the financial information of the entities or business activities within the Group to express an opinion on the consolidated financial statements. We are responsible for the direction, supervision and performance of the group audit. We remain solely responsible for our audit opinion.

We communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.

### **核數師就審計綜合財務報表承擔的責任** (續)

- 就董事採用持續經營基礎的會計法是否 恰當作出結論,並根據已獲取的審計憑 證,就是否有對 貴集團繼續以持續基 準經營的能力構成重大疑問的事件或情 況的相關重大不確定因素作出結論。倘 吾等的結論為存在重大不確定因素,則 吾等需要於核數師報告中提出須注意綜 合財務報表內的相關資料披露,或倘有 關披露資料不足,則吾等需要發表非無 保留意見。吾等的結論以截至核數師報 告日期所獲得的審計憑證為基礎。然 而,貴集團可能因未來事件或情況而 不再持續經營。
- 評估綜合財務報表的整體呈列方式、結構及內容(包括披露資料),以及綜合財務報表是否以達致公平呈列的方式反映相關交易及事件。
- 就 貴集團內實體或業務活動的財務資料獲取充足、適當的審計憑證,以便對 綜合財務報表發表意見。吾等負責 貴 集團審計的方向、監督和執行。吾等為 吾等的審計意見承擔全部責任。

吾等與管治層就(其中包括)計劃的審計範 圍、時間安排及重大審計發現(包括吾等於 審計期間識別出的內部監控的任何重大缺 陷)進行溝通。 **INDEPENDENT AUDITOR'S REPORT** 獨立核數師報告

### AUDITOR'S RESPONSIBILITIES FOR THE AUDIT OF THE CONSOLIDATED FINANCIAL STATEMENTS (Continued)

We also provide those charged with governance with a statement that we have complied with relevant ethical requirements regarding independence, and to communicate with them all relationships and other matters that may reasonably be thought to bear on our independence, and where applicable, actions taken to eliminate threats or safeguards applied.

From the matters communicated with those charged with governance, we determine those matters that were of most significance in the audit of the consolidated financial statements of the current period and are therefore the key audit matters. We describe these matters in our auditor's report unless law or regulation precludes public disclosure about the matter or when, in extremely rare circumstances, we determine that a matter should not be communicated in our report because the adverse consequences of doing so would reasonably be expected to outweigh the public interest benefits of such communication.

### **核數師就審計綜合財務報表承擔的責任** (續)

吾等亦向管治層提交聲明,説明吾等已符合 有關獨立性的相關道德要求,並就所有被合 理認為可能影響吾等獨立性的關係及其他事 宜及(如適用)為消除威脅所採取之措施或採 用之防範措施,與管治層進行溝通。

從與管治層溝通的事項中,吾等決定對本期 綜合財務報表的審計工作最為重要的事項, 而有關事項因而為關鍵審計事項。除非法律 或法規不容許公開披露此等事項,或於極罕 見的情況下,吾等認為由於可合理預期披露 此等事項的不良後果將超越公眾知悉此等事 項的利益,因而不應於報告中披露,否則吾 等會於核數師報告中説明此等事項。

### Mazars CPA Limited Certified Public Accountants

Hong Kong, 24 March 2021

The engagement director on the audit resulting in this independent auditor's report is: **Tsoi Wa Shan** 

Practising Certificate number: P07514

**中審眾環(香港)會計師事務所有限公司**  *執業會計師* 香港,二零二一年三月二十四日

出具本獨立核數師報告的審計項目董事為:

### 蔡華山

執業證書號碼: P07514

## CONSOLIDATED STATEMENT OF PROFIT OR LOSS AND OTHER COMPREHENSIVE INCOME 綜合損益及其他全面收益表

For the year ended 31 December 2020 截至二零二零年十二月三十一日止年度

		Notes 附註	2020 二零二零年 <i>RMB'000</i> 人民幣千元	2019 二零一九年 <i>RMB'000</i> <i>人民幣千元</i>
<b>Revenue</b> Cost of sales	<b>收益</b> 銷售成本	3	21,967 (7,249)	25,471 (7,580)
Gross profit Other income Other gains and losses Selling and distribution expenses Administrative expenses Research and development expenses Provision for impairment losses on	毛利 其他收入 其他收益及虧損 銷售及分銷開支 行政開支 研發開支 物業、廠房及	5 6	14,718 650 (1,062) (7,124) (10,191) (2,253)	17,891 260 508 (6,777) (9,679) (1,762)
property, plant and equipment (Provision for) Reversal of impairment losses on trade receivables, net Reversal of impairment losses on other receivables, net	設備減值虧損撥備 貿易應收款項減值虧損 (撥備)撥回淨額 其他應收款項減值虧損 撥回淨額	12 29 29	(2,556) (787) 7	- 250 39
Equity-settled share-based payment expenses Finance costs Share of results of an associate	以股權結算之股份基礎 付款開支 融資成本 分佔一間聯營公司業績	25 7 15	(2,660) (74) (40)	(72)
(Loss) Profit before tax Income tax expense	<b>除税前(虧損)溢利</b> 所得税開支	7 9	(11,372) (255)	658 (942)
Loss for the year attributable to owners of the Company Other comprehensive income	年內本公司擁有人 應佔虧損 其他全面收入(開支):		(11,627)	(284)
(expense): Item that may be reclassified subsequently to profit or loss Exchange difference on consolidation	<i>其後可能重新分類至 損益的項目</i> 綜合匯兑差額		141	(52)
Total comprehensive expense for the year attributable to owners of the Company	本公司擁有人應佔年內 全面開支總額		(11,486)	(336)
Loss per share attributable to owners of the Company	本公司擁有人應佔 每股虧損	10	<b>RMB cents</b> 人民幣仙	RMB cents 人民幣仙
Basic and diluted	基本及攤薄		(2.91)	(0.07)

### CONSOLIDATED STATEMENT OF FINANCIAL POSITION 综合財務狀況表

At 31 December 2020 於二零二零年十二月三十一日

		Notes 附註	2020 二零二零年 <i>RMB'000</i> 人民幣千元	2019 二零一九年 <i>RMB'000</i> <i>人民幣千元</i>
Non-current assets	非流動資產	10	7.050	0 700
Property, plant and equipment	物業、廠房及設備	12	7,256	9,722
Right-of-use assets	使用權資產	13	2,432	1,351
Intangible assets	無形資產	14	2,924	2,914
Interest in an associate	於一間聯營公司之	. –		
	權益	15	-	-
Deposits for acquisition of property,				
plant and equipment	設備之按金		1,079	1,257
			13,691	15,244
			,	13,211
Current assets	流動資產			
Inventories	存貨	16	2,766	2,703
Trade receivables	貿易應收款項	17	9,503	10,079
Other receivables, deposits and	其他應收款項、按金			
prepayments	及預付款項	18	4,797	1,893
Bank balances and cash	銀行結餘及現金	19	41,944	48,793
			59,010	63,468
			55,010	00,100
Current liabilities	流動負債			
Trade payables	貿易應付款項	20	1,447	1,030
Other payables and accrued	其他應付款項及應計			
charges	費用	21	3,961	3,797
Contract liabilities	合約負債	22	2,143	292
Lease liabilities	租賃負債	13	1,406	1,181
Deferred income – government	遞延收入一政府			,
grants	補助	23	45	45
Tax payable	應付税項		264	866
			9,266	7,211
Net current assets	流動資產淨值		49,744	56,257
Tatal access land arms in Park Park	次文体方试注到点店		(2.425	
Total assets less current liabilities	資產總值減流動負債		63,435	71,501

CONSOLIDATED STATEMENT OF FINANCIAL POSITION

綜合財務狀況表

At 31 December 2020 於二零二零年十二月三十一日

		Notes 附註	2020 二零二零年 <i>RMB'000</i> 人民幣千元	2019 二零一九年 <i>RMB'000 人民幣千元</i>
Non-surrent lishilities	北达新台库			
Non-current liabilities	<b>非流動負債</b> 租賃負債	13	1 226	101
Lease liabilities Deferred income – government	祖員員員 遞延收入一政府	15	1,236	431
-	補助	23	340	385
grants	而功	25	540	
			1,576	816
NET ASSETS	資產淨值		61,859	70,685
Capital and reserves	資本及儲備			
Share capital	股本	26	3,509	3,509
Reserves	儲備		58,350	67,176
TOTAL EQUITY	權益總額		61,859	70,685

The consolidated financial statements on pages 125 to 227 were approved and authorised for issue by the Board of Directors on 24 March 2021 and signed on its behalf by:

董事會於二零二一年三月二十四日批准及授 權刊發該等載列於第125至227頁的綜合財 務報表並由以下人士代表簽署:

Mr. Zhang Shuguang 張曙光先生 Director 董事 Mr. Zhang Chunguang 張春光先生 Director 董事

## CONSOLIDATED STATEMENT OF CHANGES IN EQUITY 綜合權益變動表

For the year ended 31 December 2020 截至二零二零年十二月三十一日止年度

						Reserves 儲備				
		Share capital 股本 RMB'000 人民幣千元	Share premium 股份溢價 RMB'000 人民幣千元 (Note (a)) (附註(a))	Capital reserve 資本儲備 RMB'000 人民幣千元 (Note (b)) (附註(b))	Statutory reserve 法定儲備 RMB'000 人民幣千元 (Note (c)) (附註(c))	Translation reserve 匿兑儲備 RMB'000 人民幣千元 (Note (d)) (附註(d))	Share           option           reserve           購股權儲備           RMB'000           人民幣千元           (Note 25)           (附註25)	Accumulated profits 累計溢利 RMB'000 人民幣千元	Sub-total 小計 RMB'000 人民幣千元	<b>Total equity</b> 權益總額 <i>RMB'000</i> <i>人民幣千元</i>
At 1 January 2019	於二零一九年一月一日	3,509	47,248	1,943	1,734		-	16,587	67,512	71,021
Loss for the year	年內虧損	-	-	-	-	-	-	(284)	(284)	(284)
Other comprehensive expense: Item that may be reclassified subsequently to profit or loss	<b>其他全面開支</b> : <i>其後可能重新分類至損益的</i> 項目									
Exchange difference on consolidation	綜合匯兑差額	-	-	-	-	(52)	-	-	(52)	(52)
Total comprehensive expense for the year	年內全面開支總額	-	-	-	_	(52)	-	(284)	(336)	(336)
Transactions with owners: Contributions and distributions Appropriation of statutory reserve	<b>與擁有人之交易</b> : <i>供款及分派</i> 襏付法定儲備	-	-	_	568	-	-	(568)	-	-
At 31 December 2019	於二零一九年十二月三十一日	3,509	47,248	1,943	2,302	(52)	-	15,735	67,176	70,685
At 1 January 2020	於二零二零年一月一日	3,509	47,248	1,943	2,302	(52)	-	15,735	67,176	70,685
Loss for the year	年內虧損	-	-	-	-	-	-	(11,627)	(11,627)	(11,627)
Other comprehensive income: Item that may be reclassified subsequently to profit or loss	<b>其他全面收益</b> : <i>其後可能重新分類至損益的</i> 項目									
Exchange difference on consolidation	綜合匯兑差額	-	-	-	-	141	-	-	141	141
Total comprehensive expense for the year	年內全面開支總額	-	-	-	-	141	-	(11,627)	(11,486)	(11,486)
Transactions with owners: Contributions and distributions Recognition of equity-settled	<b>與擁有人之交易</b> : <i>供款及分派</i> 確認以股權結算之									
share-based payment (Note 25)	股份基礎付款(附註25)	-	-	-	-	-	2,660	-	2,660	2,660
Forfeiture of share options (Note 25)	沒收購股權( <i>附註25)</i>	-	-	-	-	-	(52)	52	-	-
Total transactions with owners	與擁有人之交易總額	-	-	-	-	-	2,608	52	2,660	2,660
At 31 December 2020	於二零二零年十二月三十一日	3,509	47,248	1,943	2,302	89	2,608	4,160	58,350	61,859



For the year ended 31 December 2020 截至二零二零年十二月三十一日止年度

Notes:

- (a) Share premium represents the excess of the net proceeds or consideration from issuance of the Company's shares over their par value.
- (b) Capital reserve represents the difference between the combined capital of the Company's subsidiaries, King Grace Company Limited ("King Grace") and 深圳華康 生物醫學工程有限公司 (Shenzhen Huakang Bio-Medical Engineering Limited\*) ("Shenzhen Huakang") and the consideration paid for acquiring 44% equity interest of Shenzhen Huakang by King Grace in 2017.
- (c) Statutory reserve is required to be appropriated from profit after income tax of the entity which established in the People's Republic of China (the "PRC"), determined in accordance with the relevant laws and regulations in the PRC. Allocation to the statutory reserve shall be approved by the board of directors of the PRC entity. The appropriation to statutory reserve may cease if the balance of the statutory reserve has reached 50% of the registered capital of the PRC entity. The statutory reserve may be used to make up losses or for conversion into capital. The PRC entity may, upon the approval by a resolution of shareholders' general meeting/board of directors' meeting, convert the statutory reserve into capital in proportion to the then existing shareholdings. However, when converting the statutory reserve into capital, the balance of such reserve remaining unconverted must not be less than 25% of the registered capital of that entity.
- (d) Translation reserve has been set up and is dealt with in accordance with the accounting policies adopted for foreign currency translation as set out in Note 2 to the consolidated financial statements.

附註:

- (a) 股份溢價指本公司發行股份所得款項淨額或 代價超出其股份面值。
- (b) 資本儲備指於二零一七年,本公司附屬 公司 King Grace Company Limited (「King Grace」)及深圳華康生物醫學工程有限公司 (「深圳華康」)之合併資本與King Grace就收 購深圳華康44%股權支付的代價之間的差 額。
- (c) 法定儲備指根據中華人民共和國(「中國」)有 關法律及法規,於中國成立之實體的除所得 税後溢利提取之儲備。法定儲備之提取比例 須經中國實體之董事會批准。倘法定儲備結 餘達中國實體註冊資本50%,則可終止提取 法定儲備。法定儲備可用作彌償虧損或轉換 為資本。經股東大會之決議案/董事會會議 批准後,中國實體可按當時已有之持股量之 比例而將法定儲備轉換為資本。然而,如將 法定儲備轉換為資本,餘下未轉換之相關儲 備結餘不得少於該關實體註冊資本之25%。

(d) 匯兑儲備已根據綜合財務報表附註2所載就 外幣換算採納之會計政策設立及處理。

\* English translation is for identification purpose only

## CONSOLIDATED STATEMENT OF CASH FLOWS 综合現金流量表

For the year ended 31 December 2020 截至二零二零年十二月三十一日止年度

		2020 二零二零年 <i>RMB'000</i> 人民幣千元	2019 二零一九年 <i>RMB'000</i> 人民幣千元
OPERATING ACTIVITIES	<b>颁然</b> 关于		
(Loss) Profit before tax	<b>經營活動</b> 除税前(虧損)溢利	(11,372)	658
Adjustments for:	經調整:	(11,572)	050
Amortisation of intangible assets	無形資產攤銷	330	370
Depreciation of property,	物業、廠房及設備	550	570
plant and equipment	折舊	1,848	1,609
Depreciation of right-of-use assets	使用權資產折舊	1,016	783
Equity-settled share-based	以股權結算之股份		,
payment expenses	基礎付款開支	2,660	_
Gain on disposal of property,	出售物業、廠房及		
plant and equipment, net	設備收益淨額	-	(10)
Gain on lease modification	租賃修訂收益	(11)	_
Interest income	利息收入	(185)	(174)
Provision for impairment losses on	物業、廠房及設備		
property, plant and equipment	減值虧損撥備	2,556	-
Provision for (Reversal of)	貿易應收款項減值		
impairment losses on	虧損撥備(撥回)淨額		
trade receivables, net		787	(250)
Reversal of impairment loss	其他應收款項減		
on other receivables, net	值虧損撥回淨額	(7)	(39)
Release of deferred income		(45)	(45)
Share of results of an associate	分佔一間聯營公司業績 物業、廠房及設備核銷	40	-
Write-off of property, plant and equipment	初未、顾厉仪砹佣怪朝	33	3
Finance costs	融資成本	74	72
Operating cash flows before	營運資金變動前之經營現金流量		
changes in working capital		(2,276)	2,977
Changes in working capital	營運資金變動		
Inventories	宮建貝立愛動 存貨	(63)	(419)
Trade receivables	留易應收款項	(03)	879
Other receivables,	其他應收款項、按金	(211)	079
deposits and prepayments	及預付款項	(2,897)	124
Trade payables	貿易應付款項	417	103
Other payables and accrued	其他應付款項及應計費用	,	100
charges		112	(5,393)
Contract liabilities	合約負債	1,851	113
Cash used in operations	經營所用現金	(3,067)	(1,616)
Income tax paid	已付所得税	(857)	(1,774)
Net week was 11 and			
Net cash used in operating activities	經營活動所用現金	(2.024)	(2, 200)
activities	淨額	(3,924)	(3,390)

CONSOLIDATED STATEMENT OF CASH FLOWS

綜合現金流量表

For the year ended 31 December 2020 截至二零二零年十二月三十一日止年度

		2020 二零二零年 <i>RMB′000</i> 人 <i>民幣千元</i>	2019 二零一九年 <i>RMB'000 人民幣千元</i>
INVESTING ACTIVITIES	投資活動		
Acquisition of property, plant and equipment	收購物業、廠房及設備	(1,741)	(585)
Development costs paid	已付開發成本	(340)	(366)
Deposits paid for acquisition of property, plant and equipment	就收購物業、廠房及 設備之已付按金	_	(1,257)
Interest received	已收取利息	185	174
Proceeds from disposal of property,	出售物業、廠房及設備之所得款		171
plant and equipment	項	-	10
Acquisition of investment in an	收購於一間聯營公司之投資		
associate		(40)	
Net cash used in investing activities	投資活動所用現金淨額	(1,936)	(2,024)
		(1,000)	(2,02 1)
FINANCING ACTIVITIES	融資活動		
Repayment for lease liabilities	租賃負債還款	(1,107)	(594)
Net cash used in financing activities	融資活動所用現金淨額	(1,107)	(594)
		(1,107)	(394)
Net decrease in cash and cash	現金及現金等價物減少淨額		
equivalents		(6,967)	(6,008)
Cash and cash equivalents at the	年初之現金及現金等價物		
beginning of the year		48,793	54,797
Effect on exchange rate changes	匯率變動的影響	118	4
Cash and cash equivalents at the	年末之現金及現金等價物,		
end of the year, represented by bank balances and cash	指銀行結餘及現金	41,944	10 702
Dalik Dalalices allu Casil		+1,344	48,793

For the year ended 31 December 2020 截至二零二零年十二月三十一日止年度

### **1. GENERAL INFORMATION**

Huakang Biomedical Holdings Company Limited (the "**Company**") was incorporated in the Cayman Islands as an exempted company under the laws of the Cayman Islands with limited liability on 3 August 2017 and its shares are listed on GEM of The Stock Exchange of Hong Kong Limited (the "Stock **Exchange**") on 13 December 2018. The Company is ultimately controlled by Mr. Zhang Shuguang and Mr. Chang Yim Yang, who act in concert and hold equity interests in the Company indirectly through Crystal Grant Limited (wholly owned by Mr. Zhang Shuguang), a limited liability company incorporated in the British Virgin Islands (the "BVI") and Ever Charming Inc. (wholly owned by Mr. Chang Yim Yang), a limited liability company incorporated in the BVI, respectively. The addresses of the registered office and principal place of business of the Company are set out in the section headed "Corporate Information" to the annual report.

The Company is an investment holding company. The Company and its subsidiaries (collectively referred to as the "**Group**") are principally engaged in research and development, manufacture, marketing and sale of biological reagents and auxiliary reproductive supplies and equipment in the People's Republic of China (the "**PRC**"). The principal activities of its principal subsidiaries are set out in Note 32 to the consolidated financial statements.

The consolidated financial statements are presented in Renminbi ("**RMB**"), which is the same as the functional currency of the Company and its subsidiaries, and rounded to the nearest thousand unless otherwise stated.

### 1. 一般資料

華康生物醫學控股有限公司(「本公司」) 於二零一七年八月三日根據開曼群島法 律於開曼群島註冊成立為一間獲豁免有 限公司,其股份於二零一八年十二月 十三日在香港聯合交易所有限公司(「聯 交所」)GEM上市。本公司受張曙光先生 及張賢陽先生(為一致行動人士,分別 透過一間於英屬處女群島(「英屬處女群 島」)註冊成立的有限公司Crystal Grant Limited(由張曙光先生全資擁有)及一 間於英屬處女群島註冊成立的有限公司 Ever Charming Inc.(由張賢陽先生全資 擁有)間接於持有本公司權益)最終控 制。本公司之註冊辦事處及主要營業地 點地址載於本年報[公司資料]一節。

本公司為投資控股公司。本集團及其附 屬公司(統稱「本集團」)於中華人民共和 國(「中國」)主要從事生物製劑及輔助生 育用品和設備的研發、生產、營銷及銷 售。有關其主要附屬公司的主要業務之 詳情載於綜合財務報表附註32。

綜合財務報表以人民幣(「**人民幣**」)呈 列,與本公司及其附屬公司的功能貨幣 相同,且除另有註明外,均四捨五入至 最接近之千位數。



For the year ended 31 December 2020 截至二零二零年十二月三十一日止年度

### 2. SIGNIFICANT ACCOUNTING POLICIES

### **Statement of compliance**

The consolidated financial statements have been prepared in accordance with Hong Kong Financial Reporting Standards ("**HKFRSs**") issued by the Hong Kong Institute of Certified Public Accountants (the "**HKICPA**"), which collective term includes all applicable individual HKFRSs, Hong Kong Accounting Standards ("**HKASs**") and Interpretations issued by the HKICPA and the disclosure requirements of the Hong Kong Companies Ordinance. The consolidated financial statements also comply with the applicable disclosure requirements of the Rules Governing the Listing of Securities on GEM of the Stock Exchange (the "**Listing Rules**").

The consolidated financial statements have been prepared on a basis consistent with the accounting policies adopted in the 2019 consolidated financial statements except for the adoption of the following new/revised HKFRSs that are effective from the current year.

### Adoption of new/revised HKFRSs

The Group has applied, for the first time, the following new/revised HKFRSs:

Amendments to HKASs 1	Definition of Material
and 8	
Amendments to HKAS 39,	Interest Rate Benchmark Reform –
HKFRSs 7 and 9	Phase 1

Amendments to HKFRS 3 Definition of a Business

### 2. 主要會計政策

### 遵例聲明

該等綜合財務報表乃根據香港會計師公 會(「**香港會計師公會**」)頒佈之所有適用 個別香港財務報告準則(「**香港財務報告** 準則」)、香港會計準則(「**香港會計準** 則」)及詮釋(下文統稱為「**香港財務報告** 準則」)以及香港公司條例的披露規定而 編製。該等綜合財務報表亦遵守聯交所 GEM證券上市規則(「上市規則」)之適用 披露規定。

除採納以下自本年度起生效的新訂/經 修訂香港財務報告準則外,該等綜合財 務報表乃根據與二零一九年度綜合財務 報表所採用會計政策相符一致的基準編 製。

### 採納新訂/經修訂香港財務報告準則

本集團已首次採納下列新訂/經修訂香 港財務報告準則:

香港會計準則第1號及	重大之定義
第8號修訂本	
香港會計準則第39號、	利率基準改革-
香港財務報告準則第7號及	第一階段
第9號修訂本	
香港財務報告準則第3號	業務之定義
修訂本	

For the year ended 31 December 2020 截至二零二零年十二月三十一日止年度

### 2. SIGNIFICANT ACCOUNTING POLICIES 2. 主要會計政策(續) (Continued)

Adoption of new/revised HKFRSs (Continued)

### Amendments to HKASs 1 and 8: Definition of Material

The amendments clarify the definition of material and align the definition used across HKFRSs.

The adoption of the amendments does not have any significant impact on the consolidated financial statements.

### Amendments to HKAS 39, HKFRSs 7 and 9: Interest Rate Benchmark Reform – Phase 1

The amendments modify some specific hedge accounting requirements to provide relief from potential effects of the uncertainties caused by interest rate benchmark reform (the market-wide reform of an interest rate benchmark, including the replacement of an interest rate benchmark with an alternative benchmark). In addition, the amendments require companies to provide additional information to investors about their hedging relationships which are directly affected by these uncertainties.

The adoption of the amendments does not have any significant impact on the consolidated financial statements.

採納新訂/經修訂香港財務報告準則 (續)

香港會計準則第1號及第8號修訂本:重 大之定義

該等修訂本闡明重大之定義及統一香港 財務報告準則中所用之定義。

應用該等修訂本對該等綜合財務報表並 無任何重大影響。

### 香港會計準則第39號、香港財務報告準 則第7號及第9號修訂本:利率基準改 革-第一階段

該等修訂本修改若干特定對沖會計規 定,以減輕利率基準改革(市場利率基 準改革,包括以其他基準取代利率基 準)所帶來不確定因素之潛在影響。此 外,該等修訂本要求公司向投資者提供 有關直接受該等不確定因素影響之對沖 關係之額外資料。

應用該等修訂本對該等綜合財務報表並 無任何重大影響。



For the year ended 31 December 2020 截至二零二零年十二月三十一日止年度

### 2. SIGNIFICANT ACCOUNTING POLICIES 2. 主要會計政策(續) (Continued)

Adoption of new/revised HKFRSs (Continued)

### Amendments to HKFRS 3: Definition of a **Business**

The amendments, among others, revise the definition of a business and include new guidance to evaluate whether an acquired process is substantive.

The adoption of the amendments does not have any significant impact on the consolidated financial statements.

A summary of the significant accounting policies adopted by the Group is set out below.

### **Basis of measurement**

The measurement basis used in the preparation of the consolidated financial statements is historical cost.

### **Basis of consolidation**

The consolidated financial statements incorporate the financial statements of the Company and entities controlled by the Company and its subsidiaries. Control is achieved when the Company:

- has power over the investee;
- is exposed, or has rights, to variable returns • from its involvement with the investee; and
- has the ability to use its power to affect its returns.

採納新訂/經修訂香港財務報告準則 (續)

香港財務報告準則第3號修訂本:業務 之定義

該等修訂本(其中包括)修訂業務之定 義,並為評估所收購的過程是否屬重大 引入新指引。

應用該等修訂本對該等綜合財務報表並 無任何重大影響。

本集團採納的主要會計政策概述如下。

### 計量的基礎

編製該等綜合財務報表所用之計量基準 為歷史成本。

### 綜合入賬基準

综合財務報表包括本公司及本公司及其 附屬公司控制的實體的財務報表。倘屬 以下情況,則本公司獲得控制權:

- 可對投資對象行使權力;
- 因參與投資對象業務而獲得的可變 回報及獲得回報的權利;及
- 可行使權力以影響其回報。

For the year ended 31 December 2020 截至二零二零年十二月三十一日止年度

### 2. SIGNIFICANT ACCOUNTING POLICIES 2. 主要會計政策(續) (Continued)

### **Basis of consolidation** (Continued)

The Group reassesses whether or not it controls an investee if facts and circumstances indicate that there are changes to one or more of the three elements of control listed above.

Consolidation of a subsidiary begins when the Group obtains control over the subsidiary and ceases when the Group loses control of the subsidiary. Specifically, income and expenses of a subsidiary acquired or disposed of during the period are included in the consolidated statement of profit or loss and other comprehensive income from the date the Group gains control until the date when the Group ceases to control the subsidiary.

When necessary, adjustments are made to the financial statements of subsidiaries to bring their accounting policies into line with the Group's accounting policies.

All intragroup assets and liabilities, equity, income, expenses and cash flows relating to transactions between members of the Group are eliminated in full on consolidation.

### **Subsidiaries**

A subsidiary is an entity that is controlled by the Group. The Group controls an entity when it is exposed, or has rights, to variable returns from its involvement with the entity and has the ability to affect those returns through its power over the entity. The Group reassesses whether it controls an investee if facts and circumstances indicate that there are changes to one or more of the elements of control.

### 綜合入賬基準(續)

倘有事實及情況顯示上述三項控制權要 素有一項或以上出現變動,本集團會重 新評估其是否對投資對象擁有控制權。

综合附屬公司賬目於本集團取得對附屬 公司控制權時開始,並於本集團失去對 附屬公司控制權時終止。具體而言,於 本期間內購入或出售的附屬公司的收入 及開支,按自本集團獲得控制權當日起 至本集團失去附屬公司控制權當日止, 計入綜合損益及其他全面收益表。

附屬公司的財務報表於有需要情況下調 整,以使其會計政策與本集團會計政策 一致。

所有集團內公司間資產及負債、股權、 收入、開支以及與本集團成員公司間交 易有關的現金流量均於綜合賬目時悉數 抵銷。

### 附屬公司

附屬公司指本集團控制的實體。當本集 團因參與實體業務而承擔可變動回報的 風險或因此享有可變動回報,且有能力 透過向實體施加權力而影響該等回報 時,則本集團控制該實體。倘有事實及 情況顯示控制權元素有一項或以上出現 變動,本集團會重新評估其是否對投資 對象擁有控制權。



综合財務報表附註

For the year ended 31 December 2020 截至二零二零年十二月三十一日止年度

# **2. SIGNIFICANT ACCOUNTING POLICIES 2.** 主要會計政策(續) (Continued)

### Subsidiaries (Continued)

In the Company's statement of financial position which is presented within these notes, the investment in subsidiaries is stated at cost less impairment loss. The carrying amount of the investment is reduced to its recoverable amount on an individual basis, if it is higher than the recoverable amount. The results of subsidiaries are accounted for by the Company on the basis of dividends received and/or receivable.

### Associate

An associate is an entity over which the Group has significant influence. Significant influence is the power to participate in the financial and operating policy decisions of the investee but is not control or join control of those policies.

The Group's investment in associate is accounted for under the equity method of accounting, except when the investment or a portion thereof is classified as held for sale. Under the equity method, the investment is initially recorded at cost and adjusted thereafter for the post-acquisition changes in the Group's share of the investee's net assets and any impairment loss relating to the investment. Except to the extent that the Group has incurred legal or constructive obligations or made payments on behalf of the investee, the Group discontinues recognising its share of further losses when the Group's share of losses of the investee equals or exceeds the carrying amount of its interest in the investee, which includes any long term interests that, in substance, form part of the Group's net investment in the investee.

Unrealised profits and losses resulting from transactions between the Group and its associate are eliminated to the extent of the Group's interest in the investees, except where unrealised losses provide evidence of an impairment of the asset transferred, in which case they are recognised immediately in profit or loss.

### 附屬公司(續)

於本公司財務狀況表(載於該等附註中) 中,於附屬公司之投資按成本扣除減值虧 損列賬。該投資的賬面值如高於可收回金 額,則按個別基準調減至可收回金額。附 屬公司的業績由本公司按已收及/或應 收股息的基準列賬。

### 聯營公司

聯營公司為本集團對其擁有重大影響力 的實體。重大影響力為參與投資對象的 財務及營運政策的決策的權力,惟並不 能夠控制或共同控制有關政策。

本集團於聯營公司之投資根據權益會計 法入賬,惟投資或其中一部分被分類為持 作出售則作別論。根據權益法,投資初步 按成本列賬,其後就本集團應佔投資初 象資產淨值的收購後變動及與該投資有 關的任何減值虧損作出調整。除本集團 產生法定或推定責任或代表投資對象有 累虧損相等於或超過其於該投資對象之 權益包括任何實質構成本集團於該投資 對象投資淨值一部分的任何長期權益之 賬面值時,終止確認應佔的進一步虧損。

本集團與其聯營公司之間的交易所產生 之未變現溢利及虧損以本集團於投資對 象之權益為限進行對銷,除非未變現虧 損能夠提供所轉讓資產的減值證據,在 此情況下,該虧損隨即於損益內確認。

For the year ended 31 December 2020 截至二零二零年十二月三十一日止年度

### 2. SIGNIFICANT ACCOUNTING POLICIES 2. 主要會計政策(續) (Continued)

### Revenue from contracts with customers

Under HKFRS 15, the Group recognises revenue when (or as) a performance obligation is satisfied, i.e. when "control" of the goods underlying the particular performance obligation is transferred to customers.

A performance obligation represents a good or service (or a bundle of goods or services) that is distinct or a series of distinct goods or services that are substantially the same.

Control is transferred over time and revenue is recognised over time by reference to the progress towards complete satisfaction of the relevant performance obligation if one of the following criteria is met:

- the customer simultaneously receives and • consumes the benefits provided by the Group's performance as the Group performs;
- the Group's performance creates and enhances an asset that the customer controls as the Group performs; or
- the Group's performance does not create an • asset with an alternative use to the Group and the Group has an enforceable right to payment for performance completed to date.

Otherwise, revenue is recognised at a point in time when the customer obtains control of the distinct goods or service.

### 客戶合約收益

根據香港財務報告準則第15號,本集團 於履約責任獲履行時,即當與特定履約 責任相關的貨品的「控制權」轉讓予客戶 時,確認收益。

履約責任指一項明確貨品及服務(或一 組貨品或服務)或一系列大致相同的明 確貨品及服務。

倘符合以下其中一項標準,則控制權隨 時間轉移,而收益則參照完成履行相關 履約責任的進展情況而隨時間確認:

- 於本集團履約時,客戶同時取得及 享有本集團履約所提供的利益;
- 本集團的履約創建及增強客戶於本 集團履約時控制的資產;或
- 本集團的履約並未創建對本集團具 有替代用途的資產,而本集團可強 制執行權利以收取至今已完成履約 部分的款項。

否則,收益於客戶獲得明確貨品或服務 控制權的時間點確認。



For the year ended 31 December 2020 截至二零二零年十二月三十一日止年度

### 2. SIGNIFICANT ACCOUNTING POLICIES 2. 主要會計政策(續) (Continued)

# **Revenue from contracts with customers** (Continued)

A contract asset represents the Group's right to consideration in exchange for goods that the Group has transferred to a customer that is not yet unconditional. It is assessed for impairment in accordance with HKFRS 9. In contrast, a receivable represents the Group's unconditional right to consideration, i.e. only the passage of time is required before payment of that consideration is due.

A contract liability represents the Group's obligation to transfer goods to a customer for which the Group has received consideration (or an amount of consideration is due) from the customer.

A contract asset and a contract liability relating to a contract are accounted for an presented on a net basis.

Revenue from sales of goods is recognised at a point in time upon i) delivering the goods to the customers' warehouse on which the customers obtain control of the goods or ii) the customers collect the goods directly from the Group's warehouse, as appropriate.

Interest income is accrued on a time basis, by reference to the principal outstanding and at the effective interest rate applicable, which is the rate that exactly discounts the estimated future cash receipts through the expected life of the financial asset to that asset's net carrying amount on initial recognition. 客戶合約收益(續)

合約資產指本集團就換取本集團已向客 戶轉讓的貨品而收取代價的權利(尚未 成為無條件),其根據香港財務報告準 則第9號評估減值。相反,應收款項指 本集團收取代價的無條件權利,即代價 到期付款前僅需時間推移。

合約負債指本集團因其已向客戶收取代 價(或已到期代價金額),而須向客戶轉 讓貨品的責任。

與合約有關之合約資產及合約負債按淨 額基準入賬呈列。

銷售貨品收益於i)將貨品交付至客戶取 得貨品控制權的客戶倉庫時或ii)客戶於 適當時候直接向本集團倉庫收回貨品時 的時間點確認。

利息收入乃參照未償還本金按適用之實 際利率以時間基準計算,而該適用之實 際利率即準確貼現金融資產預計年期內 估計未來現金收入至資產於初始確認時 之賬面淨值之利率。

For the year ended 31 December 2020 截至二零二零年十二月三十一日止年度

### SIGNIFICANT ACCOUNTING POLICIES 2. 主要會計政策(續) (Continued)

### Leases

The Group assesses whether a contract is, or contains, a lease at inception of the contract. A contract is, or contains, a lease if the contract conveys the right to control the use of an identified asset for a period of time in exchange for consideration.

### As lessee

The Group applies the recognition exemption to short-term leases and low-value asset leases. Lease payments associated with these leases are recognised as an expense on a straight-line basis over the lease term.

The Group has elected not to separate non-lease components from lease components, and accounts for each lease component and any associated non-lease components as a single lease component.

The Group accounts for each lease component within a lease contract as a lease separately. The Group allocates the consideration in the contract to each lease component on the basis of the relative stand-alone price of the lease component.

Amounts payable by the Group that do not give rise to a separate component are considered to be part of the total consideration that is allocated to the separately identified components of the contract.

The Group recognises a right-of-use asset and a lease liability at the commencement date of the lease.

### 租賃

本集團於合約初始評估有關合約是否屬 租賃或包含租賃。倘合約授予權利以代 價獲得於一段時間內的控制使用已識別 資產,則合約屬於租賃或包含租賃。

### 作為承租人

本集團對短期租賃及低價值資產租賃應 用確認豁免。與該等租賃相關的租賃付 款已於租賃期內按直線法確認為開支。

本集團已選擇不區分非租賃成分,並將 各租賃成分及任何相關非租賃成分入賬 列作單一租賃成分。

本集團將租賃合約內各租賃成分作為單 獨租賃入賬。本集團根據租賃部分的相 對獨立價格將合約中的代價分配至各租 賃分。

倘本集團的應付款項並無產生單獨部 分,則被視為分配至合約單獨識別部分 的總代價的一部分。

本集團於租賃開始日期確認使用權資產 及租賃負債。

For the year ended 31 December 2020 截至二零二零年十二月三十一日止年度

### SIGNIFICANT ACCOUNTING POLICIES 2. 主要會計政策(續) (Continued)

Leases (Continued)

As lessee (Continued)

The right-of-use asset is initially measured at cost, which comprises

- (a) the amount of the initial measurement of the lease liability;
- (b) any lease payments made at or before the commencement date, less any lease incentives received;
- (c) any initial direct costs incurred by the Group; and
- (d) an estimate of costs to be incurred by the Group in dismantling and removing the underlying asset, restoring the site on which it is located or restoring the underlying asset to the condition required by the terms and conditions of the lease, unless those costs are incurred to produce inventories.

Subsequently, the right-of-use asset is measured at cost less any accumulated depreciation and any accumulated impairment losses and adjusted for any remeasurement of the lease liability. Depreciation is provided on a straight-line basis over the shorter of the lease term and the estimated useful lives of the right-of-use asset (unless the lease transfers ownership of the underlying asset to the Group by the end of the lease term or if the cost of the rightof-use asset reflects that the Group will exercise a purchase option – in which case depreciation is provided over the estimated useful life of the underlying asset) as follows: **租賃**(續)

作為承租人(續)

使用權資產按成本進行初始計量,包括:

- (a) 租賃負債的初步計量金額;
- (b) 於開始日期或之前所作的任何租賃 付款,減任何已收取的租賃獎勵;
- (c) 本集團產生之任何初始直接成本; 及
- (d) 本集團在拆除及移除相關資產、恢 復其所在地點或將相關資產恢復至 租賃條款及條件所要求的狀況時所 產生的估計成本,除非該等成本乃 因生產存貨而產生。

其後,使用權資產按成本減任何累計折 舊及任何累計減值虧損計量,並就租賃 負債的任何重新計量作出調整。折舊按 租賃期與使用權資產的估計可使用年期 (以較短者為準)按直線法計提撥備(除 非租賃於租賃期屆滿時將相關資產的所 有權轉讓予本集團或倘使用權資產的所 有權轉讓予本集團就行使購股權一在此情況 下,折舊乃按相關資產的估計可使用年 期計提)如下:

Factories and office premises	2 years to 3 years	工廠及辦公室物業	兩年至三年
Motor vehicles	5 years	汽車	五年

For the year ended 31 December 2020 截至二零二零年十二月三十一日止年度

### 2. SIGNIFICANT ACCOUNTING POLICIES 2. 主要會計政策(續)

(Continued)

Leases (Continued)

### As lessee (Continued)

The lease liability is initially measured at the present value of the lease payments that are not paid at the commencement date of the contract.

The lease payments included in the measurement of the lease liability comprise the following payments for the right to use the underlying asset during the lease term that are not paid at the commencement date:

- (a) fixed payments (including in-substance fixed payments), less any lease incentives receivable;
- (b) variable lease payments that depend on an index or a rate;
- (c) amounts expected to be payable under residual value guarantees;
- (d) exercise price of a purchase option if the Group is reasonably certain to exercise that option; and
- (e) payments of penalties for terminating the lease, if the lease term reflects the Group exercising an option to terminate the lease.

The lease payments are discounted using the interest rate implicit in the lease, or where it is not readily determinable, the incremental borrowing rate of the lessee.

Subsequently, the lease liability is measured by increasing the carrying amount to reflect interest on the lease liability and by reducing the carrying amount to reflect the lease payments made.

租賃(續)

作為承租人(續)

租賃負債初步按並非於合約開始日期支 付之租賃付款的現值確認。

租賃負債的計量中包括的租賃付款包括 以下並未在租賃開始日期就相關使用權 資產支付的付款:

- (a) 固定付款(包括實質上為固定付 款),減去仟何應收租賃優惠;
- (b) 可變租賃付款(視乎指數或利率而 定);
- (c) 根據剩餘價值擔保預期應支付的金 額;
- (d) 本集團合理確定行使選擇權的行使 **信**;及
- (e) 倘租賃條款反映本集團行使終止租 賃的選擇權,則支付終止租賃的罰 款。

倘未能輕易釐定租賃的增量借款利率, 則使用租賃中隱含的利率對租賃付款進 行貼現。

隨後,通過增加賬面值以反映租賃負債 的利息並通過減少賬面值以反映已支付 的租賃付款以計量租賃負債。



For the year ended 31 December 2020 截至二零二零年十二月三十一日止年度

# **2.** SIGNIFICANT ACCOUNTING POLICIES 2. 主要會計政策(續) (Continued)

### Leases (Continued)

### As lessee (Continued)

The lease liability is remeasured using a revised discount rate when there are changes to the lease payments arising from a change in the lease term or the reassessment of whether the Group will be reasonably certain to exercise a purchase option.

The lease liability is remeasured by using the original discount rate when there is a change in the residual value guarantee, the in-substance fixed lease payments or the future lease payments resulting from a change in an index or a rate (other than floating interest rate). In case of a change in future lease payments resulting from a change in floating interest rates, the Group remeasures the lease liability using a revised discount rate.

The Group recognises the amount of the remeasurement of the lease liability as an adjustment to the right-of-use asset. If the carrying amount of the right-of-use asset is reduced to zero and there is a further reduction in the measurement of the lease liability, the Group recognises any remaining amount of the remeasurement in profit or loss.

A lease modification is accounted for as a separate lease if

- (a) the modification increases the scope of the lease by adding the right to use one or more underlying assets; and
- (b) the consideration for the lease increases by an amount commensurate with the standalone price for the increase in scope and any appropriate adjustments to that standalone price to reflect the circumstances of the particular contract.

### **租賃**(續)

作為承租人(續)

當租賃期限發生變化或重新評估本集團 是否合理確定行使選擇權而導致租賃付 款發生變化時,將使用經修訂貼現率對 租賃負債進行重新計量。

當剩餘價值擔保因指數或利率變動(浮 動利率除外)而產生的實物固定租賃付 款額或未來租賃付款額發生變化時, 通過使用原始貼現率重新計量租賃負 債)。倘因浮動利率變動導致日後租賃 付款出現變動,本集團會採用經修訂貼 現率重新計量租賃負債。

本集團確認租賃負債重新計算之金額為 使用權資產調整。倘使用權資產的賬面 值減少至零及租賃負債之計算進一步減 少,則本集團於損益確認重新計算的任 何剩餘金額。

倘發生以下情況,則租賃的修改作為單 獨的租賃入賬:

- (a) 該修改通過增加一項或多項相關資 產的使用權利而擴大了租賃範圍;及
- (b) 租賃代價增加的金額相當於擴大範 圍對應的單獨價格,加上以反映特 定合約的情況對單獨價格進行的任 何適當調整。

For the year ended 31 December 2020 截至二零二零年十二月三十一日止年度

### SIGNIFICANT ACCOUNTING POLICIES 2. 主要會計政策(續) (Continued)

Leases (Continued)

#### As lessee (Continued)

When a lease modification is not accounted for as a separate lease, at the effective date of the lease modification,

- (a) the Group allocates the consideration in the modified contract on the basis of relative standalone price as described above.
- (b) the Group determines the lease term of the modified contract.
- (c) the Group remeasures the lease liability by discounting the revised lease payments using a revised discount rate over the revised lease term.
- (d) for lease modifications that decrease the scope of the lease, the Group accounts for the remeasurement of the lease liability by decreasing the carrying amount of the right-ofuse asset to reflect the partial or full termination of the lease and recognising any gain or loss relating to the partial or full termination of the lease in profit or loss.
- (e) for all other lease modifications, the Group accounts for the remeasurement of the lease liability by making a corresponding adjustment to the right-of-use asset.

**租賃**(續)

作為承租人(續)

倘租約的修改未以單獨租約入賬,則在 該租約修改生效之日,

- (a) 本公司將合約修改的代價按上述相 對獨立價格作出分配。
- (b) 本集團釐定經修訂合約之租賃期。
- (c) 本集團透過於經修訂租賃期使用經 修訂貼現率對經修訂租賃付款進行 貼現以重新計量租賃負債。
- (d) 就縮減租賃範圍之租賃修改而言, 本集團透過減少使用權資產之賬面 值將租賃負債之重新計量計入損 益,以反映部分或全面終止該租賃 及於損益中確認任何與部分或全面 終止該租賃相關之收益或虧損。
- (e) 就所有其他租賃修改而言,本集團 透過對使用權資產作出相應調整, 對租賃負債進行重新計算。



综合財務報表附註

For the year ended 31 December 2020 截至二零二零年十二月三十一日止年度

# **2. SIGNIFICANT ACCOUNTING POLICIES 2.** 主要會計政策(續) (Continued)

#### **Foreign currencies**

In preparing the financial statements of each individual group entity, transactions in currencies other than the functional currency of that entity (foreign currencies) are recognised at the rates of exchanges prevailing on the dates of the transactions. At the end of the reporting period, monetary items denominated in foreign currencies are retranslated at the rates prevailing at that date. Non-monetary items that are measured in terms of historical cost in a foreign currency are not retranslated.

Exchange differences arising on the settlement of monetary items, and on the retranslation of monetary items, are recognised in profit or loss in the period in which they arise.

For the purposes of presenting the consolidated financial statements, the assets and liabilities of the Group's foreign operations are translated into the presentation currency of the Group (i.e. RMB) using exchange rate prevailing at the end of each reporting period. Income and expenses items are translated at the average exchange rates for the period, unless exchange rates fluctuate significantly during the period, in which case, the exchange rates prevailing at the dates of transactions are used. Exchange differences arising, if any, are recognised in other comprehensive income and accumulated in equity under the heading of translation reserve (attributable to non-controlling interests as appropriate).

#### 外幣

於編製各個別集團實體之財務報表時, 以該實體功能貨幣以外之貨幣(外幣)進 行之交易均按交易日期之適用匯率確 認。於報告期末,以外幣計值之貨幣項 目均按該日之適用匯率重新換算。按歷 史成本以外幣計值之非貨幣項目毋須重 新換算。

於結算及重新換算貨幣項目時產生之匯 兑差額均於彼等產生期間內在損益確 認。

就呈列綜合財務報表而言,本集團之海 外業務資產及負債按結算日之當時匯率 換算為本集團之呈列貨幣(即人民幣)。 收入及開支按期內平均匯率換算,除非 期內匯率出現重大波幅,於此情況下, 則將採用交易當日之匯率。所產生之匯 兑差額(如有)於其他全面收入確認並於 權益下以匯兑儲備累計(於適當時撥作 非控股權益)。

For the year ended 31 December 2020 截至二零二零年十二月三十一日止年度

# SIGNIFICANT ACCOUNTING POLICIES 2. 主要 (Continued)

#### Foreign currencies (Continued)

On the disposal of a foreign operation (i.e. a disposal of the Group's entire interest in a foreign operation, or a disposal involving loss of control over a subsidiary that includes a foreign operation or a partial disposal of an interest in an associate that includes a foreign operation of which the retained interest becomes a financial assets). All of the exchange differences accumulated in a foreign exchange translation reserve in respect of that operation attributable to the owners of the company are reclassified to profit or loss.

In addition, in relation to a partial disposal of a subsidiary that includes a foreign operation that does not result in the Group losing control over the subsidiary, the proportionate share of accumulated exchange differences are re-attributed to noncontrolling interests and are not recognised in profit or loss. For all other partial disposals (i.e. partial disposals of associates that do not result in the Group losing significant influence), the proportionate share of the accumulated exchange differences is reclassified to profit or loss.

On all other partial disposals, which includes partial disposal of associates that do not result in the Group losing significant influence or joint control, the proportionate share of the cumulative amount of exchange differences recognised in the separate component of equity is reclassified to profit or loss.

### **2.** 主要會計政策(續)

#### **外幣**(續)

於出售海外業務(即出售本集團於海外 業務之全部權益,或涉及失去包含海外 業務之附屬公司控制權之出售,或部分 出售於一間聯營公司之權益(其包括海 外業務營運)而其保留權益成為金融資 產),就本公司擁有人應佔之業務於外 幣換算儲備累計之所有匯兑差額會獲重 新分類至損益。

此外,倘部分出售一間附屬公司(其包 括海外業務營運)並未導致本集團失去 對該附屬公司之控制權,則按比例將累 計匯兑差額重新歸入非控股權益,而並 不於損益內確認。對於所有其他部分出 售(即部分出售聯營公司而並無造成本 集團失去重大影響力),則按此比例將 累計匯兑差額重新分類至損益。

對於所有其他部分出售(包括部分出售 聯營公司而並無造成本集團失去重大影 響力或聯合控制力),則按此比例將於 單獨權益部分內確認之累計匯兑差額重 新分類至損益。



For the year ended 31 December 2020 截至二零二零年十二月三十一日止年度

# **2.** SIGNIFICANT ACCOUNTING POLICIES **2.** 主要會計政策(續) (Continued)

#### **Government grants**

Government grants are not recognised until there is reasonable assurance that the Group will comply with the conditions attaching to them and that the grants will be received.

Government grants are recognised in profit or loss on a systematic basis over the periods in which the Group recognises as expenses the related costs for which the grants are intended to compensate. Specifically, government grants whose primary condition is that the Group should purchase, construct or otherwise acquire non-current assets are recognised as deferred income in the consolidated statement of financial position and transferred to profit or loss on a systematic and rational basis over the useful lives of the related assets.

#### **Employee benefits**

#### Retirement benefit costs

Payments to state-managed retirement benefit schemes and the Mandatory Provident Fund Scheme are recognised as an expense when employees have rendered service entitling them to the contributions.

#### Short-term employee benefits

Short-term employee benefits are recognised at the undiscounted amount of the benefits expected to be paid as and when employees rendered the services. All short-term employee benefits are recognised as an expense unless another HKFRS requires or permits the inclusion of the benefit in the cost of an asset.

A liability is recognised for benefits accruing to employees (such as wages and salaries, annual leave and sick leave) after deducting any amount already paid.

#### 政府補助

政府補助在可合理保證本集團將遵守彼 等所附帶之條件並獲得有關補助前不作 確認。

政府補助按系統基準於本集團將政府補助擬補償的相關成本確認為開支的各期 間在損益內確認。具體而言,主要條件 為本集團須購買、興建或以其他方法獲 得非流動資產的政府補助於綜合財務狀 況表確認為遞延收入,並於有關資產的 可使用年期內有系統及合理地撥入損 益。

#### 僱員福利

#### 退休福利開支

國家管理退休福利計劃及強制性公積金 計劃之付款於僱員提供服務而可享有供 款時確認為開支。

#### 短期僱員福利

短期僱員福利於僱員提供服務時按預期 將支付之未貼現福利金額確認。除非另 有香港財務報告準則規定或允許將福利 計入資產成本,否則所有短期僱員福利 均確認為開支。

僱員應計之福利(例如工資及薪金、年 假以及病假)於扣減任何已付金額後確 認為負債。

For the year ended 31 December 2020 截至二零二零年十二月三十一日止年度

# 2. SIGNIFICANT ACCOUNTING POLICIES 2. 主要會計政策(續) (Continued)

#### Share-based payment transactions

#### Equity-settled transactions

The Group's employees, including directors, receive remuneration in the form of share-based payment transactions, whereby the employees rendered services in exchange for shares or rights over shares. The cost of such transactions with employees is measured by reference to the fair value of the equity instruments at the grant date. The fair value of share options granted to employees is recognised as an employee cost with a corresponding increase in a reserve within equity.

The cost of equity-settled transactions is recognised, together with a corresponding increase in equity, over the period in which the vesting conditions are to be fulfilled, ending on the date on which the entitlement of relevant employees to the award is no longer conditional on the satisfaction of any nonmarket vesting conditions ("vesting date"). During the vesting period, the number of share options that is expected to vest ultimately is reviewed. Any adjustment to the cumulative fair value recognised in prior periods is charged/credited to profit or loss for the year of review, with a corresponding adjustment to the reserve within equity.

When the share options are forfeited after the vesting date or are still not exercised at the expiry date, the amount previously recognised in share options reserve will be transferred to accumulated profits or losses.

# 股份基礎付款交易

#### 以股權結算之交易

本集團的僱員(包括董事)以股份基礎付 款交易的形式收取薪酬,而僱員則以提 供服務交換股份或股份權利。與僱員進 行之該等交易之成本乃參照授出日期權 益工具之公平值計量。授予僱員之購股 權之公平值確認為僱員成本,權益內之 儲備亦相應增加。

以股權結算之交易成本連同權益之相應 升幅會於達到歸屬條件之期間確認,直 至相關僱員不再須達成任何非市場歸屬 條件而可享有該報酬之日(「歸屬日」)為 止。於歸屬期內,會審閱預期最終歸屬 之購股權數目。於過往期間確認對累計 公平值之調整會於審閱當年之損益扣 除/計入,並相應調整權益內之儲備。

倘購股權於歸屬日期後被沒收,或於到 期日仍未行使,先前於購股權儲備確認 之數額,將撥至保留溢利或虧損。



综合財務報表附註

For the year ended 31 December 2020 截至二零二零年十二月三十一日止年度

# **2. SIGNIFICANT ACCOUNTING POLICIES 2.** 主要會計政策(續) (Continued)

#### Share-based payment transactions (Continued)

#### Equity-settled transactions (Continued)

No expense is recognised for awards that do not ultimately vest, except for awards that are conditional on a market condition or non-vesting condition, which are treated as vested irrespective of whether or not the market condition or non-vesting condition is satisfied, provided that all non-market vesting conditions are satisfied. Where an equitysettled award is cancelled, it is treated as if it had vested on the date of cancellation, and any expense not yet recognised for the award is recognised immediately. However, if a new award is substituted for the cancelled award, and designated as a replacement award on the date that it is granted, the cancelled and new awards are treated as if they were a modification of the original award as described above.

#### Taxation

Income tax expense represents the sum of the tax currently payable and deferred tax.

The tax currently payable is based on taxable profit for the period. Taxable profit differs from profit/loss before tax because of income or expense that are taxable or deductible in other years and items that are never taxable or deductible. The Group's liability for current tax is calculated using tax rates that have been enacted or substantively enacted by the end of the reporting period.

#### 股份基礎付款交易(續)

#### 以股權結算之交易(續)

#### 税項

所得税開支指即期應付税項及遞延税項 之總和。

即期應付税項乃根據本期間應課税溢利 計算。應課税溢利因其他年度應課税或 可扣減之收入或開支以及毋須課税或不 可扣減之項目,而有別於除税前溢利/ 虧損。本集團之即期税項負債乃使用於 報告期末已頒佈或實際上已頒佈之税率 計算。

For the year ended 31 December 2020 截至二零二零年十二月三十一日止年度

# 2. SIGNIFICANT ACCOUNTING POLICIES 2. 主 (Continued)

#### Taxation (Continued)

Deferred tax is recognised on temporary differences between the carrying amounts of assets and liabilities in the consolidated financial statements and the corresponding tax bases used in the computation of taxable profit. Deferred tax liabilities are generally recognised for all taxable temporary differences. Deferred tax assets are generally recognised for all deductible temporary differences to the extent that it is probable that taxable profits will be available against which those deductible temporary differences can be utilised. Such deferred tax assets and liabilities are not recognised if the temporary difference arises from the initial recognition (other than in a business combination) of assets and liabilities in a transaction that affects neither the taxable profit nor the accounting profit.

Deferred tax liabilities are recognised for taxable temporary differences associated with investments in subsidiaries and associates, except where the Group is able to control the reversal of the temporary difference and it is probable that the temporary difference will not reverse in the foreseeable future. Deferred tax assets arising from deductible temporary differences associated with such investments are only recognised to the extent that it is probable that there will be sufficient taxable profits against which to utilise the benefits of the temporary differences and they are expected to reverse in the foreseeable future.

The carrying amount of deferred tax assets is reviewed at the end of each reporting period and reduced to the extent that it is no longer probable that sufficient taxable profits will be available to allow all or part of the asset to be recovered.

## 2. 主要會計政策(續)

#### **税項**(續)

對於與附屬公司及聯營公司之投資相關 的應課税暫時差額會確認為遞延税項負 債,除非本集團能夠控制有關暫時差額 的轉回,而暫時差額在可預見的將來很 可能不會轉回。僅當很可能取得足夠的 應課税溢利以抵扣此類投資相關的可抵 扣暫時差額,並且暫時差額在可預見的 未來將轉回時,才確認該等可抵扣暫時 差額所產生的遞延税項資產。

遞延税項資產之賬面值於各報告期末審 閱,並於不大可能有足夠應課税利潤抵 銷全部或部分資產價值時予以削減。



For the year ended 31 December 2020 截至二零二零年十二月三十一日止年度

# **2.** SIGNIFICANT ACCOUNTING POLICIES **2.** 主要會計政策(續) (Continued)

### Taxation (Continued)

Deferred tax assets and liabilities are measured at the tax rates that are expected to apply in the period in which the liability is settled or the asset is realised, based on tax rate (and tax laws) that have been enacted or substantively enacted by the end of the reporting period.

The measurement of deferred tax liabilities and assets reflects the tax consequences that would follow from the manner in which the Group expects, at the end of the reporting period, to recover or settle the carrying amount of its assets and liabilities. Deferred tax assets and liabilities are offset when there is a legally enforceable right to set off current tax assets against current tax liabilities and when they relate to income taxes levied by the same taxation authority and the Group intends to settle its current tax assets and liabilities on a net basis.

Current tax and deferred tax are recognised in profit or loss.

#### 税項(續)

遞延税項資產及負債按償還負債或變現 資產期間的預期適用税率以於報告期末 已頒佈或實際上已頒佈之税率(及税法) 為基準計算。

遞延税項負債及資產之計量反映按照本 集團預期之方式於報告期末收回或結算 其資產及負債之賬面值之税務後果。倘 有法定可強制執行權利將即期税項資產 與即期税項負債抵銷,且兩者與同一税 務機構徵收之所得税有關,而本集團擬 按淨額基準結算即期税項資產及負債, 則可抵銷遞延税項資產及負債。

即期及遞延税項於損益內確認。

For the year ended 31 December 2020 截至二零二零年十二月三十一日止年度

# SIGNIFICANT ACCOUNTING POLICIES 2. 主要會計政策(續) (Continued)

#### Property, plant and equipment

Property, plant and equipment are stated in the consolidated statement of financial position at cost less subsequent accumulated depreciation and accumulated impairment losses, if any.

Properties in the course of construction for production, supply or administrative purposes are carried at cost, less any recognised impairment loss. Such properties are classified to the appropriate categories of property, plant and equipment when completed and ready for intended use. Depreciation of these assets, on the same basis as other property assets, commences when the assets are ready for their intended use.

Depreciation is recognised so as to write off the cost of assets over their estimated useful lives using the straight-line method. The estimated useful lives and depreciation method are reviewed at the end of each reporting period, with the effect of any changes in estimate accounted for on a prospective basis.

An item of property, plant and equipment is derecognised upon disposal or when no future economic benefits are expected to arise from the continued use of the asset. Any gain or loss arising on the disposal or retirement of an item of property, plant and equipment is determined as the difference between the sales proceeds and the carrying amount of the asset and is recognised in profit or loss.

#### 物業、廠房及設備

物業、廠房及設備按成本減去其後累計 折舊及累計減值虧損(如有)並於綜合財 務狀況表列賬。

用於生產、提供貨物或行政用途的在建 物業以成本減任何已確認減值虧損列 賬。有關物業於完工後並達到可使用狀 態時被分類為適當類別物業、廠房及設 備。當這些資產達到可用狀態時,按與 其他物業資產一樣的基準開始折舊。

折舊乃以直線法按資產之估計可使用年 期撇銷其成本確認。估計可使用年期及 折舊方法於各報告期末檢討,而任何估 計變動之影響按提前應用基準入賬。

物業、廠房及設備項目於出售時或預期 繼續使用該資產於日後將不會產生經濟 利益時終止確認。因出售或報廢物業、 廠房及設備項目所產生之任何收益或虧 損,按有關資產之出售所得款項與賬面 值間之差額釐定,並於損益確認。



For the year ended 31 December 2020 截至二零二零年十二月三十一日止年度

# 2. SIGNIFICANT ACCOUNTING POLICIES 2. 主要會計政策(續)

# (Continued)

## Intangible assets

# Internally-generated intangible assets – research and development expenditure

Expenditure on research activities is recognised as an expense in the period in which it is incurred.

An internally-generated intangible asset arising from development activities (or from the development phase of an internal project) is recognised if, and only if, all of the following have been demonstrated:

- the technical feasibility of completing the intangible asset so that it will be available for use or sale;
- the intention to complete the intangible asset and use or sell it;
- the ability to use or sell the intangible asset;
- how the intangible asset will generate probable future economic benefits;
- the availability of adequate technical, financial and other resources to complete the development and to use or sell the intangible asset; and
- the ability to measure reliably the expenditure attributable to the intangible asset during its development.

The amount initially recognised for internally generated intangible asset is the sum of the expenditure incurred from the date when the intangible asset first meets the recognition criteria listed above. Where no internally-generated intangible asset can be recognised, development expenditure is recognised in profit or loss in the period in which it is incurred.

# 無形資產

內部形成的無形資產 – 研發開支

研究活動開支於產生期內確認為開支。

開發活動所產生(或內部項目研發階段 所產生)之內部形成無形資產,僅在符 合以下所有條件時方予確認:

- 技術水平足以完成無形資產,致使 該項無形資產可供使用或銷售;
- 有意完成該無形資產並加以使用或 將之銷售;
- 使用或銷售無形資產的能力;
- 無形資產可能產生未來經濟效益;
- 具備充足的技術、財務和其他資源
   來完成其開發,並使用或銷售此無
   形資產;及
- 能夠可靠衡量用於開發期間無形資 產產生的支出。

初始確認的內部形成無形資產之金額為 無形資產首次符合上述確認條件之日起 產生之開支總和。倘並無內部形成無形 資產可予確認,則開發開支會於產生期 間於損益內確認。

For the year ended 31 December 2020 截至二零二零年十二月三十一日止年度

# 2. SIGNIFICANT ACCOUNTING POLICIES 2. 主要會計政策(續) (Continued)

#### Intangible assets (Continued)

Internally-generated intangible assets – research and development expenditure (Continued)

Subsequent to initial recognition, internally generated intangible assets are reported at cost less accumulated amortisation and accumulated impairment losses (if any), on the same basis as intangible assets that are acquired separately. Amortisation for intangible assets with finite useful lives is recognised on a straight-line basis over their estimated useful lives. The estimated useful life and amortisation method are reviewed at the end of each reporting period, with the effect of any changes in estimate being accounted for on a prospective basis.

An intangible asset is derecognised on disposal, or when no future economic benefits are expected from use or disposal. Gains and losses arising from derecognition of an intangible asset, measured as the difference between the net disposal proceeds and the carrying amount of the asset, are recognised in profit or loss when the asset is derecognised.

#### Impairment on tangible and intangible assets

At the end of the reporting period, the Group reviews the carrying amounts of its tangible and intangible assets with finite useful lives to determine whether there is any indication that those assets have suffered an impairment loss. If any such indication exists, the recoverable amount of the relevant asset is estimated in order to determine the extent of the impairment loss (if any).

## 無形資產(續)

內部形成的無形資產-研發開支(續)

初始確認後,內部形成無形資產按個別 收購無形資產相同之基準,以成本減累 計攤銷及累計減值虧損(如有)計算。可 使用年期有限之無形資產的攤銷於估計 可使用年期內以直線法確認。於各報告 期末檢討估計可使用年期及攤銷方法, 估計變動之影響按預期基準入賬。

無形資產於出售時或當預期日後不會藉 使用或出售取得經濟利益時終止確認。 終止確認無形資產時所產生之收益或虧 損,按出售所得款項淨額與資產賬面值 之差額計量,並於終止確認資產時在損 益中確認。

#### 有形及無形資產減值

於報告期末,本集團審閱其可使用年期 有限的有形及無形資產的賬面值,以釐 定是否有任何跡象顯示該等資產已出現 減值虧損。倘存在任何有關跡象,則會 估計有關資產的可收回金額,以釐定減 值虧損(如有)的程度。



综合財務報表附註

For the year ended 31 December 2020 截至二零二零年十二月三十一日止年度

# **2.** SIGNIFICANT ACCOUNTING POLICIES **2.** 主要會計政策(續) (Continued)

# Impairment on tangible and intangible assets (Continued)

The recoverable amount of tangible and intangible assets is estimated individually. When it is not possible to estimate the recoverable amount of an individual asset, the Group estimates the recoverable amount of the cash-generating unit to which the asset belongs. When a reasonable and consistent basis of allocation can be identified, corporate assets are also allocated to individual cash-generating units, or otherwise they are allocated to the smallest group of cash-generating units for which a reasonable and consistent allocation basis can be identified.

Recoverable amount is the higher of fair value less costs of disposal and value in use. In assessing value in use, the estimated future cash flows are discounted to their present value using a pre-tax discount rate that reflects current market assessments of the time value of money and the risks specific to the asset (or a cash-generating unit) for which the estimates of future cash flows have not been adjusted.

If the recoverable amount of an asset (or a cashgenerating unit) is estimated to be less than its carrying amount, the carrying amount of the asset (or a cash-generating unit) is reduced to its recoverable amount. An impairment loss is recognised immediately in profit or loss.

Where an impairment loss subsequently reverses, the carrying amount of the asset (or cash-generating unit) is increased to the revised estimate of its recoverable amount, but so that the increased carrying amount does not exceed the carrying amount that would have been determined had no impairment loss been recognised for the asset (or a cash-generating unit) in prior periods. A reversal of an impairment loss is recognised immediately in profit or loss.

### 有形及無形資產減值(續)

有形及無形資產的可收回金額單獨進行 估計。倘無法估計個別資產的可收回金 額,則本集團會估計該資產所屬現金產 生單位的可收回金額。倘可確定合理一 致之分配基準,則公司資產亦分配至個 別現金產生單位,否則有關資產將分配 至能確定合理一致分配基準的最小現金 產生單位組別。

可收回金額為公平值減出售成本與使用 價值兩者之較高者。於評估使用價值 時,估計未來現金流量會採用税前貼現 率貼現至其現值,而該税前貼現率反映 對貨幣時間價值及未來現金流量估計未 經調整之資產(或現金產生單位)之特定 風險的現時市場評估。

倘估計資產(或現金產生單位)的可收回 金額低於其賬面值,則該資產(或現金 產生單位)賬面值將減少至其可收回金 額。減值虧損即時於損益確認。

倘減值虧損於其後撥回,則有關資產 (或現金產生單位)的賬面值乃增加至其 可收回金額的經修訂估計價值,惟已增 加的賬面值不得超過倘該資產(或現金 產生單位)於過往期間並無確認減值虧 損時應釐定的賬面值。減值虧損撥回即 時於損益確認。

For the year ended 31 December 2020 截至二零二零年十二月三十一日止年度

# 2. SIGNIFICANT ACCOUNTING POLICIES 2. 主要會計政策(續) (Continued)

#### **Cash equivalents**

For the purpose of the consolidated statement of cash flows, cash equivalents represent shortterm highly liquid investments which are readily convertible into known amounts of cash and which are subject to an insignificant risk of changes in value, net of bank overdrafts (if any).

#### **Inventories**

Inventories are stated at the lower of cost and net realisable value. Cost, which comprises all costs of purchase and, where applicable, cost of conversion and other costs that have been incurred in bringing the inventories to their present location and condition, is calculated using the first in, first out method. Net realisable value represents the estimated selling price in the ordinary course of business less the estimated costs of completion and the estimated costs necessary to make the sale.

When inventories are sold, the carrying amount of those inventories is recognised as an expense in the period in which the related revenue is recognised. The amount of any write-down of inventories to net realisable value and all losses of inventories are recognised as an expense in the period of the writedown or loss occurs. The amount of any reversal of any write-down of inventories is recognised as a reduction in the amount of inventories recognised as an expense in the period in which the reversal occurs.

### 現金等價物

就綜合現金流量表而言,現金等價物指 易於轉換為現金已知款項且價值變動風 險不大的短期高流動性投資,並已扣除 銀行透支(如有)。

#### 存貨

存貨按成本及可變現淨值兩者之較低者 列賬。成本(包括所有採購成本,以及 在適用情況下計入將存貨運至現存地點 及使存貨達至現時狀況所需之轉換成本 及其他成本)乃以先入先出方式計算。 可變現淨值指日常業務中的估計售價減 估計完成成本及銷售所需估計成本。

出售存貨時,該等存貨的賬面值會於確 認相關收益的期間確認為開支。所有存 貨撇減至可變現淨值之跌價或存貨虧損 的金額在撇減或虧損發生的當期確認為 開支。任何存貨撇減之撥回金額於撥回 發生期間確認為已獲確認為開支的存貨 金額減少。



综合財務報表附註

For the year ended 31 December 2020 截至二零二零年十二月三十一日止年度

# 2. SIGNIFICANT ACCOUNTING POLICIES 2. 主要會計政策(續) (Continued)

#### **Financial instruments**

Financial assets and financial liabilities are recognised when a group entity becomes a party to the contractual provisions of the instrument.

Financial assets and financial liabilities are initially measured at fair value except for trade receivables arising from contracts with customers which are measured in accordance with HKFRS 15. Transaction costs that are directly attributable to the acquisition or issue of financial assets and financial liabilities are added to or deducted from the fair value of the financial assets or financial liabilities, as appropriate, on initial recognition.

The effective interest method is a method of calculating the amortised cost of a financial asset or financial liability and of allocating interest income and interest expense over the relevant period. The effective interest rate is the rate that exactly discounts estimated future cash receipts and payments (including all fees and points paid or received that form an integral part of the effective interest rate, transaction costs and other premiums or discounts) through the expected life of the financial asset or financial liability, or, where appropriate, a shorter period, to the net carrying amount on initial recognition.

### 泉 工 帰 金 融 工 具

倘集團實體成為工具合約條文之訂約 方,則確認金融資產及金融負債。

金融資產及金融負債初步以公平值計 量,惟根據香港財務報告準則第15號 計量的客戶合約產生的貿易應收款項除 外。因收購或發行金融資產及金融負債 而產生之直接應佔交易成本於初步確認 時加入金融資產或金融負債之公平值或 從中扣除(如適用)。

實際利率法為計算金融資產或金融負債 攤銷成本的方法,亦為於有關期間分配 利息收入及利息開支的方法。實際利率 為按金融資產或金融負債的預計年期或 (如適用)較短期間準確貼現估計未來現 金收入及付款(包括所有構成實際利率 組成部分之已付或已收費用及費率、交 易成本及其他溢價或折讓)至初始確認 時賬面淨值的利率。

For the year ended 31 December 2020 截至二零二零年十二月三十一日止年度

### SIGNIFICANT ACCOUNTING POLICIES 2. 主要會計政策(續) (Continued)

#### Financial instruments (Continued)

#### **Financial assets**

Classification and subsequent measurement of financial assets

Financial assets that meet the following conditions are subsequently measured at amortised cost:

- the financial asset is held within a business model whose objective is to collect contractual cash flows; and
- the contractual terms give rise on specified dates to cash flows that are solely payments of principal and interest on the principal amount outstanding.

Financial assets that meet the following conditions are subsequently measured at fair value through other comprehensive income:

- the financial asset is held within a business model whose objective is achieved by both collecting contractual cash flows and selling; and
- the contractual terms give rise on specified dates to cash flows that are solely payments of principal and interest on the principal amount outstanding.

All other financial assets are subsequently measure at fair value through profit or loss.

金融工具(續)

#### 金融資產

金融資產的分類及後續計量

符合下列條件的金融資產其後按攤銷成 本計量:

- 金融資產乃按旨在收取合約現金流 的業務模式持有;及
- 合約條款於指定日期產生純粹為支 付未償還本金及利息的現金流量。

符合下列條件的金融資產其後按以公平 值計入其他全面收益計量:

- 金融資產乃按旨在收取合約現金流 或出售的業務模式持有;及
- 合約條款於指定日期產生純粹為支 付未償還本金及利息的現金流量。

所有其他金融資產其後以公平值計入損 益計量。



For the year ended 31 December 2020 截至二零二零年十二月三十一日止年度

# SIGNIFICANT ACCOUNTING POLICIES 2. 主要會計政策(續) (Continued)

Financial instruments (Continued)

Financial assets (Continued)

#### Amortised cost and interest income

Interest income is recognised using the effective interest method for financial assets measured subsequently at amortised cost. Interest income is calculated by applying the effective interest rate to the gross carrying amount of a financial asset, except for financial assets that have subsequently become credit-impaired (see below). For financial assets that have subsequently become credit-impaired, interest income is recognised by applying the effective interest rate to the amortised cost of the financial asset from the next reporting period. If the credit risk on the credit-impaired financial instrument improves so that the financial asset is no longer creditimpaired, interest income is recognised by applying the effective interest rate to the gross carrying amount of the financial asset from the beginning of the reporting period following the determination that the asset is no longer credit-impaired.

#### Impairment of financial assets

The Group recognises a loss allowance for expected credit losses ("**ECL**") on financial assets which are subject to impairment under HKFRS 9 (including trade receivables, other receivables and bank balances). The amount of ECL is updated at each reporting date to reflect changes in credit risk since initial recognition.

金融工具(續)

金融資產(續)

攤銷成本及利息收入

其後按攤銷成本計量的金融資產的利息 收入乃使用實際利率法確認。利息收入 乃對金融資產賬面總值應用實際利率予 以計算,惟其後出現信貸減值的金融資 產除外(見下文)。對於其後出現信貸 值的金融資產,自下一報告期間起, 息收入乃對金融資產攤銷成本應用實 利率確認。若在釐定金融資產不要出現 信貸減值後的報告期間開始起,信貸減 值金融工具的信貸風險好轉,使金融資 產不再出現信貸減值,利息收入乃對金 融資產賬面總值應用實際利率確認。

#### 金融資產的減值

金融資產的減值本集團就根據香港財務 報告準則第9號面臨減值的金融資產(包 括貿易應收款項、其他應收款項及銀 行結餘)的預期信貸虧損(「預期信貸虧 損」)確認虧損撥備。預期信貸虧損金額 於各報告日期更新,以反映自初始確認 起的信貸風險變動。

For the year ended 31 December 2020 截至二零二零年十二月三十一日止年度

# **2. SIGNIFICANT ACCOUNTING POLICIES 2.** 主要會計政策(續) (Continued)

Financial instruments (Continued)

Financial assets (Continued)

#### Impairment of financial assets (Continued)

Lifetime ECL represents the ECL that will result from all possible default events over the expected life of the relevant instrument. In contrast, 12-month ECL ("**12m ECL**") represents the portion of lifetime ECL that is expected to result from default events that are possible within 12 months after the reporting date. Assessment are done based on the Group's historical credit loss experience, adjusted for factors that are specific to the debtors, general economic conditions and an assessment of both the current conditions at the reporting date as well as the forecast of future conditions.

The Group always recognises lifetime ECL for trade receivables. The ECL on these assets are assessed collectively using a provision matrix with appropriate groupings (i.e. high risk, normal risk and low risk type).

For all other instruments, the Group measures the loss allowance equal to 12m ECL, unless when there has been a significant increase in credit risk since initial recognition, the Group recognises lifetime ECL. The assessment of whether lifetime ECL should be recognised is based on significant increases in the likelihood or risk of a default occurring since initial recognition. 金融工具(*續*)

金融資產(續)

金融資產的減值(續)

全期預期信貸虧損指於相關工具預期年 期內發生所有可能的違約事件而導致的 預期信貸虧損。相反,12個月預期信貸 虧損(「12個月預期信貸虧損」)則指預期 於報告日期後12個月內可能發生的違約 事件而導致的部分全期預期信貸虧損。 評估乃根據本團的過往信貸虧損經驗做 出,並就債務人特有的因素、整體經濟 狀況以及對報告日期的現時狀況及未來 狀況的預測的評估做出調整。

本集團一直就貿易應收款項確認全期預 期信貸虧損。有關該等資產的預期信貸 虧損乃使用具有合適分組(即高風險、 正常風險及低風險類型)的撥備矩陣共 同作出評估。

就所有其他工具而言,本集團計量與12 個月預期信貸虧損等額的虧損撥備,除 非信貸風險自初始確認以來已大幅增 加,則本集團確認全期預期信貸虧損。 評估是否應確認全期預期信貸虧損,乃 基於自初始確認起出現違約的可能性或 風險是否大幅增加。



For the year ended 31 December 2020 截至二零二零年十二月三十一日止年度

### SIGNIFICANT ACCOUNTING POLICIES 2. 主要會計政策(續) (Continued)

#### Financial instruments (Continued)

Financial assets (Continued)

#### Impairment of financial assets (Continued)

(i) Significant increase in credit risk In assessing whether the credit risk has increased significantly since initial recognition, the Group compares the risk of a default occurring on the financial instrument as at the reporting date with the risk of a default occurring on the financial instrument as at the date of initial recognition. In making this assessment, the Group considers both quantitative and qualitative information that is reasonable and supportable, including historical experience and forward-looking information that is available without undue cost or effort.

In particular, the following information is taken into account when assessing whether credit risk has increased significantly:

- an actual or expected significant deterioration in the financial instrument's external (if available) or internal credit assessment;
- significant deterioration in external market indicators of credit risk, e.g. a significant increase in the credit spread, the credit default swap prices for the debtor;
- existing or forecast adverse changes in business, financial or economic conditions that are expected to cause a significant decrease in the debtor's ability to meet its debt obligations;
- an actual or expected significant deterioration in the operating results of the debtor;

金融工具(續)

金融資產(續)

金融資產的減值(續)

(i) 信貸風險顯著上升
 評估信貸風險自初始確認以來是否
 顯著上升時,本集團會比較金融工
 具於報告日期發生違約的風險與金
 融工具於初始確認日期發生違約的
 風險。作出評估時,本集團會考慮
 合理及具支持性的定量及定性資料,包括過往經驗及可以合理成本
 及精力獲取的前瞻性資料。

具體而言,評估信貸風險是否顯著 上升時會考慮以下資料:

- 金融工具的外部(倘可獲得)或
   內部信貸評估實際或預期顯著
   惡化;
- 信貸風險的外部市場跡象(如 信貸息差顯著增加、債務人的 信貸違約掉期價格等)顯著惡 化;
- 商業、金融或經濟情況目前或 預期有不利變動,預計將導致 債務人償還債項的能力顯著下 降;
- 債務人經營業績實際或預期顯 著惡化;

For the year ended 31 December 2020 截至二零二零年十二月三十一日止年度

# 2. SIGNIFICANT ACCOUNTING POLICIES 2. 主要會計政策(續) (Continued)

Financial instruments (Continued)

Financial assets (Continued)

#### Impairment of financial assets (Continued)

- (i) Significant increase in credit risk (Continued)
  - an actual or expected significant adverse change in the regulatory, economic, or technological environment of the debtor that results in a significant decrease in the debtor's ability to meet its debt obligations.

Irrespective of the outcome of the above assessment, the Group presumes that the credit risk has increased significantly since initial recognition when contractual payments are more than 30 days past due, unless the Group has reasonable and supportable information that demonstrates otherwise.

Despite the aforegoing, the Group assumes that the credit risk on a financial instrument has not increased significantly since initial recognition if the financial instrument is determined to have low credit risk at the reporting date. A financial instrument is determined to have low credit risk if i) the financial instrument has a low risk of default (i.e. no default history); ii) the counterparty has a strong capacity to meet its contractual cash flow obligations in the near term; and iii) adverse changes in economic and business conditions in the longer term may, but will not necessarily, reduce the ability of the borrower to fulfil its contractual cash flow obligations.

The Group regularly monitors the effectiveness of the criteria used to identify whether there has been a significant increase in credit risk and revises them as appropriate to ensure that the criteria are capable of identifying significant increase in credit risk before the amount becomes past due.

金融工具(續)

金融資產(續)

金融資產的減值(續)

- (i) 信貸風險顯著上升(續)
  - 債務人的監管、經濟或技術環 • 境有實際或預計的重大不利變 動,導致債務人償還債項的能 力顯著下降。

不論上述評估結果,本集團認為, 倘合約付款逾期超過30天,則信貸 風險自初始確認以來已顯著上升, 惟本集團擁有合理有據資料顯示並 非如此,則另作別論。

儘管上文所述,倘金融工具於報告 日期被釐定為低風險,本集團假設 金融工具之信貸風險自初步確認以 來無顯著增加。倘i)金融工具為低 違約風險(即無違約記錄); ii)對手 方近期擁有較強的履行其合約現金 流義務能力;及iii)長期經濟及業務 狀況的不利變動未必會降低借款人 履行其合約現金流量義務之能力, 則金融工具釐定為低風險。

本集團定期監察用於識別信貸風險 是否出現顯著上升的標準之有效性 並在適當時候進行修改,以確保標 準能夠在款項逾期前識別出風險有 否顯著上升。



綜合財務報表附註

For the year ended 31 December 2020 截至二零二零年十二月三十一日止年度

# **2.** SIGNIFICANT ACCOUNTING POLICIES **2.** 主要會計政策(續) (Continued)

#### Financial instruments (Continued)

#### Financial assets (Continued)

#### Impairment of financial assets (Continued)

(ii) Definition of default

For internal credit risk management, the Group considers an event of default occurs when information developed internally indicates that the debtor is unlikely to pay its creditors, including the Group, in full (without taking into account any collaterals held by the Group).

Irrespective of the above, the Group considers that default has occurred when a financial asset is more than 90 days past due unless the Group has reasonable and supportable information to demonstrate that a more lagging default criterion is more appropriate.

#### (iii) Credit-impaired financial assets

A financial asset is credit-impaired when one or more events of default that have a detrimental impact on the estimated future cash flows of that financial asset have occurred. Evidence that a financial asset is credit-impaired includes observable data about the following events:

- (a) significant financial difficulty of the issuer or the borrower;
- (b) a breach of contract, such as a default or past due event;
- (c) the lender(s) of the borrower, for economic or contractual reasons relating to the borrower's financial difficulty, having granted to the borrower a concession(s) that the lender(s) would not otherwise consider; or
- (d) it is becoming probable that the borrower will enter bankruptcy or other financial reorganisation.

金融工具(續)

金融資產(續)

金融資產的減值(續)

(ii) 違約的界定 就內部信貸風險管理而言,本集團 認為,當內部獲得的資料顯示債務 人不大可能向債權人(包括本集團) 全數付款時(並無計及本集團所持 有的任何抵押品),即出現違約事 項。

> 無論上文所述,本集團認為,倘金 融資產逾期超過90天,則違約已經 發生,惟本集團擁有合理有據資料 顯示一項更滯後的違約標準更為合 適,則另作別論。

- (iii) 信貸減值金融資產 當發生對金融資產的估計未來現金 流量產生不利影響的一起或多起違 約事件之時,該金融資產即出現信 貸減值。金融資產信貸減值的證據 包括以下事件的可觀察數據:
  - (a) 發行人或借款人陷入嚴重財 困;
  - (b) 違反合約,例如違約或逾期事件;
  - (c) 借款人的貸款人出於與借款人 財困相關的經濟或合約原因, 而向借款人授予貸款人原本不 會考慮的優惠;或
  - (d) 借款人可能破產或進行其他財務重組。

For the year ended 31 December 2020 截至二零二零年十二月三十一日止年度

# 2. SIGNIFICANT ACCOUNTING POLICIES 2. 主要會計政策(續) (Continued)

Financial instruments (Continued)

Financial assets (Continued)

Impairment of financial assets (Continued)

(iv) Write-off policy

The Group writes off a financial asset when there is information indicating that the counterparty is in severe financial difficulty and there is no realistic prospect of recovery, for example, when the counterparty has been placed under liquidation or has entered into bankruptcy proceedings, or in the case of trade receivables, when the amounts are over two years past due, whichever occurs sooner. Financial assets written off may still be subject to enforcement activities under the Group's recovery procedures, taking into account legal advice where appropriate. A writeoff constitutes a derecognition event. Any subsequent recoveries are recognised in profit or loss.

(v) Measurement and recognition of ECL The measurement of ECL is a function of the probability of default, loss given default (i.e. the magnitude of the loss if there is a default) and the exposure at default. The assessment of the probability of default and loss given default is based on historical data adjusted by forwardlooking information. Estimation of ECL reflects an unbiased and probability-weighted amount that is determined with the respective risks of default occurring as the weights.

Generally, the ECL is the difference between all contractual cash flows that are due to the Group in accordance with the contract and the cash flows that the Group expects to receive, discounted at the effective interest rate determined at initial recognition.

金融工具(續)

金融資產(續)

金融資產的減值(續)

(iv) 撇銷政策 當有資料顯示交易對手陷入嚴重財 困,且並無實際收回的可能之時 (例如交易對手已清算或進入破產 程序,或貿易應收款項逾期超過兩 年(以較早發生者為準)),本集團 會撇銷金融資產。已撇銷的金融資 產仍可根據本集團的收回程序實施 強制執行,在適當情況下考慮法律 意見。撇銷構成終止確認事件。任 何其後收回款項於損益中確認。

(v) 計量及確認預期信貸虧損 計量預期信貸虧損乃違約概率、違 約損失率程度(即倘發生違約的損 失程度)及違約風險的函數。違約 概率及違約損失率程度的評估根據 經前瞻性資料調整的歷史數據作 出。預期信貸虧損的估計反映以發 生的相關違約風險作為加權數值而 確定的無偏概率加權金額。

> 一般而言,預期信貸虧損為根據合 約應付本集團的所有合約現金流與 本集團預期將收取的所有現金流量 間的差額,並按初始確認時釐定的 實際利率貼現。



综合財務報表附註

For the year ended 31 December 2020 截至二零二零年十二月三十一日止年度

#### 2. SIGNIFICANT ACCOUNTING POLICIES 2. 主要會計政策(續) (Continued)

#### Financial instruments (Continued)

#### Financial assets (Continued)

#### Impairment of financial assets (Continued)

(v) Measurement and recognition of ECL (Continued)

Where ECL is measured on a collective basis or cater for cases where evidence at the individual instrument level may not yet be available, the financial instruments are grouped on the risk type (i.e. high risk, normal risk and low risk type) by considering:

- Past-due status; and
- Nature, size and industry of debtors.

The grouping is regularly reviewed by management to ensure the constituents of each group continue to share similar credit risk characteristics.

Interest income is calculated based on the gross carrying amount of the financial asset unless the financial asset is credit-impaired, in which case interest income is calculated based on amortised cost of the financial asset.

The Group recognises an impairment gain or loss in profit or loss for all financial instruments by adjusting their carrying amount, with the exception of trade receivables and other receivables where the corresponding adjustment is recognised through a loss allowance account. 金融工具(續)

金融資產(續)

金融資產的減值(續)

(v) 計量及確認預期信貸虧損(續)

倘預期信貸虧損按綜合基準計量, 或以處理個別工具層面的證據尚未 可得,金融工具乃按風險類型(即 高風險,正常風險和低風險類型) 進行分組:

- 逾期狀態;及
- 債務人的性質、規模及行業。

管理層定期檢討分類,以確保各類 別的組成項目仍然具有相似的信貸 風險特徵。

利息收入乃按金融資產的賬面總值 計算,惟金融資產出現信貸減值, 利息收入則按金融資產的攤銷成本 計算。

本集團通過調整賬面值於損益中確 認所有金融工具之減值收益或虧 損,惟相應調整於虧損備抵賬中確 認之貿易應收款項及其他應收款項 除外。

For the year ended 31 December 2020 截至二零二零年十二月三十一日止年度

#### 2. SIGNIFICANT ACCOUNTING POLICIES 2. 主要會計政策(續) (Continued)

#### Financial instruments (Continued)

#### Financial liabilities and equity

#### Classification as debt or equity

Debt and equity instruments are classified as either financial liabilities or as equity in accordance with the substance of the contractual arrangements and the definitions of a financial liability and an equity instrument.

#### Equity instruments

An equity instrument is any contract that evidences a residual interest in the assets of an entity after deducting all of its liabilities. Equity instruments issued by the Company are recognised at the proceeds received, net of direct issue costs.

#### Financial liabilities

All financial liabilities are subsequently measured at amortised cost using the effective interest method.

Financial liabilities including trade payables, other payables and accrued charges, and lease liabilities are subsequently measured at amortised cost, using the effective interest method.

#### Derecognition of financial liabilities

The Group derecognises financial liabilities when, and only when, the Group's obligations are discharged, cancelled or have expired. The difference between the carrying amount of the financial liability derecognised and the consideration paid and payable is recognised in profit or loss.

金融工具(續)

#### 金融負債及權益

分類為債務或權益

債務及股本工具乃根據合約安排的內容 以及金融負債與股本工具的定義分類為 金融負債或權益。

#### 權益工具

權益工具為證明本集團於扣除其所有負 債後之剩餘資產權益之任何合約。本公 司發行之權益工具按所收取之所得款項 扣減直接發行成本確認。

#### 金融負債

所有金融負債其後使用實際利率法按攤 銷成本計量。

金融負債(包括貿易應付款項、其他應 付款項及應計費用以及租賃負債)其後 使用實際利率法按攤銷成本計算。

#### 取消確認金融負債

本集團於且僅於其責任獲免除、取消或 屆滿時取消確認金融負債。取消確認之 金融負債之賬面值與已付及應付代價間 之差額於損益確認。

综合財務報表附註

For the year ended 31 December 2020 截至二零二零年十二月三十一日止年度

### SIGNIFICANT ACCOUNTING POLICIES 2. 主要會計政策(續) (Continued)

#### **Related parties**

A related party is a person or entity that is related to the Group.

- (a) A person or a close member of that person's family is related to the Group if that person:
  - (i) has control or joint control over the Group;
  - (ii) has significant influence over the Group; or
  - (iii) is a member of the key management personnel of the Group or of the holding company of the Group.
- (b) An entity is related to the Group if any of the following conditions applies:
  - the entity and the Group are members of the same group (which means that each holding company, subsidiary and fellow subsidiary is related to the others).
  - (ii) one entity is an associate or joint venture of the other entity (or an associate or joint venture of a member of a group of which the other entity is a member).
  - (iii) both entities are joint ventures of the same third party.
  - (iv) one entity is a joint venture of a third entity and the other entity is an associate of the third entity.
  - (v) the entity is a post-employment benefit plan for the benefit of employees of either the Group or an entity related to the Group. If the Group is itself such a plan, the sponsoring employers are also related to the Group.

# 關連方

關連方指與本集團有關連的個人或實 體。

- (a) 倘個別人士或其家庭近親成員符合 下列條件,即為與本集團有關連:
  - (i) 對本集團有控制或共同控制 權;
  - (ii) 對本集團有重大影響力;或
  - (iii) 為本集團或本集團控股公司的 主要管理人員。
- (b) 倘符合下列任何條件,即實體與本 集團有關連:
  - (i) 該實體與本集團為同一集團的 成員公司(即各控股公司、附 屬公司及同系附屬公司彼此互 有關連)。
  - (ii) 實體為另一實體的聯營公司或 合營企業(或另一實體為成員 公司的集團旗下成員公司之聯 營公司或合營企業)。
  - (iii) 兩間實體均為同一第三方的合 營企業。
  - (iv) 實體為第三方實體之合營企 業,而另一實體為該第三方實 體之聯營公司。
  - (v) 實體為本集團或與本集團有關 連的實體就僱員福利設立的退 休後福利計劃。倘本集團本身 為該計劃,提供資助的僱主亦 與本集團有關連。

For the year ended 31 December 2020 截至二零二零年十二月三十一日止年度

## SIGNIFICANT ACCOUNTING POLICIES 2. 主要會計政策(續) (Continued)

#### Related parties (Continued)

- (b) (Continued)
  - (vi) the entity is controlled or jointly controlled by a person identified in (a).
  - (vii) a person identified in (a)(i) has significant influence over the entity or is a member of the key management personnel of the entity (or of a holding company of the entity).
  - (viii) the entity, or any member of a group of which it is a part, provides key management personnel services to the Group or to the holding company of the Group.

Close members of the family of a person are those family members who may be expected to influence, or be influenced by, that person in their dealings with the entity and include:

- (a) that person's children and spouse or domestic partner;
- (b) children of that person's spouse or domestic partner; and
- (c) dependants of that person or that person's spouse or domestic partner.

In the definition of a related party, an associate includes subsidiaries of the associate and a joint venture includes subsidiaries of the joint venture.

#### Segment reporting

Operating segments, and the amounts of each segment item reported in the consolidated financial statements, are identified from the financial information provided regularly to Group's executive directors for the purpose of allocating resources to, and assessing the performance of, the Group's various lines of business and geographical locations.

#### **關連方**(續)

- (b) *(續)* 
  - (vi) 實體受(a)所識別人士控制或共 同控制。
  - (vii) (a)(i)段所識別並對實體有重大 影響力或為該實體(或該實體 控股公司)主要管理人員的人 士。
  - (viii) 該實體或所屬集團旗下任何成員公司向本集團或本集團之控股公司提供主要管理人員服務。

個別人士的緊密家族成員指與該實體交 易時預期可影響該個別人士或受該個別 人士影響的家族成員並包括:

- (a) 該名人士之子女及配偶或家庭夥(+);
- (b) 該名人士之配偶或家庭夥伴之子 女;及
- (c) 該名人士或該名人士之配偶或家庭 夥伴之家屬。

於界定關連方時,聯營公司包括該聯營 公司之附屬公司,而合營企業包括該合 營企業之附屬公司。

#### 分部報告

經營分部及綜合財務報表所呈報各分部 項目的金額,乃根據向本集團各項業務 及地域地區分配資源及評估其業績表現 而定期向本集團執行董事提供的財務資 料當中識別出來。



For the year ended 31 December 2020 截至二零二零年十二月三十一日止年度

# **2. SIGNIFICANT ACCOUNTING POLICIES 2.** 主要會計政策(續) (Continued)

#### Segment reporting (Continued)

Individual material operating segments are not aggregated for financial reporting purposes unless the segments have similar economic characteristics and are similar in respect of the nature of products and services, the nature of production processes, the type or class of customers, the methods used to distribute the products or provide the services, and the nature of the regulatory environment. Operating segments which are not individually material may be aggregated if they share a majority of these criteria.

#### Key sources of estimation and uncertainty

In the application of the Group's accounting policies, the directors of the Company are required to make judgements, estimates and assumptions about the carrying amounts of assets and liabilities that are not readily apparent from other sources. The estimates and associated assumptions are based on historical experience and other factors that are considered to be relevant. Actual results may differ from these estimates.

The estimates and underlying assumptions are reviewed on an on-going basis. Revisions to accounting estimates are recognised in the period in which the estimate is revised if the revision affects only that period, or in the period of the revision and future periods if the revision affects both current and future periods.

The following are the key assumptions concerning the future, and other key sources of estimation uncertainty at the end of the reporting period, that may have a significant risk of causing a material adjustment to the carrying amounts of assets and liabilities within the next financial year.

#### . . . . . . . .

# 分部報告(續)

個別重要的經營分部不會合計以供財務 報告之用,但如該等經營分部的產品和 服務性質、生產工序性質、客戶類別或 階層、分銷產品或提供服務的方法以至 監管環境的本質等經濟特性均屬類似, 則作別論。個別不重要的經營分部如果 符合以上大部分條件,則可以合計為一 個報告分部。

#### 估計及不明朗因素之主要來源

在應用本集團會計政策時,本公司董事 須對未能從其他來源輕易獲得的資產及 負債賬面值作出判斷、估計及假設。估 計及相關假設乃根據過往經驗及被視為 相關的其他因素作出。實際結果可能與 該等估計有所差異。

有關估計及相關假設按持續基準予以審 閱。倘會計估計的修訂僅影響估計作出 修訂的期間,則有關修訂會於該期間確 認,或倘修訂同時影響修訂的當前期間 及未來期間,則有關修訂會於作出該修 訂的當前期間及未來期間確認。

於報告期末,有重大風險可能導致資產 及負債賬面值於下個財政年度作出重大 調整的未來相關主要假設及估計不明朗 因素的其他主要來源如下。

For the year ended 31 December 2020 截至二零二零年十二月三十一日止年度

# 2. SIGNIFICANT ACCOUNTING POLICIES 2. 主要會計政策(續) (Continued)

## Key sources of estimation and uncertainty (Continued)

#### Impairment assessment of trade receivables

The Group adopted HKFRS 9 and the management of the Group estimates the amount of lifetime ECL of trade receivables based on provision matrix through grouping of various debtors that have similar loss patterns, after considering internal credit assessment of trade debtors and past due status of respective trade receivables. Estimated loss rates are based on historical observed default rates over the expected life of the debtors and are adjusted for forward-looking information. In addition, trade receivables that are credit impaired are assessed for ECL individually. The loss allowance amount of the credit impaired trade receivables is measured as the difference between the asset's carrying amount and the present value of estimated future cash flows with the consideration of expected future losses.

## Impairment of property, plant and equipment and right-of-use assets

The management determines whether the Group's property, plant and equipment and right-of-use assets are impaired when an indication of impairment exists. This requires an estimation of the recoverable amounts of the property, plant and equipment and right-of-use assets which is equal to the higher of fair value less costs of disposal and value in use. Estimating the value in use requires the management to make an estimate of the expected future cash flows from the property, plant and equipment and right-of-use assets and also to choose a suitable discount rate in order to calculate the present value of those cash flows. Any impairment will be charged to profit or loss.

#### 估計及不明朗因素之主要來源(續)

#### 貿易應收款項減值評估

本集團採納香港財務報告準則第9號, 及本集團管理層經考慮貿易債務人之內 部信貸評估及各貿易應收款項之逾期狀 況,透過對具有類似虧損型態的不同債 務人分組根據撥備矩陣估計貿易應收款 項的全期預期信貸虧損。估計虧損率乃 基於應收賬款預期年期內的過往可觀察 違約率並就前瞻性資料作出調整計算。 此外,發生信貸減值之貿易應收款項單 獨評估預期信貸虧損。信貸減值貿易應 收款項之虧損撥備計量為資產賬面值與 估計未來現金流量(經考慮預期未來虧 損)現值之差額。

#### 物業、廠房及設備減值及使用權資產

管理層於出現減值跡象時釐定本集團之 物業、廠房及設備及使用權資產有否減 值。此須對物業、廠房及設備以及使用 權資產之可收回金額進行估計,其相當 於公平值減出售成本與使用價值之較高 者。估計使用價值要求管理層對來自物 業、廠房及設備以及使用權資產之預期 未來現金流量作出估計,並選擇一個適 當貼現率,以計算該等現金流量之現 值。任何減值將於損益中扣除。



For the year ended 31 December 2020 截至二零二零年十二月三十一日止年度

#### SIGNIFICANT ACCOUNTING POLICIES 2. 主要會計政策(續) (Continued)

#### Future changes in HKFRSs

At the date of authorisation of the consolidated financial statements, the HKICPA has issued the following new/revised HKFRSs that are not yet effective for the current year, which the Group has not early adopted.

#### 香港財務報告準則之未來變動

本集團並未提早採納於該等綜合財務報 表獲批准之日香港會計師公會已頒佈但 本年度尚未生效之多項新訂/經修訂香 港財務報告準則。

Amendments to HKFRS 16	COVID-19-Related Rent Concessions (1)	香港財務報告準則第16號 修訂本	COVID-19相關租金 寬減 <sup>⑴</sup>
Amendments to HKAS 39, HKFRSs 4, 7, 9 and 16	Interest Rate Benchmark Reform – Phase 2 (2)	香港會計準則第39號、 香港財務報告準則第4號、 第7號、第9號及第16號 修訂本	利率基準改革- 第二階段 <sup>(2)</sup>
Amendments to HKAS 16	Proceeds before Intended Use <sup>(3)</sup>	香港會計準則第16號修訂本	作擬定用途前之 所得款項 <sup>(3)</sup>
Amendments to HKAS 37	Cost of Fulfilling a Contract <sup>(3)</sup>	香港會計準則第37號修訂本	履行合約之成本(3)
Amendments to HKFRS 3	Reference to the Conceptual Framework $^{\scriptscriptstyle (3)}$	香港財務報告準則第3號 修訂本	概念框架之提述③
Annual Improvements to HKFRSs	2018–2020 Cycle <sup>(3)</sup>	香港財務報告準則年度改進	二零一八年至 二零二零年週期 <sup>(3)</sup>
Amendments to HKAS 1	Classification of Liabilities as Current or Non- current <sup>(4)</sup>	香港會計準則第1號修訂本	負債分類為流動或 非流動 <sup>(4)</sup>
HKFRS 17	Insurance Contracts (4)	香港財務報告準則第17號	保險合約(4)
Amendments to HKFRS 10 and HKAS 28	Sale or Contribution of Assets between an Investor and its Associate or Joint Venture <sup>(5)</sup>	香港財務報告準則第10號及 香港會計準則第28號修訂本	投資者及其聯營公司 或合營企業間之 資產出售或注入 <sup>(5)</sup>

- <sup>(1)</sup> Effective for annual periods beginning on or after 1 June 2020
- (2) Effective for annual periods beginning on or after 1 January 2021
- <sup>(3)</sup> Effective for annual periods beginning on or after 1 January 2022
- (4) Effective for annual periods beginning on or after 1 January 2023
- <sup>(5)</sup> The effective date to be determined

The management of the Group does not anticipate that the adoption of these new/revised HKFRSs in future periods will have any material impact on the financial performance and financial position of the Group. (2) 於二零二一年一月一日或之後開始之年 度期間生效

⑴ 於二零二零年六月一日或之後開始之年

- ③ 於二零二二年一月一日或之後開始之年 度期間生效
- (4) 於二零二三年一月一日或之後開始之年 度期間生效
- ⑸ 生效日期待釐定

度期間生效

本集團管理層預期,於未來期間採用該 等新訂/經修訂香港財務報告準則將不 會對本集團之財務表現及財務狀況造成 任何重大影響。

For the year ended 31 December 2020 截至二零二零年十二月三十一日止年度

### 3. **REVENUE**

3. 收益

(a) Disaggregation of revenue from contracts(a) 客戶合約收益分類with customers

		2020 二零二零年 <i>RMB'000</i> 人 <i>民幣千元</i>	2019 二零一九年 <i>RMB'000</i> 人 <i>民幣千元</i>
Type of goods	貨品類別		
Sales of biological reagents: Male fertility in-vitro diagnostic	銷售生物製劑: 男性不育體外診斷		
(" <b>IVD</b> ") reagents	(「 <b>體外診斷</b> 」)試劑	15,952	19,433
Parasite antibody detection reagents Epstein-Barr Virus antibody	寄生蟲系列檢測試劑 EB病毒檢測試劑	2,900	3,499
detection reagents		978	1,221
Sales of auxiliary reproductive supplies and equipment	銷售輔助生育用品 和設備	1,361	1,318
Sales of healthcare products and	銷售健康產品及		
supplements	保健品	776	-
		21,967	25,471
		2020	2019
		二零二零年	二零一九年
		RMB'000	RMB'000
		人民幣千元	人民幣千元
Type of customers	客戶類別		
Distributors	分銷商	12,160	12,444
Non-distributors	非分銷商	9,807	13,027
		21,967	25,471

For the year ended 31 December 2020 截至二零二零年十二月三十一日止年度

#### **3. REVENUE** (Continued)

# (b) Performance obligations for contracts with customers

The Group sells biological reagents, auxiliary reproductive supplies and equipment and healthcare products and supplements to distributors and non-distributors mainly comprising hospitals and medical institutions in the PRC. Contracts with the Group's customers are mainly short term and fixed price contracts. The revenue is recognised when control of the goods has transferred, being when the goods are i) delivered to the customers' warehouse on which the customers obtain control of the goods or ii) collected by the customers directly from the Group's warehouse, as appropriate. Following delivery, the customers have full discretion over the manner of distribution and price to sell the goods, have the primary responsibility when selling the goods and bear the risks of obsolescence and loss in relation to the goods.

In general, the Group will request deposits from the customers before the goods are delivered and the amount of deposits requested varies amongst different contracts. For certain longterm customers, the Group will deliver the goods without requesting deposits and allow a credit period from 30 to 180 days (2019: 30 to 180 days) to these customers and there is no credit period granted to other customers. The customers have neither rights of return nor rights to defer or avoid payment for the goods once they are accepted by the customers upon delivery.

### 3. 收益(續)

#### (b) 客戶合約的履約責任

一般而言,本集團將要求於貨品交 付前向客戶收取按金,而且所要求 按金數額因不同合約而有所區別。 就若干長期客戶而言,本集團將於 不要求按金的情況下向該等客戶30至180 天(二零一九年:30至180天)的信 貸期,而並無向其他客戶授出信貸 期。一旦客戶於繳付時接納貨品, 客戶不得退回或延期或逃避支付貨 款。

For the year ended 31 December 2020 截至二零二零年十二月三十一日止年度

#### 3. **REVENUE** (Continued)

(b) Performance obligations for contracts with customers (Continued)

The total amount of transaction prices allocated to the remaining unsatisfied performance obligations as at 31 December 2020 are approximately RMB2,143,000 (2019: approximately RMB292,000) and the expected timing of recognising revenue is within one year.

#### 4. SEGMENT INFORMATION

The Group's operating activities are mainly attributable to a single operating segment focusing on research and development, manufacturing and sales of biological reagents and auxiliary reproductive supplies and equipment. This operating segment has been identified on the basis of internal management reports prepared in accordance with accounting policies that disclosed in Note 2 to the consolidated financial statements. Information reported to the directors of the Company, being the chief operating decision maker, for the purposes of resource allocation and assessment focuses on revenue analysis by major products. No other discrete financial information is provided other than the Group's results and financial position as a whole. Accordingly, only entity-wide disclosures, geographic information and major customers are presented.

- 3. 收益(續)
  - (b) 客戶合約的履約責任(續)

於二零二零年十二月三十一日分配 至剩餘未履行履約責任的交易價格 總額約為人民幣2,143,000元(二零 一九年:約人民幣292,000元)及預 期收益確認時間為一年內。

## 4. 分部資料

本集團的經營活動主要歸屬於單一的經 營分部,專注於研發、生產及銷售生物 製劑及輔助生育用品和設備。此經營分 部乃以根據於綜合財務報表附註2披露 的會計政策編製之內部管理報告為基 識別。就資源分配及評估而向本公司董 审(即主要經營決策者)報告的資料著重 按主要產品劃分的收益分析。除本集團 整體業績及財務狀況外,概無單獨提供 其他財務資料。因此,僅呈列整個實體 的披露資料、地域資料及主要客戶。 NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS 使合时致起主财社

綜合財務報表附註

For the year ended 31 December 2020 截至二零二零年十二月三十一日止年度

#### 4. **SEGMENT INFORMATION** (Continued)

#### 4. 分部資料(續)

#### Entity-wide disclosure

#### Revenue from major products

The following is an analysis of the Group's revenue from its major products:

# 整個實體的披露資料 主要產品收益

以下為本集團主要產品收益之分析:

		<b>2020</b> 二零二零年 <i>RMB'000</i> 人 <i>民幣千元</i>	2019 二零一九年 <i>RMB'000 人民幣千元</i>
Type of goods	貨品類別		
Sales of biological reagents:	銷售生物製劑:		
Male fertility IVD reagents	男性不育體外診斷		
Male fertility fvD feagents	試劑	15,952	19,433
Parasite antibody detection reagents	寄生蟲系列檢測試劑	2,900	3,499
Epstein-Barr Virus antibody detection	EB病毒檢測試劑		,
reagents		978	1,221
Sales of auxiliary reproductive supplies	銷售輔助生育用品		
and equipment	和設備	1,361	1,318
Sales of healthcare products and	銷售健康產品及		
supplements	保健品	776	-
		21,967	25,471

#### **Geographical information**

#### 地域資料

The following table sets out information about the geographical location of the Group's revenue from external customers which are based on the location of goods delivered.

下表載列按貨品交付的地區劃分之本集 團外部客戶收益之地域資料。

		2020 二零二零年 <i>RMB'000</i> 人民幣千元	2019 二零一九年 <i>RMB'000</i> <i>人民幣千元</i>
Revenue from external customers: The PRC Hong Kong	外部客戶收益: 中國 香港	21,191 776	25,471
		21,967	25,471

No geographical segment information of the Group's non-current assets is presented as the Group's non-current assets (except for a leased office premises and motor vehicle with total carrying amount of approximately RMB1,000,000 (2019: approximately RMB1,067,000) as presented in right-of-use assets which is located in Hong Kong) are mainly located in the PRC by physical location of assets.

由於按資產的所在位置劃分本集團之非 流動資產(除位於香港的使用權資產呈 列之總賬面值約為人民幣1,000,000元 (*二零一九年:約人民幣1,067,000元*) 之租賃辦公物業及汽車以外)主要位於 中國,故並無呈列本集團非流動資產之 地域分部資料。

For the year ended 31 December 2020 截至二零二零年十二月三十一日止年度

### 4. SEGMENT INFORMATION (Continued)

#### 4. 分部資料(續)

#### Information about major customers

Details of the customers (including entities under common control) individually accounting for 10% or more of the Group's total revenue are as follows:

# **有關主要客戶的資料** 單獨佔本集團總收益10%或以上的客戶

(包括受共同控制實體)的詳情如下:

		2020	2019
		二零二零年	二零一九年
		RMB'000	RMB'000
		人民幣千元	人民幣千元
Customer A	客戶A	2,462	3,119

# 5. OTHER INCOME

5. 其他收入

		2020 二零二零年 <i>RMB'000</i> 人 <i>民幣千元</i>	2019 二零一九年 <i>RMB'000</i> <i>人民幣千元</i>
Bank interest income Government grants <i>(Note)</i> Sundry income	銀行利息收入 政府補助 <i>(附註)</i> 雜項收入	185 441 24	174 55 31
		650	260

#### Note:

附註:

In the opinion of the management of the Group, there was no unfulfilled condition or contingency relating to the government grants.

# 未達成條件或或然事項。

本集團管理層認為,並無與政府補助有關之

# 6. OTHER GAINS AND LOSSES

# 6. 其他收益及虧損

		<b>2020</b> 二零二零年 <i>RMB'000</i> 人 <i>民幣千元</i>	2019 二零一九年 <i>RMB'000</i> <i>人民幣千元</i>
Gain on disposal of property, plant and equipment, net Gain on lease modification Foreign exchange (losses) gains, net	出售物業、廠房及 設備收益淨額 租賃修訂收益 匯兑(虧損)收益淨額	- 11 (1,073)	10 _ 498
		(1,062)	508

For the year ended 31 December 2020 截至二零二零年十二月三十一日止年度

#### 7. 除税前(虧損)溢利 7. (LOSS) PROFIT BEFORE TAX

This is stated after charging:

# 此乃經扣除下列各項:

		2020 二零二零年 <i>RMB'000</i> 人 <i>民幣千元</i>	2019 二零一九年 <i>RMB'000</i> <i>人民幣千元</i>
Finance costs	融資成本		
Finance charges on lease liabilities	租賃負債的財務費用	74	72
Staff costs, including directors' remuneration	員工成本 <sup>,</sup> 包括董事 薪酬		
Directors' emoluments (Note 8) Other staff costs: Salaries, bonuses and other benefits	董事薪酬 <i>(附註8)</i> 其他員工成本 薪金、花紅及其他	3,844	1,232
	福利	8,177	7,687
Contributions to defined contribution plans <i>(Note (i))</i> Equity-settled share-based	定額供款計劃供款 <i>(附註(i))</i> 以股權結算之股份	701	1,241
payment expenses	基礎付款開支	1,024	_
		13,746	10,160
Other items	其他項目		
Auditor's remuneration Amortisation of intangible assets	<b>兵池頃日</b> 核數師酬金 無形資產攤銷	625	619
(included in cost of sales)	(包括銷售成本)	330	370
Cost of inventories ( <i>Note (ii)</i> ) Depreciation of property,	存貨成本 <i>(附註(ii))</i> 物業、廠房及設備	7,249	7,580
plant and equipment	折舊	1,848	1,609
Depreciation of right-of-use assets	使用權資產折舊	1,016	783
Other rental and related expenses – short term leases	其他租賃及有關開支 短期租賃	42	28
Write-off of property, plant and equipment	物業、廠房及設備 核銷	33	3

#### Notes:

附註:

Starting from February 2020, the relevant PRC (i) government authorities has given certain temporary reliefs to entities incorporated in the PRC to exempt from payment of certain amount of levies on the social security insurance.

<sup>(</sup>i) 自二零二零年二月起,中國相關政府機 構已為在中國註冊成立的實體提供若干 臨時救濟,並豁免繳納一定數額的社會 保障保險費。

For the year ended 31 December 2020 截至二零二零年十二月三十一日止年度

#### 7. (LOSS) PROFIT BEFORE TAX (Continued)

Notes: (Continued)

(ii) During the year ended 31 December 2020, cost of inventories included approximately RMB2,962,000 (2019: approximately RMB3,353,000) relating to the aggregate amount of certain staff costs, amortisation, depreciation and other rental and related expenses, which were included in the respective amounts as disclosed above.

# 8. DIRECTORS' AND CHIEF EXECUTIVE'S EMOLUMENTS AND FIVE HIGHEST PAID EMPLOYEES

(a) Directors' and chief executive's emoluments

## 7. 除税前(虧損)溢利(續)

附註:(續)

 (ii) 截至二零二零年十二月三十一日止年度,存貨成本包括有關若干員工成本、 攤銷、折舊及其他租賃及有關開支的總額約人民幣2,962,000元(二零一九年: 約人民幣3,353,000元),已包括在上文 披露的相關金額。

# 8. 董事及主要行政人員薪酬以及五名 最高薪僱員薪酬

(a) 董事及主要行政人員薪酬

Name	Position	Date of appointment (resignation) as the director of the Company
姓名	職位	獲委任為(辭任)本公司董事之日期
		2.4
Mr. Zhang Shuguang	Executive director and chairman of the Board of Directors	3 August 2017
張曙光先生	執行董事兼董事會主席	二零一七年八月三日
Mr. Zhang Chunguang	Executive director and chief executive officer (Chief Executive)	3 August 2017
張春光先生	執行董事兼首席執行官(行政總裁)	二零一七年八月三日
Mr. Poon Lai Yin Michael	Executive director and chief financial officer	3 August 2017
潘禮賢先生	執行董事兼首席財務官	二零一七年八月三日
Mr. He Jiaming	Executive director and business development director	14 January 2020
何嘉明先生	執行董事兼業務發展董事	二零二零年一月十四日
Mr. Chan Kin Sang	Independent non-executive director	26 November 2018
陳健生先生	獨立非執行董事	二零一八年十一月二十六日
Dr. Yeung David Wai Chow	Independent non-executive director	26 November 2018 (resigned on 16 December 2020)
楊煒秋醫生	獨立非執行董事	二零一八年十一月二十六日 (於二零二零年十二月十六日辭任)
Mr. Kwok Chi Shing	Independent non-executive director	26 November 2018 (resigned on 1 September 2020)
郭志成先生	獨立非執行董事	二零一八年十一月二十六日 (於二零二零年九月一日辭任)
Mr. Cheng Faat Ting Gary	Independent non-executive director	1 September 2020
鄭發丁先生	獨立非執行董事	二零二零年九月一日
Mr. Chow Kwok Fai Joseph	Independent non-executive director	16 December 2020
周國輝先生	獨立非執行董事	二零二零年十二月十六日

For the year ended 31 December 2020 截至二零二零年十二月三十一日止年度

# 8. DIRECTORS' AND CHIEF EXECUTIVE'S 8. 董事及主要行政人員薪酬以及五名 EMOLUMENTS AND FIVE HIGHEST PAID **EMPLOYEES** (Continued)

## (a) Directors' and chief executive's emoluments (Continued)

Directors' and chief executive's remuneration for the year, disclosed pursuant to the applicable Listing Rules and the Hong Kong Companies Ordinance, is as follows:

#### Year ended 31 December 2020

# 最高薪僱員薪酬(續)

(a) 董事及主要行政人員薪酬(續)

根據適用上市規則及香港公司條例 披露的年內董事及及主要行政人員 薪酬如下:

截至二零二零年十二月三十一日止 年度

					Equity-settled	Contributions	
			Salaries and		share-based	to defined	
		Directors'	other	Discretionary	payment	contribution	
		fees	benefits	bonuses	expenses	plans	Total
					以股權結算之		
			薪金及		股份基礎	定額供款	
		董事袍金	其他福利	酌情花紅	付款開支	計劃供款	總計
		RMB'000	RMB'000	RMB'000	RMB'000	RMB'000	RMB'000
		人民幣千元	人民幣千元	人民幣千元	人民幣千元	人民幣千元	人民幣千元
Executive directors	執行董事						
Mr. Zhang Shuguang	張曙光先生	-	217	27	409	23	676
Mr. Zhang Chunguang	張春光先生	-	250	40	409	28	727
Mr. Poon Lai Yin Michael	潘禮賢先生	-	812	36	409	26	1,283
Mr. He Jiaming	何嘉明先生	-	429	36	409	16	890
			1 700	120	4.000	02	2 570
		-	1,708	139	1,636	93	3,576
Independent non-executive directors	獨立非執行董事						
Mr. Chan Kin Sang	陳健生先生	89	-	-	-	-	89
Dr. Yeung David Wai Chow	楊煒秋醫生	85	-	-	-	-	85
Mr. Kwok Chi Shing	郭志成先生	56	-	-	-	-	56
Mr. Cheng Faat Ting Gary	鄭發丁先生	34	-	-	-	-	34
Mr. Chow Kwok Fai Joseph	周國輝先生	4	-	-	-	-	4
		268	-	-	-	-	268
		268	1,708	139	1,636	93	3,844

For the year ended 31 December 2020 截至二零二零年十二月三十一日止年度

## 8. DIRECTORS' AND CHIEF EXECUTIVE'S 8. 董事及主要行政人員薪酬以及五名 **EMOLUMENTS AND FIVE HIGHEST PAID EMPLOYEES** (Continued)

(a) Directors' and chief executive's emoluments

- 最高薪僱員薪酬(續)
- (a) 董事及主要行政人員薪酬(續)

Year ended 31 December 2019

(Continued)

截至二零一九年十二月三十一日止 年度

		Directors' fees 董事袍金 <i>RMB'000 人民幣千元</i>	Salaries and other benefits 薪金及 其他福利 RMB'000 人民幣千元	Discretionary bonuses 酌情花紅 RMB'000 人民幣千元	Equity-settled share-based payment expenses 以股權結算之 股份基礎 付款開支 <i>RMB'000 人民幣千元</i>	Contributions to defined contribution plans 定額供款 計劃供款 <i>RMB'000</i> 人民幣千元	Total 總計 <i>RMB'000 人民幣千元</i>
			, , , , , , , , , , , , , , , , , , , ,		, (, (, , , , , )	,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,	///////////////////////////////////////
Executive directors	執行董事						
Mr. Zhang Shuguang	張曙光先生	-	214	73	-	31	318
Mr. Zhang Chunguang	張春光先生	-	227	86	-	36	349
Mr. Poon Lai Yin Michael	潘禮賢先生	-	265	22	-	14	301
		_	706	181	_	81	968
Independent non-executive directors	獨立非執行董事						
Mr. Chan Kin Sang	陳健生先生	88	-	-	-	-	88
Dr. Yeung David	楊煒秋醫生						
Wai Chow		88	-	-	-	-	88
Mr. Kwok Chi Shing	郭志成先生	88	-	-	-		88
		264	-	-	-	-	264
		264	706	181	-	81	1,232

For the year ended 31 December 2020 截至二零二零年十二月三十一日止年度

## 8. DIRECTORS' AND CHIEF EXECUTIVE'S EMOLUMENTS AND FIVE HIGHEST PAID EMPLOYEES (Continued)

## (a) Directors' and chief executive's emoluments (Continued)

Mr. Zhang Chunguang's emoluments disclosed above included those for services rendered by him as chief executive officer during the years ended 31 December 2020 and 2019.

The executive directors' emoluments shown above were for their services in connection with the management of the affairs of the Company and the Group. The independent non-executive directors' emoluments shown above were for their services as directors of the Company.

Discretionary bonuses are determined based on the results of the Group during both years.

During the years ended 31 December 2020 and 2019, no emoluments were paid by the Group to the directors of the Company as an inducement to join or upon joining the Group or as compensation for loss of office. There was no arrangement under which a director or the chief executive waived or agreed to waive any remuneration during both years.

## 8. 董事及主要行政人員薪酬以及五名 最高薪僱員薪酬(續)

(a) 董事及主要行政人員薪酬(續)

上文披露的張春光先生之薪酬包括 彼於截至二零二零年及二零一九年 十二月三十一日止年度擔任行政總 裁所提供服務的薪酬。

上述執行董事薪酬為彼等就本公司 及本集團管理事務方面所提供的服 務而獲得。上述獨立非執行董事薪 酬為彼等就擔任本公司董事所提供 的服務而獲得。

於該兩個年度,酌情花紅乃根據本 集團業績釐定。

截至二零二零年及二零一九年十二 月三十一日止年度,本集團概無支 付薪酬予董事作為加入本集團或於 加入本集團後之聘金或離職補償。 於該兩個年度概無董事或主要行政 人員放棄或同意放棄任何薪酬的安 排。

For the year ended 31 December 2020 截至二零二零年十二月三十一日止年度

## 8. DIRECTORS' AND CHIEF EXECUTIVE'S EMOLUMENTS AND FIVE HIGHEST PAID EMPLOYEES (Continued)

#### (b) Five highest paid employees

The five highest paid employees of the Group for the year ended 31 December 2020 included four (2019: three) directors, details of whose remuneration are set out above. Details of the remuneration of the remaining one (2019: two) highest paid employee who are neither a director of the Company nor chief executive of the Group are as follows:

## 8. 董事及主要行政人員薪酬以及五名 最高薪僱員薪酬(續)

#### (b) 五名最高薪僱員

截至二零二零年十二月三十一日止 年度,本集團五名最高薪僱員包括 四名董事(二零一九年:三名),彼 等之薪酬詳情已披露於上文。剩餘 一名(二零一九年:兩名)既非本公 司董事亦非本集團主要行政人員的 最高薪僱員之薪酬詳情如下:

		2020 二零二零年 <i>RMB'000</i> 人民幣千元	2019 二零一九年 <i>RMB'000</i> 人民幣千元
Salaries and other benefits	薪金及其他福利	643	1,061
Discretionary bonuses	酌情花紅	45	156
Contributions to defined	定額供款計劃供款		
contribution plans		25	32
Equity-settled share-based	以股權結算之股份基礎		
payment expenses	付款開支	205	-
		918	1,249

The number of these non-director individuals whose emoluments fell within the following emoluments band is as follows:

其薪酬介乎下列薪酬範圍的該等非 董事人士數目如下:

			Number of individuals 人數		
		<b>2020</b> 二零二零年	2019 二零一九年		
Nil to HK\$1,000,000	零至1,000,000港元	1	2		

For the year ended 31 December 2020 截至二零二零年十二月三十一日止年度

## 8. DIRECTORS' AND CHIEF EXECUTIVE'S EMOLUMENTS AND FIVE HIGHEST PAID EMPLOYEES (Continued)

#### (b) Five highest paid employees (Continued)

During the years ended 31 December 2020 and 2019, no remuneration was paid by the Group to any of these highest paid non-director individuals as an inducement to join or upon joining the Group, or as a compensation for loss of office. There was no arrangement under which any of these highest paid non-director individuals waived or has agreed to waive any emoluments during the years ended 31 December 2020 and 2019.

## 9. INCOME TAX EXPENSE

## 8. 董事及主要行政人員薪酬以及五名 最高薪僱員薪酬(續)

#### (b) 五名最高薪僱員(續)

截至二零二零年及二零一九年十二 月三十一日止年度,本集團概無支 付薪酬予任何該等最高薪非董事人 士作為加入本集團或於加入本集團 後之聘金或離職補償。截至二零二 零年及二零一九年十二月三十一日 止年度,概無任何該等最高薪非董 事人士根據任何安排放棄或同意放 棄任何酬金。

## 9. 所得税開支

		2020	2019
		二零二零年	二零一九年
		RMB'000	RMB'000
		人民幣千元	人民幣千元
Current tax	即期税項		
PRC Enterprise Income Tax	中國企業所得税		
– current year	一本年度	255	942

The Company and the subsidiaries incorporated in the BVI are tax-exempted. Entity established in the PRC is subject to PRC Enterprise Income Tax at a statutory rate of 25%. Since the Group's PRC subsidiary, Shenzhen Huakang is recognised as "New and High Technology Enterprise" and therefore is entitled to a concessional tax rate of 15%. The entitlement of this tax benefit is subject to renewal by respective tax bureau in the PRC every three years. The latest approval for Shenzhen Huakang enjoying this tax benefit was obtained in December 2020 for the three years ending 31 December 2023.

Hong Kong Profits Tax has not been provided as the Group had no assessable profit arising from Hong Kong for the years ended 31 December 2020 and 2019.

於英屬處女群島註冊成立的本公司及附 屬公司均免税。於中國成立之實體須按 中國企業所得税法定税率25%繳納税 項。由於本集團的中國附屬公司深圳華 康獲評為「高新技術企業」,因此可享有 15%的優惠税率。該項税務優惠資格須 每三年獲相關中國税務局重續。深圳華 康最近獲此税務優惠審批之時間為二零 二零年十二月,有效期為截至二零二三 年十二月三十一日止三年。

由於本集團於截至二零二零年及二零 一九年十二月三十一日止年度並無在香 港產生應課税溢利,故並無就香港利得 税作出撥備。

For the year ended 31 December 2020 截至二零二零年十二月三十一日止年度

## 9. INCOME TAX EXPENSE (Continued)

## **9.** 所得税開支(續)

Reconciliation of income tax expense

## 所得税開支對賬

		2020	2019
		二零二零年	二零一九年
		RMB'000	<i>RMB'000</i>
		人民幣千元	人民幣千元
(Loss) Profit before tax	除税前(虧損)溢利	(11,372)	658
Income tax at applicable tax rate of 25%	按適用税率25%(二零		
(2019: 25%)	<i>一九年:25%)</i> 計算的		
	所得税	(2,843)	165
Tax effect of expenses not deductible for	不可扣税開支的税務		
tax purpose	影響	3,574	1,608
Additional tax deduction on research and	研發開支附加税扣減		
development expenses		(311)	(228)
Effect of tax concession granted	獲授税項優惠的影響	(195)	(662)
Others	其他	30	59
Income tax expense for the year	年內所得税開支	255	942



### **9. INCOME TAX EXPENSE** (Continued)

## **Unrecognised deferred tax liabilities**

Under the relevant tax law and implementation regulations in the PRC, withholding income tax is applicable to dividend earned and payable to investors that are "non-tax resident enterprises" in respect of profits earned by PRC subsidiary since 1 January 2008, which do not have an establishment or place of business in the PRC, or which have such establishment or place of business but the relevant income is not effectively connected with the establishment or place of business, to the extent such interest or dividends have their sources within the PRC. Under such circumstances, dividends paid by the PRC subsidiary to offshore group entities shall be subject to the withholding tax at 10% or a lower treaty rate. The Group is subject to withholding tax in relation to the dividend paid by the PRC subsidiary. As the Company has decided not to declare any dividends from undistributed earnings of the PRC subsidiary amounting to approximately RMB42,676,000 (2019: approximately RMB42,216,000) as at 31 December 2020 to the immediate holding company of the PRC subsidiary in the foreseeable future, no deferred tax liability has been recognised in respect of these undistributed earnings during the years ended 31 December 2020 and 2019.

No provision for deferred taxation has been made in the consolidated financial statements as there were no significant temporary differences arising during the years ended 31 December 2020 and 2019 or at the end of each reporting period.

## **9.** 所得税開支(續)

## 未確認遞延税項負債

根據中國相關税法及實施條例,若利息 或股息源於中國境內,自二零零八年一 月一日起就中國附屬公司所獲溢利所賺 取並應支付予「非税收居民企業」(並非 在中國成立或在中國並無營業地點,或 在中國成立或設有營業地點但相關收入 與有關成立或營業地點無實際關連)投 資者的股息,須繳納預扣所得税。在這 種情況下,中國附屬公司向境外集團實 體支付的股息應按10%或更低的協定税 率繳納預扣税。本集團須就中國附屬公 司支付的股息繳納預扣税。於二零二零 年十二月三十一日,由於本公司決定於 可預見未來將不宣派中國附屬公司未分 配盈利任何股息約人民幣42,676,000元 (二零一九年:約人民幣42,216,000元) 予中國附屬公司的直接控股公司,因此 截至二零二零年及二零一九年十二月 三十一日止年度, 並未就該等未分配盈 利確認遞延税項負債。

由於截至二零二零年及二零一九年十二 月三十一日止年度或各報告期末並無重 大暫時性差異,因此綜合財務報表並無 計提遞延税項撥備。

For the year ended 31 December 2020 截至二零二零年十二月三十一日止年度

## **10. LOSS PER SHARE**

## 10. 每股虧損

The calculation of the basic loss per share attributable to owners of the Company is based on the following data: 本公司擁有人應佔每股基本虧損的計算 乃基於以下數據:

		2020 二零二零年 <i>RMB'000</i> 人民幣千元	2019 二零一九年 <i>RMB'000</i> 人民幣千元
Loss: Loss for the year attributable to owners of the Company for the purpose of basic loss per share	<b>虧損:</b> 計算每股基本虧損 所用本公司擁有人 應佔虧損	(11,627)	(284)
Number of shares: Weighted average number of ordinary shares of the Company in issue for the purpose of basic loss per share	<b>股份數目:</b> 計算每股基本虧損 所用本公司已發行 普通股加權平均數	400,000,000	400,000,000

Diluted loss per share is the same as basic loss per share as the effect of potential ordinary shares is anti-dilutive during the year ended 31 December 2020.

Diluted loss per share is the same as basic loss per share as there were no dilutive potential ordinary shares in issue during the year ended 31 December 2019.

## **11. DIVIDENDS**

No dividend was paid or declared by the Company during the years ended 31 December 2020 and 2019, nor has any dividend been proposed since the end of each reporting period. 截至二零二零年十二月三十一日止年 度,由於普通股具有潛在反攤薄效應, 故每股攤薄虧損與每股基本虧損相同。

截至二零一九年十二月三十一日止年 度,由於已發行普通股並無潛在攤薄效 應,故每股攤薄虧損與每股基本虧損相 同。

## 11. 股息

截至二零二零年及二零一九年十二月 三十一日止年度,本公司概無派付或宣 派任何股息,及自各報告期末亦無建議 派付任何股息。



## **12. PROPERTY, PLANT AND EQUIPMENT**

**12.** 物業<sup>、</sup>廠房及設備

		Leasehold improvements 租賃物業裝修 RMB'000 人民幣千元	Plant and machinery 廠房及機械 RMB'000 人民幣千元	Office equipment 辦公設備 RMB'000 人民幣千元	Motor vehicles 汽車 RMB'000 人民幣千元	Construction in-progress 在建工程 RMB'000 人民幣千元	<b>Total</b> 總計 <i>RMB'000 人民幣千元</i>
COST At 1 January 2019	<b>成本</b> 於二零一九年一月一日	3,511	7,202	1,242	1,001	303	13,259
Additions	添置 二令 九十 万 百	433	1,189	1,242	138	-	1,767
Transfer from construction-in-	自在建工程轉撥	155	1,105	,	150		1,707
progress		158	19	74	-	(251)	-
Disposals/written-off	處置/核銷	-	-	-	(141)	(3)	(144)
At 31 December 2019 and 1 January 2020	於二零一九年 十二月三十一日及						
A 1 192	二零二零年一月一日	4,102	8,410	1,323	998	49	14,882
Additions	添置	704	-	316	554	397	1,971
Transfer from construction-in-	自在建工程轉撥	16				(16)	-
progress Written-off	核銷	-	_	_	_	(10)	(33)
At 31 December 2020	於二零二零年 十二月三十一日	4,822	8,410	1,639	1,552	397	16,820
	Т-Л-Т н	7,022	0,+10	1,055	1,552	557	10,020
ACCUMULATED DEPRECIATION AND IMPAIRMENT LOSSES	累計折舊及減值虧損						
At 1 January 2019	於二零一九年一月一日	756	1,987	355	594	-	3,692
Provided for the year	本年度撥備	560	855	138	56	-	1,609
Eliminated on disposals/written-off	處置時抵銷/核銷	-	-	-	(141)	-	(141)
At 31 December 2019 and 1 January 2020	於二零一九年 十二月三十一日及						
	二零二零年一月一日	1,316	2,842	493	509	-	5,160
Provided for the year	本年度撥備	627	954	176	91	-	1,848
Impairment loss	減值虧損	-	2,556	-	-	-	2,556
At 31 December 2020	於二零二零年 十二月三十一日	1,943	6,352	669	600	-	9,564
CARRYING VALUES At 31 December 2020	賬面值 於二零二零年						
ALST DECEMBER 2020	<i>於一</i> 奄一奄午 十二月三十一日	2,879	2,058	970	952	397	7,256
At 31 December 2019	於二零一九年 +-日=+-日	2 706	E ECO	020	100	40	0 700
	十二月三十一日	2,786	5,568	830	489	49	9,722

For the year ended 31 December 2020 截至二零二零年十二月三十一日止年度

## 12. PROPERTY, PLANT AND EQUIPMENT 12. 物業、廠房及設備(續)

## (Continued)

The above items of property, plant and equipment are depreciated on a straight-line basis over the following periods:

上述物業、廠房及設備項目乃於下列期 間以直線法折舊:

Leasehold improvements	5 years to 10 years or	租賃物業裝修	五年至
	over the lease period		於租賃
Plant and machinery	5 years to 10 years	廠房及機械	五至-
Office equipment	5 years to 10 years	辦公設備	五至-
Motor vehicles	5 years	汽車	五年

The management of the Group has reviewed the carrying value of property, plant and equipment and determined that one of plant and machinery with carrying amount of approximately RMB2,556,000 (2019: approximately RMB2,959,000) which has been idled for a prolonged period of time and the recoverable amount from the use or sale of the asset has significantly declined below its carrying amount. Accordingly, the carrying value of the asset has been reduced by approximately RMB2,556,000 (2019: Nil) to reflect this impairment loss.

1賃物業裝修	五年至十年或
	於租賃期內
反房及機械	五至十年
·公設備	五至十年

本集團管理層已審閱物業、廠房及設 備之賬面值,並確定賬面值約為人民 幣2,556,000元(二零一九年:約人民幣 2,959,000元)廠房及機械已閒置一段時 間,且從使用或出售該資產的可收回金 額大幅低於其賬面值。因此,該資產的 賬面值已減少約人民幣2,556,000元(二 *零一九年: 無)*,以反映該減值虧損。

## **13. LEASES**

## 13. 租賃

		At	At
		31 December	31 December
		2020	2019
		於二零二零年	於二零一九年
		十二月	十二月
		三十一日	三十一日
		RMB'000	<i>RMB'000</i>
		人民幣千元	人民幣千元
Right-of-use assets (Note (a))	使用權資產 <i>(附註(a))</i>	2,432	1,351
Lease liabilities (Note (b))	租賃負債 <i>(附註(b))</i>		
Current	即期	1,406	1,181
Non-current	非即期	1,236	431
		2,642	1,612



For the year ended 31 December 2020 截至二零二零年十二月三十一日止年度

## 13. LEASES (Continued)

(a)

## **13. 租賃**(續)

Right-of-use assets		(a) 使用權	資產	
		Motor vehicles	Factories and office premises 工廠及	Total
		<b>汽車</b> <i>RMB'000</i> 人民幣千元	<b>辦公室物業</b> RMB'000 人民幣千元	<b>總計</b> <i>RMB'000</i> 人民幣千元
Reconciliation of carrying amount – year ended 31 December 2019 At 1 January 2019 – upon adoption of HKFRS 16 Additions	賬面值對賬 一截至二零一九年 十二月三十一日止年度 於二零一九年一月一日一 採納香港財務報告準則 第16號後 添置	- 542	1,592	1,592 542
Depreciation	折舊	-	(783)	(783)
At 31 December 2019	於二零一九年 十二月三十一日	542	809	1,351
Reconciliation of carrying amount – year ended 31 December 2020 At 1 January 2020 Addition Lease modification Depreciation	<b>賬面值對賬</b> - 截至二零二零年 十二月三十一日止年度 於二零二零年一月一日 添置 租賃修訂 折舊	542 - - (108)	809 2,461 (364) (908)	1,351 2,461 (364) (1,016)
At 31 December 2020	於二零二零年 十二月三十一日	434	1,998	2,432
At 31 December 2019 Cost	於二零一九年 十二月三十一日 成本	542	1,592	2,134
Accumulated depreciation	累計折舊	_	(783)	(783)
		542	809	1,351
At 31 December 2020	於二零二零年 十二月三十一日			
Cost	成本	542	3,171	3,713
Accumulated depreciation	累計折舊	(108) <b>434</b>	(1,173) <b>1,998</b>	(1,281) <b>2,432</b>

For the year ended 31 December 2020 截至二零二零年十二月三十一日止年度

## 13. LEASES (Continued)

#### (a) Right-of-use assets (Continued)

The Group leases various motor vehicles, factories and office premises for its operation. The lease contracts are entered into for fixed term of 2 to 5 year (2019: 2 to 5 years).

The total cash outflow for leases (including other rental and related expenses) for the year ended 31 December 2020 were approximately RMB1,149,000 (2019: approximately *RMB622,000*).

Certain leases impose a restriction that, unless the approval is obtained from the lessor, the right-of-use asset can only be used by the Group and the Group is prohibited from selling or pledging the underlying assets.

## (b) Commitments and present value of lease liabilities

#### 13. 租賃(續)

### (a) 使用權資產(續)

本集團租賃若干汽車、廠房及辦公 物業用於運營。租賃合約已訂立, 固定年期二至五年(二零一九年: 二至五年)。

截至二零二零年十二月三十一日止 年度,租賃的現金流出總額(包括 其他租賃及相關開支)約為人民幣 1,149,000元(二零一九年:約人民 幣622,000元)。

若干租賃實施一項限制,除非獲得 出租人批准,否則使用權資產僅限 由本集團使用,並且禁止本集團出 售或抵押相關資產。

## (b) 租賃負債的承擔及現值

		Lease pa 租賃	<b>ayments</b> 付款	Present lease pa 租賃付募	yments
		<b>At 31 D</b> e 於十二月		<b>At 31 December</b> 於十二月三十一日	
		2020 二零二零年 <i>RMB'000</i> <i>人民幣千元</i>	2019 二零一九年 <i>RMB'000 人民幣千元</i>	2020 二零二零年 <i>RMB'000</i> 人 <i>民幣千元</i>	2019 二零一九年 <i>RMB'000 人民幣千元</i>
Amounts payable: Within 1 year	應付款項: 一年內	1,484	1,223	1,406	1,181
More than 1 year but within 2 years More than 2 years but	超過一年 但少於兩年 超過兩年	692	121	647	106
within 5 years	但少於五年	2 780	1 685	2 642	325
Less: future finance charges	減:未來財務費用	2,780 (138)	1,685 (73)	2,642	1,612
		2,642	1,612		



For the year ended 31 December 2020 截至二零二零年十二月三十一日止年度

## **14. INTANGIBLE ASSETS**

## 14. 無形資產

		Development costs 發展成本
		<i>RMB'000</i> 人民幣千元
	-5	
COST	成本	2.055
At 1 January 2019	於二零一九年一月一日	3,955
Additions	添置	366
At 31 December 2019 and	於二零一九年十二月三十一日	
1 January 2020	及二零二零年一月一日	4,321
Additions	添置	340
At 31 December 2020	於二零二零年十二月三十一日	4,661
ACCUMULATED AMORTISATION	累計攤銷	4
At 1 January 2019	於二零一九年一月一日	1,037
Provided for the year	本年度撥備	370
At 31 December 2019 and	於二零一九年十二月三十一日	
1 January 2020	及二零二零年一月一日	1,407
Provided for the year	本年度撥備	330
At 31 December 2020	於二零二零年十二月三十一日	1,737
	e 王 佐	
CARRYING VALUES	賬面值	2.024
At 31 December 2020	於二零二零年十二月三十一日	2,924
At 31 December 2019	於二零一九年十二月三十一日	2,914
Development costs are internally gene	rated at the 發展成本乃於發展	展階段內部產生,並放
development phase and amortised on a		准治。堂出現減值跡象

development phase and amortised on a straight-line basis over 5 years. This asset is tested for impairment where an indicator of impairment appears.

5年內按直線法攤銷。當出現減值跡象 時,該項資產須進行減值測試。

For the year ended 31 December 2020 截至二零二零年十二月三十一日止年度

## **15. INTEREST IN AN ASSOCIATE**

## 15. 於一間聯營公司的權益

		<b>2020</b> 二零二零年	2019 二零一九年
		<b>RMB'000</b> 人民幣千元	<i>RMB'000</i> 人民幣千元
Share of net assets	分佔資產淨值	_	_

As at 31 December 2020, the Group had interests in the following associate:

於二零二零年十二月三十一日,本集團 於以下聯營公司擁有權益:

	Principal place of business and place of	Paid-up issued	Proportion of value of issued capital held by	
Name of associate	incorporation 主要營業地點	capital	the Company 本公司所持已發行	Principal activities
聯營公司名稱	及註冊成立地點	繳足股本	股本價值比例	主要業務活動
Smartronic Limited (" <b>Smartronic</b> ") (formerly known as Worth Access Limited) 智能創力有限公司(「 <b>智能創力</b> 」) (前稱百爾有限公司)	Hong Kong 香港	HK\$100,000 100,000港元	49% (Note) 49% (附註)	Sales of healthcare products and supplements 銷售健康產品及 保健品
(前倍日兩有限公司) Note:		₿H 1	(PD)m)) 註:	体健阳
On 3 June 2020, the Group enter				日,本集團與獨立第三

agreement with an independent third party to acquire Smartronic with nil identifiable assets, pursuant to which the Group and the independent third party held as to 49% and 51%, respectively. 於二零二零年六月三日,本集團與獨立第三 方訂立股東協議,以收購並無可識別資產之 智能創力,據此,本集團與獨立第三方分別 持有49%及51%之股權。



For the year ended 31 December 2020 截至二零二零年十二月三十一日止年度

## **15. INTEREST IN AN ASSOCIATE** (Continued)

The associate is accounted for using the equity method in the consolidated financial statements. There are no capital commitment and contingent liabilities in relation to Smartronic.

## **Relationship with associate**

Smartronic is engaged in sales of healthcare products and supplements in PRC and HK through the crossborder e-commerce platforms and other platforms and channels, which could allow the Group to benefit from Smartronic's operations.

## Fair value of investment

Smartronic is not listed and there is no quoted market price available for the investment.

## Financial information of associate

Summarised financial information of the associate of the Group is set out below, which represents amounts shown in the associate's financial statements prepared in accordance with HKFRSs and adjusted by the Group for equity accounting purpose including any differences in accounting policies and fair value adjustments.

## 15. 於一間聯營公司的權益(續)

聯營公司乃採用權益法於綜合財務報表 入賬。概無與能創力有關的資本承擔及 或然負債。

## 與聯營公司的關係

合營企業透過跨境電子商務平台以及其 他平台及渠道於中國及香港從事銷售健 康產品及保健品,令本集團可從智能創 力的業務中受益。

## 投資之公平值

智能創力並未上市且並無投資的市場報 價。

## 聯營公司之財務資料

本集團聯營公司之財務資料概述如下, 其指聯營公司根據香港財務報告準則編 製之財務報表所示金額,並經本集團就 權益會計目的作出調整,包括會計政策 及公平值調整之任何差額。

For the year ended 31 December 2020 截至二零二零年十二月三十一日止年度

#### **15. INTEREST IN AN ASSOCIATE** (Continued)

#### 15. 於一間聯營公司的權益(續)

### At 31 December 2020

## 於二零二零年十二月三十一日

		<i>RMB'000</i> 人民幣千元
Gross amounts	總金額	
Current assets	流動資產	5,770
Non-current assets	非流動資產	-
Current liabilities	流動負債	(6,182)
Non-current liabilities	非流動負債	
Net liabilities	負債淨額	(412)
Included in above:	計入上述項目:	
Cash and cash equivalents	現金及現金等價物	1,829
Reconciliation	對賬	
Gross amount of net liabilities	到版 淨負債總額	(412)
		(+12)
Group's ownership interests and	本集團之所有權權益及	
voting rights	投票權	49%
Carrying amount of the Group's	本集團之所有權權益之	
Carrying amount of the Group's ownership interests	本集團之所有權權益之 賬面值	_
	賬面值	 二零年十二月三十一
ownership interests Period from date of acquisition to 31	賬面值       December     由收購日期至二零日	_ =零年十二月三十− RMB'000 人民幣千元
ownership interests Period from date of acquisition to 31	賬面值 December 由收購日期至二零二日期間 總金額	<i>RMB'000</i> 人民幣千元
ownership interests Period from date of acquisition to 31 2020	賬面值 December 由收購日期至二零二日期間	RMB'000
ownership interests Period from date of acquisition to 31 2020 Gross amounts	賬面值 December 由收購日期至二零二日期間 總金額	<i>RMB'000 人民幣千元</i> 1,392
ownership interests Period from date of acquisition to 31 2020 Gross amounts Revenue Loss and total comprehensive expense for the period	版面值   December 由收購日期至二零日期間   個本語   期內虧損及全面開支總額	<i>RMB'000 人民幣千元</i> 1,392
ownership interests Period from date of acquisition to 31 2020 Gross amounts Revenue Loss and total comprehensive expense		<i>RMB'000</i> 人民幣千元

The Group's share of loss of the associate amounted to approximately RMB40,000 (2019: Nil) during the year ended 31 December 2020. The unrecognised share of loss of the associate for the year ended 31 December 2020 amounted to approximately RMB218,000 (2019: Nil). 截至二零二零年十二月三十一日止年 度,本集團分佔聯營公司虧損約為人民 幣40,000元(二零一九年:無)。截至 二零二零年十二月三十一日止年度,未 確認之分佔聯營公司虧損約為人民幣 218,000元(二零一九年:無)。



For the year ended 31 December 2020 截至二零二零年十二月三十一日止年度

#### **16. INVENTORIES**

16. 存貨

		2020	2019
		二零二零年	二零一九年
		RMB'000	RMB'000
		人民幣千元	人民幣千元
Raw materials	原材料	1,634	1,944
Finished goods	製成品	1,132	759
		2,766	2,703

## **17. TRADE RECEIVABLES**

17. 貿易應收款項

		2020 二零二零年 <i>RMB'000</i> 人民幣千元	2019 二零一九年 <i>RMB'000</i> <i>人民幣千元</i>
Trade receivables from third parties Less: allowance for credit losses	應收第三方之貿易 應收款項 減:信貸虧損撥備	12,864 (3,361)	12,653 (2,574)
		9,503	10,079

In general, the Group will request deposits from the customers before the goods are delivered and the amount of deposits requested varies amongst different contracts. For certain long-term customers, the Group will deliver the goods without requesting deposits and allow a credit period from 30 to 180 days (2019: 30 to 180 days) to these customers and there is no credit period granted to other customers. The following is an aged analysis of trade receivables (net of allowances for credit losses) presented based on the dates of delivery of goods. 一般而言,本集團將要求於貨品交付前 向客戶收取按金,而且所要求按金數額 因不同合約而有所區別。就若干長期客 戶而言,本集團將於不要求按金的情況 下向該等客戶交付貨品,且授予該等客 戶30至180天(二零一九年:30至180 天)的信貸期,而並無向其他客戶授出 信貸期。下列為按貨品交付日期呈列的 貿易應收款項(扣除信貸虧損撥備)賬齡 分析。

For the year ended 31 December 2020 截至二零二零年十二月三十一日止年度

**17. TRADE RECEIVABLES** (Continued)

		2020 二零二零年 <i>RMB'000</i> 人 <i>民幣千元</i>	2019 二零一九年 <i>RMB'000</i> <i>人民幣千元</i>
0–30 days	0至30天	2,051	2,488
31–90 days	31至90天	2,617	2,811
91–180 days	91至180天	2,570	2,698
Over 181 days	超過181天	2,265	2,082
		9,503	10,079

17. 貿易應收款項(續)

As at 31 December 2020, included in the Group's trade receivables balance are debtors with aggregate carrying amount of approximately RMB7,829,000 (2019: approximately RMB8,831,000) which are past due as at the reporting date. Out of the past due balances, approximately RMB3,672,000 (2019: approximately RMB3,593,000) has been past due 90 days or more and is not considered as in default by considering the historical payment arrangement of these trade receivables. The Group does not hold any collateral over these balances.

Details of impairment assessment of trade receivables are set out in Note 29 to the consolidated financial statements. 於二零二零年十二月三十一日,本集團 的貿易應收款項結餘為賬面總值約為人 民幣7,829,000元(二零一九年:約人民 幣8,831,000元)的應收款項,該等款項 已於報告日期逾期。該等逾期結餘中, 約人民幣3,672,000元(二零一九年:約 人民幣3,593,000元)已逾期90天或超過 90天且經計及該等貿易應收款項的過往 付款安排,不被視為違約。本集團並無 就該等結餘持有任何抵押品。

有關貿易應收款項減值評估詳情載於綜 合財務報表附註29。



綜合財務報表附註

For the year ended 31 December 2020 截至二零二零年十二月三十一日止年度

# **18. OTHER RECEIVABLES, DEPOSITS AND 18.** 其他應收款項、按金及預付款項 **PREPAYMENTS**

		2020	2019
		二零二零年	二零一九年
		RMB'000	<i>RMB'000</i>
		人民幣千元	人民幣千元
Other receivables	其他應收款項	825	333
Less: allowance for credit losses	減:信貸虧損撥備	-	(7)
		825	326
Advance payment to suppliers	預付供應商墊款	2,732	856
Other prepaid expenses	其他已預付開支	1,093	261
Refundable deposits paid to a supplier	可退回供應商按金	-	294
Rental and other deposits	租金及其他按金	147	156
		4,797	1,893
		4,797	1,893

Details of impairment assessment of other receivables are set out in Note 29 to the consolidated financial statements. 有關其他應收款項減值評估詳情載於綜 合財務報表附註29。

For the year ended 31 December 2020 截至二零二零年十二月三十一日止年度

#### **19. BANK BALANCES AND CASH**

Bank balances are carrying interest at prevailing market rate at the end of each reporting period and the bank balances and cash that are not denominated in the functional currency of the relevant group entities are as follows:

## 19. 銀行結餘及現金

銀行結餘於各報告期末按現行市場利率 計息及並非按有關集團實體功能貨幣計 值之銀行結餘及現金如下:

		2020	2019
		二零二零年	二零一九年
		RMB'000	RMB'000
		人民幣千元	人民幣千元
Hong Kong Dollars (" <b>HK\$</b> ")	港元(「 <b>港元</b> 」)	6,619	15,205
United State Dollars (" <b>US\$</b> ")	美元(「 <b>美元</b> 」)	5,556	7,483
Canadian Dollars ("CAD\$")	加拿大元(「 <b>加元</b> 」)	54	58

As at 31 December 2020, bank balances that were placed with banks in the PRC amounted to approximately RMB29,715,000 (2019: approximately RMB26,047,000). Remittance of funds out of the PRC is subject to the exchange controls imposed by the PRC government.

The Group performed impairment assessment on bank balances and concluded that the probability of defaults of the counterparty banks are insignificant and accordingly, no allowance for credit losses is provided for the years ended 31 December 2020 and 2019. 於二零二零年十二月三十一日,存放 於中國的銀行之銀行結餘約為人民幣 29,715,000元(二零一九年:約人民幣 26,047,000元)。資金匯出中國時須受 到中國政府的外匯控制規定限制。

本集團對銀行結餘進行減值評估並認為 對手方銀行違約的可能性微乎其微,因 此,截至二零二零年及二零一九年十二 月三十一日止年度,概無計提撥備信貸 虧損。



## **20. TRADE PAYABLES**

on the invoice date:

In general, the Group will make advance payment to suppliers before the materials are received. Some of the suppliers may deliver the materials to the Group without requesting advance payment and a credit period ranged from 30 to 90 days (2019: 30 to 90 days) is granted by these suppliers. The following is an aging analysis of trade payables presented based

## 20. 貿易應付款項

通常,本集團會在取得材料前向供應商 預付款項。部份供應商可在無需預付款 的情況下將材料交付予本集團,該等供 應商已授出介乎30天至90天(二零一九 年:30天至90天)之信貸期。基於發票 日期的貿易應付款項的賬齡分析如下:

		2020 二零二零年 <i>RMB'000</i> 人民幣千元	2019 二零一九年 <i>RMB'000</i> 人民幣千元
0–30 days 31–90 days	0至30天 31至90天	115 302	435 58
Over 90 days	超過90天	1,030	537
		1,447	1,030

For the year ended 31 December 2020 截至二零二零年十二月三十一日止年度

## 21. OTHER PAYABLES AND ACCRUED CHARGES 21. 其他應付款項及應計費用

		2020 二零二零年 <i>RMB'000</i> 人民幣千元	2019 二零一九年 <i>RMB'000 人民幣千元</i>
Other accrual and payables	其他應計費用及應付 款項	1,403	000
		1,405	990
Other taxes payable	其他應付税項	-	13
Payables for purchase of property,	收購物業、廠房及		
plant and equipment	設備應付款項	1,192	1,140
Salaries payables	應付薪金	1,366	1,654
		3,961	3,797

Other payables and accrued charges that are not denominated in the functional currency of the relevant group entities are as follows: 並非按有關集團實體功能貨幣計值之其 他應付款項及應計費用如下:

		2020	2019
		二零二零年	二零一九年
		RMB'000	RMB'000
		人民幣千元	人民幣千元
HK\$	港元	1,186	1,007

## **22. CONTRACT LIABILITIES**

## 22. 合約負債

		2020 二零二零年 <i>RMB′000</i> 人民幣千元	2019 二零一九年 <i>RMB'000</i> 人民幣千元
Contract liabilities regarding sales of biological reagents, auxiliary reproductive supplies and equipment and healthcare products and supplements	銷售生物診斷試劑、 輔助生育用品和設備 以及健康產品及保健 品之合約負債	2,143	292



## 22. CONTRACT LIABILITIES (Continued)

When the Group receives a deposit before delivery of goods, this will give rise to contract liabilities at the start of a contract, until the revenue recognised when the goods are i) delivered to the customers' warehouse on which the customers obtain control of the goods or ii) collected by the customers directly from the Group's warehouse, as appropriate. The amount of deposits requested varies amongst different contracts. The significant increase in contract liabilities in the current year was mainly attributable to the advance received from a customer arising from the new healthcare products and supplements business.

The contract liabilities amounting to approximately RMB292,000 and RMB179,000 as at 1 January 2020 and 2019 were recognised as revenue in profit or loss for years ended 31 December 2020 and 2019, respectively. In the opinion of the directors of the Company, the contract liabilities as at 31 December 2020 and 2019 are expected to be recognised as revenue within 12 months and therefore classified as current liabilities.

## 23. DEFERRED INCOME – GOVERNMENT 2 GRANTS

The Group received grants from the PRC government authorities for funding of acquisitions of plant and equipment for conducting research and development of the biological reagents which benefits the society as a whole. The relevant deferred income would be amortised over periods ranging from 5 to 10 years which represented the useful lives of the relevant assets.

## 22. 合約負債(續)

倘本集團於交付貨品前收到按金,則此 將於合約開始時產生合約負債,直至i) 將貨品交付至客戶獲得貨品控制權的倉 庫或ii)客戶直接自本集團倉庫提取貨品 (如適用)時,方可確認收益。所要求按 金數額因不同合約而有所區別。合約負 債於本年度顯著增加乃主要由於因全新 的健康產品及保健品業務向客戶收取之 墊款所致。

於二零二零年及二零一九年一月一日的 合約負債分別約為人民幣292,000元及 人民幣179,000元,並分別於二零二零 年及二零一九年十二月三十一日止年度 於損益中確認為收益。本公司董事認 為,於二零二零年及二零一九年十二月 三十一日的合約負債預期將於12個月內 確認為收益,因此分類為流動負債。

## 23. 遞延所得税一政府補助

本集團自中國政府機構收到的補助乃用 於為收購廠房及設備撥資以進行生物製 劑研發,此舉符合社會整體利益。有關 遞延收入將於5至10年內攤銷,即有關 資產的可使用年期。

		2020 二零二零年 <i>RMB'000</i> 人 <i>民幣千元</i>	2019 二零一九年 <i>RMB'000</i> <i>人民幣千元</i>
Analysed for reporting purposes as: Non-current liabilities Current liabilities	就報告目的分析如下: 非流動負債 流動負債	340 45	385 45
		385	430

For the year ended 31 December 2020 截至二零二零年十二月三十一日止年度

## **24. RETIREMENT BENEFIT SCHEMES**

The employees of Shenzhen Huakang are members of a state-managed retirement benefit scheme operated by the PRC government. The Group is required to contribute certain percentage of payroll costs to the retirement benefit scheme to fund the benefits. The only obligation of the Group with respect to the retirement benefit scheme is to make the specified contributions.

The Group also participate the Mandatory Provident Fund Scheme (the "**MPF Scheme**") under the rules and regulations of the Mandatory Provident Fund Schemes Authority in Hong Kong. The Group's eligible employees are required to join the MPF Scheme. The Group has followed the minimum statutory contribution requirement of 5% of eligible employees' relevant aggregated income with a cap of HK\$1,500 per employee per month.

The total expense recognised in profit or loss of approximately RMB794,000 (2019: approximately RMB1,322,000) for the year ended 31 December 2020, represents contributions payable to these plans by the Group at rates specified in the rules of the plans.

As at 31 December 2020, contributions which had not been paid over to the plans amounted to Nil (2019: Nil).

## 24. 退休福利計劃

深圳華康僱員為中國政府營運之國家管 理退休福利計劃成員。本集團須按薪金 成本若干百分比向退休福利計劃供款, 為福利提供資金。本集團就退休福利計 劃之唯一義務乃作出指定供款。

本集團亦根據強制性公積金計劃管理局 之條例及規例於香港參與強積金計劃 (「**強積金計劃**」)。本集團符合資格的僱 員須參與該計劃。本集團已依據最低法 定供款要求(即合資格僱員有關總收入 的5%,惟每名僱員每月不超過1,500 港元)作出。

截至二零二零年十二月三十一日止年 度,於損益確認開支總額約人民幣 794,000元(二零一九年:約人民幣 1,322,000元),為本集團應按計劃規則 指定比率向該等計劃繳付之供款。

於二零二零年十二月三十一日,該等計 劃中並無供款尚未繳付(二零一九年: 無)。



## **25. SHARE OPTION SCHEME**

The Company has adopted a share option scheme pursuant to an ordinary resolution passed by the shareholders in the extraordinary general meeting on 13 January 2020 (the "**Share Option Scheme**"). The Share Option Scheme is a long-term incentive scheme of the Company to reward its employees, Directors and other eligible participants for their contributions to the Group and to assist the Group in its recruitment and retention of high caliber employees and other eligible participants who are instrumental to the growth and development of the Group.

The total number of shares which may be allotted and issued upon exercise of all options to be granted under the Share Option Scheme and any other shares option schemes of the Group must not in aggregate exceed 10% of the total number of shares in issue on the date which the Share Option Scheme is approved, which is 40,000,000 shares ("**Scheme Limit**"). The maximum number of shares issued and issuable to each eligible person under the Scheme in any 12-month period shall not exceed 1% of the total number of shares of the Company in issue as at proposed grant date. Any further grant of share options in excess of this limit is subject to shareholders' approval in a general meeting.

Share options granted to a director, chief executive or substantial shareholder of the Company, or to any of their associates, are subject to approval in advance by the independent non-executive directors. In addition, any share options granted to an independent non-executive director or a substantial shareholder of the Company, or to any of their associates, in excess of 0.1% of the total number of shares of the Company in issue at any time and with an aggregate value (based on the closing price of the Company's shares at the date of grant) in excess of HK\$5,000,000 within any 12-month period, are subject to shareholders' approval in advance in a general meeting.

## 25. 購股權計劃

本公司已根據股東於二零二零年一月 十三日的股東特別大會上通過的一項普 通決議案採納購股權計劃(「**購股權計** 劃」)。購股權計劃乃本公司的長期激勵 計劃,旨在獎勵其僱員、董事及其他合 資格參與者對本集團作出貢獻,同時協 助本集團招聘及挽留高素質僱員及其他 對本集團成長及發展至關重要的合資格 參與者。

因行使根據購股權計劃及本集團任何其 他購股權計劃授出之所有購股權而可能 配發及發行之股份總數合共不得超過 購股權獲批准當日已發行股份總數的 10%,即40,000,000股股份(「計劃限 額」)。於任何十二個月期間根據計劃已 發行及可發行予每一名合資格人士之數 目,最多不得超過本公司於建議授出日 期之已發行股份總數之1%。任何進一 步授出超出此限額之購股權須獲股東於 股東大會上批准。

向董事、主要行政人員或本公司主要股 東授出購股權,須預先經獨立非執行董 事批准。此外,倘於十二個月期間,向 本公司獨立非執行董事或主要股東或其 任何聯繫人所授出之任何購股權,超過 本公司於任何時間之已發行股份總數的 0.1%且其總值(按本公司於授出日期之 股份成交價計算)超過5,000,000港元, 則須預先經股東於股東大會上批准。

For the year ended 31 December 2020 截至二零二零年十二月三十一日止年度

#### **25. SHARE OPTION SCHEME** (Continued)

On 9 April 2020, the Company announced the granting of an aggregate of 26,008,000 share options, subject to the acceptance by the grantees, at an exercise price of HK\$0.125 per share of the Company to the eligible person under the Share Option Scheme. The market price of the Company's shares at the date of grant was HK\$0.125 per share. All of the share options are exercisable from the date of acceptance by a grantee to 8 April 2030 (both days inclusive). Each of the grantees has paid HK\$1 to the Company on acceptance of the offer of share option. Details are set out in the Company's announcement dated 9 April 2020.

The movement during the year and the share options outstanding as at 31 December 2020 were as follows:

## 25. 購股權計劃(續)

於二零二零年四月九日,本公司公佈根 據購股權計劃向合資格人士授出合共 26,008,000份購股權,惟受限於承授人 接納,行使價為每股本公司股份0.125 港元。於授出日期,本公司股份的市價 為每股股份0.125港元。全部購股權可 由承授人接納日至二零三零年四月八日 行使(包括首尾兩日)。各承授人已於接 納購股權要約時向本公司支付1港元。 有關詳情載於本公司日期為二零二零年 四月九日的公告。

於二零二零十二月三十一日尚未行使購 股權的年內變動情況如下:

	_	Number of share options 購股權數目				
		As at 1 January 2020 於二零二零年	Granted during the period	Exercised during the period	Forfeited during the period	As at 31 December 2020 於二零二零年
Category of the grantees	承授人類別	一月一日	於期內授出	於期內行使	於期內沒收	十二月三十一日
Executive Directors	執行董事					
Mr. Zhang Shuguang (Note)	張曙光先生 <i>(附註)</i>	-	4,000,000	-	-	4,000,000
Mr. Zhang Chunguang (Note)	張春光先生 <i>(附註)</i>	-	4,000,000	-	-	4,000,000
Mr. Poon Lai Yin Michael	潘禮賢先生 <i>(附註)</i>					
(Note)		-	4,000,000	-	-	4,000,000
Mr. He Jiaming (Note)	何嘉明先生 <i>(附註)</i>	-	4,000,000	-	-	4,000,000
Other employees (Note)	其他員工(附註)	-	10,008,000	-	(504,000)	9,504,000
Total	總計	-	26,008,000	-	(504,000)	25,504,000

#### Note:

The closing price of the shares immediately before the date on which the options were granted during the year ended 31 December 2020 is HK\$0.125. The exercise price is HK\$0.125. The exercise period during which the options may be exercised is the period from the date of acceptance to 8 April 2030 (both days inclusive). The date of grant was 9 April 2020.

#### 附註:

於截至二零二零年十二月三十一日止年度內 緊接授出之購股權的當日前之股份收市價為 0.125港元。行使價為0.125港元。可行使購 股權之行使期由接納購股權當日至二零三零 年四月八日(首尾兩天包括在內)。授出日期 為二零二零年四月九日。



## 25. SHARE OPTION SCHEME (Continued)

During the year ended 31 December 2020, 504,000 share options granted were forfeited upon the resignation of the grantees as employee of the Group ("**Resignation**"). None of the share options were exercised and such grantees were no longer eligible to the Share Option Scheme upon the Resignation.

All the existing share options of the Company are vested upon granting.

During the year ended 31 December 2020, share options were granted on 9 April 2020. The fair values of share options determined at the date of grant using the Binomial Option Pricing Model was at HK\$0.1125 per option, with the following key inputs:

The following assumptions were used to calculate the fair values of share option:

Share price at the date of grant	HK\$0.125
Exercise price	HK\$0.125
Expected life	10 years
Expected volatility	103.1%
Dividend yield	Nil
Risk-free interest rate	0.778%

The Binomial Option Pricing Model has been used to estimate the fair value of the share options. The value of the share options is subject to the limitation of the Binomial Option Pricing Model and a number of assumptions which are subjective and difficult to ascertain. Changes in the subjective input assumptions could materially effect the fair value estimate.

During the year ended 31 December 2020, with reference to the fair value of the share options granted, the Group recognised approximately HK\$2,926,000 (equivalents to approximately RMB2,660,000) (2019: Nil) as equity-settled sharebased payment expenses. The equity-settled sharebased payment expenses recognised in share option reserve were transferred to accumulated profits or losses upon forfeiture.

## 25. 購股權計劃(續)

截至二零二零年十二月三十一日止年 度,承授人辭任本集團僱員(「**辭任**」) 後,已授出之504,000份購股權遭沒 收。概無行使購股權及該等承授人於辭 任後不再合資格享有購股權計劃。

本公司之所有現有購股權乃於授出時歸屬。

截至二零二零年十二月三十一日止年 度,購股權於二零二零年四月九日授 出。於授出日期使用二項式購股權定價 模式釐定之購股權之公平值為每份購股 權0.1125港元,且關鍵輸入數據如下:

計算購股權之公平值時已使用以下假 設:

授出日期之股價	0.125港元
行使價	0.125港元
預期年期	十年
預期波幅	103.1%
股息率	無
無風險利率	0.778%

二項式購股權定價模式乃用於估計購股 權之公平值。購股權之價值受限於二項 式購股權定價模式的限制及多項假設, 相關假設屬主觀因素且難以確定。主觀 輸入值假設如有變動會對公平值估值造 成重大影響。

截至二零二零年十二月三十一日止年 度,經參考所授出購股權之公平值,本 集團確認以股權結算之股份基礎付款 開支約2,926,000港元(相當於約人民幣 2,660,000元)(二零一九年:無)。於購 股權儲備中確認之以股權結算之股份基 礎付款開支轉撥至累計溢利或沒收虧 損。

For the year ended 31 December 2020 截至二零二零年十二月三十一日止年度

#### **26. SHARE CAPITAL**

26. 股本

			Numbe of shar	•	Equivalent to RMB'000 相當於
			股份數目	<b>唐</b> 志	人民幣千元
	sed: ecember 2019 and ecember 2020	法定: 於二零一九年十二月三十一日及 二零二零年十二月三十一日	1,000,000,00	0 10,000,000	8,851
at Hk At 31 D	nd fully paid ordinary shares (\$0.01 per share: ecember 2019 and ecember 2020	每股0.01港元之已發行及 繳足普通股: 於二零一九年十二月三十一日及 二零二零年十二月三十一日	400,000,00	0 4,000,000	3,509
27. COM	MITMENTS	2	7. 承擔		
				2020 二零二零年 <i>RMB'000</i> 人民幣千元	2019 二零一九年 <i>RMB'000</i> <i>人民幣千元</i>
acqı equ prov	l expenditure in respect uisition of property, plar ipment contracted for b vided in the consolidate	nt and 設備之已訂 out not 於綜合財務	約但並無	26	70
state	ements			26	78

## **28. CAPITAL RISK MANAGEMENT**

The Group manages its capital to ensure that entities in the Group will be able to continue as a going concern while maximising the return to shareholders through the optimisation of the debt and equity balance. The Group's overall strategy remains unchanged from the current and prior years.

The capital structure of the Group consists of equity attributable to owners of the Company, comprising issued share capital, accumulated profits and other reserves.

The directors of the Company review the capital structure regularly. As part of this review, the directors consider the cost of capital and the risks associated with each class of capital. Based on recommendations of the directors, the Group will balance its overall capital structure through the payment of dividends and new share issues as well as the issue of new debt.

#### 28. 資金風險管理

本集團管理層管理其資金,務求透過優 化債務與權益間之平衡,確保本集團可 持續經營,同時為股東方帶來最大回 報。本集團本年度之整體策略較過往年 度維持不變。

本集團的資本架構由本公司擁有人應佔 股權(包括已發行股本、累計溢利及其 他儲備)組成。

本公司董事經計及資本成本及各類資本 相關風險定期檢討資本架構。根據董事 之推薦意見,本集團將透過派息、新股 份發行以及發行新債務方式平衡其整體 資本架構。



#### 29. 金融工具 **29. FINANCIAL INSTRUMENTS Categories of financial instruments** 金融工具類別 2020 2019 二零一九年 二零二零年 RMB'000 RMB'000 人民幣千元 人民幣千元 按攤銷成本計量之 Financial assets at amortised cost 金融資產 52,272 59.492 Financial liabilities at amortised cost 按攤銷成本計量之 金融負債 6,684 4,772

## Financial risk management objectives and policies

The Group's major financial instruments include trade receivables, other receivables, bank balances and cash, trade payables, other payables and accrued charges, and lease liabilities. Details of these financial instruments are disclosed in respective notes. The risks associated with these financial instruments include market risks (currency risk and interest rate risk), credit risk and impairment assessment and liquidity risk. The policies on how to mitigate these risks are set out below. The management manages and monitors these exposures to ensure appropriate measures are implemented on a timely and effective manner.

### 財務風險管理目標及政策

我們的主要金融工具包括貿易應收款 項、其他應收款項、銀行結餘及現金、 貿易應付款項、其他應付款項及應計費 用以及租賃負債。該等金融工具的詳情 於相關附註披露。與該等金融工具的詳情 的風險包括市場風險(貨幣風險及利率 風險)、信貸風險及減值評估以及流動 資金風險。減低該等風險之政策載於下 文。管理層管理及監察該等風險,確保 以及時及有效之方式實行適當措施。

For the year ended 31 December 2020 截至二零二零年十二月三十一日止年度

#### 29. FINANCIAL INSTRUMENTS (Continued)

Financial risk management objectives and policies (Continued)

## Market risk

## Currency risk

The Group has certain bank balances and cash, and other payables and accrued charges which are denominated in foreign currency which exposed the Group to foreign exchange risk. The carrying amounts of the Group's foreign currency denominated monetary assets and monetary liabilities at the end of the reporting period are as follows: 29. 金融工具(續)

財務風險管理目標及政策(續)

市場風險

貨幣風險

本集團有若干銀行結餘及現金以及其他 應付款項及應計費用以外幣計值,因而 令本集團面臨匯兑風險。本集團於報告 期末以外幣計值之貨幣資產及貨幣負債 之賬面值如下:

			Assets 資產		lities 債
		2020	2019	2020	2019
		二零二零年	二零一九年	二零二零年	二零一九年
		RMB'000	RMB'000	RMB'000	RMB'000
		人民幣千元	人民幣千元	人民幣千元	人民幣千元
HK\$	港元	6,619	15,205	1,186	1,007
US\$	美元	5,556	7,483	_	-

The Group currently does not have a foreign exchange hedging policy. However, the management of the Group monitors foreign exchange exposure and will consider hedging significant foreign exchange exposure should the need arises. 本集團現時並無任何匯兑對沖政策。然 而,本集團管理層監察匯兑風險,將於 有需要時考慮對沖重大匯兑風險。



#### 29. FINANCIAL INSTRUMENTS (Continued)

Financial risk management objectives and policies (Continued)

Market risk (Continued)

Currency risk (Continued)

#### Sensitivity analysis

The Group is mainly exposed currency risk related to HK\$ and US\$. The sensitivity analysis includes only outstanding monetary items which are denominated in HK\$ and US\$ and adjusts its translation at the end of the reporting date for a 5% and 5% change in HK\$ and US\$ exchange rates, respectively. 5% (2019: 5%) is the sensitivity rate used when reporting foreign currency risk internally to key management personnel and represents management's assessment of the reasonably possible change in foreign exchange rates. The analysis below illustrates the impact for a 5% and 5% strengthening of the functional currency of the relevant group entities against HK\$ and US\$ and a positive number below indicates an increase in post-tax loss, respectively. For a 5% and 5% weakening of the functional currency of the relevant group entities against the HK\$ and US\$, respectively, there would be an equal and opposite impact on the loss and the number below would be negative.

## 29. 金融工具(續)

財務風險管理目標及政策(續)

市場風險(續)

貨幣風險(續)

敏感度分析

本集團主要承擔港元和美元相關貨幣風險。敏感度分析僅包括以港幣和美元列 值的未結算貨幣項目,並在年末分別對 有關項目按5%港元和5%美元匯率變化 進行換算調整。內部使用5%(二零一九 年:5%)的敏感度比率向主要管理層人 士報告外幣風險,其亦指管理層所評估 外幣匯率的合理變幅。以下分析表示相 關集團實體功能貨幣兑港元和美元分別 升值5%和5%的影響,及下文正數表示 除税後虧損增加。倘相關集團實體功能 貨幣兑港元和美元分別貶值5%和5%, 虧損則會受等額相反影響及下文顯示為 負數。

			Increase in post-tax loss 除税後虧損增加		
		<b>2020</b> 二零二零年 <i>RMB'000</i> 人民幣千元	2019 二零一九年 <i>RMB'000</i> <i>人民幣千元</i>		
HK\$ US\$	港元	231 236	603 318		

For the year ended 31 December 2020 截至二零二零年十二月三十一日止年度

#### 29. FINANCIAL INSTRUMENTS (Continued)

Financial risk management objectives and policies (Continued)

Market risk (Continued)

Interest rate risk

The Group is exposed to cash flow interest rate risk in relation to variable-rate bank balances (Note 19).

The Group's cash flow interest rate risk is mainly concentrated on the fluctuation of prevailing market interest rates on bank balances. The Group currently does not have any interest rate hedging policy. However, the management of the Group monitors interest rate exposure and will consider hedging significant interest rate exposure should the need arises.

Total interest income from financial assets that are measured at amortised cost is as follows:

29. 金融工具(續)

財務風險管理目標及政策(續)

市場風險(續)

利率風險

本集團須承擔有關浮息銀行結餘(附註 19)之現金流量利率風險。

本集團的現金流量利率風險主要集中於 來自本集團銀行結餘的現行市場利率波 動。本集團目前並無任何利率對沖政 策,然而,本集團管理層監控利率風險 並將於需要時考慮對沖重大利率風險。

來自按攤銷成本計量之金融資產之利息 收入總額如下:

		2020 二零二零年 <i>RMB'000</i> 人民幣千元	2019 二零一九年 <i>RMB'000</i> <i>人民幣千元</i>
Financial assets at amortised cost	按攤銷成本計量之 金融資產	185	174



#### 29. FINANCIAL INSTRUMENTS (Continued)

Financial risk management objectives and policies (Continued)

#### Market risk (Continued)

#### Interest rate risk (Continued)

#### Sensitivity analysis

In the opinion of the directors of the Company, the expected change in interest rate will not have significant impact on the interest income from variable-rate bank balances, hence sensitivity analysis is not presented.

#### Credit risk and impairment assessment

The Group's maximum exposure to credit risk which will cause a financial loss to the Group due to failure to discharge the obligations by counterparties is arising from the carrying amount of the respective recognised financial assets, including trade receivables, other receivables and bank balances as stated in the consolidated statement of financial position at the end of each reporting period.

The Group's concentration of credit risk by geographical locations is in the PRC, which accounted for 100% (2019: 100%) of the total trade receivables as at 31 December 2020.

The Group has concentration of credit risk as 10% (2019: 16%) and 35% (2019: 43%) of the total trade receivables was due from the Group's largest customer and the five largest customers, respectively.

## 29. 金融工具(續)

財務風險管理目標及政策(續)

市場風險(續)

利率風險(續)

敏感度分析

本公司董事認為,預期利率變動將不會 對自浮息銀行結餘產生之利息收入產生 重大影響,因此並無呈列敏感度分析。

## 信貸風險及減值評估

因對手方未能履行責任而為本集團帶來 財務虧損之本集團最大信貸風險,乃來 自於各報告期末綜合財務狀況表所列各 項已確認金融資產之賬面值,包括貿易 應收款項、其他應收款項及銀行結餘。

於二零二零年十二月三十一日,按地理 位置劃分,本集團的信貸風險集中在中 國,佔全部貿易應收款項的100%(二零 一九年:100%)。

本集團應收本集團最大客戶及五大客戶 的貿易應收款項總額之信貸風險集中度 分別為10%(二零一九年:16%)及35% (二零一九年:43%)。

For the year ended 31 December 2020 截至二零二零年十二月三十一日止年度

### 29. FINANCIAL INSTRUMENTS (Continued)

Financial risk management objectives and policies (Continued)

## Credit risk and impairment assessment (Continued)

Trade receivables arising from contracts with customers

In order to minimise the credit risk, the management of the Group is responsible for determination of credit approvals and other monitoring procedures to ensure that follow-up action is taken to recover overdue debts. The Group also requests deposits from certain customers prior to goods delivery. In addition, the Group performs impairment assessment under ECL model on trade balances based on provision matrix. In this regard, the directors of the Company consider that the Group's credit risk is significantly reduced.

## Other receivables

The credit risks on other receivables are significantly reduced as the management of the Group periodically monitors the balances to ensure that the counterparties are viable to settle the debts.

The credit risks on bank balances are limited because the counterparties are banks with high credit ratings assigned by international credit-rating agencies.

In this regard, the directors of the Company consider that the Group's credit risk on other receivables and bank balances are significantly reduced. **29. 金融工具**(續)

財務風險管理目標及政策(續)

信貸風險及減值評估(續)

來自合約客戶的貿易應收款項

為最大限度降低信貸風險,本集團管理 層負責釐定信貸批核及其他監控程序, 以確保採取跟進行動收回逾期債務。於 交付貨品前,本集團亦要求若干客戶交 付按金。此外,本集團根據預期信貸虧 損模式基於撥備矩陣就貿易結餘進行減 值評估。就此而言,本公司董事認為本 集團之信貸風險已大為減少。

其他應收款項

由於本集團定期監控結餘以確保交易對 手方能夠結算債項,其他應收款項之信 貸風險大幅減少。

銀行結餘之信貸風險有限,乃由於交易 對手方為具國際評級機構授予較高信貸 評級的銀行。

就此而言,本公司董事認為本集團其他 應收款項及銀行結餘之信貸風險已顯著 減少。



For the year ended 31 December 2020 截至二零二零年十二月三十一日止年度

## **29. FINANCIAL INSTRUMENTS** (Continued)

29. 金融工具(續)

Financial risk management objectives and policies (Continued)

Credit risk and impairment assessment (Continued)

The Group's internal credit risk grading assessment comprises the following categories:

財務風險管理目標及政策(續)

信貸風險及減值評估(續)

本集團的內部信貸風險分級評估包括以下類別:

Internal credit assessment	Description	Trade receivables	Other financial assets
內部信貸評估	描述	貿易應收款項	其他金融資產
Low risk	The counterparty has a low risk of default and does not have any past-due amounts.	Lifetime ECL – not credit- impaired	12m ECL
低風險	交易對手方違約風險低且無任 何逾期款項。	全期預期信貸虧損-無信 貸減值	12個月預期信貸虧損
Normal risk	Debtor frequently repays after due dates but usually settle after due date.	Lifetime ECL – not credit- impaired	12m ECL
正常風險	債務人經常於到期日後償付, 但通常於到期日後結清。	全期預期信貸虧損-無信 貸減值	12個月預期信貸虧損
High risk	There have been significant increases in credit risk since initial recognition through information developed internally.	Lifetime ECL – not credit- impaired	Lifetime ECL – not credit-impaired
高風險	信貸風險自初步確認後於內部 資料完善過程中大幅增加。	全期預期信貸虧損-無信 貸減值	全期預期信貸虧損-無信 貸減值
Credit impaired	There is evidence indicating the asset is credit-impaired.	Lifetime ECL – credit- impaired	Lifetime ECL – credit-impaired
出現信貸減值	有跡象表明資產出現信貸減值。	全期預期信貸虧損-出現 信貸減值	全期預期信貸虧損-出現 信貸減值
Write-off	There is evidence indicating that the debtor is in severe financial difficulty and the Group has no realistic prospect of recovery.	Amount is written off	Amount is written off
核銷	有跡象表明債務人陷入嚴重的 財務困境,因而本集團收回 款項的希望渺茫。	款項已被核銷	款項已被核銷

For the year ended 31 December 2020 截至二零二零年十二月三十一日止年度

## **29. FINANCIAL INSTRUMENTS** (Continued)

**29. 金融工具(續)** 

Financial risk management objectives and policies (Continued)

Credit risk and impairment assessment (Continued)

The table below details the credit risk exposures of the Group's financial assets which are subject to ECL assessment: 財務風險管理目標及政策(續)

信貸風險及減值評估(續)

下表為須進行預期信貸虧損評估的本集 團金融資產的信貸風險詳情:

Financial assets at amortised cost 按攤銷成本計量之	Internal credit assessment 內部信貸評估	12m or lifetime ECL 12個月或全期	Gross carrying amount	
金融資產		預期信貸虧損	賬面	總值
			2020	2019
			二零二零年	二零一九年
			RMB'000	RMB'000
			人民幣千元	人民幣千元
Trade receivables	Note (a)	Lifetime ECL		
		(provision matrix)	10,170	9,601
貿易應收款項	附註(a)	全期預期信貸虧損		
		(撥備矩陣)		
	Credit-impaired	Lifetime ECL –		
		credit-impaired	2,694	3,052
	出現信貸減值	全期預期信貸虧損-		
		出現信貸減值		
			12,864	12,653
			0.25	22.5
Other receivables	Note (b)	12m ECL	825	326
其他應收款項	附註(b)	12個月預期信貸虧損		
	Credit-impaired	Lifetime ECL –		_
		credit-impaired	-	7
	出現信貸減值	全期預期信貸虧損-		
		出現信貸減值		
			025	222
			825	333
		Total	12 600	12.090
		iotai 總計	13,689	12,986
		「「「」」		



#### 29. FINANCIAL INSTRUMENTS (Continued)

Financial risk management objectives and policies (Continued)

## Credit risk and impairment assessment (Continued)

Notes:

- (a) For trade receivables, the Group has applied the simplified approach in HKFRS 9 to measure the loss allowance at lifetime ECL. Except for debtors that are credit-impaired, the Group determines the ECL on these items by using a provision matrix, grouped by internal credit assessment.
- (b) For the purposes of internal credit risk management, the Group uses past due information to assess whether credit risk has increased significantly since initial recognition. At 31 December 2020 and 2019, the Group has no past due other receivables.

As part of the Group's credit risk management, the Group applies internal credit assessment for its customers in relation to its operation. The following table provides information about the exposure to credit risk for trade receivables (not credit-impaired), which are assessed based on provision matrix at the end of the reporting period within lifetime ECL. 29. 金融工具(續)

財務風險管理目標及政策(續)

信貸風險及減值評估(續)

附註:

- (a) 就貿易應收款項而言,本集團已應用香 港財務報告準則第9號內的簡化方法計 量全期預期信貸虧損的虧損撥備。除出 現信貸減值之債務人外,本集團使用撥 備矩陣按內部信貸評估分組就該等項目 釐定預期信貸虧損。
- (b) 就內部信貸風險管理而言,本集團使用 逾期資料評估信貸風險自初始確認以來 是否大幅增加。於二零二零年及二零 一九年十二月三十一日,本集團概無其 他應收款項逾期。

作為本集團信貸風險管理之一部分,本 集團就其營運相關客戶應用內部信貸評 估。下表為有關貿易應收款項於報告期 末基於撥備矩陣之信貸風險資料,乃於 全期預期信貸虧損(無信貸減值)內評 估。

For the year ended 31 December 2020 截至二零二零年十二月三十一日止年度

FINANCIAL INSTRUMEN	NTS (Continued)	<b>29.</b> 金融工具(續)			
Financial risk management objectives and policies (Continued)			財務風險管理目標及政策( <i>續</i> )		
Credit risk and impa (Continued)	airment assessment		信貸風險及	減值評估(續)	
At 31 December 2020			於二零二零	年十二月三十·	一日
Internal credit assessment	內部信貸評估		Average loss rate 平均虧損率 %	Gross carrying amount 賬面總值 <i>RMB'000</i> 人民幣千元	Impairment losses 減值虧損 <i>RMB'000</i> 人民幣千元
Low risk Normal risk High risk	低風險 正常風險 高風險		4.5 9.9 11.4	6,888 1,044 2,238	308 103 256
			6.6	10,170	667

At 31 December 2019

於二零一九年十二月三十一日

			Gross	
		Average	carrying	Impairment
Internal credit assessment	內部信貸評估	loss rate	amount	losses
		平均虧損率	賬面總值	減值虧損
		%	RMB'000	RMB'000
			人民幣千元	人民幣千元
Low risk	低風險	3.0	4,008	120
Normal risk	正常風險	4.6	4,217	194
High risk	高風險	8.5	1,376	117
		4.5	9,601	431

The estimated loss rates are estimated based on historical observed default rates over the expected life of the debtors and are adjusted for forwardlooking information that is available without undue cost or effort. The grouping is regularly reviewed by management of the Group to ensure relevant information about specific debtors is updated.

估計虧損率乃基於債務人於預期年期的 過往觀察所得的違約率估計,並按毋需 花費過多成本或精力可取得的前瞻性資 料調整。本集團管理層定期檢討分組以 確保及時更新有關特定債務人的相關資 料。



For the year ended 31 December 2020 截至二零二零年十二月三十一日止年度

#### 29. FINANCIAL INSTRUMENTS (Continued)

29. 金融工具(續)

Financial risk management objectives and policies (Continued)

Credit risk and impairment assessment (Continued)

The following table shows the movement in lifetime ECL that has been recognised for trade receivables under the simplified approach.

財務風險管理目標及政策(續)

信貸風險及減值評估(續)

下表載示就貿易應收款項使用簡化法確 認之全期預期信貸虧損變動。

		Lifetime ECL (not credit- impaired)	Lifetime ECL (credit- impaired) 全期預期	Total
		全期預期 信貸虧損	信貸虧損 (出現信貸	
		后貝虧預 (無信貸減值)	(山児信員 減值)	總計
		RMB'000	RMB'000	RMB'000
		人民幣千元	人民幣千元	人民幣千元
At 1 January 2019	於二零一九年一月一日	427	2,397	2,824
Impairment recognised	い 二令 パー 万 ロ 已確認減値	320	864	2,824 1,184
Impairment losses reversed	已撥回減值虧損	(316)	(1,118)	(1,434)
At 31 December 2019 and 1 January 2020	於二零一九年 十二月三十一日及			
	二零二零年一月一日	431	2,143	2,574
Impairment recognised	已確認減值	389	1,215	1,604
Impairment losses reversed	已撥回減值虧損	(153)	(664)	(817)
At 31 December 2020	於二零二零年			
	十二月三十一日	667	2,694	3,361

Changes in the loss allowance for trade receivables during the year ended 31 December 2020 are mainly due to the provision of lifetime ECL for trade receivables, including those not credit-impaired and credit-impaired with gross carrying amounts of approximately RMB10,170,000 (2019: approximately RMB9,601,000) and approximately RMB2,694,000 (2019: approximately RMB3,052,000), respectively.

截至二零二零年十二月三十一日止年 度,貿易應收款項虧損撥備變動主要由 於就貿易應收款項計提全期預期信貸 虧損撥備,包括賬面總值約為人民幣 10,170,000元之無信貸減值貿易應收 款項(二零一九年:約人民幣2,694,000 元)及賬面總值約為人民幣2,694,000 元的信貸減值貿易應收款項(二零一九 年:約人民幣3,052,000元)。

For the year ended 31 December 2020 截至二零二零年十二月三十一日止年度

29.	FINANCIAL INSTRUMENTS (Continued)	29.	金融工具(續)
	Financial risk management objectives and policies (Continued)		財務風險管理目標及政策 <i>(續)</i>
	Credit risk and impairment assessment (Continued)		信貸風險及減值評估(續)
	The following tables show reconciliation of loss allowances that has been recognised for other receivables.		下表顯示已就其他應收款項確認之虧損 撥備對賬。
			Lifetime ECL
			(credit-impaired)
			全期預期信貸虧損
			(出現信貸減值)
			RMB'000
			人民幣千元

At 1 January 2019 Impairment losses reversed	於二零一九年一月一日 已撥回減值虧損	46 (39)
At 31 December 2019 and 1 January 2020	於二零一九年十二月三十一日	
At ST December 2015 and 1 January 2020	及二零二零年一月一日	7
Impairment losses reversed	已撥回減值虧損	(7)
At 31 December 2020	於二零二零年十二月三十一日	_

Changes in the loss allowance for other receivables during the year ended 31 December 2020 are mainly due to the settlement of other receivables previously impaired amounting approximately RMB7,000 (2019: approximately RMB39,000).

#### Liquidity risk

In the management of the liquidity risk, the Group monitors and maintains a level of cash and cash equivalents deemed adequate by the management to finance the Group's operations and mitigate the effects of fluctuations in cash flows. 截至二零二零年十二月三十一日止年 度,其他應收款項虧損撥備變動主要由 於結算早前出現減值之其他應收款項約 人民幣7,000元(二零一九年:約人民幣 39,000元)。

#### 流動資金風險

管理流動資金風險方面,本集團監察及 維持現金及現金等價物於管理層視為充 足的水平,以提供本集團經營業務所需 資金,並減少現金流波動的影響。



For the year ended 31 December 2020 截至二零二零年十二月三十一日止年度

#### 29. FINANCIAL INSTRUMENTS (Continued)

#### 29. 金融工具(續)

# Financial risk management objectives and policies (Continued)

#### Liquidity risk (Continued)

The following table details the Group's remaining contractual maturity for its non-derivative financial liabilities. The table has been drawn up based on the undiscounted cash flows of financial liabilities based on the earliest date on which the Group can be required to pay. 財務風險管理目標及政策(續)

#### 流動資金風險(續)

下表詳列本集團非衍生金融負債的剩餘 合約期。下表乃根據金融負債的未貼現 現金流量編製,該等金融負債乃根據本 集團可能須付款的最早日期分類。

		Weighted average effective interest rate 加權平均 實際利率 %	On demand or within 1 year 按要求 或一年內 <i>RMB'000</i> 人民幣千元	<b>1 to 2 years</b> 一至兩年 <i>RMB'000 人民幣千元</i>	<b>2 to 5 years</b> 兩至五年 <i>RMB'000 人民幣千元</i>	Total undiscounted cash flows 未貼現現金 流量總額 <i>RMB'000 人民幣千元</i>	Total carrying amount 賬面值總額 <i>RMB'000 人民幣千元</i>
At 31 December 2020	於二零二零年						
Trade payables	十二月三十一日 貿易應付款項 共体應付款項又	-	1,447	-	-	1,447	1,447
Other payables and accrued charges Lease liabilities	其他應付款項及 應計費用 租賃負債	- 4.83	2,595 1,484	- 692	- 604	2,595 2,780	2,595 2,642
	ЖЖЖ	100	1,101	001		2,700	2/012
			5,526	692	604	6,822	6,684
		Weighted					
		average	On demand			Total	Total
		effective	or within			undiscounted	carrying
		interest rate	1 year	1 to 2 years	2 to 5 years	cash flows	amount
		加權平均	按要求		<b></b>	未貼現現金	
		實際利率	或一年內	一至兩年	兩至五年	流量總額	賬面值總額
		%	RMB'000 <i>人民幣千元</i>	RMB'000 <i>人民幣千元</i>	RMB'000 <i>人民幣千元</i>	RMB'000 <i>人民幣千元</i>	RMB'000 <i>人民幣千元</i>
At 31 December 2019	於二零一九年 十二月三十一日						
Trade payables Other payables and	貿易應付款項 其他應付款項及	-	1,030	-	-	1,030	1,030
accrued charges	應計費用	-	2,130	-	-	2,130	2,130
Lease liabilities	租賃負債	4.53	1,223	121	341	1,685	1,612
			4,383	121	341	4,845	4,772

For the year ended 31 December 2020 截至二零二零年十二月三十一日止年度

#### 29. FINANCIAL INSTRUMENTS (Continued)

Fair value measurements of financial instruments

Financial assets and financial liabilities that are not measured at fair value on recurring basis

The directors of the Company consider that the carrying amount of financial assets and financial liabilities recorded at amortised cost in the consolidated financial statements approximate their fair values based on a discounted cash flow analysis.

#### 30. ADDITIONAL INFORMATION ON CASH 30 FLOWS

#### (a) Major non-cash transactions

The Group recognised right-of-use assets by incurring lease liabilities of approximately RMB1,612,000 during the year ended 31 December 2020.

In addition, the Group adjusted right-ofuse assets by remeasuring lease liabilities of approximately RMB849,000 upon entering into a new lease with reduced lease consideration together derecognising right-of-use assets by reducing lease liabilities of approximately RMB375,000 in relation to the early termination of original lease term.

Right-of-use assets with a total capital value of approximately RMB1,592,000 with the corresponding amount of lease liabilities were initially recognised on 1 January 2019 upon adoption of HKFRS 16 and the Group further recognised right-of-use assets by incurring lease liabilities of approximately RMB542,000 during the year ended 31 December 2019. **29. 金融工具**(續)

#### 金融工具之公平值計量

並非按循環基準公平值計量的金融資產 及金融負債

本公司管理層認為,基於貼現現金流量 分析,按攤銷成本於綜合財務報表入賬 的金融資產及金融負債的賬面值與其公 平值相若。

#### 30. 現金流量之其他資料

#### (a) 主要非現金交易

截至二零二零年十二月三十一日止 年度,本集團產生租賃負債約人 民幣1,612,000元確認使用權資產。

此外,本集團於簽訂新租賃合同 後以重新計量租賃負債約人民幣 849,000元的方式調整使用權資 產,並以減少有關提前終止原租期 之租賃負債約人民幣375,000元的 方式減少租賃對價連同終止確認使 用權資產。

採納香港財務報告準則第16號後, 總資本值約為人民幣1,592,000元 的使用權資產及相應租賃負債於二 零一九年一月一日首次確認,於截 至二零一九年十二月三十一日止年 度,本集團產生租賃負債約人民幣 542,000元,繼而進一步確認使用 權資產。



For the year ended 31 December 2020 截至二零二零年十二月三十一日止年度

## **30. ADDITIONAL INFORMATION ON CASH** 30. 現金流量之其他資料(續) FLOWS (Continued)

# (b) Reconciliation of liabilities arising from financing activities

The table below details changes in the Group's liabilities arising from financing activities. Liabilities arising from financing activities are those for which cash flows were, or future cash flows will be, classified in the Group's consolidated statement of cash flows as cash flows from financing activities.

# (b) 融資活動產生之負債之對賬

下表詳述本集團融資活動產生之負 債變動。融資活動產生之負債乃指 其現金流量或未來現金流量將於本 集團綜合現金流量表中分類為融資 活動現金流量之負債。

		Lease liabilities 租賃負債 RMB'000 人民幣千元
At 1 January 2019	於二零一九年一月一日	_
Financing cash flows, net	融資現金流量・淨值	(594)
Initial recognition upon adoption of	採納香港財務報告準則	(001)
HKFRS 16	第16號後初始確認	1,592
Additions of new leases	增添新租賃	542
Interest expenses	利息開支	72
At 31 December 2019 and	於二零一九年十二月三十一日及	
1 January 2020	二零二零年一月一日	1,612
Financing cash flows, net	融資現金流量,淨值	(1,107)
Addition of new leases	增添新租賃	2,461
Lease modification	租賃修訂	(375)
Interest expenses	利息開支	74
Exchange difference	匯兑差額	(23)
At 31 December 2020	於二零二零年十二月三十一日	2,642

For the year ended 31 December 2020 截至二零二零年十二月三十一日止年度

#### **31. RELATED PARTY TRANSACTIONS**

#### **31.** 關連方交易

(a) 關連方交易

#### (a) Related party transactions

Save as disclosed elsewhere in the consolidated financial statements, the Group had entered into following transactions with its related party during the years ended 31 December 2020 and 2019:

除於綜合財務報表其他地方之披露 外,截至二零二零年及二零一九年 十二月三十一日止年度,本集團與 其關連方訂立以下交易:

	2020 二零二零年 <i>RMB'000</i> 人民幣千元	2019 二零一九年 <i>RMB'000</i> 人民幣千元
Lease and utilities expenses paid 已付深圳市君軒生物 to Shenzhen Junxuan Biological 技術有限公司(「 <b>深圳</b> Technology Co., Ltd.* ("Shenzhen Junxuan") (Note) 用支(附註)	(953)	(912)
Sales to Smartronic 向智能創力銷售	767	-

Note:

附註:

Shenzhen Junxuan is a related company controlled by Mr. Zhang Shuguang, an executive director of the Company. 深圳君軒為本公司執行董事張曙光先生 控制的關連公司。

\* English translation is for identification purpose only

綜合財務報表附註

For the year ended 31 December 2020 截至二零二零年十二月三十一日止年度

#### 31. RELATED PARTY TRANSACTIONS (Continued)

# 31. 關連方交易(續)

(b) 主要管理人員薪酬

(b) Compensation of key management personnel

董事(作為本集團主要管理人員)截 至二零二零年及二零一九年十二月

The	emolum	nents	of	dire	ctors	as	key
mana	igement pe	ersonne	el of	the G	roup d	uring	g the
years	ended 31	Decem	ber	2020	and 2	019	were
as fol	lows:						

三十一日止年度之薪酬如下:

	2020 二零二零年 <i>RMB'000</i> 人 <i>民幣千元</i>	2019 二零一九年 <i>RMB'000 人民幣千元</i>
Salaries, bonuses and other benefits 新金、花紅及其他福利 Contributions to defined contribution 界定供款計劃供款 plans	2,115 93	1,151 81
Equity-settled share-based payment 以股權結算之股份基礎 expenses 付款開支	1,636	

For the year ended 31 December 2020 截至二零二零年十二月三十一日止年度

## 32. PARTICULARS OF PRINCIPAL SUBSIDIARIES 32. 本公司主要附屬公司之詳情 OF THE COMPANY

Details of principal subsidiaries at the end of the reporting period are as follows:

於報告期末,主要附屬公司詳情如下:

Name of subsidiary 附屬公司名稱	Place of incorporation/ establishment 註冊成立/ 成立地點	Paid up issued/ registered capital 已發行及繳足股本/ 已繳足註冊股本	interest and held by th 本公司所持	ownership voting power e Company 所有權權益 權比例 Indirectly	Principal activities/ place of operation 主要業務/營運地點
			直接	間接	
Huakang Biomedical Company Limited	The BVI	Issued and fully paid share capital US\$1	100% (2019: 100%)	N/A	Investment holdings/ Hong Kong
Huakang Biomedical Company Limited	英屬處女群島	已發行及繳足股本1美元	100% <i>(二零一九年:</i> <i>100%)</i>	不適用	投資控股/香港
Nutronic Biomedical Group Limited	Hong Kong	Issued and fully paid share capital HK\$80 (2019: HK\$1)	100% (2019: 100%)	N/A	Investment holdings/ Hong Kong
Nutronic Biomedical Group Limited	香港	已發行及繳足股本80港元 (二零一九年:1港元)	100% <i>(二零一九年:</i> <i>100%)</i>	不適用	投資控股/香港
King Grace	The BVI	Issued and fully paid share capital US\$10	100%	(2019: 100%)	Investment holdings/ Hong Kong
King Grace	英屬處女群島	已發行及繳足股本10美元	100%	( <i>二零一九年:</i> 100%)	投資控股/香港
Shenzhen Huakang (Note (b))	The PRC	Paid-up registered capital US\$1,800,000	N/A	100% (2019: 100%)	Research and development, manufacture, marketing and sale of biological reagents and auxiliary reproductive supplies and equipment/The PRC
深圳華康( <i>附註(b</i> ))	中國	繳足註冊股本1,800,000 美元	不適用	100% <i>(二零一九年:</i> <i>100%)</i>	研發、生產、營銷及銷售 體外診斷試劑及輔助生 育用品和設備/中國
Nutronic Healthcare Company Limited (" <b>Nutronic</b> <b>Healthcare</b> ")	Hong Kong	Issued and fully paid share capital HK\$1	N/A	,	Sales of healthcare products and supplements/Hong Kong
Nutronic Healthcare Company Limited ([Nutronic Healthcare])	香港	已發行及繳足股本1港元	不適用	100% <i>(二零一九年:</i> <i>100%)</i>	銷售健康產品及保健品/ 香港



综合財務報表附註

For the year ended 31 December 2020 截至二零二零年十二月三十一日止年度

#### 32. PARTICULARS OF PRINCIPAL SUBSIDIARIES OF THE COMPANY (Continued)

Notes:

- (a) None of the subsidiaries had issued any debt securities at the end of reporting period.
- (b) Shenzhen Huakang is a wholly foreign owned enterprise.

#### 33. EVENTS AFTER THE REPORTING PERIOD

In January 2021, Nutronic Healthcare, a whollyowned subsidiary of the Company, was granted a banking facility in respect of inward invoice financing amounted to HK\$4,000,000 (equivalent to approximately RMB3,636,000). Such banking facility are secured and guaranteed by (i) bank deposit amounted to HK\$1,000,000 and (ii) unlimited corporate guarantee given by the Company.

#### 32. 本公司主要附屬公司之詳情(續)

附註:

- (a) 於報告期末,概無附屬公司發行任何債 務證券。
- (b) 深圳華康為一間外資全資擁有企業。

#### 33. 報告期後事項

於二零二一年一月,本公司全資附屬 公司Nutronic Healthcare就購貨發票融 資獲授銀行融資4,000,000港元(相當 於約人民幣3,636,000元)。該銀行融 資已獲下列各項抵押及擔保(i)銀行存款 1,000,000港元;及(ii)本公司作出之無 限額公司擔保。

For the year ended 31 December 2020 截至二零二零年十二月三十一日止年度

## 34. STATEMENT OF FINANCIAL POSITION OF 34. 本公司財務狀況表 THE COMPANY

		Notes 附註	2020 二零二零年 <i>RMB'000</i> 人 <i>民幣千元</i>	2019 二零一九年 <i>RMB'000 人民幣千元</i>
Non-current assets Interests in subsidiaries	<b>非流動資產</b> 於附屬公司之權益		9,318	9,278
Property, plant and equipment Right-of-use assets	が出國公司之福祉 物業、廠房及設備 使用權資產		98 1,000	224 1,067
			10,416	10,569
<b>Current assets</b> Other receivables, deposits and prepayments	<b>流動資產</b> 其他應收款項、按金及 預付款項		1,122	687
Amounts due from subsidiaries Bank balances and cash	應收附屬公司款項 銀行結餘及現金	34(a)	5,544 5,113	2,535 15,193
			11,779	18,415
<b>Current liabilities</b> Other payables and accrued charges Lease liabilities Amount due to a subsidiary	<b>流動負債</b> 其他應付款項及 應計費用 租賃負債 應付一間附屬公司款項	34(a)	1,186 526 1,743	1,007 594 1,852
			3,455	3,453
Net current assets	流動資產淨值		8,324	14,962
Total assets less current liabilities	資產總值減流動負債		18,740	25,531
Non-current liabilities Lease liabilities	<b>非流動負債</b> 租賃負債		268	431
NET ASSETS	資產淨值		18,472	25,100
<b>Capital and reserves</b> Share capital Reserves	<b>資本及儲備</b> 股本 儲備	34(b)	3,509 14,963	3,509 21,591
TOTAL EQUITY	權益總額		18,472	25,100

綜合財務報表附註

For the year ended 31 December 2020 截至二零二零年十二月三十一日止年度

### 34. STATEMENT OF FINANCIAL POSITION OF 34. 本公司財務狀況表(續) **THE COMPANY** (Continued)

#### (a) Amounts due from (to) subsidiaries

The amounts due from (to) subsidiaries were unsecured, interest-free and repayable on demand.

# (a) 應收(付)附屬公司款項 應收(付)附屬公司款項屬無抵押、

不計息及按要求償還。

Movement in the Comp	oany's reserves	(			
		Share premium 股份溢價 RMB'000 人民幣千元	Share option reserve 購股權儲備 <i>RMB'000</i> 人民幣千元	Accumulated losses 累計虧損 RMB'000 人民幣千元	<b>Total</b> 總計 <i>RMB'000</i> 人民幣千元
At 1 January 2019	於二零一九年				
	一月一日	47,248	-	(20,424)	26,824
Loss and total comprehensive expense for the year	年內虧損及 全面開支總額	_	-	(5,233)	(5,233)
At 31 December 2019 and 1 January 2020	於二零一九年 十二月三十一日 及二零二零年				
	一月一日	47,248	-	(25,657)	21,591
Loss and total comprehensive expense for the year	年內虧損及全面開支 總額	-	-	(9,288)	(9,288)
Transactions with owners: Contributions and distributions Equity-settled share-based payment expenses (Note 25)	與擁有人之交易: <i>供款及分派</i> 以股權結算之股份基 礎付款開支				
	(附註25)	-	2,660	-	2,660
Forfeiture of share options (Note 25)	沒收購股權 <i>(附註25)</i>	-	(52)	52	-
Total transactions with owners	與擁有人之交易總額	_	2,608	52	2,660
At 31 December 2020	於二零二零年				
	十二月三十一日	47,248	2,608	(34,893)	14,963

#### (b)

# FINANCIAL SUMMARY 財務概要

A summary of the results, assets and liabilities of the Group for the last five financial years is set out below. This summary does not form part of the consolidated financial statements.

本集團於過往五個財政年度之業績、資產及 負債概要載列如下。本概要並不構成綜合財 務報表之其中一部分。

RESULTS			業績			
		2020	2019	2018	2017	2016
		二零二零年	二零一九年	二零一八年	二零一七年	二零一六年
		RMB'000	RMB'000	RMB'000	RMB'000	RMB'000
		人民幣千元	人民幣千元	人民幣千元	人民幣千元	人民幣千元
Revenue	收入	21,967	25,471	28,677	26,541	25,410
(Loss) Profit before taxation	除税前(虧損)溢利	(11,372)	658	1,242	(247)	9,944
Taxation	税項	(255)	(942)	(1,701)	(1,705)	(1,518)
(Loss) Profit for the year	本公司擁有人					
attributable to the	應佔年度(虧損)					
owners of the Company	溢利	(11,627)	(284)	(459)	(1,952)	8,462

# ASSETS, LIABILITIES AND NON-CONTROLLING 資產、負債及非控股權益 INTERESTS

Assets	資產					
Non-current assets	非流動資產	13,691	15,244	13,667	12,507	7,666
Current assets	流動資產	59,010	63,468	69,767	35,915	29,782
Total assets	資產總值	72,701	78,712	83,434	48,422	37,448
Equity and liabilities	權益及負債					
Total equity	權益總額	61,859	70,685	71,021	37,390	24,201
Non-current liabilities	非流動負債	1,576	816	430	220	615
Current liabilities	流動負債	9,266	7,211	11,983	10,812	12,632
Total liabilities	負債總額	10,842	8,027	12,413	11,032	13,247
Total equity and liabilities	權益及負債總額	72,701	78,712	83,434	48,422	37,448



Huakang Biomedical Holdings Company Limited 華康生物醫學控股有限公司